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With little recent improvement in osteosarcoma (OS) outcomes, identification of 
therapeutic targets is critical. RNA interference (RNAi) and drug screens using OS 
tumour cell lines (TCL) were used to identify novel genetic dependencies and validate 
tractable therapeutic targets.  
 
Cell viability data from RNAi screens in 18 OS TCL was integrated with whole-exome 
sequencing and protein expression data. Comparison with non-osteosarcoma TCL, 
demonstrated OS to be more reliant on skeletal morphogenesis pathways and FGFR1/2, 
with increased sensitivity to FGFR1 inhibitors. OS TCL positive for FGFR1 amplification 
and polysomy were significantly more sensitive to FGFR1 inhibitors than unknown or 
non-amplified OS TCL, providing further evidence for a clinical trial in an enriched 
population. 
 
Correlation of RNAi results with the presence of recurrent driver gene alterations revealed 
that sensitivity to selective silencing of DYRK1A was associated with deficiency of RB1. 
This finding was validated using RNAi in the OS TCL, an additional 34 breast TCL, and a 
DYRK1A kinase inactive model. Harmine, a DYRK1A inhibitor, resulted in greater 
apoptosis in an RB1 deficient OS TCL than in a RB1 wildtype model. DYRK1A has been 
identified as a protein interaction partner of RB1 and is pharmacologically tractable. 
Further work is necessary to mechanistically understand this synthetic lethality.  
 
The model system was also used as a tool to validate the potential role of BRCAness in 
OS, recently identified as a potential target in genomic studies. This determined the 
majority of OS TCL not to be profoundly sensitive to PARP inhibition. However, LM7 (an 
OS TCL) created by repeated pulmonary murine passage of SAOS2, demonstrated this 
acquired phenotype. Absence of RAD51 foci in LM7 in contrast to SAOS2, identifies this 
as a suitable, mechanistically relevant, tool for studying ‘BRCAness’ in OS. 
  
Integrated screens provided a framework for pre-clinical identification and validation of 
tractable therapeutic targets to facilitate translation into development of clinical trials.  
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1.1.1 Incidence and mortality of Osteosarcoma 
Osteosarcoma (OS) is the most common primary tumour of bone, occurring more 
frequently in males than females (ratio 1.3:1) (Whelan, McTiernan, Cooper, et al., 2012). 
The incidence of osteosarcoma has a bimodal distribution, with the first peak occurring in 
adolescence (10-24 years), and a second occurring in those aged 70 years and over 
(Whelan, McTiernan, Cooper, et al., 2012). Patients 40 years and older have been shown 
to have a worse outcome than those under 40 years of age, and have an overall survival 
at five years of just 22% compared to 53% (Whelan, McTiernan, Cooper, et al., 2012). 
The overall five year survival across all age groups is under 45%, and no significant 
improvement in outcome has been achieved since 1987 (Whelan, McTiernan, Cooper, et 
al., 2012). The site of disease also influences survival, with non-extremity (cranial, 
thoracic, spinal and pelvic) osteosarcoma having an inferior outcome (16%) compared to 
extremity (48%) and craniofacial tumours (52%) (p<0.0001) (Gorlick, Anderson, Andrulis, 
et al., 2003). 
 
1.1.2 Treatment of Osteosarcoma 
Historical treatment of osteosarcoma focused on amputation, with dismal survival rates of 
15-20% (Eilber, Giuliano, Eckardt, et al., 1987), and patients succumbing to pulmonary 
metastases. In the 1970s, the M.D. Anderson Hospital, Houston, studied a combination of 
cytoxan, vincristine, melphalan, and adriamycin which delivered an overall two year 
survival rate of over 50% (Sutow, Sullivan, Fernbach, et al., 1975; Sutow, Sullivan, 
Wilbur, et al., 1975). Further studies from several institutions at this time showed a 
definite disease-free and overall survival advantage for patients receiving chemotherapy 
(Eilber, Giuliano, Eckardt, et al., 1987). Methotrexate was first used in osteosarcoma in 
1974, in combination with vincristine, after local control by surgery or irradiation with a 
significant reduction in reported pulmonary metastases (Jaffe, Frei, Traggis, et al., 1974). 
Subsequent trials confirmed the benefit of multi-agent therapy comprising of neo-adjuvant 
and adjuvant chemotherapy (high-dose methotrexate, doxorubicin, and cisplatin), and 
surgical resection (Eilber, Giuliano, Eckardt, et al., 1987) and shaped modern multi-




modality treatment (Bacci, Briccoli, Longhi, et al., 2005; Kempf-Bielack, Bielack, Jürgens, 
et al., 2005; Bacci, Picci, Ruggieri, et al., 1990).  
 
At present, in patients with localised, operable disease, histological response to neo-
adjuvant chemotherapy is the most robust clinical marker of outcome, with ‘good’ 
response generally classified as a tumour showing 90% or more necrosis, and ‘poor’ if 
less than 90% tumour necrosis (Bacci, Mercuri, Longhi, et al., 2005; Bacci, Picci, 
Ruggieri, et al., 1990; Pakos, Nearchou, Grimer, et al., 2009; Bielack, Kempf-Bielack, 
Delling, et al., 2002). For patients with a good response, event free survival is in the order 
of 70% whilst those with a ‘poor’ response this lies below 50% (Bielack, 2002). 
 
Collaboration between European and American clinicians led to the largest randomised 
Phase III trial to date, European and American Osteosarcoma Study Group 1 
(EURAMOS 1), which investigated optimising treatment strategies based on the 
histological response to two cycles of neo-adjuvant chemotherapy (Marina, Bielack, 
Whelan, et al., 2009). The study investigated the benefit of the addition of interferon 
maintenance therapy to methotrexate, doxorubicin and cisplatin (MAP) chemotherapy for 
‘good’ responders (Bielack, Smeland, Whelan, et al., 2015), and the addition of 
ifosfamide and etoposide for patients with a ‘poor response’ (Marina, Smeland, Bielack, 
et al., 2016). Neither of the experimental arms was found to confer any benefit, thus, the 
standard of care remains MAP (Marina, Smeland, Bielack, et al., 2016) and unfortunately 
despite international collaboration, there has been little improvement in survival over the 
past two decades since the introduction of this therapy (Kempf-Bielack, Bielack, Jürgens, 
et al., 2005; Janeway, Barkauskas, Krailo, et al., 2012; Mirabello, Troisi & Savage, 2009) 
with 5 year survival remaining in the order of 70% for young patients with localised 
disease. For those with metastatic disease at diagnosis, outcome is poor with only 20-
30% surviving for 5 years and remains even more dismal for those with recurrence 
(Luetke, Meyers, Lewis, et al., 2014). There is a paucity of early phase clinical trials 
available for these patients and unfortunately results from these have generally been 
disappointing. The Children’s Oncology Group recently performed an analysis of outcome 
of patients with recurrent osteosarcoma treated on seven phase II clinical trials, 
demonstrating a very poor event free survival of 12 % at 4 months (Lagmay, Krailo, 
Dang, et al., 2016). 
 




Recently, liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) has been 
approved by the National Institute of Clinical Excellence (NICE) as an adjunct to standard 
first line therapy in patients up to 30 years presenting with non-metastatic osteosarcoma. 
MTP-PE is now part of established therapy in the United Kingdom, in combination with 
post-operative MAP, in patients with resectable disease, after macroscopically complete 
surgical resection. MTP-PE is reported to be a nonspecific immune modulator; it is a 
synthetic analogue of a component of bacterial cell walls, which once incorporated into 
macrophages and monocytes residing in the lungs, activates these cells to become 
tumouricidal (Chou, Kleinerman, Krailo, et al., 2009). However, the role of MTP-PE in the 
treatment of osteosarcoma remains unclear. Meyers et al. performed a Phase III study to 
answer two independent questions: first, if the addition of ifosfamide to standard MAP 
chemotherapy improved event free survival (EFS); and second, if the addition of MTP-PE 
improved EFS (Meyers, Schwartz, Krailo, et al., 2016a). Patients under thirty years with 
OS were randomised at diagnosis to either regimen A- (MAP), A+ (MAP plus MTP-PE) or 
regimen B- (MAP plus ifosfamide (MAPI)) or B+ (MAPI plus MTP-PE). Clinically detectable 
metastases were not absolute exclusion criteria, but patients with metastatic disease 
were only enrolled at certain institutions and then analysed separately. They used a 
factorial 2x2 design that assumed that there were no interactions between the 
interventions tested, so that the four study arms could be collapsed, and aggregated 
together to analyse the results for each question (Meyers, Schwartz, Krailo, et al., 
2016a). Describing the patients with clinically undetectable disease, the percentage of 
necrosis at resection was only available for 264 of 559 (47.1%) patients, but although the 
difference between the four arms was not considered statistically significant, a greater 
number of patients in A+ had less than 95% necrosis than the other arms. The five year 
EFS for each arm was as follows: A-: 64%; A+ 63%; B- 56%; and B+ 72%. From this 
analysis, the authors concluded there was an interaction between ifosfamide and MTP-
PE which had not previously been recognised and so were unable to analyse the data as 
first anticipated, making the study under powered to analyse each of the four arms 
separately. From these limited results, it therefore appeared that in patients under the 
age of thirty years with clinically undetectable metastases, MTP-PE in combination with 
MAP and ifosfamide might provide some benefit (Meyers, Schwartz, Krailo, et al., 2016a). 
Further analysis of this data by the authors lead to a second publication, which 
ascertained that no interaction had been observed between MTP-PE and ifosfamide, 
enabling the authors to analyse the study as first anticipated (Meyers, Schwartz, Krailo, et 
al., 2016b). The six year EFS for the four individual arms at six years was reported as: A-: 




64%; A+ 63%; B- 58%; and B+ 71%. Once the data was aggregated the authors reported 
that there was no significantly different (p = 0.91) EFS at four or six years between A- 
(MAP) or B- (MAPI) with overall EFS post chemotherapy of 61% at six years (Meyers, 
Schwartz, Krailo, et al., 2016b). The overall reported EFS for patients treated with 
chemotherapy and MTP-PE was 67% at six years, which was not significantly different 
from chemotherapy alone 61% (p = 0.08), while overall survival at six years was 78 % 
with chemotherapy and MTP-PE, and 70% with chemotherapy alone (p = 0.03) (Meyers, 
Schwartz, Krailo, et al., 2016b). The authors concluded from this study that the addition of 
ifosfamide to MAP did not improve outcome, but the addition of MTP-PE in patients with 
clinically undetectable metastases did improve overall survival (Meyers, Schwartz, Krailo, 
et al., 2016b). The outcome for the 91 patients with clinically detectable metastases at 
diagnosis were reported in a further paper (Chou, Kleinerman, Krailo, et al., 2009). The 
five year EFS for each of the regimens was as follows: A-: 29%; A+ 41%; B- 23%; and B+ 
44%. No statistically significant differences between the five-year EFS between these 
groups were recorded. Once the data was aggregated the authors reported that there 
was no significantly different (p = 0.91) EFS at five years between A- (MAP) or B- (MAPI) 
with overall EFS post chemotherapy of 26% at six years. The overall reported EFS for 
patients treated with chemotherapy and MTP-PE was 42% at six years, which was not 
significantly different from chemotherapy alone (p = 0.23). A similar trend was observed, 
with five-year overall survival for patients who received chemotherapy of 40% and 
addition of MTP-PE of 53%, which was not significantly different (p=0.27). The authors 
concluded from this study that the addition of MTP-PE to chemotherapy did not improve 
outcome in patients with clinically detectable metastases (Chou, Kleinerman, Krailo, et 
al., 2009). There are a number of limitations to this trial. Firstly, at present histological 
response to neo-adjuvant chemotherapy is the most robust clinical marker of outcome but 
concerns were raised that a greater proportion of patients in regimen A+ had a poorer 
histological response. Second, the test for statistical interaction between MTP-PE and 
ifosfamide for disease-free survival was very close to the pre-specified threshold for 
interaction of 0.01 (p = 0.102), which would have invalidated the method of aggregation 
and analysis.  
 
A number of unanswered questions remain but would require a further costly Phase III 
study sufficiently powered to answer the questions: (i) does the addition of MTP-PE to 
standard MAP significantly improve survival in patients randomised on the basis of 
histological response at resection with or without metastases; (ii) what are the effects on 




survival in patients greater than 30 years; (iii) are there robust biomarkers of sensitivity to 
MTP-PE. A clinical trial to determine if ABCB1/P-glycoprotein over-expression can be 
used as a biological stratification factor for outcome of patients with localised disease 
undergoing treatment with either standard MAP or the addition of ifosfamide and MTP-PE 
is currently recruiting (NCT01459484). Another trial aiming to understand why some 
patients respond differently to MTP-PE alone and in combination with ifosfamide has just 
completed and the results are awaited (NCT02441309).  
 
Neo-adjuvant and adjuvant chemotherapy along with resection is the conventional 
treatment for all histological variants of high-grade osteosarcoma. Complete surgical 
resection of both primary and relapsed disease (Wong, Lee, Shing, et al., 2013; Kempf-
Bielack, Bielack, Jürgens, et al., 2005; Ferrari, Briccoli, Mercuri, et al., 2003), comprising 
limb salvage surgery where possible (85% of children) (Grimer, 2005), is vital for cure 
(Bacci, Briccoli, Longhi, et al., 2005). The use of radiotherapy in osteosarcoma is limited 
to local treatment of un-resectable disease, intra-lesional resection (DeLaney, Park, 
Goldberg, et al., 2005) or as palliation of symptomatic metastases (Schwarz, Bruland, 
Cassoni, et al., 2009).  
 
1.1.3 Overview of clinical trials in OS 
The objectives of Phase I clinical trials are to determine the maximum tolerated dose of 
the agent, toxicity profile, adverse events, pharmacokinetics and pharmacodynamics. 
Phase II trial objectives are to determine the efficacy of the agent by measuring response 
of the tumour, or a measure of survival (overall or event/progression free). Phase III trials 
are used to compare treatment with the novel agent with the recognised standard of care 
for a specific tumour type. These trials are usually randomised. Phase IV studies are 
used to gather further information about agents that have already been approved for use, 
such as quality of life metrics, longer-term safety and cost-effectiveness.  
 
A literature search and summary of clinical trials between 1990 and 2010 enrolling 
patients with Ewing’s sarcoma and OS was performed (van Maldegem, Bhosale, 
Gelderblom, et al., 2012a). Of the 42 trials identified, 20 were specific for patients with OS 
(two phase I, 16 phase II, two phase I/II), with a total of 1114 patients enrolled, which 
represented only 0.2% of the world-wide potential patient recruitment (van Maldegem, 
Bhosale, Gelderblom, et al., 2012a). From the twenty OS specific trials, 780 patients were 




enrolled, 762 were evaluable with only 58 patients (8%) achieving a complete response, 
21 (2.8%) a partial response, and 30 (4%) had stable disease (van Maldegem, Bhosale, 
Gelderblom, et al., 2012a). At the time of this review, the majority of phase III trials were 
still chemotherapy, despite a shift towards more biologically based treatments in phases 
I/II (van Maldegem, Bhosale, Gelderblom, et al., 2012a).  
 
At present, 44 registered clinical trials (phase I: 15; phase Ib: two; phase I/II: seven; 
phase II: seventeen; phase II/II: two; phase IV: one) testing chemotherapy or biological 
treatments are currently actively recruiting patients with OS (Table 1). The majority of 
these studies are open for patients with either sarcoma in general, or solid tumours, only 
12/44 (27%) are for the investigation of patients with OS alone. At present there is one 
phase IV trial actively recruiting patients with OS to determine if the addition of lithium 
carbonate to standard chemotherapy improves outcome (NCT01669369). The phase II/III 
studies are to first determine if MAPI chemotherapy plus MTP-PE in patients who over 
express ABCB1/P-glycoprotein improves outcome compared to MAP chemotherapy in 
patients who do not over express ABCB1/P-glycoprotein (NCT01459484), and second to 
answer if apatinib improves progression free survival in patients (>14 years) with 
relapsed and unresectable OS. Of the 44 studies, 27 are for chemotherapeutic agents, 
while 17 are for biological agents, which include anti-PDL1 anti-bodies (pembrolizumab, 
nivolumab, duralumab and avelumab), anti-GD2 antibodies (Hu14.18K322A), anti-
receptor activator of nuclear factor kappa-B ligand (RANKL) antibodies (denosumab), T 
cells with a GD2 antibody in combination with interleukin 2, dendritic cells vaccine, 
activated Natural Killer cells, anti-B7-H3 antibodies (enoblituzumab), an oncolytic virus 
(HSV1716), anti-CTLA-4 antibodies (iIpilimumab, tremelimumab), and anti-cyclin 
dependent kinases 4/6 (CDK4/6) antibodies (abemaciclib).  
 
  




Table 1 Actively recruiting clinical trials in patients with osteosarcoma 
Trial Phase Treatment Primary Aims 
NCT01459484 II/III MAP/MAPI + MTP-PE Overall survival 
NCT03063983 II Cyclophosphamide  
MTX 
EFS 
NCT03013127 II Pembrolizumab PFS 
NCT02718482 II Gemcitabine and docetaxel or 
ifosfamide 
PFS 
NCT03006848 II Avelumab PFS 
NCT01669369 IV Lithium carbonate PFS 
NCT01987102 I/II Leucovorin rescue Toxicity  
NCT02502786 II Humanised anti-GD2 antibody EFS 
NCT03163381 II Apatinib PFS 
NCT02711007 II/III Apatinib PFS 
NCT02470091 II Denosumab  Disease control 
rate 




NCT02273583 II Cyclophosphamide and MTX EFS 




NCT02389244 II Regorafenib PFS 
NCT02173093 I/II IL2, GD2Bi-aATC  MTD 
NCT02357810 II Pazopanib hydrochloride and 
topotecan 
PFS 
NCT02301039 II pembrolizumab ORR 
NCT01803152 
 
I Dendritic cells vaccine, 
imiquimod and gemcitabine 
Toxicity  














NCT02945800 II Nab-paclitaxel and gemcitabine PFS 
NCT02013336 I Irinotecan and 
cyclophosphamide 
MTD 
NCT02100891 II Natural Killer cells post DCR 
  
[IL2: interleukin 2; GD2Bi-aATC: chimeric T cells with GD2 antibody; MTD: maximum tolerated 
dose; RP2D: recommended phase II dose; ORR: objective response rate; PK: pharmacokinetics; 
PD: pharmacodynamics; TAEST16001: TCR Affinity Enhancing Specific T cell Therapy; PFS: 
progression free survival; MAP: methotrexate, cisplatin, doxorubicin; MTX: methotrexate]. 




In addition to patient recruitment, due to the rarity of the disease, there are other 
challenges for clinical trials in OS. The need to acrue patients must be balanced by 
recruitment of a heterogeneous group of patients with OS, which imposes limitations on 
what conclusions can be drawn (Janeway & Gorlick, 2016). EURAMOS1 demonstrated 
that international collaboration is feasible, enrolling 2260 patients with OS over six years 
(Whelan, Bielack, Marina, et al., 2015; Bielack, Smeland, Whelan, et al., 2015). Most 
clinical trials use the WHO radiographic response criteria, or Response Evaluation 
Criteria in Solid Tumours (Eisenhauer, Therasse, Bogaerts, et al., 2009) for response to 
treatment, or radiological assessment of disease response. However, in localised OS, 
optimal assessment of tumour response is limited by calcified tumour matrix, and in 
metastatic OS, surgical excision where possible of pulmonary metastases is standard, 
resulting in minimal residual disease and possible exclusion from trials that require 
measurable disease for enrolment (Lagmay, Krailo, Dang, et al., 2016; van Maldegem, 
Bhosale, Gelderblom, et al., 2012b). Even with complete histological necrosis, 
radiological response to neo-adjuvant therapy is rare (Lagmay, Krailo, Dang, et al., 2016). 
Instead of radiological response, survival has been employed as an alternative end point. 
Therefore, for clinical trials to be successful in OS they must take into consideration these 
challenges.  
 
1.1.4 Molecular and genomic biology of osteosarcoma 
Osteosarcoma derives from primitive bone-forming mesenchymal cells and is typically 
composed of spindle cell lineages that produce osteoid (Gorlick, 2009). The current 
World Health Organisation (WHO) classification (Whelan, McTiernan, Cooper, et al., 
2012; Raymond, Ayala & Knuutila) describes three major subtypes of high-grade 
osteosarcoma: osteoblastic which comprise the majority (~60%), and approximately 
equal representation of fibroblastic and chondroblastic subtypes (Kempf-Bielack, Bielack, 
Jürgens, et al., 2005; Bacci, Longhi, Fagioli, et al., 2005; Janeway, Barkauskas, Krailo, et 
al., 2012; Mirabello, Troisi & Savage, 2009). A fourth rare subtype telangectatic 
osteosarcoma occurs in less than 12% of patients (Angelini, Mavrogenis, Trovarelli, et al., 
2016).  Although differences exist in response to chemotherapy between the subtypes, 
no overall survival differences have been demonstrated between these groups and thus, 
currently no stratification of therapy exists on the basis of subtype.    
 




Limited understanding of the molecular and cellular mechanisms that influence the 
behaviour of osteosarcoma has potentially hindered the development of novel 
therapeutics. Early genetic events are thought to relate to the deletion or mutation of 
tumour suppressors such as Tumour Protein P53 (TP53) and other genetic abnormalities 
including deletion of Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) and MDM2 Proto-
Oncogene (MDM2) amplification. However, currently no molecular sub-classification of 
osteosarcoma exists on which stratification of therapy is based (Kansara & Thomas, 
2007; Gorlick, 2009; Kuijjer, Hogendoorn & Cleton-Jansen, 2013) apart from the 
detection of MDM2 amplification in low grade central and parosteal osteosarcomas, 
which helps classify these tumours as not requiring adjuvant therapy (Mejia-Guerrero, 
Quejada, Gokgoz, et al., 2010). At present there are a small number of reports which 
correlate gene expression with clinical outcome, (PosthumaDeBoer, Witlox, Kaspers, et 
al., 2011; Angstadt, Motsinger-Reif, Thomas, et al., 2011; Man, Lu, Jaeweon, et al., 2004; 
Sadikovic, Park, Selvarajah, et al., 2013). For example expression of Thrombospondin 3 
(THBS3), and Secreted Protein Acidic And Cysteine Rich (SPARC) are associated with 
poor outcome, whereas Secreted Phosphoprotein 1 (SPPI) expression is associated with 
good outcome (Dalla-Torre, Yoshimoto, Lee, et al., 2006). However, these only serve to 
increase the limited understanding of the biology of the disease, and have not yet 
translated into clinical practice. Fibroblastic growth factor receptor 1 (FGFR1) gene 
amplification assessed by interphase fluorescence in situ hybridization of the tumour 
samples from 288 patients was reported in 18.5% of patients whose tumours responded 
poorly to chemotherapy, but not seen in patients whose tumours responded well 
(Fernanda Amary, Ye, Berisha, et al., 2014). In addition, amongst the rare histological 
variants of osteosarcoma, FGFR1 amplification was more frequent (Fernanda Amary, Ye, 
Berisha, et al., 2014). A greater understanding about the role of FGFR in OS and 
investigation of inhibition is worthy of exploration.  
 
Osteosarcomas are typically aneuploid (Schlabach, Luo, Solimini, et al., 2008; Kansara & 
Thomas, 2007), with frequent extensive genomic aberrations (Kresse, Rydbeck, Skårn, et 
al., 2012; Tarkkanen, Karhu, Kallioniemi, et al., 1995). Unlike other types of sarcoma 
such as Ewings sarcoma, which are characterised by gene fusions of EWS to different 
members of the ETS transcription factor gene family (Toomey, Schiffman & Lessnick, 
2010), there do not appear to be unifying genetic aberrations amongst high grade 
osteosarcomas. Contrary to other malignancies such as colorectal adenocarcinoma, no 
precursor lesions have been identified in OS (Mohseny, Hogendoorn & Cleton-Jansen, 




2012). It is likely that there is extensive genetic heterogeneity both between and within 
high-grade osteosarcomas (Kansara & Thomas, 2007; Burrell, McGranahan, Bartek, et 
al., 2013; Gorlick, 2009; Kuijjer, Hogendoorn & Cleton-Jansen, 2013; Behjati, Tarpey, 
Haase, et al., 2017). This genetic heterogeneity has helped to obscure the identification 
of potential driver alterations involved in OS genesis.  
 
Mutations in Retinoblastoma 1 (RB1), CDKN2A and TP53 are the most common known 
recurrent mutational events in sporadic osteosarcoma (Gorlick, Anderson, Andrulis, et al., 
2003). The frequency of these events varies widely between reported cohorts, with some 
reporting that 20-70% of osteosarcomas harbour mutations of TP53 (Gokgoz, Wunder, 
Mousses, et al., 2001), and more recently when structural variants in the first intron were 
included, as many as 80% harbour a mutation (Chen, Bahrami, Pappo, et al., 2014). 
Structural alterations of RB1 have been reported in up to 35% of sporadic cases of 
osteosarcoma (Araki, Uchida, Kimura, et al., 1991). 
 
Very recently, eight out of 112 (7%) tumour OS samples that were either whole genome 
or exome sequenced were found to have mutations of the IGF signalling pathway 
(Behjati, Tarpey, Haase, et al., 2017). Dependency on IGF-1R signalling and activation of 
IGF-1R by IGF-1 leading to stimulation of the growth of OS tumour cells both in vitro 
(Kappel, Velez-Yanguas, Hirschfeld, et al., 1994) and in vivo (Kolb, Gorlick, Houghton, et 
al., 2008) has already been described. Blockade of this pathway was thought to be 
therapeutically attractive (Kuijjer, Peterse, van den Akker, et al., 2013; Fleuren, 
Versleijen-Jonkers, Boerman, et al., 2014) with a number of IGF-1R inhibitors which 
entered early phase trial. However, all clinical trials in sarcoma have been closed or 
halted due to perceived lack of activity and no biomarker to stratify patients for therapy.  
 
Molecular characterisation by whole exome sequencing (n = 59), whole genome 
sequencing (n = 13) and RNA-sequencing (n = 35) of OS tumour samples, identified 
alterations in the Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide / Mechanistic 
Target Of Rapamycin (PI3K/mTOR) pathway in 24% of patients with OS (Perry, Kiezun, 
Tonzi, et al., 2014). Perry et al. therefore hypothesised that the PI3K/mTOR pathway was 
a unifying vulnerability required for OS tumour proliferation, which could be exploited 
therapeutically; using the dual PIK3CA/mTOR inhibitors GSK2126458 and BEZ235, they 
demonstrated sensitivity in four OS tumour cell lines to the dual PIK3CA/mTOR inhibitors 
GSK2126458 and BEZ235 that was comparable with the breast cancer cell line MCF7, 




known to harbour a PIK3CA p.E545K mutation, and previously established to undergo 
apoptosis in response to treatment with these inhibitors (Perry, Kiezun, Tonzi, et al., 
2014). Inhibitors of mTOR in early clinical trials have demonstrated clinical activity in OS, 
but not thought sufficient to be incorporated into treatment protocols (Chawla, Staddon, 
Baker, et al., 2012; Demetri, Chawla, Ray-Coquard, et al., 2013; Broto, Redondo, 
Valverde, et al., 2015). 
 
Chromothripsis, which describes the fragmentation of a single chromosome, which is 
then reassembled, was proposed as a mechanism for genetic instability in 2-3% of a 
diverse panel of 746 cancer cell lines (Bignell, Greenman, Davies, et al., 2010), but is 
observed in up to 29% of OS samples affecting several chromosomes, creating hundreds 
of genetic rearrangements (Behjati, Tarpey, Haase, et al., 2017; Stephens, Greenman, 
Fu, et al., 2011). Kuijjer et al. have postulated that this process many explain the 
considerable complexity and heterogeneity seen within the disease and sudden onset 
(Kuijjer, Hogendoorn & Cleton-Jansen, 2013). Many of these genomic aberrations might 
not provide a growth advantage, representing instead collateral damage caused by 
chromothripsis (Kresse, Rydbeck, Skårn, et al., 2012). A recent analysis of 37 whole 
genome sequences from OS tumour samples demonstrated three cytogenetic 
configurations of the OS genome; 11% (4/37) exhibited few or no rearrangements likely 
to represent an artifact due to inadequate tumour content; 30% (11/37) harboured 
chromothripsis on one or more chromosomes while 59% (22/37) exhibited combined 
chromothripsis and amplification (Behjati, Tarpey, Haase, et al., 2017). Of these 22 
genomes, chromothripsis amplification recurrently affected discrete genomic regions 
including chromosomes five, 12 and 17 postulated by the authors to represent 
chromosomal fragility or be the result of selection for driver events such as amplification 
of RPTOR Independent Companion Of MTOR Complex 2 (RICTOR) (4/37), Telomerase 
Reverse Transcriptase (TERT) (2/37) and disruption of TP53 (5/37) and Neurofibromin 1 
(NF1) (3/37) (Behjati, Tarpey, Haase, et al., 2017).  
 
Recent whole genome sequencing of 20 osteosarcoma tumour samples has also 
reported the presence of areas of kataegis, (hypermutation localized to small genomic 
regions (Alexandrov, Nik-Zainal, Wedge, et al., 2013)), in approximately half of the 
samples, although these were not of recurrent regions of the genome, or associated with 
recurrently mutated genes (Chen, Bahrami, Pappo, et al., 2014). This study of whole-
genome sequencing of 20 osteosarcoma tumour samples and matched normal tissue, 




observed that the most frequent method of mutation was by structural variation and copy 
number alteration, not single-nucleotide variations (SNVs), occurring in TP53, RB1 and 
Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX) (Chen, Bahrami, 
Pappo, et al., 2014). Whole genome sequencing of 37 and exome sequencing of 75 OS 
tumour samples confirmed recurrent genetic alterations in TP53, RB1, CDKN2A, ATRX 
and the insulin like growth factor (IGF) signalling pathway despite considerable inter-
tumour heterogeneity (Behjati, Tarpey, Haase, et al., 2017). Structural variations of TP53 
have only previously been reported in osteosarcoma and prostate cancers (Chen, 
Bahrami, Pappo, et al., 2014; Berger, Lawrence, Demichelis, et al., 2011). Since most 
TP53 mutations are structural variants in intron 1, suggesting either a high frequency or 
susceptibility, Chen et al. postulate that the “genomic instability characterised by high 
rates of copy number variants and structural variants may precede TP53 inactivation, and 
may be the underlying mechanism that initiates and promotes osteosarcoma” (Chen, 
Bahrami, Pappo, et al., 2014). Others previously postulated the reverse, that mutations of 
the mitotic check points led to this genomic instability or at least permit cell viability in the 
face of genomic instability (Cahill, Lengauer, Yu, et al., 1998). 
 
Comparison of genome-wide expression profiles from tumour samples of osteoblastomas 
with high-grade osteosarcomas identified cell cycle regulation as the most prominently 
changed pathway (Cleton-Jansen, Anninga, Briaire-de Bruijn, et al., 2009; Lovejoy, Li, 
Reisenweber, et al., 2012). A recent genome-wide association study using germ-line 
DNA from patients with OS, and matched cancer-free controls, highlighted loci for further 
investigation (Savage, Mirabello, Wang, et al., 2013); a locus in the Glutamate 
Metabotropic Receptor 4 (GRM4) gene at 6p21.3 which encodes the glutamate receptor 
metabotropic 4 which has been implicated in intracellular signalling (Savage, Mirabello, 
Wang, et al., 2013). The GRM4 receptor is expressed in osteoblasts and osteoclasts and 
a possible role in involvement in cell differentiation and regulation during bone formation 
and resorption (Savage, Mirabello, Wang, et al., 2013). The second locus is within a gene 
desert at 2p25.2, with some evidence that this region might affect gene expression 
(Savage, Mirabello, Wang, et al., 2013). Kuijjer et al. integrated DNA copy number 
profiles from tumour samples with expression profiles of high-grade OS as compared to 
mesenchymal stem cells or osteoblasts and suggested 31 new OS driver genes by this 
method (Kuijjer, Rydbeck, Kresse, et al., 2012); these warrant further investigation. 
 




1.1.4.1 BRCAness phenotype and osteosarcoma 
A recent publication revealed a significant proportion of OS tumours to potentially have a 
‘BRCAness’ phenotype (Kovac, Blattmann, Ribi, et al., 2015), which describes tumour 
cells that possess histopathological and molecular characteristics similar to tumour cells 
with Breast cancer 1 (BRCA1) or Breast cancer 2 (BRCA2) gene defects (Lord & 
Ashworth, 2016; Turner, Tutt & Ashworth, 2004). BRCA1 has a number of cellular roles, 
such as chromatin remodelling, transcriptional regulation, and DNA repair (Turner, Tutt & 
Ashworth, 2004). In contrast, BRCA2 is primarily involved in DNA recombination and 
repair, including interaction with RAD51, a protein with a critical role in the catalysis 
reaction required for homologous recombination (HR) (Turner, Tutt & Ashworth, 2004; 
Tarsounas, Davies & West, 2004). In the presence of DNA double strand breaks (DBSs), 
cells which are deficient for BRCA1 or BRCA2 are unable to perform DNA repair by the 
conservative HR, but are forced to rely on potentially mutagenic mechanisms such as 
NHEJ and single strand annealing (Turner, Tutt & Ashworth, 2004). BRCAness therefore 
describes a phenotype with an underling distinctive DNA-repair defect arising from loss of 
HR, due to deficiency of the BRCA pathways (Turner, Tutt & Ashworth, 2004); tumour 
cells with this phenotype are therefore more dependent on base excision repair, 
conferring sensitivity to inhibition of PARP, as the tumour cells are unable to repair the 
cumulative DNA damage and undergo cell death (Lord, Tutt & Ashworth, 2015; Lord & 
Ashworth, 2013). 
 
The mutational spectra of whole genome sequencing from tumour samples have recently 
been classified according to the six base substitutions and information of the bases 
immediately 3’ and 5’ to the mutated base, resulting in 21 different ‘mutational signatures’ 
(Alexandrov, Nik-Zainal, Wedge, et al., 2013). Different mutational processes have been 
shown to generate different combinations of mutation signatures, for example, mutation 
signature three, is strongly associated with tumours that harbour BRCA1 and BRCA2 
mutations and exhibit approximately equal representation of all possible 96 mutations 
(Alexandrov, Nik-Zainal, Wedge, et al., 2013).  
 
Kovac et al. performed whole-exome sequencing on 31 treatment naive OS tumour 
samples (Kovac, Blattmann, Ribi, et al., 2015). The single nucleotide variant (SNV) 
spectrum showed the majority of tumours (29/31) had C:G>T:A changes, followed by 
C:G>A:T and T:A>C:G changes (Kovac, Blattmann, Ribi, et al., 2015). Some tumours 
had a mutation spectra (Signature three) associated with kataegis strongly associated 




with mutations of BRCA1 and BRCA2 mutations within breast and pancreatic cancer 
types (Kovac, Blattmann, Ribi, et al., 2015; Alexandrov, Nik-Zainal, Wedge, et al., 2013). 
In addition to the previously reported driver mutations (TP53 and RB1), Kovac et al. 
reported driver mutations not previously reported in OS (Ret Proto-Oncogene (RET), 
MutY DNA Glycosylase (MUTYH), Nuclear Mitotic Apparatus Protein 1 (NUMA1), 
Fanconi Anaemia Complementation Group (FANCA), Breast cancer 2 (BRCA2) and 
Ataxia-Telangiectasia Mutated (ATM)) that were either truncating / spice mutations or 
protein coding mutations present in two or more tumours (Kovac, Blattmann, Ribi, et al., 
2015). Somatic copy-number alterations (SCNA) of single-nucleotide polymorphism 
arrays identified large-scale genomic instability and LOH signatures similar to that of 
breast and ovarian cancers with BRCA1 inactivation using this methodology in 91% and 
BRCA2 inactivation in 78% of the OS tumour samples (Kovac, Blattmann, Ribi, et al., 
2015). SCNA mutations were also reported in BRCA1 (26%) and other members of the 
HR pathway such as BRCA1 Associated Protein 1 (BAP1) (38%), Phosphatase And 
Tensin Homolog (PTEN) (50%) and Partner And Localizer Of BRCA2 (PALB2) (43%), in 
the absence of identification of mutations by exome sequencing (Kovac, Blattmann, Ribi, 
et al., 2015). Kovac et al. reported that of the 31 tumours samples profiled, a typical OS 
sample carried 17 SCNA mutations in BRCA genes and their core binding partners 
(Kovac, Blattmann, Ribi, et al., 2015). To further validate the observed copy number 
changes, whole genome copy number profiles of 123 independent OS tumour samples 
were used; 85% had copy number changes with hallmarks of BRCA1/2 mutated breast 
cancer (Nik-Zainal, Alexandrov, Wedge, et al., 2012; Alexandrov, Nik-Zainal, Wedge, et 
al., 2013; Kovac, Blattmann, Ribi, et al., 2015). 
 
Mutations of genes known to be involved in HR such as PALB2, Checkpoint Kinase 2 
(CHEK2), PTEN and ATM can have functionally equivalent results to BRCA deficiency, 
resulting in chromosomal instability (Kovac, Blattmann, Ribi, et al., 2015). The notion of 
‘BRCAness’ in OS has been offered as an explanation of how the vulnerability to 
chromosomal breakage may be sustained in the absence of TP53 mutations or in 
parallel, not as a replacement of the existing view of OS as a monoclonal expansion of 
one initial TP53 mutant cell (Kovac, Blattmann, Ribi, et al., 2015). 
 
Kovac et al. postulated that a BRCA-like phenotype is a unifying trait of OS, independent 
of driver mutation, with varying degrees of BRCAness acquired throughout polyclonal OS 
evolution (Kovac, Blattmann, Ribi, et al., 2015). They therefore postulated that a BRCA-




like phenotype could therefore represent a potential therapeutic opportunity in OS 
(Kovac, Blattmann, Ribi, et al., 2015; Engert, Kovac, Baumhoer, et al., 2016). Four 
(MG63, ZK58, SAOS2, and HOSMMNG) OS tumour cell lines known to have disruptive 
gains in PTEN and FANCD2 and / or losses of ATM, BAP1, BRCA1 Associated RING 
Domain 1 (BARD1), FANCA or CHK2 and therefore functionally analogous to BRCA 
mutations, were observed to be susceptible to PARP inhibition by talazoparib (BMN-673 
(Engert, Kovac, Baumhoer, et al., 2016).  
 
Whole genome sequencing was recently performed on thirty-seven OS tumour samples 
and suggests only one, a radiation-induced OS, harboured evidence of HR deficiency 
using HRdetect methodology (mutational signature three) (Behjati, Tarpey, Haase, et al., 
2017; Davies, Glodzik, Morganella, et al., 2017). From this series, nine different 
mutational signatures were represented, the most prevalent were signatures five (age-
related mutational process), and eight (unknown origin) (Behjati, Tarpey, Haase, et al., 
2017). It was determined from that analysis that detection of the BRCAness molecular 
phenotype should only be performed on whole genome sequencing, not the whole-exome 
sequencing performed by Kovac et al. (Kovac, Blattmann, Ribi, et al., 2015). In addition, 
the doses of talazoparib utilised in the above analysis by Engert et al. were noted to be 
higher than those used in similar studies in other malignancies. 
 
1.1.4.2 Familial pre-disposition syndromes in osteosarcoma 
While the majority of OS are sporadic, a minority are radiation-induced (Hawkins, Wilson, 
Burton, et al., 1996), and there is a cluster of familial syndromes that predispose to the 
development of OS: Li-Fraumeni is an autosomal dominant disorder associated with a 
germ-line mutation of TP53; Familial Retinoblastoma is associated with germ-line 
mutation of RB1, a gate-keeper tumour suppressor, involved in the cell cycle checkpoint; 
the DNA helicase disorders include Werner Syndrome, Bloom Syndrome and Rothmund-
Thomson Syndrome (RTS) and are associated with germ-line mutations of RecQ Like 
Helicases 2, 3 and 4 (RECQL2, RECQL3 and RECQL4) respectively (Vogelstein, 
Papadopoulos, Velculescu, et al., 2013; Kansara & Thomas, 2007); Pagetic bone 
diseases may occur as an inherited disorder, and are associated with mutations of 
Sequestosome 1 (SQSTM1) and Mitogen-Activated Protein Kinase 8 (MAPK8) in the 
(Receptor Activator of Nuclear Factor κ B) RANK signalling pathway, and TNF Receptor 
Superfamily Member 11a (LOH18CR1) in Interleukin1/Tumour necrosis factor (IL-1/TNF) 




signalling (Kansara & Thomas, 2007). RECQL4 mutations have not been observed in 
sporadic OS. Recently in 1120 oncology patients of less than 20 years of age, the whole 
genomes (n = 595), whole exomes (n = 456) or both (n = 69) were sequenced (Zhang, 
Walsh, Wu, et al., 2015). The DNA sequences of 565 genes were analysed for the 
presence of germline mutations. Probably pathogenic or pathogenic mutations were 
identified in 8.5 % of cancer patients compared to 1.1% in the 1000 Genomes project 
(Ishida, Kitagawa, Hatakeyama, et al., 2000). The most commonly mutated genes in the 
affected patients were TP53 (n = 50), Adenomatous Polyposis Coli (APC) (in 6), BRCA2 
(n = 6), Neurofibromin 1 (NF1) (n = 4), PMS1 Homolog 2 Mismatch Repair System 
Component (PMS2) (n = 4), RB1 (n = 3), and Runt Related Transcription Factor 1 
(RUNX1) (n = 3) (Zhang, Walsh, Wu, et al., 2015). Fifty-eight patients with a predisposing 
mutation had available information on family history, and of these 40% had a family 
history of cancer (Zhang, Walsh, Wu, et al., 2015). The study concluded that family 
history did not predict the presence of an underlying predisposition syndrome in most 
patients (Zhang, Walsh, Wu, et al., 2015). 
 
Combinations of mutations in the p53 and RB pathways have been demonstrated in the 
majority of sporadic OS (Wang, Luo & Kelley, 2004; Wang, Levy, Lewis, et al., 2001; 
Miller, Aslo, Tsay, et al., 1990; Toguchida, Yamaguchi, Ritchie, et al., 1992; Duan, Zhang, 
Choy, et al., 2012; Marina, Gebhardt, Teot, et al., 2004), however, they are rare (~3%) in 
germline DNA of these patients (Yamaguchi, Honda, Satow, et al., 2009; Marina, 
Gebhardt, Teot, et al., 2004). In contrast, germ-line TP53 mutations, particularly of the 
core DNA binding domain are found in the majority (>50%) (Birch, Blair, Kelsey, et al., 
1998) of cases with Li-Fraumeni cancer predisposition syndrome (Duan, Jia, Koshkina, et 
al., 2006; Li & Fraumeni, 1969). Despite being the second most frequent malignancy in 
Li-Fraumeni Syndrome, OS only has a 12% incidence in these patients (Siddiqui, Onel, 
Facio, et al., 2005), suggesting a role for other driver mutations or epigenetic drivers in 
addition to TP53. Structural rearrangements of RB1 have been observed in 30% of 
primary OS tumours, with point mutations in a further 10%, and loss of heterozygosity in 
60% (Kansara & Thomas, 2007).  
 
1.1.4.3 The role of RB1 in osteosarcoma 
As discussed above, RB1 is recurrently altered in sporadic OS (Kansara & Thomas, 
2007) and long-term survivors of retinoblastoma with germline mutations of RB1 have a 




twenty-fold increased risk of developing a secondary malignancy (including OS) and 
death (Kleinerman, Schonfeld & Tucker, 2012). RB1 plays a central role as a negative 
regulator of cell proliferation, and is frequently mutated in a number of different tumour 
types (Knudsen & Wang, 2010). Active RB1 binds the E2F transcription factors, thereby 
repressing expression of cell cycle genes, and preventing cell cyling beyond the G1 
restriction point (Mittnacht, 2005; Knudsen & Wang, 2010; Dyson, 2016). Phosphorylation 
of RB1 leads to inactivation, dissociation of the E2F transcription factors with resultant 
expression of cell cycle genes needed for proliferation and progression past the G1 
restriction point. Phosphorylation of RB1 is controlled by Cyclin D1 and E, which are 
regulated by the cyclin dependent kinases (Mittnacht, 2005; Dyson, 2016; Knudsen & 
Wang, 2010).  
 
OS are characterised by a high degree of genomic instability but also frequent activation 
of the alternative lengthening of telomeres pathway of telomere maintenance, associated 
with karyotypic instability (Gonzalez-Vasconcellos, Anastasov, Sanli-Bonazzi, et al., 
2013). In addition to cell proliferation via control of the G1 restriction point, there is some 
evidence that heterozygous loss of Rb1 in mouse models is associated with spontaneous 
genomic instability and sustained telomeric attrition and in cells of the osteoblastic 
lineage (Gonzalez-Vasconcellos, Anastasov, Sanli-Bonazzi, et al., 2013). 
 
Osteosarcomas are characterized by the frequent activation of the alternative lengthening 
of telomeres pathway of telo- mere maintenance (10) and a high degree of genomic 
insta- bility. As the loss of telomeric DNA may lead to karyotypic instability (11), and as 
RB1 haploinsufficiency has been asso- ciated with increased genomic instability in 
premalignant retinoma cells (12), we postulate that the Rb1 gene may be the common 
denominator-linking susceptibility, genomic instability, and telomeric integrity. We report 
here that the loss of a single copy of the Rb1 gene is sufficient to cause sustained 
telomeric attrition and spontaneous genomic insta- bility in cells of the osteoblastic 
lineage. The extent of the genomic instability is increased after exposure to radiation. 
 
A recent meta-analysis found that loss of RB1 function results in a 1.62 fold increase in 
the mortality rate for patients with OS, a significant increase in metastasis (OR 3.95), and 
a significant reduction in the histological response to chemotherapy (OR 0.35) (Ren & 
Gu, 2015), with suggestions that RB1 status could be used as an additional prognostic 




marker. However, at present it is unknown if RB1 status predicts response to 
chemotherapy or outcome in OS. 
 
1.1.4.3.1 DYRK1A 
One of the most profound candidate genetic dependencies associated with RB1 
deficiency was DYRK1A. The DYRK (dual-specificity tyrosine-regulated kinase) family 
represents a highly conserved subfamily of seven protein kinases (DYRK1A, DYRK1B, 
DYRK1C, DYRK2, DYRK3, DYRK4A, and DYRK4B), that auto-phosphorylate a 
conserved tyrosine residue in their own activation loop during translation, but 
phosphorylate their substrates at serine or threonine residues (Fernández-Martínez, 
Zahonero & Sánchez-Gómez, 2015; Himpel, Panzer, Eirmbter, et al., 2001). Members of 
this family have been identified as cell cycle regulators in a range of organisms (Becker, 
2012). The DYRK1A gene is the only member of the DYRK family to be located on 
chromosome 21 in the Down Syndrome critical region and is ubiquitously expressed in 
mammalian tissues (Guimera, Casas, Estivill, et al., 1999). Absence of DRYK1A in mice 
has been shown to be lethal at the embryonic stage, while heterozygous animals are 
viable but have a persistently reduced size (Fernández-Martínez, Zahonero & Sánchez-
Gómez, 2015). Over expression and reduced expression of DYRK1A lead to deregulation 
of neurogenesis and resultant neuro-developmental alterations in transgenic models in 
mice, chicken and Drosophila (Tejedor & Hämmerle, 2011). Furthermore, truncation of 
the protein leads to microcephaly in humans (Møller, Kübart, Hoeltzenbein, et al., 2008), 
while 1.5 fold overexpression in Trisomy 21, is thought to play a role in the altered brain 
development associated with the syndrome (Dowjat, Adayev, Kuchna, et al., 2007; 
Tejedor & Hämmerle, 2011). 
 
DYRK1A and DYRK1B have been described as paralogous genes (Aranda, Laguna & la 
Luna, 2011), however, differing functions have been reported. Litovchick et al. 
demonstrated in vitro phosphorylation of LIN52 DREAM MuvB Core Complex Component 
(LIN52) by DYRK1B, but could not replicate this observation in vivo (Litovchick, Florens, 
Swanson, et al., 2011). Phosphorylation of LIN52, appears to be one of the key roles of 
DYRK1A, controlling formation of the DREAM complex (Litovchick, Florens, Swanson, et 
al., 2011; Sadasivam & Decaprio, 2013).  
 




1.1.5 Murine models of osteosarcoma 
Preclinical models of disease are valuable to investigate biology. Tumour cell lines have 
pragmatic utility, but are limited by lack of three-dimensional structure, presence of 
tumour-associated osteoid, vascularisation and interaction with the immune response. To 
mitigate some of these challenges, mouse models can be employed. Previous murine 
models of osteosarcoma created by radiation or carcinogens have been limited by low 
disease penetrance of an unpredictable nature. Furthermore, the majority of 
osteosarcoma formation in humans is sporadic, meaning that comparison with these 
models is potentially less valuable. Germ-line homozygous deletion of RB1 is fatal 
(Jones, 2011), while mice germ-line heterozygous for RB1 develop neither OS nor 
retinoblastoma (Walkley, Qudsi, Sankaran, et al., 2008), despite being associated with a 
500-fold increased risk of formation of OS in humans (Clarke, Maandag, van Roon, et al., 
1992). Recent studies have demonstrated inactivation of the p53 pathway as the driving 
genetic alteration required to generate experimental OS, and that concurrent deletion of 
RB1 potentiates OS formation, although deletion of RB1 is insufficient to initiate tumour 
formation alone (Mutsaers, Ng, Baker, et al., 2013; Kansara & Thomas, 2007). Cre-lox 
homozygous silencing of germ-line RB1 created a mouse model with radiation 
susceptibility to osteosarcoma which is also seen in patients with germ-line RB1 
mutations (Gonzalez-Vasconcellos, Anastasov, Sanli-Bonazzi, et al., 2013). 
 
Mouse models of Li-Fraumeni syndrome (LFS) have been established by engineering 
structural or contact point mutations of TP53 common to patients with LFS, into 
endogenous TP53, which demonstrated dominant negative effects over the wildtype 
allele (Olive, Tuveson, Ruhe, et al., 2004). One of these models was shown to induce the 
formation of twice as many osteosarcomas, compared to a p53+/- model (Olive, Tuveson, 
Ruhe, et al., 2004). Tractable genetically defined murine models of OS based on the 
genetics of human disease have only recently been established, and are thought to be 
more representative of sporadic disease (Mutsaers, Ng, Baker, et al., 2013). Cre-Lox 
conditional silencing technology has been used to tissue restrict inactivation of RB1 and 
Tp53 in osteoblastic lineage in mice following Cre expression, which have a high 
penetrance of development of predominantly poorly differentiated/fibroblastic OS 
(Walkley, Qudsi, Sankaran, et al., 2008; Berman, Calo, Landman, et al., 2008). These 
models reproduce some of the key features of human osteosarcoma including 
comparable gene expression signatures, cytogenetic complexity, histology and 
metastiatic behaviour providing valueable insights into the disease (Walkley, Qudsi, 




Sankaran, et al., 2008). For example, these models have added further evidence that 
mutation of Rb alone is insufficient to act as an initiating event of OS formation, but 
instead likely acts as a potentiator (Walkley, Qudsi, Sankaran, et al., 2008). 
 
Mutsears et al. created a murine model that is highly representative of osteoblastic OS, 
by in vivo lineage restricted shRNA technology to deliver osteoblast specific silencing of 
Tp53 and concomitant Rb1 (Mutsaers, Ng, Baker, et al., 2013). These tumours frequently 
develop in the long bones, demonstrating a homogenous osteoblastic OS phenotype, and 
are highly metastatic to the lungs (Mutsaers, Ng, Baker, et al., 2013). Using comparative 
genomic techniques, these offer a new avenue for understanding the driving molecular 
events of OS.  
 
Orthotopic mouse models created by human xenograft transplantation into nude mice are 
limited to cells that grow in culture, with potential transformation from original tumour 
biology and thus potential loss of microenvironment (Mills, Matos, Charytonowicz, et al., 
2009). Murine models of colonising and non-colonising OS have been created by 
orthotopic intra-tibial injection of the human OS cell line HOS and its derivatives 143b 
(virally transformed using a K-Ras oncogene (Rhim, Park, Arnstein, et al., 1975)) and 
HOSMNNG (chemically transformed by N-methyl-N-nitro-N-nitrosoguanidine (Rhim, Park, 
Arnstein, et al., 1975)), which demonstrated that HOS was tumorigenic, but non-
colonising to secondary sites, while 143b and HOSMNNG were both tumorigenic and 
colonised the lungs (Luu, Kang, Park, et al., 2005; Mohseny, Machado, Cai, et al., 2011). 
Furthermore, LM7-J99 was developed by multiple in vitro selection of SAOS2 cells in 
nude mice with pulmonary metastases (Jia, Worth & Kleinerman, 1999). Since these 
parental lines and their derivates are genetically similar, for example HOS, 143b and 
HOSMNNG all possess an identical TP53 mutation, additional events must be needed for 
metastatic potential (Mohseny, Machado, Cai, et al., 2011). Of interest, no association 
with patient outcome or metastasis formation has been found with TP53 status (Wunder, 
Gokgoz, Parkes, et al., 2005) which suggests additional genetic events are required for 
metastatic spread other than loss/gain of function of TP53. These models provide 
feasible models for investigation of both progression and metastases in osteosarcoma.   
 
Patient derived xenograft (PDX) mouse models may help to conserve more of the 
molecular characteristics of the tumour sample, but still lack the interactions with tumour 
microenvironment (Goodspeed, Heiser, Gray, et al., 2016). As yet, this methodology is 




nascent in OS, and requires further investigation by comparison of molecular differences 
between OS PDX models and the parental tumour samples.  
 
1.2 RATIONALE FOR PhD / OVERALL RESEARCH APPROACH 
1.2.1 Synthetic lethality and oncogenic addiction 
The reliance of a tumour cell on an oncogene is termed oncogenic addiction (Weinstein & 
Joe, 2008). This concept is seen in chronic myeloid leukaemia, where the translocation of 
chromosome 9:22 causes constitutive activation of the BCR-ABL fusion gene (Konopka, 
Watanabe & Witte, 1984), which can be exploited by the use of inhibitors of Proto-
Oncogene 1 Non-Receptor Tyrosine Kinase (ABL), such as imatinib (Druker, Talpaz, 
Resta, et al., 2001).  
 
The concept of synthetic lethality, where loss of function of gene A or B does not alter the 
fitness of the cell, but the combination of loss of function of both A and B is lethal, is well 
established (Ashworth, Lord & Reis-Filho, 2011; Lord, Tutt & Ashworth, 2015). 
Furthermore, synthetic lethalities that are relatively unaffected by changes in additional 
genes are termed ‘hard’, whereas those that can be readily rescued by alterations in 
other genes are termed ‘soft’ (Ashworth, Lord & Reis-Filho, 2011). This concept of 
synthetic lethality has been exploited by the use of (Poly ADP-ribose) polymerase 
(PARP) inhibitors in tumour cells harbouring BRCA1 or BRCA2 mutations derived from a 
number of tumour types and is an example of a ‘hard’ synthetic lethality (Bryant, Schultz, 
Thomas, et al., 2005; Farmer, McCabe, Lord, et al., 2005). Subsequent clinical trials 
using PARP inhibitors have validated the concept in patients with durable antitumor 
activity being demonstrated in some BRCA mutation carriers (Fong, Boss, Yap, et al., 
2009; Tutt, Robson, Garber, et al., 2010). Genetic interactions involving RAS such as 
Tank Binding Kinase 1 (TBK1) and Serine/Threonine Kinase 33 (STK33)(Ashworth, Lord 
& Reis-Filho, 2011; Barbie, Tamayo, Boehm, et al., 2009), have been shown to be more 
susceptible to changes in genetic background, cell type and context, and are therefore 
examples of ‘soft’ synthetic lethalities. 
 
One approach to systematically identifying oncogene addiction and synthetic lethality 
effects has been to use high-throughput small interfering ribonucleic acid (siRNA) viability 
profiling. For example Brough et al. defined in detail the genetic dependencies for a set of 




pharmacologically tractable genes in a panel of 20 breast tumour cell line models, using a 
library of siRNA targeting the kinome (Brough, Frankum, Sims, et al., 2011). Each cell 
line was characterised by RNA interference (RNAi) targeting 720 genes. Cell viability was 
estimated five days later and this data was used to calculate a cell inhibitory Z score for 
each gene in each cell line. Each model was then classified according to mutations in 
well-established driver genes, for example the identification of two cohorts 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) mutant 
and PIK3CA wildtype. Using the RNAi data they were able to identify siRNA that 
selectively targeted cell lines with PIK3CA mutations but not wildtype, by the use of 
statistical methods such as the median difference permutation test and Student’s t test. 
By combining the RNAi analysis with gene expression, gene mutation and genomic 
analysis, they were able to reaffirm the impact of Peptidase Inhibitor 3 (PI3) kinase and 
Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) signalling in breast cancer, but also to 
identify essential determinants of specific breast cancer subtypes, which are potential 
novel therapeutic targets (Brough, Frankum, Sims, et al., 2011). This approach has been 
used to comprehensively detail genetic dependencies for a number of other tissue types 
in the Lord / Ashworth laboratory, including cancer cell lines derived from the pancreas, 
ovary, brain and gastrointestinal tract. This methodology was utilised as a framework for 
identifying genetic dependencies in osteosarcoma (Figure 2). 
 
The Lord / Ashworth group have now screened a total of 99 cell lines derived from 10 
tissue types, which provides a valuable resource for comparison with data generated 
from screening the osteosarcoma cell lines. A number of candidate targets generated 
from these screens have been published (Brough, Frankum, Sims, et al., 2011; 
Campbell, Ryan, Brough, et al., 2016). Optimisation and screening methods are well 
established. One of the most challenging aspects of such screens is validation of results 
due to the expected high level of false positive results seen with any high-throughput 
screening methodology. Methods used by the group to improve validation include 
deconvolution using siRNA, targeted chemical inhibition where possible, and genome 
editing by use of clustered regularly interspaced short palindromic repeats (CRISPR) 
methodology (Mali, Yang, Esvelt, et al., 2013).  
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Figure 1 Schematic of synthetic lethality. 
The cellular inhibition or dysfunction of either gene A or gene B is compensated by the action of 
the remaining gene. However, cellular inhibition or dysfunction of both genes A and B results in 
synthetic lethality and cellular death.  
 
 








Figure 2: Summary of methodology.  
A panel of 18 osteosarcoma tumour cell lines was used to investigate genetic vulnerabilities and 
drug dependencies for a set of pharmacologically tractable genes. Molecular characterisation of 
the tumour cell lines was performed by exome sequencing, transcriptome profiling, protein 
expression by western blotting, and protein abundance by mass spectrometry to enable 
identification of genetic vulnerabilities and drug dependencies associated with recurrent driver 
alterations. This data set was integrated with RNAi and drug screens. The Wellcome Trust Sanger 
Institute and the Tumour Profiling Unit at the ICR performed exome sequencing of the tumour cell 
lines, while copy number profiling and transcriptome data was obtained from the publically 
available Catalogue of somatic mutations in cancer (COSMIC 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) and Cancer Cell Line Encyclopaedia 
(CCLE www.broadinstitute.org/ccle) data bases. Adapted from Brough et al. (Brough, Frankum, 
Sims, et al., 2011). 
 
 




1.2.2 RNA interference 
Tumour cells commonly exhibit between 103 and 105 genetic changes when compared to 
germline DNA, but theoretical estimates have suggested that it is likely fewer than 10 are 
critical ‘drivers’ of tumour formation and its survival (Schlabach, Luo, Solimini, et al., 
2008), with the remaining ‘passenger’ mutations conferring no selective growth 
advantage (Vogelstein, Papadopoulos, Velculescu, et al., 2013). RNAi enables post-
transcriptional gene silencing and has been performed using either small interfering RNA 
(siRNA) or small hairpin RNA (shRNA) (Willingham, Deveraux, Hampton, et al., 2004; 
Lord, Martin & Ashworth, 2009; Brough, Frankum, Sims, et al., 2011; Iorns, Lord, Turner, 
et al., 2007) to identify novel genes involved in biological processes. The ability to 
modulate expression artificially of a single target gene enables dissection of the biological 
processes of the cell and identification of synthetic lethal relationships (Iorns, Lord, 
Turner, et al., 2007). Identification of genetic dependencies, also termed ‘addiction’, by 
this method, distinguishes these critical driver mutations from passenger mutations. RNAi 
screening has already enabled the identification of genetic dependencies in cancer cells 
derived from a range of tissue types (Brough, Frankum, Sims, et al., 2011; Schlabach, 
Luo, Solimini, et al., 2008; Iorns, Lord, Grigoriadis, et al., 2009; Arora, Gonzales, 
Hagelstrom, et al., 2010). Both methodologies have advantages and disadvantages 
which are summarised by Lord et al. (Lord, Martin & Ashworth, 2009). One of the major 
limitations of using siRNA, is off-target effects caused by degradation of siRNAs that have 
only partial complementarity by acting as microRNAs (miRNAs) (Doench, Petersen & 
Sharp, 2003), reinforcing the need for robust validation.   
 
At present, RNAi has only been applied to a limited number of models of osteosarcoma. 
Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APE1) silencing by siRNA was shown to 
enhance the sensitivity of osteosarcoma to DNA damaging agents in a single cell line 
(HOS) (Wang, Luo & Kelley, 2004). Polo Like Kinase 1 (PLK1) was initially identified as a 
potential therapeutic target in a function genomic screen (Yamaguchi, Honda, Satow, et 
al., 2009; Duan, Ji, Weinstein, et al., 2010), but has since been shown to be ubiquitously 
fatal amongst many tumour types and is now commonly used as a positive control for 
RNAi silencing (Brough, Frankum, Sims, et al., 2011). An siRNA screen of the kinome in 
a single cell line (KHOS) demonstrated Cyclin Dependent Kinase 11 (CDK11) has a role 
in cell survival, validated by immunohistochemistry of 57 tumour samples and xenograft 
mouse model (Duan, Zhang, Choy, et al., 2012). In two cell lines (KHOS and U2OS), Rho 




Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) (Liu, Choy, Hornicek, et al., 
2011) and GLI Family Zinc Finger 2 (GLI-2) were demonstrated as having a role in cell 
survival by shRNA silencing. This was validated again by immunohistochemistry 
(approximately 50 tumour samples). siRNA silencing in MG63, HOSMNNG and SAOS2 
demonstrated that Y-Box Binding Protein 1 (YBX-1) has a role in proliferation, which was 
validated by immunohistochemistry of 40 tumour samples (Fujiwara-Okada, Matsumoto, 
Fukushi, et al., 2013). In the mouse (cell line K7M2), Erbb3 has been shown to play a role 
in survival and migration by shRNA screening (Jullien, Dieudonné, Habel, et al., 2013). 
These RNAi screens have been limited by inclusion of only a small number of cell lines 
and mouse models, with limited clinical correlation and small number of genes.  
 
RNA interference (RNAi) screening technology enables dissection of biological processes 
and disease-related phenotypes by silencing specific genes, resulting in the selective 
death of cells that are ‘addicted’ to these genes (Iorns, Lord, Turner, et al., 2007). 
Deregulation of genes that result in this ‘addiction’ are tractable drug targets; kinases 
appear particularly important in cancer survival, demonstrated by successful development 
of therapeutics against deregulated epidermal growth factor receptor, B-Raf Proto-
Oncogene Serine/Threonine Kinase (BRAF) and others (Zhang, Yang & Gray, 2009). To 
date, there are no published studies that have undertaken a comprehensive genetic 
screening approach to generate a framework of genetic dependency profiles of this 
disease (Duan, Ji, Weinstein, et al., 2010; Yamaguchi, Honda, Satow, et al., 2009; 
Zhang, Yang & Gray, 2009).  
 
1.3 SUMMARY  
Osteosarcoma represents a malignancy with significant unmet clinical need. Despite 
increased understanding of the molecular landscape of OS, this has not yet translated 
into any specific therapies. Although tumour cell models of OS exist, to date a systematic 
analysis of genetic dependencies in these models has not been performed. Identification 
of such dependencies may in turn identify novel targets in OS.  
 
Recent analyses of clinical samples have determined the mutation spectrum of 
osteosarcoma to exhibit a significant amount of inter-tumoural heterogeneity (Alexandrov, 
Nik-Zainal, Wedge, et al., 2013; Chen, Bahrami, Pappo, et al., 2014; Behjati, Tarpey, 
Haase, et al., 2017), however, mutation of TP53, RB1 and CDKN2A are recurrent. This 




raises the possibility that targeting RB1 deficiency might be one approach to developing 
novel therapies for OS, forming the basis of this thesis.  
 
1.4 AIMS  
The aim of this project was to identify potential novel therapeutic targets in OS that could 
be translated into clinical use, by the following objectives: (i) identification of genetic 
dependencies specific to OS via genetic perturbation screens in OS tumour cell lines, (ii) 
identification of genetic dependencies specific to recurrent known mutations in OS such 
as RB1, (iii) identification of potential novel therapeutic drug targets in OS, (iv) validation 
of potential genetic dependencies and drug targets. 
 
To systematically identify genetic dependencies in OS, a disease that is known to be 
genetically heterogeneous, as large a panel as possible of well-characterised OS cell 
lines was compiled, totalling 18 different lines to reflect the genetic and histopathological 
diversity (five osteoblastic; five fibroblastic; two chondroblastic; one 
osteoblastic/telangectatic; three epithelial; one mixed and two unknown). These cell lines 
exhibit the recurrent tumour suppressor gene mutations seen in OS, described in Chapter 
3, and have been demonstrated to be representative of the clinical disease, thus 
providing useful clinically relevant models for investigation of genetic dependency 
analysis.  
 
With the aim of identification of genetic and drug dependencies specific to RB1 
dependency, in the absence of an available isogenic model of RB1 deficiency in OS, two 
stable isogenic models were generated using CRISPR-Cas9 methodology. The 
generation and characterisation of these models is described in Chapter 4, together with 
discussion of the advantages and disadvantages of use of both an isogenic model and a 
diverse panel of tumour cell lines. 
 
To characterise the genetic and drug dependencies of osteosarcoma, a relatively 
unbiased approach was undertaken using parallel high-throughput RNAi and chemical 
screening. Comparison of data generated from screening the OS tumour cell lines was 
possible with a diverse panel of 99 non-osteosarcoma tumour cell lines, which provided 
context for both scale of effects observed and OS specific dependencies. Chapter 5 
describes the use of siRNA screens using a library that targeted the kinome, tumour 




suppressor genes and the Cancer Gene Cenus thought to be the most tractable targets 
within the genome. Identification of genes which cause significant loss of viability in some 
tumour cell lines, but not all were identified as thought more likely to identify genes 
representing tumour-specific dependencies and potential candidate therapeutic targets.  
 
Identification of genetic dependencies associated with specific driver mutations, in 
particular associated with deficiency of RB1, known to be recurrent in up to 30% of OS 
tumours (Araki, Uchida, Kimura, et al., 1991) were deemed worthy of investigation. 
Identification of genetic dependencies associated with RB1 deficiency in OS using both 
the panel of 18 OS tumour cell lines and isogenic models are described in Chapter 6. An 
association between RB1 deficiency and a genetic dependency with DYRK1A was 
identified, and experiments are described with the aim of investigation of the mechanism 
of this dependency. 
 
In the absence of stratification of drugs for the treatment of OS at present, a focused 
high-throughput cell based drug screen using both the OS tumour cell line panel and RB1 
deficient isogenic models with the aim of identification of potential novel therapeutic 
targets was performed and observations described in Chapter 7. Given the recent interest 
in the potential BRCAness of OS, investigation of the relative sensitivity of the OS tumour 
cell line panel in comparison to BRCA1/2 deficient models, known to exhibit sensitivity to 
PARP inhibitors in the clinic was performed to determine any potential therapeutic 
potential in OS.  
 
This thesis describes (i) characterisation of osteosarcoma cell line models, (ii) screening 
with high-throughput cell based RNAi libraries to characterise the candidate genetic 
dependencies of OS, (iii) more specifically RB1 synthetic lethalities, (iv) high-throughput 
cell based drug screens to identify potential therapeutics for OS, and (v) PARP inhibitor 
sensitivity in OS and identification of an isogenic model for ‘BRCAness’ of osteosarcoma. 
A flow chart describes the data presented in each Chapter (Figure 3). 





Description and classification of OS tumour cell line panel 
Generation of isogenic RB1 deficient OS tumour cell line 
models in U2OS 
siRNA profiling of OS tumour cell lines and comparison with 99 
non-OS tumour cell lines derived from nine tissue types 
 
Identification of OS specific dependency on ‘skeletal system 
morphogenesis’  
Validation of siRNA screen results.  
Identification of synthetic lethal relationship between RB1 
deficiency and DYRK1A 
Drug sensitivity profiling of OS tumour cell lines 
 FGFR1 amplification and polysomy are associated with 
sensitivity to FGFR1 inhibition 
 
PARP inhibitor sensitivity in OS  
Chapter 3: Characterisation of tumour cell 
lines  
Chapter 4: Characterisation of RB1 
deficient U2OS tumour cell lines engineered 
by CRISPR-Cas9 mutagenesis 
Chapter 5: Identifying genetic dependencies 
in osteosarcoma 
Chapter 6: identification of genetic 
dependencies associated with driver 
mutations in osteosarcoma 
Chapter 7: Identifying drug dependencies 
using a focused high-throughput cell based 
drug screen 
 
Figure 3 Summary of data presented in this thesis. 
Schematic illustration of the work presented in each chapter of this thesis, including 








2 Materials and Methods  
2.1 REAGENTS 
2.1.1 General chemicals and solutions 
All chemicals were purchased from Sigma unless otherwise stated. 
PBS: 137nM NaCl, 2mM KCL, 8mM Na2HPO, 1.5mM KH2PO4 in H2O. pH adjusted to 7.4 
with HCL. 
NP250 lysis buffer: 10ml Tris pH 7.6 (1M), 1000µl EDTA (0.5M), 2500µl NP450 (5M), 
500mls H2O, 25mls NaCl (5M) 
Lysis buffer for proteomic abundance via mass spectroscopy: 1% SDS, Tris 7.5 
(20mM) and NaCl (150mM) with protease inhibitors. 
EDTA 0.5M:  di-sodium salt of ethylenediaminetetraacetate in H2O. pH adjusted to 8.0 
with NaOH. 
MOPS: 3-(N-morpholino)propanesulfonic acid (Invitrogen) 
Transfer buffer: 14.4g glycine, 3.03g Tris, 200ml methanol made up to 1 litre with H2O. 
10x TBS-T: 200ml 1M Tris pH 7.5, 300ml 5M NaCl, 10ml Tween in 1L of H2O. 
Tris: tris(hydroxymethyl)aminomethane (Invitrogen)  
TCA: 10% trichloroacetic acid in H2O. 
IFF (Immunofluorescence buffer): PBS, 1% bovine serum albumin (Sigma, UK) and 
2% foetal calf serum (Life Technologies, UK), filtered through a 0.2µM filter) 
PFAL 4% (w/v) paraformaldehyde in PBS 
10x TAE: 48.4g Trizma base, 20ml of EDTA pH 8.0 (0.5M), and 11.44ml glacial acetic 
acid, to a final volume of 1000ml with deionised H2O. 
 
2.1.2 Drugs  
All cell lines were profiled using a customised in-house drug library containing 80 drugs, 
which have either been licenced for clinical use in cancer or are in early phase clinical 
trials and are listed by their primary target (Table 2). All drugs were purchased from 
Sigma, except those listed below, dissolved in 100% DMSO and stored at -20˙C unless 
















Blasticidin: dissolved in deionised H2O (Invitrogen) 
 
Each drug was dissolved to give 5mM and 2.5mM stock solutions and then diluted to 500, 
250, 50, 25, 5, 2.5, 0.5, 0.25uM stocks in 96-well 2D-matrix plates. 384-well daughter 
plates were then aliquoted from the master plates using the Hamilton Microlab Star 
robotic liquid handler platform. Drugs were stored under a nitrogen atmosphere using a 
StoragePod (Roylan Developments).  Final plate concentrations were 0.5, 1, 5, 10, 50, 
100, 500 and 1000nM and final concentration of DMSO in all wells was 0.2% (v/v). 
Controls for viability included 0.2% (v/v) DMSO and controls for cell death included 100 % 
DMSO.  
 
An additional library consisting of 395 drugs, which have either been licenced for clinical 
use in cancer or are in early phase clinical trials prepared in the same manner, was also 
used to screen only the isogenic RB1 deficient U2OS models created by CRSIPR-Cas9 
mutagenesis (Table 3). Final plate concentrations were 0.5, 5, 50, and 500nM with 
controls as above. 
 
2.1.3 Antibodies 
Primary antibodies are listed in Table 4, and all were incubated overnight at 4°C. HRP-
conjugated secondary antibodies were purchased from Sigma and diluted 1:10,000. For 
images obtained using the Odyssey Infrared Imaging System from LI-COR, LI-COR 
fluorescent dye labelled secondary antibodies at 800CW or 650CW were purchased from 
Odyssey and diluted 1:10,000. 
 




Table 2 Drug library 
Compound Mechanism of action Compound Mechanism of action 
MK-2206 AKT inhibitor 17-AAG HSP 90 inhibitor 
Carboplatin Alkylating agent PF-04929113 HSP 90 inhibitor 
Doxorubicin Anthracyline Decitabine Hypomethylating agent 
5-fluorouracil  Anti-metabolite Linsitinib (OSI-906) IGF1R, IR inhibitor 
Gemcitabine Anti-metabolite GSK1904529A IGF1R, IR inhibitor 
methotrexate Anti-metabolite BMS-911543 JAK2 inhibitor 
Vinorelbine Anti-mitotic Lestaurtinib 
JAK2, FLT3 and TrkA 
receptor tyrosine kinase 
inhibitor 
Bleomycinsulfate Anti-tumour antibiotic Nutlin-3 MDM2 inhibitor 
KU60019 ATM inhibitor PD-184352 MEK inhibitor 
PF-03814735 Aurora kinase inhibitor PF-02341066 MET/ALK inhibitor 
Temozolomide Alkylating agent Paclitaxel microtubule poison 
ABT-737 Bcl-2 inhibitor Everolimus mTOR inhibitor 
Dasatinib Bcr-Abl, Src inhibitor BEZ-235 mTOR/PI3K inhibitor 
Nilotinib 
Bcr-Abl, c-Kit, PDGR 
inhibitor MLN-4924 NEDDylation inhibitor 
Crizotonib c_MET, ALK inhibitor Sapacitabine Nucleoside analogue 
Foretinib c-MET inhibitor PF-03758309 PAK inhibitor 
Flavopiridol CDK inhibitor Canertinib pan-ErbB inhibitor 
RO-3306 CDK1 inhibitor PF-00299804 pan-ErbB inhibitor 
Palbociclib CDK4/6 inhibitor AG-14699 PARP inhibitor 
PF-332991 CDK4/6 inhibitor BMN-673 PARP inhibitor 
PF-00477736 CHEK1 inhibitor Olaparib PARP inhibitor 
SAR-20106 CHEK1 inhibitor Imatinib PDGFR inhibitor 
Cabozantinib 
VEGF2, c-MET, RET, 
KIT, FLT1/3/4, TEK, AXL 
inhibitor Sunitinib PDGFR inhibitor 
Celecoxib COX2 inhibitor PF-04691502 PI3K inhibitor 
MDV-3100 CRCP inhibitor Sotrastaurin/AEB071 PKC inhibitor 
Abiraterone CYP17A1 inhibitor BI2536 PLK1 inhibitor 
KU0057788 DNA-PK inhibitor PLX-4720 RAF inhibitor 
MSC2358705A DNA-PK inhibitor Sorafenib Raf inhibitor 
Tamoxifen EF inhibitor Resveratrol SIRT1 activator 
Erlotinib EGFR inhibitor YM155 Survivin- suppressant 
Gefitinib EGFR inhibitor 6-thioguanine Thiopurine 
BIBW2992 EGFR/HER2 inhibitor DMX_1783 TNKS inhibitor 
GSK2194069A FAS inhibitor DMX_2320 TNKS inhibitor 
AZ4547 FGFR inhibitor XAV-939 TNKS/Wnt signalling inhibitor 
PD173074 FGFR inhibitor Camptothecin  Topoisomerase inhibitor 
MK-0752 
Gamma secretase 
inhibitor Etoposide Topoisomerase inhibitor 
voronostat HDAC inhibitor Salinomycin Unknown 
GDC-0449 
hedgehog/smoothened 
signalling inhibitor Lenvatinib VEGFR1/2/3 inhibitor 
lapatinib HER2 inhibitor MK-1175 Wee1 inhibitor 
2-Methoxyestradiol HIF inhibitor 
 	
 




Table 3 Additional drug library 
Drug Mechanism of action Drug Mechanism of action 
Zileuton 5-lipooxygenase AT-406 IAP inhibitor 
Pentostatin 
Adenosine Deaminase 
Inhibitor GSK1904529A IGR1, IR inhibitor 
GDC-0068 AKT inhibitor Linsitinib (OSI-906) IGFR1, IR inhibitor 
GSK690693 AKT inhibitor BAY11-7082 IKK inhibitor 
MK-2206 AKT inhibitor Dexamethasone IL receptor inhibitor / steroid 
Perifosine AKT inhibitor Mycophenolic 
inhibitor of inosine 
monphosphate 
dehydrogenase 
Triciribine AKT inhibitor TPCA-1 IκB/IKK inhibitor 
EBPC aldose reductase CEP33779 JAK inhibitor 
LDN193189 ALK inhibitor Cyt387 JAK inhibitor 
TAE684 ALK inhibitor NVP-BSK805 JAK inhibitor 
Bendamustine Alkylating agent Ruxolitinib JAK inhibitor 
Carboplatin Alkylating agent S-Ruxolitinib JAK inhibitor 
Cisplatin Alkylating agent Tofacitinib JAK inhibitor 
Dacarbazine Alkylating agent TG101348 JAK2 inhibitor 
Doxercalciferol Alkylating agent BI78D3 JNK inhibitor 
Ifosfamide Alkylating agent S7333KRAS K-RAS G12C inhibitor 
Oxaliplatin Alkylating agent Ispinesib kinesin spindle inhibitor 
Procarbazine Alkylating agent SB 743921 kinesin spindle inhibitor 
Clafen Alkylating agent GW3965 liver x receptor inhibitor 
Altretamine Alkylating agent Nutlin-3 MDM2 inhibitor 
Cyclophosphamide Alkylating agent SJ172550 MDMX inhibitor 
Lomustine Alkylating agent AZD6244 MEK inhibitor 
Tosedostat aminopeptidase CI-1040 MEK inhibitor 
A-769662 AMPK inhibitor GSK1120212 MEK inhibitor 
Andarine androgen receptor inhibitor PD0325901 MEK inhibitor 
Bicalutamide androgen receptor inhibitor TAK-733 MEK inhibitor 
Flutamide androgen receptor inhibitor BMS794833 MET/VEGFR2 inhibitor 
Ostarine androgen receptor inhibitor Lomeguatrib MGMT inhibitor 
Doxorubicin Anthracyline EpothiloneA microtubule inhibitor 
Epirubicin Anthracyline EpothiloneB microtubule inhibitor 
MDV3100 anti-androgen NPI-2358 microtubule inhibitor 
Pomalidomide anti-angiogenesis Vinblastine microtubule inhibitor 
Itraconazole 
anti-angiogenic and Hh 
signalling inhibitor Nocodazole microtubule poison 
Phloretin 
anti-inflammatory and 
immuno-suppressive Paclitaxel microtubule poison 
Capecitabine Anti-metabolite Lonidamine 
mitochondrial hexokinase 
inhibitor 
Cladribine Anti-metabolite Vincristine mitotic inhibitor 
Clofarabine Anti-metabolite Marimastat MMP inhibitor 




Floxuridine Anti-metabolite AZ3146 MSP1 inhibitor 
Ftorafur Anti-metabolite Rapamycin mTOR inhibitor 
Gemcitabine Anti-metabolite AZD8055 mTOR inhibitor 
Pemetrexed Anti-metabolite Deforolimus mTOR inhibitor 
Azathioprine Anti-metabolite Everolimus mTOR inhibitor 
ABT-751 anti-mitotic INK 128  mTOR inhibitor 
Docetaxel anti-mitotic KU-0063794 mTOR inhibitor 
Bleomycin Anti-tumour antibiotic Temsirolimus mTOR inhibitor 
(-)-
Epigallocatechin Antioxidant Torin2 mTOR inhibitor 
TAME APC inhibitor WYE-354 mTOR inhibitor 
Aminoglutethimide Aromatase BEZ235 mTOR/PI3K inhibitor 
Anastrozole Aromatase APO866 NAMPT inhibitor 
Exemestane Aromatase FK866 NAMPT inhibitor 
Formestane Aromatase Bay117085 NF-κB inhibitor 
Letrozole Aromatase QNZ NF-κB inhibitor 
CP-466722 ATM inhibitor L-NNA NOS inhibitor 
KU-55933 ATM inhibitor Isotretinoin nucelar RAR activator 
KU-60019 ATM/ATR inhibitor Toremifene oestrogen inhibitor 
NU6027 ATR inhibitor Evista oestrogen inhibitor 
VE-821 ATR inhibitor DFMO 
ornithine decarboxylase 
inhibitor 
Vx-970 ATR inhibitor PH-797804 p38 MAPK inhibitor 
AMG 900 Aurora kinase inhibitor SB 203580 p38 MAPK inhibitor 
AT9283 Aurora kinase inhibitor BIRB796 p38 MAPK inhibitor 
Barasertib Aurora kinase inhibitor LY2228820 p38 MAPK inhibitor 
CYC116 Aurora kinase inhibitor PF03758309PAKi PAK inhibitor 
Danusertib Aurora kinase inhibitor BMS-599626 pan HER inhibitor 
JNJ-7706621 Aurora kinase inhibitor ABT-888 PARP inhibitor 
MLN8237 Aurora kinase inhibitor AG14361 PARP inhibitor 
PF-03814735 Aurora kinase inhibitor BMN673 PARP inhibitor 
SNS-314Mesylate Aurora kinase inhibitor Iniparib PARP inhibitor 
VX-680 Aurora kinase inhibitor Olaparib PARP inhibitor 
Temozolomide Alkylating agent Rucaparib PARP inhibitor 
Vemurafenib B-Raf inhibitor UPF1035 PARP inhibitor 
ABT-263 Bcl-2 inhibitor AnagrelideHCl PDE inhibitor 
ABT-737 Bcl-2 inhibitor Imatinib ABL, KIT, PDGFR inhibitor 
Obatoclax Bcl-2 inhibitor Sunitinib 
PDGFR, VEGFR, KIT, RET, 
CSF-1R, Flt3 inhibitor 
TW-37 Bcl-2 inhibitor 3-Methyladenine PI3K inhibitor 
Bafetinib Bcr-Abl inhibitor AS-605240 PI3K inhibitor 
Dasatinib Bcr-Abl, Src inhibitor BKM120 PI3K inhibitor 
DCC-2036 Bcr-Abl inhibitor CAL-101 PI3K inhibitor 





Bcr-Abl, c-Kit, PDGR 
inhibitor CH5132799 PI3K inhibitor 
Ponatinib 
Bcr-Abl, VEGF, FGFR, 
TIE2, Flt3 inhibitor GDC-0941 PI3K inhibitor 
WP1130 
Bcr-Abl, Deubiquitinase 
inhibitor GSK2126458 PI3K inhibitor 
Ibrutinib Btk inhibitor IC-87114 PI3K inhibitor 
Amuvatinib c_KIT inhibitor LY294002 PI3K inhibitor 
Masitinib c_KIT inhibitor PF-04691502 PI3K inhibitor 
OSI-930 c_KIT inhibitor PI-103 PI3K inhibitor 
SU11274 c_MET inhibitor PIK-75 PI3K inhibitor 
BMS 777607 c_MET inhibitor PIK-90 PI3K inhibitor 
Crizotinib c_MET, ALK inhibitor XL147 PI3K inhibitor 
JNJ-26481585 c_MET inhibitor YM201636 PI3K inhibitor 
JNJ-38877605 c_MET inhibitor ZSTK474 PI3K inhibitor 
PF-04217903 c_MET inhibitor PIK-93 PI4K inhibitor 
PHA-665752 c_MET inhibitor SGI-1776 PIM inhibitor 
SGX-523 c_MET inhibitor TCSPIM PIM-1/-2 Kinase inhibitor 
TTP22 caesin kinase 2 inhibitor PIM-1Inhibitor PIM1 inhibitor 
CX-4945 caesin kinase 2 inhibitor Chelerythrine PKC inhibitor 
CyclosporinA Calcineurin Inhibitor Enzastaurin PKC inhibitor 
Calpeptin calpain inhibitor Sotrastaurin PKC inhibitor 
PAC-1 caspase inhibitor BI2536 PLK1 inhibitor 
LY320135 CB1 receptor inhibitor GSK461364 PLK1 inhibitor 
Maraviroc CCR inhibitor BI6727 PLK1 inhibitor 
NSC663284 Cdc25 inhibitor Rigosertib PLK1 inhibitor 
ML-141 Cdc42 inhibitor Rosiglitazone PPAR inhibitor 
AT7519 CDK inhibitor GSK3787 PPARδ inhibitor 
Flavopiridol CDK inhibitor Mifepristone progesterone inhibitor 
PHA-793887 CDK inhibitor Bortezomib proteasome inhibitor 
Roscovitine CDK inhibitor MLN2238 proteasome inhibitor 
SNS-032 CDK2,7,9 inhibitor MLN9708 proteasome inhibitor 
Palbociclib CDK4/6 inhibitor Disulfiram PTEN inhibitor 
Dalcetrapib CETP inhibitor Mercaptopurine purine nucleoside analogue 
AZD7762 CHK1 inhibitor Nelarabine purine nucleoside analogue 
PF477736 CHK1 inhibitor Carmofur pyrimidine analogue 
LY2603618 CHK2 inhibitor NSC23766 Rac1 inhibitor 
BML-277 CHK2 inhibitor AZ628 Raf inhibitor 
Ezetimibe 
cholesterol absorption 
inhibitor GDC-0879 Raf inhibitor 
PF670462 CK1ε inhibitor SB590885 Raf inhibitor 
Celecoxib COX-2 inhibitor Sorafenib Raf inhibitor 
SB265610 CXCR2 inhibitor CD437 retinoid 
Abiraterone CYP17A1 inhibitor Fenretinide retinoid 




Mycophenolate dehydrogenase inhibitor Hydroxyurea 
ribonucleotide reductase 
inhibitor 
Abitrexate DHFR inhibitor Necrostatin-1 RIPK1 inhibitor 
Azacitidine 
DNA methyl transferase 
inhibitor Triptolide RNA poly II inhibitor 
RG108 
DNA methyltransferase 
inhibitor Y-27632 ROCK inhibitor 
NU7441 DNA-PK inhibitor Pazopanib RTK inhibitor 
Vx-984 DNA-pk inhibitor Fingolimod S1P receptor inhibitor 
Adrucil 
DNA/RNA Synthesis 
inhibitor PF-4708671 S6 kinase inhibitor 
DMXAA DT-diaphorase inhibitor Ranolazine 
selective inhibition of late 
sodium currents  
Harmine DYRK1A inhibitor SID7969543 SF-1 inhibitor 
SMER3 
E3 Ubiquitin Ligase (SCF) 
Inhibitor inhibitor GSK650394 SGK inhibitor 
Tamoxifen EF inhibitor Canagliflozin SGLT inhibitor 
Afatinib EGFR inhibitor Dapagliflozin SGLT inhibitor 
Chrysophanicacid EGFR inhibitor PB28 Sigma 2 receptor inhibitor 
CUDC-101 EGFR inhibitor SRT1720 SIRT1 activator 
Dacomitinib EGFR inhibitor EX527 SIRT1 inhibitor 
Erlotinib EGFR inhibitor Quercetin Sirtuin inhibitor 
Gefitinib EGFR inhibitor Sirtinol Sirtuin inhibitor 
OSI-420 EGFR inhibitor SANT1 smoothened inhibitor 
PD153035 EGFR inhibitor SK1 
Sphingosine Kinase-1 
Inhibitor 
Pelitinib EGFR inhibitor SKI_ll 
Sphingosine Kinase-1 
Inhibitor 
WZ4002 EGFR inhibitor Bosutinib Src inhibitor 
GSK264220A endothelial lipase inhibitor KX2-391 src inhibitor 
Zibotentan endothelin receptor inhibitor Saracatinib Src inhibitor 
FR180204 ERK1/2 inhibitor SrcI1 Src inhibitor 
Fulvestrant Estrogen receptor inhibitor Fludarabine STAT inhibitor 
PF-3845 FAAH inhibitor Fludarabine STAT inhibitor 
PF 573228 FAK inhibitor STAT5Inhibitor STAT5 inhibitor 
PF-562271 FAK inhibitor Hydrocortisone steroid 
GSK837149A FAS inhibitor YM155 Survivin inhibitor 
PD173074 FGFR inhibitor R406 Syk inhibitor 
Quizartinib FLT3 inhibitor R935788 Syk inhibitor 
Crenolanib FLT3 inhibitor Estrone synthetic oestrogen 
Dovitinib FLT3 inhibitor Estradiol Synthetic oestrogen  
ENMD-2076 FLT3 inhibitor Medroxyprogesterone synthetic progesterone 
Tandutinib FLT3 inhibitor Megestrol synthetic progesterone 
GW4064 FXR inhibitor BX795 TBK1/IKKepsilon  inhibitor 
WAY-362450 FXR inhibitor BIBR1532 Telomerase inhibitor 




DAPT Gamma secretase inhibitor LY2109761 TGF beta receptor inhibitor 
YO-01027 Gamma secretase inhibitor SB42 TGF beta/ smad inhibitor 
MK-0752 Gamma secretase inhibitor LY2157299 TGF beta/Smad inhibitor 
SecinH3 
GDP/GTP Exchange Factor 
inhibitor SB525334 TGF beta/Smad inhibitor 
Pioglitazone glitazones Raltitrexed 
thymidylate synthase 
inhibitor 
Gossypol glycolytic inhibitor Tie2 Tie-2 inhibitor 
GW9508 GPR40 inhibitor MG149 
TIP60 Histone 
Acetyltransferase inhibitor 
AR-A014418 GSK-3 inhibitor Lenalidomide TNF- alpha inhibitor 
CHIR-99021 GSK-3 inhibitor 2131TNKSi TNKS inhibitor 
SB 216763 GSK-3 inhibitor 877TNKSi TNKS inhibitor 
4-Phenylbutyrate HDAC inhibitor C43TNKSi TNKS inhibitor 
AR-42 HDAC inhibitor DMX_051_1783 TNKS inhibitor 
Belinostat HDAC inhibitor DMX_051_2384 TNKS inhibitor 
Entinostat HDAC inhibitor JW55 TNKS inhibitor 
Mocetinostat HDAC inhibitor camptothecin Topoisomerase I inhibitor 
Panobinostat HDAC inhibitor Irinotecan Topoisomerase I inhibitor 
PCI-24781 HDAC inhibitor Topotecan Topoisomerase I inhibitor 
Pyroxamide HDAC inhibitor Daunorubicin Topoisomerase inhibitor 
SB939 HDAC inhibitor Etoposide Topoisomerase inhibitor 
Trichostatin HDAC inhibitor Idarubicin Topoisomerase inhibitor 
Valproic HDAC inhibitor Irinotecan Topoisomerase inhibitor 
Vorinostat HDAC inhibitor MitoxantroneHCl Topoisomerase inhibitor 
JNJ 26854165  HDM2 inhibitor Palomid529 TORC1/2 inhibitor 
Cyclopamine 
Hedgehog signalling 
inhibitor Tipifarnib transferase inhibitor 
JK184 
Hedgehog signalling 
inhibitor ITX3 TrioN RhoGEF inhibitor 
LDE225 
hedgehog/smoothened 











Lapatinib HER2 inhibitor Cediranib VEGFR inhibitor 
2-Methoxyestradiol HIF inhibitor E7080 VEGFR inhibitor 
SKF91488 
histamine N-
methyltransferase inhibitor Linifanib VEGFR inhibitor 
Fluvastatin 
HMGCoA reductase 
inhibitor Motesanib VEGFR inhibitor 
BIX01294 HMTase inhibitor Tivozanib VEGFR inhibitor 
Elesclomol HSP 90 inhibitor Vandetanib VEGFR inhibitor 
17-AAG HSP 90 inhibitor Vatalanib VEGFR inhibitor 
17-DMAG HSP 90 inhibitor Brivanib VEGFR,FGFR inhibitor 
AUY922 HSP 90 inhibitor Regorafenib VEGFR2-TIE2 inhibitor 




BIIB021 HSP 90 inhibitor Telatinib 
VEGGFR2/3,C-KIT,PDGFR 
inhibitor 
CCT18159 HSP 90 inhibitor MK-1775 Wee1 inhibitor 
Ganetespib HSP 90 inhibitor MK1775 Wee1 inhibitor 
Geldanamycin HSP 90 inhibitor PD407824 Wee1/Chk1 inhibitor 
Decitabine Hypomethylating agent Febuxostat Xanthine oxidase inhibitor 
 
 




2.1.4  SiRNA library targeting the human genome 
A SMARTpool® kinase siRNA custom library comprised of 720 kinases (Appendix Table 
1), 80 tumour suppressor genes (Appendix Table 2) and 480 genes included in the 
Cancer Gene Census (Appendix Table 3), was obtained from GE life sciences. The 
library was supplied in 96 well plate format with each well representing one gene, with 80 
genes per plate. Each well contained four individual siRNA species that targeted the 
same gene, with different target sequences, termed a SMARTpool®. Target sequence 
information was not supplied. Additional positive (siPLK) and non-targeting controls 
(siAllstar, siControl1, and siControl2) were added to the plate, prior to being aliquoted by 
the Hamilton Robot into 384 well daughter plates for use for the screens. All siRNA 
oligonucleotides were supplied by GE healthcare, except siAllstar from Qiagen. 
 
2.1.5 SiRNA oligonucleotides 
Individual siRNA oligonucleotides were purchased from GE Life Sciences and were 
supplied lyophilised and 2’ACE protected. DEPC (0.1% diethylpyrocarbonate) treated 
water (Ambion) was used to reconstitute the siRNA to 20µM, and aliquots were stored at 
-20˙Celcius.  
 
2.1.6 CRISPR constructs 
Edit-R crRNA and tracer RNA targeting two individual sequences of RB1 were purchased 
from GE Life Sciences and were supplied lyophilised. Both were reconstituted with DEPC 
treated water (Ambion) and stored at -80˙Celcius.  
 
2.2 PROTOCOLS 
2.2.1 Tissue culture 
2.2.1.1 Cell line identification confirmation 
Short Tandem Repeat (STR) typing performed using GenePrint 10 (Promega UK Ltd) 
was used to confirm identification of the cell lines at the ICR. The Leibniz-Institute DSMZ-
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH online STR analysis 
website (http://www.dsmz.de/fp/cgi-bin/str.html), was used as reference for the STR cell 




line profiles. Genome wide array single nucleotide polymorphisms (SNP) 6.0 (Affymetrix) 
were performed at the Wellcome Trust Sanger Institute (WTSI) instead of STR typing.  
 
2.2.1.2 Cell lines 
A total of 18 cell lines comprising a range of histological subtypes of osteosarcoma as 
classified by tumour of origin (Table 5), were used: 143b and HOSMMNG were 
purchased from the American Type Culture Collection (ATCC); G292 clone A141B1, 
MG63, CAL72, HU03N1, OSA/SJSA-1, NOS1, SAOS2, U2OS, HU09, NY and HOS were 
gifts from Ultan McDermott at the Wellcome Trust Sanger Institute (WTSI); LM7, OHSN, 
OSH25HAL (HAL) MHM, and KPD were kind gifts from Ola Myklebost, Norway. Included 
in this panel two isogenic models of murine metastasis formation derived from HOS 
(HOSMNNG and 143b), and SAOS2 (daughter LM7).  
 
In addition, isogenic models of RB1 deficiency were also used. Two isogenic RB1 
deficient and wildtype breast models were kind gifts from Eric Knudsen, Thomas 
Jefferson University, Philadelphia, USA; metastatic breast adencarcinoma tumour cell 
line (MDAMB231) and a non-tumourigenic epithelial breast cell line (MCF10A) both 
created by shRNA mediated silencing of RB1. Two RB1 isogenic models (U2OS clone 
4.2 and 4.5) generated in the OS cell line U2OS by CRISPR-Cas9 mutagenesis, 
described in Chapter 4.  




Table 4 Compilation of primary antibodies used 





Cell signalling 9309 Mouse  1:1000 
P16INKa Abcam Ab108349 Rabbit  1:1000 
PARP Santa cruise D513 Mouse  1:1000 





ABIN 78590 Rabbit  1:2000 
pTP53 
(Serine15) 
Cell signalling 9284 Rabbit  1:2000 
P21 waf/lip1 Cell signalling 2946s Mouse 1:1000 
CHK1 Cell signalling Sc-8408 Mouse 1:500 
pCHK1 (S345) Cell signalling 2348s Rabbit 1:1000 
CHK2 Abcam Ab109413 Rabbit 1:1000 
pCHK2 (Thr68) Cell signalling CS2661 Rabbit 1:1000 
P27Kipl1 Cell signalling 2552 Rabbit 1:1000 
SKP2 Cell signalling 4358 Rabbit  1:1000 
Cyclin E1 Cell signalling HE12 Mouse 1:1000 
Cyclin A2 Cell signalling BF683 Mouse 1:1000 
DYRK1A Abcam Ab69811 Rabbit  1:1000 
DYRK1A Cell signalling 2771 Rabbit 1:1000 
ATM Cell signalling 2873 Rabbit 1:1000 
pATM 
(Ser1981) 
Cell signalling 4526S Mouse 1:1000 
BRCA2 Genetex GTX70121 Mouse 1:500 
ATR Cell signalling SCC0514 Goat 1:1000 
pATR 
(Thr1989) 
GENETEX GTX128145 Rabbit 1:1000 
Cyclin B1  Cell signalling 12231S Rabbit 1:1000 













ABIN785970 Rabbit 1:1000 
 
 




A number of mutant clones of SUM149 and CAPAN1 were created by CRISPR-Cas9 
mutagenesis within the Lord laboratory. Two isogenic BRCA deficient and proficient 
models were created by Amy Dréan using CRISPR-Cas9 mutagenesis of the pancreatic 
ductal adenocarcinoma cell line CAPAN1 (BRCA2 defective: c.6174delT, p.S1982fs*22) 
(Edwards, Brough, Lord, et al., 2008) to create an intragenic mutation in BRCA2 that 
restored the native open reading frame termed CAPAN1.B2.S* (Dréan, Williamson, 
Brough, et al., 2017). This secondary mutation restored BRCA2 function. Amy Dréan 
used the same method to restore BRCA1 function to the BRCA1 deficient breast tumour 
cell line SUM149 (BRCA1 mutant c.2288delT, p.N723fsX13) (Elstrodt, Hollestelle, Nagel, 
et al., 2006), creating a BRCA1 ‘revertant’ clone termed SUM149.B1.S* (Dréan, 
Williamson, Brough, et al., 2017). A SUM149 REV7 mutant clone with a truncating 
mutation in REV7 (MADL2L2) and a SUM149 53BP1 mutant clone with a truncating 
mutation in 53BP1 were created by Inger Brandsma, ICR. A SUM149 PARP1 mutant 
clone with a missense mutation in PARP1 was created by Stephen Pettitt, ICR. 
 
2.2.1.3 U2OS tetracycline inducible cell lines 
Tetracycline-controlled transcriptional activation (Tet-on) U2OS cells generated using 
pRev Tet-On system (Clontech Takara Bio) were a generous gift from James DeCaprio, 
Dana-Farber Cancer Institute, Boston (Litovchick, Florens, Swanson, et al., 2011). 
Litovchick et al. sublconed human DYRK1A complementary DNA (cDNA) (gift of W. 
Hahn) into tet-inducible pRevTre vector and generated a kinase-inactive DYRK1A-K188R 




DMEM, RPMI, MEM, F12, IMDM and McCoys’s were all supplied by Gibco and 
supplemented with 5mL L-Glutamine (Gibco) and five or ten percent Fetal Bovine Serum 
(FBS) (Gibco) depending on the cell line (Table 5). Penicillin-streptomycin 5ml 
(Invitrogen) was added to media for routine culture only.  




Table 5 Origins and growth conditions for cell lines used. 
[OS: osteosarcoma; ATCC: American Type Culture Collection; Wellcome Trust Sanger Institute: 
WTSI; FBS: Foetal bovine serum; EGF: epidermal growth factor] 
Cell Lines Tissue 
Type 
Histology Source Media FBS Additives 
CAL72 OS Osteoblastic  Ultan McDermott, 
WTSI 
DMEM 10% 2mM L-Glutamine 
NOS-1 OS Osteoblastic  Ultan McDermott, 
WTSI 
DMEM 10% 2mM L-Glutamine 
OS25-HAL OS Osteoblastic  Ola Myklebost, 
Norway 
RPMI 10% 2mM L-Glutamine 
HU09 OS Osteoblastic  Ultan McDermott, 
WTSI 
RPMI 10% 2mM L-Glutamine 
OHSN OS Osteoblastic  Ola Myklebost, 
Norway 
RPMI 10% 2mM L-Glutamine 
KPD OS Chondroblastic  Ola Myklebost, 
Norway 
RPMI 10% 2mM L-Glutamine 
MHM OS  Chondroblastic  Ola Myklebost, 
Norway 
RPMI 10% 2mM L-Glutamine 
G292 clone 
A141B1 
OS  Osteoblastic / 
telangectatic  
ATCC McCoys 10% 2mM L-Glutamine 
OSA/  
SJSA-1 
OS  Fibroblastic  Ultan McDermott, 
WTSI 
RPMI 10% 2mM L-Glutamine 
MG63 OS Fibroblastic  Ultan McDermott, 
WTSI 
 
RPMI 10% 2mM L-Glutamine 
LM7 OS  Fibroblastic  Ola Myklebost, 
Norway 
DMEM 10% 2mM L-Glutamine 
HOS OS Fibroblastic  Ultan McDermott, 
WTSI 
MEM 10% 2mM L-Glutamine 
143B 
 
OS Epithelial  ATCC DMEM 10% 2mM L-Glutamine 
HOSMNNG 
 
OS Epithelial  ATCC DMEM 10% 2mM L-Glutamine 
SAOS2 OS Epithelial  Ultan McDermott, 
WTSI 
DMEM 10% 2mM L-Glutamine 
U2OS OS Mixed histology  Ultan McDermott, 
WTSI 
DMEM 10% 2mM L-Glutamine 




RPMI 10% 2mM L-Glutamine 




RPMI 10% 2mM L-Glutamine 
MDAMB231 Breast Adenocarcinoma  Eric Knudsen, 
USA 
DMEM 10% 2mM L-Glutamine 













5% horse serum 
CAPAN1 
 
Pancreas  Adenocarcinoma  ATCC IMDM 20% 2nm L-Glutamine 
SUM149 Breast Triple negative 
breast cancinoma  
ATCC DMEM/F
12 










2.2.1.5 General culture conditions 
Cells were maintained at 37 °C in a humidified atmosphere at 5% CO2. Antibiotic-free 
media specific to each cell line (Table 5) was used for all drug and siRNA screening. To 
passage cells, growth media was removed, the cells washed with PBS and the cells 
incubated at 37˙C in a covering volume of trypsin/EDTA (Sigma). Once the cells 
detached, media was added to the cells to neutralise the trypsin and the cells seeded into 
new flasks or plates. To count the cell density, a single cell suspension was ensured by 
running the cells through a pipette multiple times, a 10µL alliquote of the cells was then 
stained with an equal volume of trypan blue and counted using the Countess automated 
cell counter (Invitrogen), which also provided an estimate of viability. Cells were frozen in 
a solution of 90% FBS and 10% DMSO, and maintained in liquid nitrogen. As per 
laboratory protocol, cell lines were tested monthly for mycoplasma infection. 
 
2.2.1.6 Reverse transfection of siRNA 
A transfection mix of serum free media (Opti-MEM, Gibco) and transfection reagent 
lipofectamine 2000 (Life Technologies), lipofectamine 3000 (Life Technologies), 
RNAimax (Life Technologies), or Dharmafect 4 (GE Lifesciences) was incubated at room 
temperature for 10 minutes according to the manufacturer’s instructions. The siRNA was 
added to the transfection mix, and incubated for 10 minutes before being mixed with the 
cell suspension and plated at the required density. The final concentration of siRNA was 
20nM. 
 
For reverse transfection using siRNA oligonucleotides targeting two different genes, the 
same volume of siRNA was used as above, so the final concentration of each species of 
siRNA remained 20nM, but overall was 40nM. 
 
2.2.1.7  Clonogenic / colony formation cell survival assays 
Cells were plated in triplicate at a density of 500 cells per well of a 6 well plate for each 
condition, and repeated in triplicate. The media (tetracycline free and doxycycline 
positive) was replaced every four days. After 14 days, the cells were fixed in 10% 
trichloroacetic acid (TCA) and incubated overnight at 4oC. The cells were then stained 
with sulforhodamine-B (SRB) for 30 minutes after which excess dye was removed by 
repeated washing with 1% (vol/vol) acetic acid, and the colonies counted. For cell lines 




that failed to form discrete colonies, after 14 days the media was discarded, and cells 
were incubated in CTG (Promega), shaken for 10 minutes, transferred to a 96 well plate, 
and then luminescence measured using the Victor X5 Multilabel plate reader (Perkin 
Elmer) as a measure of viability. The survival fraction (cell viability) was then calculated 
as a fraction of the luminescence in vehicle treated wells, and GraphPad Prism was used 
to plot dose response curves. 
 
2.2.1.8 High-throughput drug library screens 
Cell lines were profiled using a customised in-house drug library containing 80 drugs 
(Table 2) and an additional library consisting of 395 drugs was also used to screen the 
isogenic RB1 deficient U2OS models created by CRSIPR-Cas9 mutagenesis (Table 3). 
Cell lines were seeded at a density of 500 cells well using antibiotic free media, into white 
384-well plates (Greiner Bio-one) using a MultiDrop Combi Dispenser (Thermo Fisher 
Scientific) and incubated overnight. Replicate cell plates were then loaded onto the 
Microlab Star screening platform and drug plates were serially diluted (final 1:500 fold 
dilution) in media before being added to the cell plates. After five days of continuous 
exposure to drug, cell viability was quantified via a highly sensitive luminescent assay 
measuring cellular ATP levels (CellTiter Glo; Promega) and using a Victor X5 Multilabel 
plate reader luminescence protocol (Perkin Elmer Las UK Ltd). Each screen was 
performed in triplicate on the same day.    
 
2.2.1.9 Smaller scale drug screens 
For smaller-scale drug screens and revalidation, the Echo Acoustic (Labcyte) was used 
because of ease of performing combination screens. Cells were first plated at a density of 
500 cells per well into a 384 well plate (Greiner Bio-one) using a MultiDrop Combi 
Dispenser (Thermo Fisher Scientific) and incubated overnight. Drugs were prepared in a 
384 well plate at doses of 10µM and 0.1µM. The Echo Acoustic was used to eject small 
droplets of liquid from wells of the mother plate using ultrasonic acoustic energy at the 
meniscus of the fluid sample, and position them precisely onto a surface (daughter plate) 
suspended above the ejection point. From this method seven final drug concentrations 
can be achieved (0.01, 0.05, 0.1, 0.5, 1, 5, 10µM). After five days of continuous exposure 
to drug, cell viability was quantified via a highly sensitive luminescent assay measuring 
cellular ATP levels (Cell Titer-Glo; Promega) and using a Victor X5 Multilabel plate reader 




luminescence protocol (Perkin Elmer Las UK Ltd). Each screen was performed in 
triplicate on the same day.    
 
2.2.1.10 High-throughput siRNA screen 
A siRNA library targeting 720 known and putative human protein kinases (Appendix 
Table 1), 80 tumour suppressor genes (Appendix Table 2), and 480 genes included in the 
Cancer Gene Census (Appendix Table 3), was obtained in 384 well plates from GE Life 
Sciences. Each well contained 5µL (200nM) of a SMART pool of four distinct siRNA 
species targeting different sequences of the single target transcript. Additional positive 
(siRNA targeting PLK1 (GE Life Sciences)) and negative (nontargeting siRNA: siCON1, 
siCON2 (GE Life Sciences), and siAllstar (Qiagen)) controls were added to the edges of 
each plate (8 wells of each control), with an internal well of siPLK within the first plate 
(each screen consisted of three 384 well plates).  
 
Cell lines were transfected with SMART pool siRNA using RNAiMAX (Invitrogen), 
Lipofectamine 2000 (Invitrogen) or Dharmafect4 (GE Life Sciences) according to results 
of prior optimisation. After the addition of 35µL cell suspension to each well, the final 
concentration of siRNA was 20nM. Each cell line was screened in triplicate on the same 
day. At 90% confluency (approximately five population doublings (Brough, Frankum, 
Sims, et al., 2011)), established via prior microscopy, cell viability was measured as 
before (CellTiter-Glo; Promega). 
 
For the olaparib resistance screen, 24 hours post reverse transfection, olaparib at a final 
concentration of 500nM or DMSO was added to the wells. After five days of continuous 
drug exposure, cell viability was then estimated using CellTiter Glo (Promega). 
 
2.2.1.11 siRNA validation of target inhibition 
To validate siRNA silencing of a target gene, protein expression level by western blotting 
and cell viability were determined using individual oligonucleotides targeting different 
regions of the same gene. Cells were reverse transfected in 6-well plates in duplicate with 
four individual oligonucleotide siRNAs (GE Life Sciences). Forty-eight hours post reverse 
transfection half the cells were collected for preparation of protein lysates and viability 
was assessed for the remainder using CellTiter Glo. 




2.2.2 Analysis of cell cycle distribution by Fluorescence-activated cell sorting 
Cells were plated at a density of 1x106 cells per 10cm plate. After 24 hours of incubation 
the drugs and vehicles were added. At 24 and 48 hours post commencement of drug 
exposure, the cells were stained with 5-ethynyl-2′-deoxyuridine (EDU) (1:1000 incubated 
for 90 minutes) and both the adherent and non-adherent cells were collected for fixing. 
Prior to fixing, the cells were washed with 500µl of 1% Bovine serum albumin (BSA), 
centrifuged at 300g for five minutes, re-suspended in 100µl 1% BSA, mixed with 100µl 
Click-It Fixative (from the Click-iT® EdU Alexa Fluor® 488 Imaging Kit, Thermo Fisher) as 
per the manufacture’s instructions, incubated for 15 minutes in the dark, centrigued at 
300g for five minutes, re-suspended in 300µl PBS, and then 700µl ice-cold 100% ethanol 
added drop wise while gently vortexed. Fixed cells were then stored at -20˙C until ready 
for staining.  
 
Cells were washed with 100µl of saponin-based permeabilisation and wash reagent (from 
the Click-iT® EdU Alexa Fluor® 488 Imaging Kit, Thermo Fisher), incubated for 30 
minutes in the dark, centrifuged for five minutes at 300g, and then resuspended in 500µl 
5% goat serum (made in 1% BSA). Cells were then incubated for an hour in the dark. 
After which they were further centrifuged at 300g for five minutes, and then 120µl of 
1:200 diluted (using the saponin-based permeabilisation and wash reagent) anti-H3-
Ser10 mouse antibody (Millipore 05-806) was added. The cells were then incubated at 
4˙Celcius overnight in the dark. Next 500µl of saponin-based-permeabilisation and wash 
reagent was added, cells centrifuged for five minutes at 300g, 120µl of 1:500 diluted 
(using the saponin-based permeabilisation and wash reagent) secondary mouse-633 
antibody was added and incubated for one hour in the dark. Cells were then washed with 
500µl of saponin-based permeabilisation and wash reagent, centrifuged for 5 minutes at 
300g, washed with 500µl 1% BSA, and centrifuged for five minutes at 300g. The Click-It 
cocktail (from the Click-iT® EdU Alexa Fluor® 488 Imaging Kit, Thermo Fisher), was 
prepared according to the manufacture’s instructions and 500µl was added to each tube. 
The cells were then incubated again for 30 minutes in the dark, and centrifuged for five 
minutes at 300g. The cells were suspended in 500µl saponin-based permeabilisation and 
wash reagent with 1:10000 4',6-diamidino-2-phenylindole (DAPI) and incubated for a 
further 30 minutes in the dark. Each sample was then filtered into a FACS-cuvette and 
placed on ice in the dark until analysed on the BD LSR II Flow Cytometer (BD 
Biosciences) using BD FACSDiva software (BD Biosciences). 
 




2.2.2.1 Apoptosis assay 
OS tumour cells were plated at high density (10,000 cells per well) in a 96 well plate. 
After 24 hours of incubation the drugs and vehicle (DMSO) were added. At 24 and 48 
hours post addition of drug, the Apo-Tox-Glo Triplex Assay (Promega) was performed as 
per the manufacture’s instructions. The Victor X5 (Perkin Elmer) was used to measure 
luminescence. CellTiter-Glo was used in parallel to estimate cell viability. 
 
2.2.2.2 Tetracycline inducible cell line U2OS 
The three tumour cell lines U2OS preRev (empty vector), KR (kinase inactive DYRK1A-
K188R), and WT (wildtype DYRK1A) were grown for one week in tetracycline free media, 
before division and the addition of doxycycline at 5µg/ml to half of the cells. After four 
days, cells were reverse transfected with a siRNA smart-pools targeting RB1, PLK and a 
non-targeting control (Allstar). At 24 hours, cells were then seeded in triplicate at low 
density (500 cells per well of six well plate), and after two weeks, the cells were fixed and 
stained (Figure 4 and Figure 58). 
 





- doxycyline + doxycycline 
pRev 
- doxycyline + doxycycline 
KR 
- doxycyline + doxycycline 
WT 
Expanded for 1 
week in doxycyline 
free media 
Expanded 
for 5 days 
Reverse Transfection 
Smart-pools targeting siRB1, siPLK, and siAllstar 
Media changed after 24 hours 
Plated at low density for colony formation 
2 weeks: colonies fixed and stained 
 
Figure 4 Schematic of methodology of colony formation assay post reverse transfection 
with siRNA. 
Three U2OS tumour cell lines were used with either a tetracycline inducible empty vector (pRev), 
kinase inactive DYRK1A-K188R (KR), or wildtype DYRK1A (WT). Each U2OS tumour cell line was 
expanded for a week in tetracycline free media, split and half were treated with doxycycline 
(5µg/ml) for five days. Cells were then reverse transfected with siRNA targeting RB1, Allstar 
(negative control), and PLK (positive control), and after 24 hours plated at low density (500 cells 








2.2.3  Protein manipulation 
2.2.3.1 Western blots 
Cells were washed twice with cold PBS and lysed at 4°C for 30 minutes in buffer (100 
mmol/L NaCl, 1 mmol/L phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.1% SDS, 0.5% 
sodium deoxycholate, 20 µg/mL aprotinin, 20 µg/mL leupeptin). Insoluble material was 
removed by centrifugation at 4°C for 30 minutes at 16,000g, and protein concentrations 
were determined by Bradford Assay using a BCA protein assay kit (Pierce, United States 
of America). For each lysate, 1ml of BioRad Protein assay [5x] diluted in 1:5 with ultra-
filtered water was used and loaded into a cuvette. Absorbance values for each lysate 
were then interpolated on GraphPadPrism using a standard curve of absorbance value 
for known concentrations of BSA. For each lysate, fifty was then divided by the 
interpolated concentration, and the resultant value combined with 10µl of NuPAGE 
sample buffer (Life Technologies), which was heated to 96˚C for 10 minutes and snap 
frozen on dry ice.  
 
Cell lysates were separated using either 4-12% SDS-PAGE Bis-Tris gels or 3-8% Tris-
Acetate Gel, transferred to nitrocellulose membrane, blocked in 5% milk and blotted with 
antibodies as per the manufacturers instructions. Blots were washed using Tris-buffered 
saline tween (TBST) (500mls ultra-filtered water, 50mls Tris-buffered saline (TBS) [10x], 
500µL Tween 20). All secondary antibodies were IRDye 700CW and 800CW (LI-COR 
Ltd), diluted 1:10000 in 5% milk, and incubated for one to two hours at room temperature 
in the dark. Blots were imaged for two minutes using the LI-COR Odyssey FC imager 
according to the manufacturer’s instructions. Image-studio lite (LI-COR) was used for 
graphic display of blots. All primary anti-bodies and conditions used for western blot are 
listed in Table 4. 
 
2.2.3.2 Proteomic Abundance 
Proteomic abundance for the panel of OS tumour cell lines and isogenic RB1 deficient 
U2OS models generated by CRISPR-Cas9 mutagenesis was performed in collaboration 
with Colm Ryan (Systems Biology Ireland, University College Dublin, Ireland). Cells were 
washed twice with cold PBS to remove all traces of serum proteins, and then air-dried by 
tilting plate on ice for 30 seconds to remove the PBS. Cell lysis was performed using a 




lysis buffer (2.1.1), and transferred into eppendorfs. Following lysis, protein purification, 
and tryptic digest, peptides were separated by liquid chromatography and measured by 
mass spectrometer as described in Ryan et al. (Ryan, Kennedy, Bajrami, et al., 2017). 
Label-free proteome quantification was performed using the MaxQuant software 
environment (Coscia, Watters, Curtis, et al., 2016; Cox, Hein, Luber, et al., 2014) to 
determine the quantitative abundance of 6696 peptides with a false discovery rate of less 
than one percent. 
 
2.2.4 DNA analysis 
2.2.4.1 Extraction of genomic DNA from cell lines  
Extraction of the DNA from cell lines was performed using the DNeasy Kit (Qiagen Ltd), 
according to the manufacturer’s recommendations and stored at -20˙Celcius. 
 
2.2.4.2 Spectrophotometric quantification of DNA 
The concentration of DNA was determined by measuring the UV absorbance at 260nm of 
diluted samples on a spectrophotometer. 
 
2.2.4.3 Sanger sequencing 
The DNeasy Kit (Qiagen Ltd.) was used to extract DNA from cell lines according to the 
manufacturer’s recommendations. Sanger sequencing was performed by Eurofins 
Genomics, Germany, using standard methods and RB1 primers. 
 
2.2.4.4 Polymerase Chain Reaction (PCR) 
Sequencing primers were synthesised by Integrated DNA technologies and purchased as 
lyophilised powder, which was resuspended in DEPC-treated H2) (Ambion) to a 
concentration of 100µM and stocks stored at -20˙C. Prior to use in PCR reactions, the 
stock primers were further diluted to 10µM. PCR products were approximately 330 base 
pairs in length. PCR reactions were performed in 50 or 100µl volumes using Q5® High-
Fidelity DNA Polymerase (New England Biolabs) and purified using the QUIquick PCR 
purification kit (Qiagen Ltd.). The following RB1 primers were used: 
 




RB1 1D forwards: 5’ – CCGCGGAAAGGCGTCAT – 3’ 
RB1 1D reverse:  3’ – GAACCCAGAATCCTGTCACCA – 5’ 
 
The following PCR conditions were used on a thermocycler: 
1. 94˙C three minutes 
2. 94˙C one minute (melting) 
3. 57.5˙C two minutes (annealing) 
4. 72˙C one minute (elongation) 
5. go to step two for 29 cycles 
6. 72˙C three minutes 
7. 4˙C for ever 
 
Agarose gel electrophoresis was used to separate the PCR products. Agarose gels were 
made as follows: 1.5% ultra-pure agarose (Life Technologies) dissolved in 1xTAE butter 
+ 1/10,000 GelRed nucleic acid stain (Biotum). Hyperladder 1 (Bioline) was used to 
estimate the length of PCR products. DNA was visualised using an ultraviolet trans-
illuminator (Syngene). 
 
2.2.4.5 Generation of CRISPR-Cas9 induced mutant clones  
RB1 encodes for a phosphoprotein 928 amino acids in length comprised of 27 exons. 
Two CRISPR guides (CrAA4 and CrAA5), were designed by Professor Alan Ashworth, 
both of which targeted a different 21 base pair region in Exon 1 of RB1 (Table 6). To 
amplify Exon 1 of RB1 by PCR, a pair of oligonucleotides flanking Exon 1 of RB1, was 
designed (Table 7). 
 
U2OS cells were reverse transfected with the Cas9 plasmid, tracer RNA, and guide RNA 
and controls were transfected with the Cas9 plasmid alone. Transfection efficiency was 
confirmed at 24-48 hours, by presence of green luminescence in a cohort of cells treated 
with GFP. At 72 hours cells were selected in blastocydin (10µg/µl) and plated at a low 
density (5000 cells per 15cm dish in 25mls of media). Once colonies were established, 
100 clones were picked and expanded. Sixteen of the fastest growing clones were 
picked, and pelleted for genomic DNA (gDNA). The Gentra Puregene cell kit (Qiagen 
Ltd.) was used to prepare DNA according the manufacturer’s instructions.  
 




To efficiently screen for mutations generated by CRISPR-Ca9 mutagenesis in the 
selected clones, the Surveyor assay (Integrated DNA technologies) was used. Firstly 
PCR amplification of Exon 1 of RB1 was performed for each of the selected clones, and 
PCR product confirmed on a TAE 1.5% agarose gel (Figure 5).  
The remaining PCR product for each clone was quantified, and then mixed in equal 
quantities with the Cas9 control (U2OS cells reverse transfected with Cas9 alone). The 
Surveyor assay kit  (Integrated DNA technologies), an enzyme mismatch cleavage assay, 
was followed according to manufacture’s instructions and a known mutant was used as a 
positive control. The Surveyor nuclease recognised and cleaved mismatches due to the 
presence of single nucleotide polymorphisms (SNPs), or small indels. The subsequent 
product was then confirmed on a further TAE 1.5% agarose gel and the presence of 
multiple bands used to confirm the existence of mutants (Figure 6). The 1kb Hyperladder 
I (BioLine) which contained 14 bands from 200bp to 10,037bp, was used as a size 
marker.  
 
2.2.4.6 Topo Cloning 
To amplify as many alleles of Exon one of RB1 as possibe, each CRISRP-Cas9 
generated mutant clone was subcloned. Competent Escherichia coli cells were used to 
subclone cleaned PCR product from each clone. Vector sample was prepared using the 
Topo TA cloning kit (Invitrogen) according to the manufacturer’s instructions. Topovector 
(1µl), sodium chloride (1µl), DEPC treated water (2.3µl) and cleaned PCR product (2µl) 
from each clone were mixed and incubated at room temperature for 20 minutes. 1µl of 
vector sample was added to 40µl of competent E.coli and incubated on ice for 30 
minutes. This was then heat shocked at 42˙Celcius for one minute, and incubated on ice 
for a further two minutes. Next 900µl of warmed L-broth was added and incubated at 
37˙Celcius for an hour. Ampicillin selection marker agar plates were pre-warmed at 
37˙Celcius and stained with 30µl of B3928 blue-white select screening reagent (Sigma 
Ltd.) for selection of recombinant bacterial colonies and left to dry for 20 minutes. The 
E.coli cells were centrifuged and re-suspended in 40µl of warmed L-broth and plated out 
onto the ampicillin selection agar plates and incubated overnight, inverted at 37˙Celcius. 
Twenty-five white colonies were picked per mutant clone and amplified by miniprep using 
Quiaprep spin miniprep kit (Quiagen) and cleaned using QUIAquick PCR purification kit 
(Quiagen) according to the manufacturer’s instructions. The amplified RB1 PCR product 




from each clone was then Sanger sequenced by Eurofins Genomics, (Ebersberg, 
Germany) using Sanger sequencing methodology.  
 
2.2.4.7 Exome sequencing 
The OS tumour cell lines LM7, SAOS2, U2OS 4.2, U2OS 4.5, U2OS 9.1 were exome- 
sequenced by the Tumour Profiling Unit (TPU), ICR. Targeted exome capture was 
performed using SureSelect Human All Exome v5 reagents (Agilent). Paired-end libraries 
were prepared from the captured target regions and sequenced on a HiSeq2500 
(Illumina) using v4 chemistry acquiring two x 100 bp reads. Bcl2fastq software (v1.8.4, 
Illumina) was used for converting the raw basecalls to fastqs and to further demultiplex 
the sequencing data. The paired-end fastq files were used for further analysis. 
 
The OS tumour cell lines SAOS2, 143b, HOS, HOSMNNG, MG63, CAL72, U2OS, KPD, 
MHM, OHS25, OHSN, SJSA-1/OSA, NY, NOS1, HU09, HU03N1 and G292 Clone 
A141B1 were whole exome sequenced by the Wellcome Trust Sanger Institute (WTSI) as 
described by Garnett et al. (Garnett, Edelman, Heidorn, et al., 2012). Mutations were 
considered driver events if they represented canonical changes. 
 
2.2.4.8 Fluorescence in situ hybridisation (FISH) 
FISH was performed by Fernanda Amary as described by Amary et al. and FGFR1 
amplification was classified as positive if ≥10% of the cells showed (a) FGFR1/CEN8 ratio 
>2, (b) clusters of FGFR1 signals, or (c) >15 copies of FGFR1 per cell (Fernanda Amary, 
Ye, Berisha, et al., 2014). 
 
2.2.5 RNA manipulation 
2.2.5.1 RNA extraction 
The RNAeasy kit (Qiagen Ltd.) was used to extract RNA from cell lines according to the 
manufacturer’s instructions, eluted in 50µl water and stored at – 80˙Celcius. 
Concentration and quality of the RNA was measured using a 2100 Bioanalyzed® platform 
(Agilent® technologies) and a spectrophotometer. 




Table 6 CRISPR guides targeting Exon 1 of RB1 










Table 7 Oligonucleotide primers for a 336 base pair region including Exon 1 of RB1 
 RB1 1D forwards 5’ – 3’ RB1 1D reverse 5’ – 3’ 
Sequence CCGCGGAAAGGCGTCAT GAACCCAGAATCCTGTCACCA 






























































































































336 base pair 
DNA fragment of 
exon 1 of RB1 
 
Figure 5 PCR amplification of Exon 1 of RB1 in 12 U2OS CRISPR-Cas9 transfected clones. 
The CRISPR crDNA crAA4 was used to generate these clones using the OS tumour cell line 
U2OS. Individual numbered clones and all clones pooled together were visualised using a 1.5% 
TAE agarose gel. The RB1 oligonucleotide primers RB1 1D forwards and reverse were used to 
amplify a 336 base pair fragment shown here. Red boxes highlight clones with multiple band sizes 
















































































































336 base pair 
DNA fragment of 
exon 1 of RB1 		 
Figure 6 The surveyor assay was used to screen for generation of mutants generated by 
CRISPR-Cas9 mutagenesis.  
A 336 base pair fragment of Exon 1 of RB1 was amplified by PCR from each U2OS CRISPR-Cas9 
transfected clone, and mixed in equal quantities with that from control (U2OS reverse transfected 
with Cas9 only). The surveyor assay (Integrated DNA technologies), an enzyme mismatch 
cleavage assay, was used to screen for generation of mutants generated by CRISPR-Cas9 
mutagenesis. The surveyor nuclease recognised and cleaved mismatches, which were seen on 
agarose gel as multiple bands, highlighted here by red boxes. The CRISPR crDNA crAA5 was 









2.2.5.2 Whole transcriptome Sequencing / RNA-seq 
Whole transcriptome sequencing was performed by the Tumour Profiling Unit, Institute of 
Cancer Research. Samples were sequenced and checked for quality. The Ribo-zero kit 
(Illumina) was used to select the RNA according to the manufacturer’s instructions. 
Strand specific libraries were generated from the RNA using the NEBnext ultra directional 
RNA library preparation kit (Illumina) as specified by the manufacturer. Paired-end 
libraries were sequenced on a HiSeq2500 (Illumina) using v4 chemistry acquiring 2X75bp 
paired-end (PE) reads. Bcl2fastq software (v1.8.4, Illumina) was used for converting the 
raw basecalls to fastqs and to further demultiplex the sequencing data. The paired-end 
fastq files were used for further analysis. 
 
2.2.5.3 Real-time PCR (rtPCR) 
The Superscript III First Strand Synthesis System for rt-PCR (Invitrogen) using oligo-
hexamers according to the manufacturer’s instructions was used to prepare cDNA. 
Quantatitive rtPCR was performed using Taqman Universal mastermix II with UNG 
(Thermo Fisher) according to the manufacturer’s instructions in 96-well optical plates 
(Applied Biosystems). The following primer/probe sets were purchased from Thermo 
Fisher: DYRK1A (Hs00176369_m1) and endogenous control GAPDH (Hs03929097_g1). 
Real-time PCR was performed on the 7900HT HT Fast Real-Time PCR System (Applied 
Biosystems) according to the manufacturer’s instructions. Target gene expression was 
calculated as expression relative to the expression of control cDNA after adjusting for 
expression of GAPDH as the endogenous control. 
 
2.2.5.4 RAD51 foci assay 
Cells were plated in triplicate at 500,000 cells per well of 6 well plates on sterile 
coverslips. After 24 hours the tumour cells were irradiated at 10Gray. Four hours post 
irradiation the cells were fixed using a covering volume of 4% Paraformaldehyde (PFA) in 
PBS for one hour at room temp and then washed with PBS before staining. Cells were 
permeabilised using a covering volume of 0.2% Triton X-100 in PBS for 10 minutes at 
room temp. Next, the coverslips were washed three times with PBS. The coverslips were 
inverted onto a 50µL drop of DNAse I (Thermo Fisher)(10,000 units/mL stock diluted 1:10 
in PBS) for two hours at 37˙C in a humidified container, prior to three washes in PBS. The 




coverslips were incubated for 30 minutes at room temperature in a covering volume of 
IFF (1% BSA, 2% FCS in PBS). The coverslips were inverted onto a 50µl drop of RAD51 
primary antibody (Abcam) and phospho-yH2AX Millipore primary antibody diluted 1:1000 
in IFF, prior to incubation for one hour at room temperature in an air tight container. The 
coverslips were washed three times in PBS, prior to inversion onto a 50µl drop of 
secondary Rabbit 488 and Mouse 555 antibody diluted 1:1000 in IFF, and incubated in 
the dark for 40 minutes at room temperature. The coverslips were then washed twice with 
PBS and then once with DAPI (1:10,000 dilution in PBS). Each coverslip was then rinsed 
in distilled water and blotted dry. To mount, each coverslip was inverted onto a 4ml drop 
of vector shield (Vector Laboratories) and sealed with nail varnish. The Leica or Ziess 
confocal microscopes with a 63x objective were used to visualise and score the phospho-
γH2AX and RAD51 foci. Cells were scored as positive for foci if they contained at least 
five or more foci, and at least 100 cells were counted per condition.  
 
2.3 STATISTICAL ANALYSIS 
2.3.1 General statistical analysis 
Microsoft Excel or GraphPad Prism were used to perform statistical tests except for the 
median permutation test (MPT) which was performed in R using a custom script. All tests 
were two-sided unless otherwise stated. The MPT is a random sampling test that 
calculates the p (probability) value whether or not there is an observed difference 
between the median Z scores of two groups. One million random samples for the two 
groups were performed. A False Discovery Rate (FDR), a method for conceptualising the 
number of False Positive errors was set at 0.1, meaning 10% of significant tests will be 
false positives. This test accounts for multiple test corrections. The MPT was used to 
compare non-parametric datasets, while the Student’s t-tests used for parametric 
datasets. Significance was set at p<0.05.  
 
2.3.1.1 Drug dose response curves 
Survival fractions for each well of a 96 or 384-well plate were calculated as follows: 
luminescence in drug treated well / luminescence in vehicle (DMSO) treated well. 
Survival fractions were expressed as a percentage and plotted in GraphPad Prism where 
a five-parameter logistic equation with preliminary Log-transformation of the data, was 




used to draw dose response curves. Comparison of dose-response curves was 
performed using the two-way ANOVA function in GraphPad Prism for the median effect of 
each drug compared to a control curve as indicated in the figures. For comparison of 
repeated measures, the ANOVA and the Bonferroni post hoc test was calculated using 
GraphPad Prism. The Survival Fraction 50 (SF50), the drug concentration required to elicit 
a 50% inhibition of the cell population, and the SF80 (concentration required to elicit an 
80% inhibition of the cell population) were calculated from the dose response curves 
using GraphPad Prism. The Area Under the Curve (AUC) for each dose response curve 
was also calculated using GraphPad Prism. Comparison of SF50 and AUC was by a two-
sided Student’s t-test.  
 
2.3.1.2 Viability assessment post-siRNA transfection 
Survival fractions for siRNA of interest were generated by dividing the luminescence 
readings from each well by the median of the negative non-targeting controls (siCON1, 
siCON2, siAllstar) for each plate: 
 
 Surviving fraction =  (luminescence in siRNA of interest treated well) /   
    (luminescence in non-targeting siRNA treated wells) 
 
2.3.1.3 Analysis of high-throughput siRNA screen data 
Raw luminescence values were first analysed using the CellHTS2 software 
(BioConductor) (Boutros, Brás & Huber, 2006). The dynamic range of each screen was 
determined by calculating Z prime values (Zhang, Chung & Oldenburg, 1999), based on 
positive (siPLK) and negative (siCON1, siCON2 and allstar) control wells in each plate, 
which were used as a marker of quality. A minimum of two negative controls and one 
positive control was used for each analysis. Z prime values greater than >0.3 have been 
shown to be representative of reproducible data (Zhang, Chung & Oldenburg, 1999), and 
were considered acceptable, with a Z prime 0.5 – 1 demonstrating a robust and powerful 
screen (Brough, Frankum, Sims, et al., 2011). The Z prime for each screen was 
calculated using a modified version of the script HTS on the statistical program R: 
 
 Z prime = 1 – 3(σp + σn) / (µp – µn) 




Where σp and σn refer to the mean of the positive and negative controls respectively, and 
µp and µn refer to the standard deviations of the positive and negative controls 
respectively. 
 
Spearman Rank Correlation determined the reproducibility between the replicates and 
was calculated as follows using Microsoft Excel:  
 
 Spearman’s Rank Correlation = 1 - 6 ΣD 2/ n(n2-1) 
 
Where n refers to the number of wells, and D is the difference between rank order of size 
of the two replicates. A cut off of Spearman’s Rank Correlation co-efficient was set at 
>0.7. 
 
To account for the plate-to-plate variation common in high-throughput screens, raw 
luminescence readings from each well were log transformed, centred by the plate median 
and standardised using a Z score, calculated as follows: 
 
 Z = (x-median screen) / median absolute deviation 
 
Where x represents the plate centred log2 luminescence value, median screen represents 
the median luminescence value for all the siRNAs in the screen, and the median absolute 
deviation (MAD) the standard deviation of all the siRNAs (Brough, Frankum, Sims, et al., 
2011; Boutros, Brás & Huber, 2006). The distribution of each screen was assumed to 
approximate to normal, allowing comparison of the individual siRNA effects across cell 
lines. A Z score of zero represented no change in viability, while a negative Z score 
represented loss of viability (Brough, Frankum, Sims, et al., 2011). 
 
Quantile normalisation of the Z scores was performed by James Campbell using the 
preProcessCore package (Bioconductor). This method (originally described by Bolstad et 
al. (Bolstad, Irizarry, Astrand, et al., 2003)) adjusts the distribution of z-scores for each 
cell line so as to make each of them identical whilst maintaining the approximate 
magnitude of the original z-scores. The principle of quantile normalisation is to first rank 
order (sort) z-scores for each cell line, average the values across each rank and then 
return the averaged values to the original order. 




As a graphical measure of similarity between two groups of cell lines, heatmaps were 
generated by comparison of QN Z scores of each group by the median difference 
permutation test, using an in-house R script at the ICR. To identify genetic dependencies 
associated with a particular subtype of cell line, the cell lines were divided into two 
conditions, for example loss of function of RB1, and wildtype RB1. Both the median 
difference permutation test using an in-house R script at the ICR and the student’s T test 
were used to calculate the probability of the difference between the QN Z scores of each 
group.  
 
2.3.1.4 High-throughput siRNA screen with olaparib and calculation of Drug 
Effect 
The effect of each siRNA on olaparib sensitivity was determined by calculation of a drug 
effect (DE) score for each siRNA. DE scores were calculated by the difference between 
the median of replicate wells with drug and median of replicate corresponding wells with 
no drug for each siRNA. The median absolute deviation (MAD) was used to account for 
variance of the DE data. The DE was calculated as follows: 
 
 DE of siRNA = (drug effect of each siRNA – median drug effect of all siRNA) /  
   standard deviation of DE values for all siRNA in the screen 
 
Negative DE scores suggested the siRNA increased sensitivity to olaparib, while positive 
DE suggested increased resistance. DE scores of -2 < or > 2 were considered significant 
for sensitising and resistance causing effects. The Delta Drug Effect was calculated as 
the difference between the DE for each tumour cell line.  
 
2.3.1.5 Drug Screen Analysis 
The quality of the data was examined using Z prime (Zhang, Chung & Oldenburg, 1999),  
based on positive (puromycin-treated) and negative (DMSO-treated) control wells in each 
plate to determine the dynamic range of the screen. Spearman's Rank Correlation was 
performed to determine the reproducibility between the plates and was calculated on 
Excel for the 3 combinations of pairs of replicates for each of the drug plates. 
 
Spearman’s Rank Correlation = 1 - 6 ΣD 2/ n(n2-1) 





Where n refers to the number of wells, and D is the difference between rank order of size 
of the 2 replicates. Stringent quality control with Spearman's Rank correlation 
approaching 1 and Z prime >0.7 were set (Iorns, Lord, Grigoriadis, et al., 2009).  
 
2.3.1.6 Exome sequencing 
Exome sequencing analysis for the cell lines LM7, SAOS2, U2OS 4.2, U2OS 4.5, and 
U2OS 9.1 sequenced by the TPU was performed by James Campbell, ICR, according to 
the following steps: Burrow Wheeler Aligner (BWA)-mem (v0.7.5a) (University of 
Birmingham), was used to align reads to the human reference genome (GRCh37). PCR 
duplicates were removed prior to further processing and variant detection. Variant calling 
was done using GATK Broad Best Practice pipeline V3 (Broad Institute), with standard 
settings. Variants called in regions not covered by the capture probes were excluded, as 
were those with genotype qualities below 20 and those covered by fewer than 10 reads in 
either sample. 
 
Somatic single nucleotide variants (SNV) were identified using MuTect (v1.1.4) (Broad 
Institute). Short insertion/deletion (indel) mutations were selected from the complete set 
of variants called using the GATK HaplotypeCaller (Broad Institute) based on differences 
in the variant allele fractions observed in the tumour and normal exome sequence data. 
Indel variants were considered to be candidate somatic mutations where the variant was 
detected at less than 5% in the normal sample and greater than 15% in the tumour 
sample. Additionally, indel variants detected when the depth of coverage in either sample 
was less than 10 reads were rejected. All mutations were annotated using the SnpEff 
(v3.3h) (Source Forge), (Cingolani, Platts, Wang, et al., 2012) which provided information 
on genes affected by mutations and the likely consequences for the encoded gene 
products. Analysis was performed using CNVkit software tool (v0.7.8) (Talevich, Shain, 
Botton, et al., 2016). For this, the exome-sequencing data on blood samples from nine 
patients sequenced by Irene Chong, ICR, was used as normal samples. The copy 
number scores were represented as log2 ratio of the read depths of each tumour and 
nine pooled normal samples. The differences in Copy Number Variants (CNVs) between 
the two tumour cell line models (LM7 and SAOS2) were Z-normalized to determine the 
distribution of CNVs. Further analyses for detection of LOH regions and data visualization 
were performed using R programming. 




2.3.1.7 Analysis of RNA-seq data 
The Tophat2 spliced alignment software (v2.0.7) was used to align reads to the reference 
genome (GRCH37) in combination with Bowtie2 (v2.1.0). Once the reads were aligned, 
HTSeq-count (HTSeq v0.6.1) was used to count the number of reads mapping 
unambiguously to genomic features in each sample. Differential expression analysis of 
the count data was performed by James Campbell and Aditi Gulati, from the ICR, in R 
using the Bioconductor package, DESeq2  (v1.14.1). The package used negative 
binomial generalized linear models to test for differential expression. The results were 
reported as log2 fold changes in expression along with associated p-values and adjusted 










3 Characterisation of tumour cell lines 
3.1 INTRODUCTION 
My primary aim was to identify therapeutic vulnerabilities in osteosarcoma via a series of 
parallel high-throughput genetic and chemical screens. To do this I first collated and 
characterised a panel of osteosarcoma tumour cell lines that were representative of the 
histological subtypes of OS. Completion of exome sequencing and characterisation of the 
remaining tumour cell line models was performed to assess whether these reflected the 
mutational spectrum of the disease, and confirm a clinically relevant model for 
investigation of recurrent driver mutations in OS. 
 
To identify the presence or absence of cancer driver gene defects in osteosarcoma, a 
large panel of 18 OS tumour cell lines was assembled. These were molecularly profiled to 
detect pathogenic mutations and then classified into groups; those with a pathogenic 
mutation in an oncogene or tumour suppressor (deficient) and those without (wildtype). 
This enabled a ‘class analysis’ by comparison of deficient and wildtype phenotypes for 
specific driver genes. The phenotype of the ‘wildtype’ cohort was used as a surrogate to 
estimate the effect of target inhibition in a non-tumour cell, in an attempt to minimise the 
risk of identification of targets that would also impair essential processes in normal cells. 
This ‘class analysis’ approach is limited by potential cancer-specific alterations in the 
‘wildtype’ group that phenocopy the cancer driver gene defect seen in the ‘deficient’ 
group. For example while defects in TP53 are proposed to be tumourigenic, disruption of 
apoptosis downstream of TP53, phenocopies TP53 loss with respect to its impact on 
tumour onset and dissemination (Schmitt, Fridman, Yang, et al., 2002). The presence of 
these phenocopy effects, whether they are well described at the molecular level or not 
(‘cryptic phenocopies’), most likely impair the power of any class analysis that makes the 
assumption that the “wild type” cohort of tumour cells lines has a relatively minor 
proportion of phenocopies.  
 
Therefore characterisation of the panel of tumour cell lines by exome sequencing, mRNA 
expression, copy number profiling, protein expression by western blotting, and proteomic 
profiling was performed in order to classify the panel according to RB1 status. This 
enabled classification of the panel into ‘deficient’ and ‘wildtype’ RB1 groups, enabling 
class analyses to be performed to identify candidate genetic dependencies in the 
presence of deficient RB1. To identify the genetic and therapeutic dependencies of the 




panel of osteosarcoma tumour cell lines thought to be representative of the disease, 
parallel high-throughput siRNA screens and drug screens were performed. Integration of 
the screen data and molecular characterisation was performed to identify the genetic 
vulnerabilities and drug dependencies associated with driver alterations in osteosarcoma, 
and any possible tractable targets (Figure 7).  
 
This panel of OS tumour cell lines was further comprised of both non-isogenic and 
isogenic models (HOS and SAOS2), which have inherent advantages and 
disadvantages. Isogenic models all derive from a single progenitor cell line, whereby a 
specific genetic deficiency is engineered in daughter cells by genetic manipulation. This 
results in a minimal number of genetic differences between the daughter and parental cell 
lines, so that any observed differences are likely to be due to the gene of interest 
(Rehman, Lord & Ashworth, 2010). However, the limitation of an isogenic system is that 
any candidate genetic dependency identified has the potential to be context specific to 
the cell line, preventing extrapolation to a wider panel of tumour cell lines or clinical 
samples, and can be readily rescued by alterations in other genes (Ashworth, Lord & 
Reis-Filho, 2011). While non-isogenic models may more closely represent the tumour 
heterogeneity observed in the clinical setting, the observations seen may be due to 
mutations in genes other than the gene of interest, and thus make interpretation more 
challenging (Rehman, Lord & Ashworth, 2010). Therefore, both isogenic and non-
isogenic OS tumour cell line models were used to investigate for candidate genetic 
dependencies. Any synthetic lethalities identified in a panel of tumour cell lines, are more 
likely a ‘hard’ synthetic lethality, relatively unaffected by changes in additional genes 
(Rehman, Lord & Ashworth, 2010). Therefore an ideal approach would be to use the 
isogenic model for discovery of candidate genetic dependencies, which could then be 
validated to confirm clinical relevance using a panel of tumour cell lines. 
 
At the beginning of this thesis, a number of OS tumour cell lines were in the process of 
characterisation by the Wellcome Trust Sanger Institute. However, no human isogenic 
models of loss of RB1, or CDKN2A in osteosarcoma had been described. Therefore, the 
panel of tumour cell lines was used to perform genetic perturbation and drug screens in 
osteosarcoma, while isogenic models (RB1 deficient and wildtype U2OS tumour cell lines 
created by CRISPR-Cas9 mutagenesis described in the next chapter) were used to 
assess candidate synthetic lethalities from the screen.
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Figure 7 Project Overview – Framework for Identification of novel therapeutic dependencies 
in osteosarcoma.  
Characterisation by parallel siRNA and drug screens was performed to identify candidate genetic 
dependencies (‘hits’). The molecular characterisation of the tumour cells lines was integrated with 
the candidate genetic dependencies generated from the screens, and used to perform ‘class 
analyses’ to identify genetic vulnerabilities associated with driver alterations in osteosarcoma such 
as RB1 status, prior to validation and mechanistic studies. 
 
 





3.2.1 Characterisation of the panel of osteosarcoma tumour cell line models 
A panel of 18 non-isogenic OS tumour cell lines, representing histological subtypes of OS 
was profiled (Table 8). Molecular profiling some of the lines (MG63, MHM, HOSMMNG, 
143B, OSA/SJSA-1, U2OS, SAOS2, OHS, KPD, and HAL) was performed (DNA copy 
number, DNA methylation status of ~27,000 CpG sites, and global mRNA expression 
data) by the EuroBoNeT, a European Network of Excellence on bone tumours 
(http://www.eurobonet.eu) (Ottaviano, Schaefer, Gajewski, et al., 2010). Further 
characterisation including exome sequencing and RNAseq on the remaining tumour cell 
lines (NY, HU03N1, HU09, HOS, G292 clone A141B1, NOS-1, CAL72, and LM7) was 
undertaken by Ultan McDermott, Wellcome Trust, Sanger Institute. Thirteen of these 
tumour cell lines are capable of tumour formation in mice (Lauvrak, Munthe, Kresse, et 
al., 2013) (Table 8), and have been shown to have similar mRNA profiles to tumour 
samples (Kresse, Rydbeck, Skårn, et al., 2012). The tumour cell lines were also profiled 
for the TP53 and CDKN2A status (Table 9). 
 
3.2.2 Exome Sequencing 
To assess whether the mutations found amongst the OS tumour cell line panel included 
candidate driver mutations found in clinical OS, these osteosarcoma models were 
compared to the known mutation profiles of OS tumours. Seventeen of the osteosarcoma 
tumour cell lines have been exome sequenced in collaboration with the Wellcome Trust 
Sanger Institute (information kindly provided by Dr Ultan McDermott). LM7 and SAOS2 
underwent exome sequencing at the Tumour Profiling Unit at the Institute of Cancer 
Research, London. 
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*COSMIC: Catalogue of somatic mutations in cancer 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ 
N/A: not all tumour cell lines have been studied for their tumourigenic potential 




Table 9: Further characterisation of OS tumour cell lines in the EuroBoNet Consortium 
Adapted from Ottaviano et al. (Ottaviano, Schaefer, Gajewski, et al., 2010) 
Tumour Cell Line CDKN2A* (Ottaviano, 
Schaefer, Gajewski, et 
al., 2010) 
aCGH of CDKN2A 
(Ottaviano, Schaefer, 
Gajewski, et al., 2010) 
Mutation status of 
TP53 (Ottaviano, 
Schaefer, Gajewski, et 
al., 2010) 
HAL Diploid Diploid Wildtype  
HOS Homozygous deletion Homozygous loss p.Arg156Pro 
143b Homozygous deletion Homozygous loss p.Arg156Pro 
HOSMNNG Homozygous deletion Homozygous loss p.Arg156Pro 
KPD Diploid Hemizygous loss Wildtype 
MG63 Homozygous deletion Homozygous loss Wildtype 
MHM Hemizygous deletion Diploid Wildtype 
OHS Diploid Gain p.Glu286Lys 
OSA / SJSA1 Hemizygous deletion Hemizygous loss Wildtype 
SAOS2 Diploid Diploid del2>EX4-EX8 
U2OS Hemizygous deletion Diploid Wildtype 
  
*CDKN2A homozygous deletion by muliplex ligation-dependent probe amplification 
(MLPA)(Ottaviano, Schaefer, Gajewski, et al., 2010)  
 




Of the 17 OS tumour cell lines sequenced and analysed by the Sanger Institute, there 
were 11864 exonic mutations were identified, with 3606 classified as insertions, deletions 
or complex. The most recurrent mutations are shown in Table 10, and the details of 
mutations seen in two or more tumour cell lines shown in Table 11. 
 
Five tumour cell lines had mutations in RB1 (HU09, HU03N1, NY, OHS and SAOS2), five 
had mutations in CDKN2A (CAL72, HOS, HOSMNNG, 143b and MG63) and seven had 
mutations in TP53 (HOS, 143b, HOSMNNG, HU03N1, NOS-1, OHS and SAOS2). LM7 
(daughter of SAOS2) was confirmed to have 95 private mutations (8 stopgain, 4 
splicesite, 3 frameshift, and 80 missense), not shared with SAOS2. Conversely, across 
the entire exome SAOS2 only had 27 private mutations (1 splicesite, 3 frameshift, and 23 
missense) not seen in LM7. Genetic alterations, (homozygous deletions, genomic 
amplification, essential splice, and indels) for each tumour cell line were diverse with few 
recurrent alterations observed. 
 
3.2.3 Categorisation of RB1 and p16 (CDKN2A) by molecular profiling, mRNA 
expression, western blotting and proteomic profiling for the panel of non-isogenic 
osteosarcoma tumour cell lines 
Mutations in RB1 and CDKN2A are amongst the most common known recurrent 
mutational events in sporadic osteosarcoma (Gorlick, Anderson, Andrulis, et al., 2003). 
Loss of function of RB1 is reported in many cancer types (Knudsen & Wang, 2010). 
Furthermore, germ-line mutations of RB1 have been associated with occurrence of 
osteosarcoma, while structural alterations and point mutations of the RB1 gene have 
been reported in up to 40% of sporadic cases (Araki, Uchida, Kimura, et al., 1991). 
Furthermore, in patients with OS, inhibition of the RB pathway has been associated with 
poorer prognosis, reduction in chemo-sensitivity and increased risk of metastasis (Ren & 
Gu, 2015). Thus genetic dependencies associated with loss of function of RB1 and 
CDKN2A are worthy of further investigation. One objective was to identify synthetic lethal 
effects associated with RB1 or CDKN2A dysfunction. This necessitated clustering of the 
tumour cell lines according to wildtype and ‘deficient’ status for both RB1 and p16. 
Therefore, to augment the genomic profiling I used mRNA expression data, and western 
blotting to assess protein expression, and proteomic abundance of RB1 and p16 
(CDKN2A).  




Table 10 Perturbation grid of recurrent alterations identified by the Sanger Institute in a 
panel of 17 OS tumour cell lines  























































































TP53                                     
CDK4                                     
MDM2                                     
RB1                                     
CDKN2A                                     
MYC                                     
ATRX                                     
COPS3                                     
CCNE1                                     
NF2                                     
EXT1                                     
FGFR1                                     
IGF1R                                     
NF1                                     
PIK3CA                                     
PTEN                                     
DNM2                                     
MDM4                                     
TSC2                                     
ARID2                                     
BRCA2                                     
CDKN1A                                     
CHEK2                                     
ERCC5                                     
FANCA                                     
FANCC                                     
FANCD2                                     
FBXW7                                     
FIP1L1                                     
IGF1                                     
PALB2                                     
PBRM1                                     
SMARC
A4                                     
WRN                                     
 
 




Table 11 Recurrent mutations identified in two or more of the OS tumour cell line panel by 
the Sanger Institute.  
Homozygous mutations are highlighted in red.  [TCL: tumour cell line panel] 
OS TCL TP53 RB1 CDKN2A ATRX TSC2 PBRM1 
HOS c.467G>C  Homozygous 
deletion 
   
HOSMNNG c.467G>C  Homozygous 
deletion 
 c.5116C>T  
143B c.467G>C  Homozygous 
deletion 
 c.5116C>T  
CAL72   Homozygous 
deletion 
   
G292 clone 
A141B1 
     c.4636+5_ 
4636+6insGAG 
HAL       
HU03N1 c.225_226insT Homozygous 
deletion 
    
HU09  Homozygous 
deletion 
    
KPD       
MG63   Homozygous 
deletion 
   
MHM       
NOS-1 c.818G>A   Homozygous 
deletion 
  
NY  c.2107-4C>G     
OHS c.856G>A c.1183C>T     






    
SJSA1/OSA       


















































































































































































































































































































































































































Figure 8 Comparison of exome sequencing and protein expression for RB1 and 
p16/CDKN2A of 18 osteosarcoma tumour cell lines.  
Western blot and the mutation status for RB1 and CDKN2A is shown for each tumour cell line. 
Exome sequencing was performed by the Wellcome Trust Sanger Institute for all OS tumour cell 
lines except LM7, which was undertaken by the Tumour Profiling Unit at the ICR. Total cell lysates 
from untreated cells were electrophoresed and immunoblotted as described in the Methods. 
Immunoblotting of actin was used as the loading control. The mutation status correlated with loss 
of protein expression for all tumour cell lines except U2OS and NY. NY harbours a homozygous 
substitution mutation of RB1 (c.2107-4C>G) of unknown significance, but RB1 expression was not 
detected by western blotting. No mutations of CDKN2A have been reported for U2OS, but p16 
expression was not detected by western blotting.  
 




3.2.3.1 Determining expression of RB1 and p16 (CDKN2A) by western blotting 
To confirm whether RB1 or CDKN2A mutations identified in OS tumour cell lines caused 
loss of wildtype protein the presence of RB1 and p16 (CDKN2A) were probed for by 
western blotting (Figure 8). The mutation status correlated with loss of protein expression 
for all tumour cell lines except U2OS and NY. NY harbours a homozygous substitution 
mutation of RB1 (c.2107-4C>G) of unknown significance, but RB1 expression was not 
detected by western blotting. No mutations of CDKN2A have been reported for U2OS, 
but p16 expression was not detected by western blotting. 
 
3.2.3.2 Determining mRNA expression and copy number status for RB1  
To categorise the tumour cell line panel according to RB1 expression, protein expression 
by western blotting was compared to known mutations of RB1. Absent protein expression 
of RB1 by western blotting in all tumour lines known to harbour non-functional mutations 
of RB1 was seen, except for the tumour cell line NY. Wildtype protein expression on 
western blotting was compared to the known mutational status of the OS tumour panel. 
Of the tumour cell lines with absent expression of RB1 on western blot, HU031N1 and 
HU09 were known to have homozygous deletions of RB1. OHS-N had a nonsense 
mutation of RB1, while SAOS2 and LM7 had essential splice mutations. NY harboured a 
homozygous substitution mutation of RB1 (c.2107-4C>G) of unknown significance, but 
RB1 expression was not detected by western blotting. Therefore, to identify if the 
mutation correlated with the loss of wildtype mRNA expression, as further confirmation of 
the RB1 status, both the copy number and mRNA expression of RB1 obtained from the 
Catalogue Of Somatic Mutations In Cancer (COSMIC www.cancer.sanger.ac.uk) 
(Forbes, Beare, Gunasekaran, et al., 2015) were compared to other tumour lines known 
to harbour homozygous deletions of RB1 (HU03N1, HU09, and SAOS2). This 
demonstrated that NY had a level of expression and copy number of RB1 comparable to 
those tumour cell lines and compatible with undetectable levels of protein expression on 
western blot (Figure 9). Therefore, NY was included in the RB1 deficient group. To 
confirm these observations, mRNA expression and copy number data from the Cancer 
Cell Line Encylopedia (CCLE www.broadinstitute.org/ccle) was obtained, but since data 
was only available for one OS tumour cell line with RB1 deficiency, comparison was not 
possible (data not shown).  
























































































Figure 9 NY exhibited a level of expression and copy number of RB1 comparable to those 
OS tumour cell lines with homozygous deletion of RB1 and undetectable levels of protein 
on western blotting, and therefore included in the RB1 deficient group. 
NY was determined to have a homozygous substitution mutation of RB1 (c.2107-4C>G) and 
absent expression of RB1 on western blot.  
(A) Scatter plot to illustrate expression of RB1 using normalised mRNA expression data from 
COSMIC to compare the OS tumour cell lines with known homozygous deletion of RB1 (HU03N1, 
HU09, and SAOS2), RB1 wildtype OS tumour cell lines (CAL72, HOS, MG63, NOS1, OSA/SJSA1 
and U2OS) with NY. Tumour cell lines with wildtype RB1 exhibited significantly greater normalised 
mRNA RB1 expression levels than tumour cell lines harbouring homozygous deletion of RB1 (p = 
0.0002).  
(B) Scatter plot to illustrate copy number data for RB1 from COSMIC was used to compare the OS 
tumour cell lines with known homozygous deletion of RB1, wildtype RB1 and NY.  
Median and range shown. P values calculated by Student’s t test. [hom del: homozygous deletion; 
COSMIC: Catalogue of somatic mutations in cancer www.cancer.sanger.ac.uk (Forbes, Beare, 
Gunasekaran, et al., 2015)] 




3.2.3.3 Determining mRNA expression and copy number status for CDKN2A 
To categorise the tumour cell panel according to expression of p16 (CDKN2A), protein 
expression determined by western blotting was compared to the known mutations of 
CDKN2A in the panel of tumour cell lines. Five cell lines had absent expression of p16 
(CDKN2A) by western blot, and five of these were known to have homozygous deletions 
of CDKN2A (143b, HOSMNNG, HOS, CAL72 and MG63). Levels of p16 (CDKN2A) 
protein were undetectable for the tumour cell line U2OS by western blotting, despite an 
absence of reported mutations when profiled by exome sequencing. Therefore, to further 
characterise the tumour cell line, CDKN2A copy number data and mRNA expression data 
were used for further annotation. Copy number data obtained from COSMIC 
www.cancer.sanger.ac.uk (Forbes, Beare, Gunasekaran, et al., 2015) confirmed that 
U2OS had two copies of CDKN2A in keeping with the wildtype sequencing (Figure 10). 
However, when mRNA expression of CDKN2A was plotted using data from COSMIC, it 
was apparent that the level of CDKN2A gene expression in U2OS was comparable with 
that seen in those tumour cell lines that were known to harbour a homozygous deletion 
(CAL72, HOS and MG63) (Figure 10). These observations were also confirmed using 
CDKN2A mRNA expression and copy number data from the CCLE (Figure 11). U2OS 
has been previously demonstrated to have undetectable levels of p16 (CDKN2A) on 
western blot and is used by anti-body manufactures as a negative control. On the basis of 
these results, U2OS was determined to be CDKN2A deficient.  
 
3.2.3.4 Characterisation of RB1 and p16/CDKN2A status by proteomic profiling 
In addition to the mRNA expression, protein expression by western blotting, and copy 
number described above, proteomic profiling undertaken by Colm Ryan, was used as 
another layer of annotation to further categorise the tumour cell lines into RB1 and 
CDKN2A deficient or wildtype groups. Following lysis, protein purification, and tryptic 
digest, peptides were separated by liquid chromatography and measured by mass 
spectrometer. Label-free proteome quantification was performed using the MaxQuant 
software environment (Coscia, Watters, Curtis, et al., 2016; Cox, Hein, Luber, et al., 
2014) to determine the quantitative abundance of 6696 proteins with a false discovery 
rate of less than one percent.  
 

























































































Figure 10 U2OS exhibited a copy number of CDKN2A comparable to those OS tumour cell 
lines with wildtype CDKN2A, but normalised mRNA expression levels of CDKN2A were 
undetectable comparable to those tumour cell lines with homozygous deletion of CDKN2A 
and absent expression by western blotting; therefore U2OS was categorised as CDKN2A 
deficient. 
Levels of p16 (CDKN2A) protein were undetectable for the tumour cell line U2OS by western 
blotting, despite an absence of reported mutations when profiled by exome sequencing.  
(A) Scatter plot to illustrate expression of CDKN2A using normalised mRNA expression data from 
COSMIC to compare the OS tumour cell lines with known homozygous deletion of CDKN2A 
(CAL72, HOS, and MG63), CDKN2A wildtype OS tumour cell lines (HU03N1, OSA/SJSA1 and 
SAOS2) with U2OS. Tumour cell lines with wildtype CDKN2A exhibited significantly greater 
normalised mRNA CDKN2A expression levels than tumour cell lines harbouring homozygous 
deletion of CDKN2A (p = 0.0088).  
(B) Scatter plot of copy number data for CDKN2A from COSMIC to compare the OS tumour cell 
lines with known homozygous deletion of CDKN2A, wildtype CDKN2A and U2OS.  
Median and range shown. P values calculated by Student’s t test. [hom del: homozygous deletion; 
COSMIC: Catalogue of somatic mutations in cancer www.cancer.sanger.ac.uk (Forbes, Beare, 
Gunasekaran, et al., 2015)] 























































































Figure 11 U2OS exhibited a copy number of CDKN2A comparable to those OS tumour cell 
lines with wildtype CDKN2A, but mRNA expression levels were comparable with tumour 
cell lines harbouring homozygous deletion using data from the CCLE, concordant with 
observations using data from COSMIC.  
Levels of p16 (CDKN2A) protein were undetectable for the tumour cell line U2OS by western 
blotting, despite an absence of reported mutations when profiled by exome sequencing. 
(A) Scatter plot illustrating expression of CDKN2A using normalised mRNA expression data from 
CCLE to compare the OS tumour cell lines with known homozygous deletion of CDKN2A (HOS, 
and MG63), CDKN2A wildtype OS tumour cell lines (G292 clone A141B1 OSA/SJSA1 and 
SAOS2) with U2OS. Tumour cell lines with wildtype CDKN2A exhibited significantly greater 
normalised mRNA CDKN2A expression levels than tumour cell lines harbouring homozygous 
deletion of CDKN2A (p = 0.0018). 
(B) Scatter plot illustrating copy number data for CDKN2A from COSMIC to compare the OS 
tumour cell lines with known homozygous deletion of CDKN2A, wildtype CDKN2A and U2OS.  
Median and range shown. P values calculated by Student’s t test. [hom del: homozygous deletion; 








Proteomic abundance of RB1 for all the OS tumour cell lines including the isogenic RB1 
deficient and wildtype U2OS models engineered by CRISPR-Cas9 mutagenesis, 
clustered into two groups, concordant with RB1 expression levels observed by western 
blotting (Figure 12). This provided further confirmation of the classification into RB1 
deficient and wildtype groups (Figure 12). NY had the lowest level of RB1 protein 
abundance in the panel of tumour cell lines, providing further confirmation that the known 
mutation in RB1 leads to loss of expression at the protein level in this tumour cell line. 
 
In addition, proteomic abundance of p16 (CDKN2A) for all the OS tumour cell lines, 
clustered into two groups, concordant with CDKN2A expression levels observed by 
western blotting. U2OS clustered with tumour cell lines with known loss of p16 
(CDKN2A)(Figure 13). 
 
3.2.4 Classification of Osteosarcoma Tumour Cell line panel into RB1 and 
CDKN2A deficient and wildtype groups 
On the basis of the exome sequencing, protein expression as determined by western 
blotting, mRNA expression data, copy number and proteomic profiling the osteosarcoma 
tumour cell line panel was classified according to RB1 (Table 12) and CDKN2A (Table 
13) status, for the purpose of identification of candidate genetic dependencies for these 
genetic markers. 
 
3.2.5 TP53 mutation status and protein expression in the panel of non-isogenic 
osteosarcoma cell lines 
A variety of stress signals can activate the p53 pathway, and loss of function of p53 is 
common feature in cancer (Muller & Vousden, 2014), with as many as 80% OS tumours 
harbouring a mutation (Chen, Bahrami, Pappo, et al., 2014). It is not possible to 
determine the protein expression of p53 by TP53 mutation status alone, since mutations 
can exert both a dominant-negative regulation over any remaining wildtype p53, or can 
acquire new oncogenic functions (Muller & Vousden, 2014). 









































































































Figure 12 RB1 protein abundance in osteosarcoma tumour cell lines defined by mass 
spectroscopy proteomic profiling.  
Bar chart illustrating protein abundance of RB1 for each OS tumour cell line; red columns indicate 
tumour cell lines classified as RB1 deficient by western blotting (Figure 8), copy number and 
mRNA expression levels (Figure 9). Isogenic RB1 wildtype (U2OS 9.1) and mutant U2OS tumour 
cell lines (U2OS 4.2 and U2OS 4.5) generated by CRISPR-Cas9 mediated mutagenesis 
(described in next chapter) are shown as contrasts. Following lysis, protein purification, and tryptic 
digest, peptides were separated by liquid chromatography and measured by mass spectrometer. 
Label-free proteome quantification was performed using the MaxQuant software environment 
(Coscia, Watters, Curtis, et al., 2016; Cox, Hein, Luber, et al., 2014) to determine the quantitative 
abundance of 6696 peptides with a false discovery rate of less than one percent.  
 




Therefore, in an attempt to determine the protein expression profile of p53 in the panel of 
OS tumour cell lines, all the OS tumour cell lines were exposed to 1µM doxorubicin for 
four hours to induce a DNA damage response and p53 expression. Lysates were 
collected at four and 24 hours post doxorubicin exposure. The protein expression of total 
p53, phosphorylated p53 (Serine 15) and p21 (downstream of p53) in the panel of OS 
tumour cell lines was determined by western blotting (Figure 14, Figure 15, Figure 16, 
Figure 17 and Figure 18). 
 
Western blotting demonstrated that the expression of phosphorylated and total p53 in the 
presence of DNA damage was disrupted in the majority of OS tumour cell lines, in 
keeping with that observed in tumour samples (Chen, Bahrami, Pappo, et al., 2014). 
Inspection of mutation alone was inadequate to determine the functional status of the 
pathway. 
 
3.2.5.1 Characterisation of TP53 status of OS cells using proteomic expression 
To further aid classification of the OS tumour cell line panel with regards p53 status, 
proteomic profiling was undertaken. Label-free proteome quantification was performed 
using the MaxQuant software environment (Coscia, Watters, Curtis, et al., 2016; Cox, 
Hein, Luber, et al., 2014) to determine the quantitative abundance of 6696 peptides with 
a false discovery rate of less than one percent. The majority of OS tumour cell lines with 
a mutation of TP53 clustered together, with increased abundance of the protein (Figure 
19). 





















































































































Figure 13 p16 (CDKN2A) protein abundance in osteosarcoma tumour cell lines defined by 
mass spectroscopy proteomic profiling.  
Bar chart illustrating protein abundance of p16 (CDKN2A) for each OS tumour cell line; red 
columns indicate tumour cell lines classified as CDKN2A deficient by western blotting (Figure 8), 
copy number (Figure 10) and mRNA expression levels (Figure 11). Isogenic RB1 wildtype (U2OS 
9.1) and mutant U2OS tumour cell lines (U2OS 4.2 and U2OS 4.5) generated by CRISPR-Cas9 
mediated mutagenesis (described in the next chapter) are shown as contrasts. Following lysis, 
protein purification, and tryptic digest, peptides were separated by liquid chromatography and 
measured by mass spectrometer. Label-free proteome quantification was performed using the 
MaxQuant software environment (Coscia, Watters, Curtis, et al., 2016; Cox, Hein, Luber, et al., 
2014) to determine the quantitative abundance of 6696 peptides with a false discovery rate of less 
than one percent.  
 




Table 12 Summary of classification of osteosarcoma tumour cell lines into RB1 deficient 
and wildtype groups on the basis of exome sequencing, mRNA expression data, copy 
number and proteomic profiling. 












 G292 clone A141B1 
 
 
Table 13 Summary of classification of osteosarcoma tumour cell lines into CDKN2A 
deficient and wildtype groups on the basis of exome sequencing, mRNA expression data, 
copy number and proteomic profiling. 
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Figure 14 Heterogeneity of p21, p53 and phospho serine 15-p53 responses to doxorubicin 
in OS tumour cell lines (HOS, MG53, U2OS and 143b).  
Western blot is shown. OS tumour cell lines were exposed to the DNA damaging agent 
doxorubicin (1µM) or drug vehicle, DMSO (“untreated”) for four or 24 hours to induce DNA 
damage. Total cell lysates isolated after drug exposure were electrophoresed and immunoblotted 
as described in the Methods. Immunoblotting of actin was used as the loading control. All OS 
tumour cell lines with the exception of MG63, exhibited p53 and phospho-p53 induction in 
response to doxorubicin; only U2OS exhibited induction of p21 in response to doxorubicin.  



















































































































p53 (53 kDa) 







Figure 15 Heterogeneity of p21, p53 and phospho serine 15-p53 responses to doxorubicin 
in OS tumour cell lines (SAOS2, HOSMNNG, NY and SJSA-1/OSA).  
Western blot is shown. OS tumour cell lines were exposed to the DNA damaging agent 
doxorubicin (1µM) or drug vehicle, DMSO (“untreated”) for four or 24 hours to induce DNA 
damage. Total cell lysates isolated after drug exposure were electrophoresed and immunoblotted 
as described in the Methods. Immunoblotting of actin was used as the loading control. Only 
HOSMNNG exhibited p53 and phospho-p53 induction in response to doxorubicin; only SJSA-
1/OSA exhibited induction of p21 in response to doxorubicin.  
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Figure 16 Heterogeneity of p21, p53 and phospho serine 15-p53 responses to doxorubicin 
in OS tumour cell lines (HU09, NOS1 and HAL).  
Western blot is shown. OS tumour cell lines were exposed to the DNA damaging agent 
doxorubicin (1µM) or drug vehicle, DMSO (“untreated”) for four or 24 hours to induce DNA 
damage. Total cell lysates isolated after drug exposure were electrophoresed and immunoblotted 
as described in the Methods. Blots for p21 and phosphorulated p53 were developed using film, 
while total p53 and actin were processed on the Liquor. Immunoblotting of actin was used as the 
loading control. Only NOS1 exhibited p53 and phospho-p53 induction in response to doxorubicin 
and was constitutively activated in DMSO; none of the tumour cell lines exhibited induction of p21 
in response to doxorubicin.  
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Figure 17 Heterogeneity of p21, p53 and phospho serine 15-p53 responses to doxorubicin 
in OS tumour cell lines (MHM, CAL72 and HU03N1).  
Western blot is shown. OS tumour cell lines were exposed to the DNA damaging agent 
doxorubicin (1µM) or drug vehicle, DMSO (“untreated”) for four or 24 hours to induce DNA 
damage. Total cell lysates isolated after drug exposure were electrophoresed and immunoblotted 
as described in the Methods. Immunoblotting of actin was used as the loading control. MHM 
exhibited phospho-p53 induction in response to doxorubicin, while an increase of phospho-p53 
was seen only at four hours with HU03N1; only MHM exhibited induction of p21 in response to 
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	 Figure 18 Heterogeneity of p21, p53 and phospho serine 15-p53 responses to doxorubicin 
in OS tumour cell lines (KPD, G292 clone A141B1, OHSN and LM7).  
Western blot is shown. OS tumour cell lines were exposed to the DNA damaging agent 
doxorubicin (1µM) or drug vehicle, DMSO (“untreated”) for four or 24 hours to induce DNA 
damage. Total cell lysates isolated after drug exposure were electrophoresed and immunoblotted 
as described in the Methods. Immunoblotting of actin was used as the loading control. Only OHSN 
exhibited p53 and phospho-p53 induction in response to doxorubicin; none of the tumour cell lines 
exhibited induction of p21 in response to doxorubicin, but p21 expression was constiuatively 






















































































































Figure 19 TP53 protein abundance in osteosarcoma tumour cell lines defined by mass 
spectroscopy bated proteomic profiling.  
Bar chart illustrating protein abundance of TP53 for all the OS tumour cell lines; red columns 
indicated tumour cell lines classified as TP53 mutant by exome sequencing, and black columns 
TP53 wildtype. Tumour cell lines with known mutations in TP53 (HOS, HOSMNNG, 143b, SAOS2, 
NOS-1, HU03N1 and OHS-N) clustered together with the exception of LM7. Isogenic RB1 wildtype 
(U2OS 9.1) and mutant U2OS tumour cell lines (U2OS 4.2 and U2OS 4.5) generated by CRISPR-
Cas9 mediated mutagenesis (described in the next chapter), were shown as contrasts. Following 
lysis, protein purification, and tryptic digest, peptides were separated by liquid chromatography 
and measured by mass spectrometer. Label-free proteome quantification was performed using the 
MaxQuant software environment (Coscia, Watters, Curtis, et al., 2016; Cox, Hein, Luber, et al., 
2014) to determine the quantitative abundance of 6696 peptides with a false discovery rate of less 








3.2.6 Comparison of OS tumour cell line panel with OS tumour samples 
Characterisation of the panel of OS tumour cell lines was performed with the primary aim 
of comparison with the reported molecular landscape of tumour samples to determine 
whether the panel of OS tumour cell lines represented a valid model to investigate 
recurrent driver mutations. For this comparison, the isogenic daughter tumour cell lines 
143b and HOSMNNG (daughters of HOS), and LM7 (daughter of SAOS2), were 
excluded to prevent skewing of the data set. Whole exome sequencing data confirmed 
that the pattern of somatic mutations seen in the tumour cell line panel, was similar to that 
observed in clinical tumour samples (Kansara & Thomas, 2007; Chen, Bahrami, Pappo, 
et al., 2014). The frequency of OS tumour samples that harbour mutations of TP53 vary 
between cohorts from 20-80% (Gokgoz, Wunder, Mousses, et al., 2001; Chen, Bahrami, 
Pappo, et al., 2014). Mutations of TP53 were seen in 26% (4/15) of the tumour cell line 
panel.  
 
Mutations of RB1 were seen in 33% (5/15) of the tumour cell lines, compared to up to 
35% in sporadic cases of osteosarcoma (Araki, Uchida, Kimura, et al., 1991). Mutations 
in CDKN2A and ATRX were present in 20% (3/15), and 13% (2/15) of the tumour cell 
lines respectively. Less than 25% of tumour samples have been reported to harbour 
mutations of CDKN2A (Nielsen, Burns, Rosenberg, et al., 1998; Kansara & Thomas, 
2007). Mutations of ATRX are seen at a frequency of 29% in the clinical disease, (Chen, 
Bahrami, Pappo, et al., 2014), slightly higher than seen in the tumour cell line panel. 
 
Of these candidate driver mutations it was only possible to study those with sufficient 
statistical power. Only two tumour cell lines had mutations of ATRX (NOS-1 and U2OS), 
lower than the frequency seen in the clinical disease (29%) (Chen, Bahrami, Pappo, et 
al., 2014), which prevented further investigation. Cells harbouring mutations of TP53 and 
expression of p53 post exposure to DNA damage were too ambiguous to cluster into two 
definite groups. Therefore, given the recurrent nature of the driver mutations RB1 and 
CDKN2A and sufficient cohorts for deficient and wildtype groups, these two genes were 
chosen for investigation of synthetic lethality. 
 
To further confirm the clinical relevance of the tumour cell line models used, comparison 
of the OS tumour cell line panel to a library of 112 tumour samples at the Wellcome 
Institute, Sanger Centre, was sought. (Behjati, Tarpey, Haase, et al., 2017) Whole 




genome sequencing of the tumour samples was performed and a schematic of the driver 
mutations is shown in Figure 20 (Behjati, Tarpey, Haase, et al., 2017). The frequency and 
specificity of the driver mutations observed in these tumour samples closely resembles 
those seen in the panel of 18 OS tumour cell lines. However, it is likely that the frequency 
of driver mutations recorded probably represents an under estimate of the molecular 
changes seen in OS tumour samples, due to the lack of matched normal genomes for 
comparison (Behjati, Tarpey, Haase, et al., 2017). 
 
3.3 ISOGENIC MODELS 
Isogenic models derive from a single progenitor cell line, with minimal genetic differences 
between the daughter and parental cell lines, so that any observed differences are more 
likely to be due to the gene of interest (Rehman, Lord & Ashworth, 2010). Therefore to 
identify candidate genetic dependencies associated with the driver mutations of RB1 or a 
specific phenotype such as PARP sensitivity (LM7 and SAOS2), isogenic models were 
sought. In the absence of any available models of RB1 deficiency and wildtype in 
osteosarcoma, breast models were used, while the generation of a model in 
osteosarcoma was undertaken by CRISPR-Cas9 mediated mutagenesis.  
 
3.3.1 Osteosarcoma isogenic models 
Two isogenic models were included amongst the OS tumour cell line panel. The OS 
tumour cell line HOS has been virally transformed using a K-Ras oncogene to 143B, and 
was previously chemically transformed by N-methyl-N-nitro-N-nitrosoguanidine to 
HOSMNNG (Rhim, Park, Arnstein, et al., 1975). HOS and its derivatives 143B and 
HOSMMNG, have been shown to cluster together in terms of gene expression, DNA 
methylation, and DNA copy number but within this clustering, HOS and HOSMMNG were 
more similar in terms of gene expression and methylation, and 143B and HOS in terms of 
copy number (Kresse, Rydbeck, Skårn, et al., 2012). The second LM7, was developed by 
multiple in vivo selection of SAOS2 cells in nude mice with pulmonary metastases (Jia, 
Worth & Kleinerman, 1999). 
 




3.3.2 RB1 isogenic breast models 
To provide a robust model to investigate specific genetic lethalities associated with loss of 
RB1 function, an isogenic model of RB1 loss was sought. Two RB1 deficient and wildtype 
breast models were kind gifts from Eric Knudsen, Thomas Jefferson University, 
Philadelphia, USA; metastatic breast adenocarcinoma tumour cell line (MDAMB231) and 
a non-tumourigenic epithelial breast cell line (MCF10A) both created by shRNA mediated 




At the commencement of this thesis, no human isogenic models of loss of RB1, or 
CDKN2A in osteosarcoma had been described. Therefore, a panel of tumour cell lines 
was used to describe the genetic dependencies in osteosarcoma with the aim of 
identification of candidate synthetic lethalities, while an isogenic model was created using 
CRISPR-Cas9 mutagenesis (described in the next chapter).  
 
Some of these models were already partially characterised by the EuroBoNet Consortium 
(Ottaviano, Schaefer, Gajewski, et al., 2010). The principle aim of completion of the 
exome sequencing of the remaining tumour cell lines was to ascertain their similarity with 
OS tumour samples, and confirm a clinically relevant model for investigation of the 
recurrent driver mutations RB1 and CDKN2A. After exclusion of 143b and HOSMNNG 
(daughters of HOS), and LM7 (daughter of SAOS2), to prevent skewing of the data set, 
the whole exome sequencing confirmed a pattern of mutations representative of those 
seen in the tumour samples at similar frequencies (Gokgoz, Wunder, Mousses, et al., 
2001; Chen, Bahrami, Pappo, et al., 2014; Araki, Uchida, Kimura, et al., 1991; Nielsen, 
Burns, Rosenberg, et al., 1998; Kansara & Thomas, 2007) with recurrent mutations in 
TP53, RB1, CDKN2A, with the exception of ATRX which was seen at a lower frequency 
than expected. 






















































































Driver events in 113 osteosarcomas
 
Figure 20 Summary of the driver events in osteosarcoma tumour samples.  
Bar chart illustrating the percentage driver mutations in each mutated cancer gene observed in 
112 OS tumours that under went exome (n = 75) or whole genome (n = 37) sequencing at the 
Wellcome Trust Sanger Institute. Mutations were subdivided by mutation type; blue: point mutation 
(substitutions; indels); and green: structural variant (amplification, homozygous deletion or 
disruptive breakpoint). Reproduced from Behjati et al. (Behjati, Tarpey, Haase, et al., 2017).
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Figure 21 RB1 deficient stable isogenic breast cancer cell line MDMAM231 and non-
tumourigenic epithelial breast cell line MCF10A do not express RB1. 
Western blot shown. The metastatic breast adencarcinoma tumour cell line (MDAMB231) and a 
non-tumourigenic epithelial breast cell line (MCF10A), both kind gifts from Eric Knudsen, were 
both created by shRNA mediated silencing of RB1 and a non-targeting control (shNS). Cell lysates 
were collected from untreated cells, electrophoresed and immunoblotted as described in the 
Methods. Immunoblotting of actin was used as the loading control. [shRB1: shRNA RB1 specific 
RNA; shNS: non-silencing RNA.] 
 




This panel of OS tumour cell lines was comprised of both non-isogenic and isogenic 
models that have inherent advantages and disadvantages as discussed in section 3.1. 
Therefore, both isogenic and non-isogenic OS tumour cell line models were used to 
investigate for candidate genetic vulnerabilities and drug dependencies.  
 
The OS tumour cell line panel was classified according to RB1 and CDKN2A deficiency 
by comparison of mutation status, mRNA expression, copy number, proteomic 
abundance and protein expression via western blotting to enable a ‘class analysis’ and 
identification of genetic vulnerabilities and drug dependencies associated with these 
recurrent alterations observed in both tumour samples and the TCL panel. This analysis 
forms the basis of Chapter six.  
 
In order to investigate the transcriptional changes associated with RB1 and CDKN2A 
deficiency, whole transcriptome analysis was performed in RB1 isogenic U2OS tumour 
cell lines created by CRISPR-Cas9 mutagenesis. As another layer of annotation to further 
categorise the tumour cell lines into RB1 and CDKN2A deficient or wildtype groups, 
proteomic profiling was undertaken. Only a preliminary analysis of this data-set has been 
performed as the data was only available towards the end of this PhD, therefore only 








4 Characterisation of RB1 deficient U2OS tumour cell lines 
engineered by CRISPR-Cas9 mutagenesis  
4.1 INTRODUCTION 
One of the limitations of using the combination of both breast and osteosarcoma tumour 
cell lines for loss of function of RB1, was the uncertainty of tissue specific genetic co-
occurrences, which had the potential to make interpretation of candidate genetic 
dependencies more challenging. Therefore, to identify candidate genetic dependencies in 
OS specific to RB1 deficiency, an isogenic model was developed. The advantages and 
limitations of isogenic and non-isogenic models have already been discussed previously 
section 3.1. In the absence of human isogenic models of RB1 deficiency and wildtype in 
osteosarcoma, I engineered a stable isogenic model of RB1 deficiency by genomic 
editing using clustered regularly interspaced short palindromic repeat and associated 
protein 9 (CRISPR-Cas9) mediated mutagenesis using the OS tumour cell line U2OS. 
 
While RNAi is a well-established method for high-throughput screening, siRNA are only 
able to temporarily silence the target gene. However, gene editing by CRISPR-Cas9 
mutagenesis is able to permanently inactivate the target gene and thus provides an 
alternative for validation. A schematic of the CRISPR-Cas9 methodology is shown in 
Figure 22. 
 
Bacteria rely on CRISPR-Cas9 mediated systems for acquired immunity against invading 
foreign nucleic acids, including those of viruses and plasmids, by sequence specific 
detection and silencing via RNA-guided DNA cleavage (Wiedenheft, Sternberg & 
Doudna, 2012). This system has been adapted for use in human cells, by the co-delivery 
of plasmids expressing the CRISPR-associated protein 9 (Cas9) nuclease isolated from 
Streptococcus pyogenes and guide RNA (Gaj, Gersbach & Barbas, 2013). Cas9 is 
directed to a specific target DNA site by 20 nucleotides at the 5’ end of the guide RNA 
(Sander & Joung, 2014). The correct protospacer adjacent motif (PAM) sequence must 
immediately follow the target sequence to allow successful binding of Cas9 (Sander & 
Joung, 2014). This means that the CRISPR-Cas9 system is highly maneuverable, simply 
by altering the guide RNA sequence, reviewed by (Sander & Joung, 2014). Double-strand 
breaks (DSBs) induced by Cas9, lead to both non-homologous end-joining (NHEJ) 
mediated indel mutations and homology-directed repair (HDR) (Sander & Joung, 2014). 




The CRISPR-Cas9 methodology provides a rapid and efficient alternative to Zinc-Finger 
Nucleases (ZFNs) and Transcription-Activator Like Effector Nuclease (TALENs) for gene 
editing (Gaj, Gersbach & Barbas, 2013) because of reliance on RNA-guided nucleases 
which use simple, base-pairing rules between the target DNA site and the engineered 
RNA, as opposed to protein-DNA interactions (Sander & Joung, 2014). One of the 
disadvantages of CRISPR-Cas9 is the potential for off-target effects due to mis-match of 
the guide RNA and target DNA, although the true frequency of these effects is unknown 
(Sander & Joung, 2014). One method of combating this problem is the use of multiple 




4.2 GENERATION OF NEW ISOGENIC OSTEOSARCOMA MODELS OF RB1 
DEFICIENCY  
In the absence of previously described models of RB1 deficiency in OS, generation of 
RB1 deficient models by CRIPSR-Cas9 were undertaken using an OS tumour cell line 
U2OS (Figure 23). This generated two clones U2OS 4.2 and 4.5 with premature stop 
(nonsense) mutations.   
 
4.2.1 Characterisation of two U2OS RB1 deficient isogenic models engineered 
by CRISPR-Cas9  
To determine the RB1 status of both U2OS clones 4.2 and 4.5, characterisation by 
Sanger sequencing, exome sequencing, mRNA expression, RB1 protein expression by 
western blotting, and proteomic abundance described below were undertaken. 






Figure 22: Schematic of targeted gene editing by CRISPR (clustered regularly interspaced 
short palindromic repeat) Cas9.  
The Cas9 protein, shown in blue is directed to the target DNA sequence by 20 nucleotides at the 
5’ end of the guide RNA and the protospacer adjacent motif (PAM) sequence that follows the 
target sequence. Binding of the Cas9 causes double–strand breaks (DSBs) that can be repaired 
by non-homologous end-joining (NHEJ) which mediate indel mutations and homology-directed 
repair (HDR). Using this methodology, stable isogenic cell lines with the inactivation of a targeted 
gene can be produced (reproduced from http://ko.cwru.edu/services/directtargeting.shtml) 




RB1 mutant Cas9 control 
RB wildtype 
Transfection of Cas9 
plasmid and guide DNA 
Manufacture of genomic DNA 
from CRISPR clones for PCR 
of target region of RB1 
Surveyor Assay performed using 
RB1 PCR product to identify 
mutants by multiple DNA bands 
Subclones of 25 
colonies per CRISPR-
Cas9 clone  


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































U2OS 4.2 U2OS 4.5 
	
Further annotation of mutant RB1 clones 
by RNAseq and exome sequencing 
 
Figure 23 Schematic of generation of RB1 isogenic osteosarcoma model by CRISPR 
(clustered regularly interspaced short palindromic repeat) Cas9 mutagenesis. 
A: U2OS cells were reverse transfected with Cas9 and guide DNA, or Cas9 alone (control); B: 
Transfection efficiency was monitored using an EGFP control. Cells were selected by blastocydin, 
and seeded for colony formation. 100 colonies were picked and expanded; C: Manufacture of 
genomic DNA from single colony clones, and subsequent amplification of target region of RB1 by 
PCR; D: Surveyor Assay performed using the RB1 PCR product of all clones to further identify 
possible mutants by multiple DNA bands; E: Subclones of mutant clones identified, using 25 
colonies per clone; F: Sanger sequencing of all subclones, for comparison with sequencing from 
Cas9 control (parental) clone; G: Confirmation of expression of RB1 protein level using western 
blot of both N-terminus and C-terminus of RB1; H: Further annotation of the RB1 mutant clones by 
RNAseq and exome sequencing.  
 
 




4.2.1.1 Sanger sequencing confirms nonsense mutations of RB1 
Sanger sequencing of subclones of both U2OS clones 4.2 and 4.5 was performed to 
determine the mutation status of each clone, and the translational effect on the protein 
(Figure 26). Both clones were confirmed to have premature stop (nonsense) mutations 
(Table 14). Translation of mutant product for the U2OS CRISPR-Cas9 clone 4.2 
demonstrated truncation of the protein at p.61 (TAA). Translation of mutant product for 
U2OS CRISPR-Cas9 clone 4.5 demonstrated truncation of the protein at p.30 (TGA) by 
insertion of a T insertion (c.87Tins), highlighted by the red box.  
 
Only one AUG start codon with a single protein coding transcript has been reported for 
RB1. Other splice variants are subject to nonsense mediated decay. 
 
4.2.1.2 Exome sequencing of the isogenic RB1 deficient and wildtype U2OS 
tumour cell lines 
The exome sequences of the U2OS RB1 mutant clones were each compared to the RB1 
wild type (U2OS 9.1) clone separately. Contrastive analysis of the U2OS 4.2 and U2OS 
9.1 exome sequences identified a total of 85 protein-altering mutations, 43 of which were 
specific to the RB1 wild type U2OS 9.1 clone and 42 were specific to the RB1 deficient 
U2OS 4.2 clone. Of 85 protein-altering mutations, 67 were missense, eight were 
frameshifts, four were splice site alterations and six were nonsense (stop-gained) 
mutations depicted in red in Figure 27. The 10 base pair deletion of RB1 previously 
identified by Sanger sequencing was confirmed by exome sequencing in U2OS 4.2, not 
seen in the parental 9.1.  
 
A contrastive analysis of the U2OS 4.5 and U2OS 9.1 exome sequences identified a total 
of 49 protein-altering mutations that were present in either U2OS 4.5 or U2OS 9.1 clones. 
Of these 49 mutations, 23 were specific to the RB1 wild type U2OS 9.1 clone and 26 
were specific to the RB1 deficient U2OS4.5 clone (Figure 27). Of these 49 mutations, 40 
were missense mutations, five were frame shift mutations, two were splice site alterations 
and two were nonsense mutations. The frameshift mutation of RB1 caused by T insertion 
in U2OS 4.5 identified by Sanger sequencing was also confirmed by exome sequencing.  
 




A summary of the genetic alterations of the protein altering mutations at splice sites, or 
causing frameshifts or stop-gains is shown in Table 15. Apart from the engineered 
mutations in RB1 in both daughter cell lines, none of the other alterations were in known 
key driver genes, and are therefore unlikely to significantly influence the therapeutic 
response of the models. 
 
The number of genetic alterations in addition to the mutations identified in RB1 are small, 
and most likely represent a combination of processes; the process of CRISPR-Cas9 
mediated mutagenesis requires a number of passages during cell culture, and given that 
U2OS is a tumour cell line, genetic drift could occur between the cell lines during routine 
culture; some alterations could be the result of off-target effects of the CRISPR guide, 
although the majority of the alterations noted are in the parental 9.1 clone; although the 
parental clone was not transfected with a guide sequence, it was still transfected with 
Cas9, which is stably expressed. Theoretically there is the potential for some nonspecific 
activity of the Cas9 nuclease (Jinek, Chylinski, Fonfara, et al., 2012). Without the 
formation of the Cas9 complex with CRISPR guide RNA, the Cas9 is not thought to 
mediate non-specific double strand breaks (Anders, Niewoehner, Duerst, et al., 2014). 
Therefore, the presence of RNA sequences that can act as a guide RNA substrate, and 
the expression level of Cas9, will likely determine the extent of the off target effect. In 
addition the majority of reported mutations were single base pair alterations, which were 








Table 14 Characteristics of the mutations generated in RB1 in two isogenic RB1 deficient 
U2OS CRISPR-Cas9 engineered clones 
 U2OS CRISRP-Cas9 clone 
4.2 
U2OS CRIPSR-Cas9 clone 
4.5 
CRISPR guide used AA4 AA4 
Generated mutation 10bp deletion (c.90-99del) T insertion (c.87Tins) 
Effect of mutation p.61 stop p.30 stop 
 





Figure 24 Sanger sequencing from five subcloned products for U2OS CRISPR-Cas9 clone 
4.2 confirm a 10 base pair deletion (c.90-99del) in all alleles. 
Sanger sequencing from five subclones for the RB1 Exon 1 PCR product were aligned to the 
reference sequence of RB1 cDNA to identify any alterations, and enable naming based on 
standard nomenclature. Highlighted by the red box is a 10 base pair deletion identified in this 
clone, replicated in five subcloned sequences, depicted alphabetically and also by 
electropherogram. The U2OS clone 4.2 was subcloned, DNA isolated and Exon one of RB1 
amplified by PCR. Sanger sequencing for five representative subclones are shown. Sequencher 
DNA Sequence Analysis Software was (www.genecodes.com) was used to visualise the 
sequencing. 




		 Figure 25 Sanger sequencing from three subcloned products for U2OS CRISPR-Cas9 clone 
4.5 confirm an insertion of T (c.87Tins) in all alleles. 
Sanger sequencing from three subclones for the RB1 Exon 1 PCR product were aligned to the 
reference sequence of RB1 cDNA to identify any alterations, and enable naming based on 
standard nomenclature. Highlighted by the red arrow and box is a single T insertion identified in 
this clone, replicated in three subcloned sequences, depicted alphabetically and also by 
electropherogram. The U2OS clone 4.5 was subcloned, DNA isolated and Exon one of RB1 
amplified by PCR. Sanger sequencing for three representative subclones are shown. Sequencher 
DNA Sequence Analysis Software was (www.genecodes.com) was used to visualise the 
sequencing. 








Pro Domain A Domain B Domain C 
373 - 579 640 - 771 771 - 928 10 - 18 20 - 29 
Pocket 
CDK4 and cyclin 
E binding sites U2OS 4.5  
p.30 stop 
U2OS 4.2  
p.61 stop 
	 
Figure 26 Schematic of the structure of the RB1 protein, and predicted effects of mutations 
seen in U2OS CRIPSR-Cas9 clones 4.2 and 4.5.  
The RB1 protein comprises 3 domains (A, B and C). Together the region between Domains A and 
B comprise the Pocket, which binds to Domain C preventing interaction with heterodimeric 
E2F/DP transcription factor complexes (adapted from 
www.uniprot.org/uniprot/P06400#family_and_domains) (Dick, 2007). Only one AUG start codon 
with a single protein coding transcript has been reported for RB1. Other splice variants are subject 










Figure 27 Contrast analysis of the exome sequencing of U2OS clones 4.2 and 4.5 compared 
to the parental line U2OS 9.1, determined mutations specific to each clone. 
Scatter plots of the protein changing mutation profiles of RB1 wildtype (U2OS 9.1) and RB1 
deficient cell line models (U2OS 4.2 and 4.5) determined by exome sequencing. The points 
highlighted in red along the x-axis represent the mutations unique to RB1 wildtype model, while 
the points highlighted in red along the y-axis represent the mutations unique to RB1 deficient 
models U2OS 4.2 and 4.5. Black dots represent mutations seen in both parental and daughter 
clones. The exome sequences of the U2OS RB1 mutant clones were each compared to the RB1 
wild type (U2OS 9.1) clone separately. Contrastive analysis of the U2OS 4.2 and U2OS 9.1 
exome sequences identified a total of 85 protein-altering mutations, 43 of which were specific to 
the RB1 wild type U2OS 9.1 clone and 42 were specific to the RB1 deficient U2OS 4.2 clone. A 
contrastive analysis of the U2OS 4.5 and U2OS 9.1 exome sequences identified a total of 49 
protein-altering mutations, of these 23 were specific to the RB1 wild type U2OS 9.1 clone and 26 
were specific to the RB1 deficient U2OS 4.5 clone. DNA was extracted from the OS tumour cell 
lines U2OS 4.2, 4.5 and 9.1 and members of the TPU (ICR) performed targeted exome capture. 
James Campbell (ICR) aligned the reads to the human reference genome, and performed somatic 
variant calling. Graphical depiction by James Campbell and Aditi Gulati (ICR) using R.  
 




4.2.1.3 Whole Transcriptome Sequencing of RB1 isogenic models 
RNAseq was also performed on the RB1 isogenic models MDAMB231 and MCF10A 
within the laboratory group. Comparison of all the RB1 deficient cell line models (U2OS 
4.2, U2OS 4.5, MDAMB231 and MCF10A), to identify up-regulated and down-regulated 
genes that were in common between the models was performed. Nine genes 
(Centromere Protein E (CENPE), Ankyrin Repeat Domain 50 (ANKRD50), RP11-
492E3.1, Glucosamine (UDP-N-Acetyl)-2-Epimerase/N-Acetylmannosamine Kinase 
(GNE), Tet Methylcytosine Dioxygenase 2 (TET2), Paralemmin 2 (PALM2), UDP-N-
Acetylglucosamine Pyrophosphorylase 1 Like 1 (UAP1L1), Glia Maturation Factor 
Gamma (GMFG) and RP11-420A23.1) were up-regulated in all models, of which, 
CENPE, GNE and ANKRD50 are known to be involved in cell division. Four genes 
(Baculoviral IAP Repeat Containing 3 (BIRC3), ST6 Beta-Galactoside Alpha-2,6-
Sialyltransferase 1 (ST6GAL1), Cytochrome B Reductase 1 (CYBRD1) and Mitochondrial 
Ribosomal Protein L45 (MRPL45)), other than RB1, were down regulated in all cell line 
models. 
 
It was not possible to compare expression levels of RB1 in the RB1 deficient daughter 
models U2OS 4.2 and 4.5 with that of OS tumour cell lines from the panel with known 
homozygous deletion of RB1, due to lack of values for mRNA expression of RB1 from 
publically available data sets (COSMIC and CCLE).  
 
Further annotation of the list of genes with protein altering mutations that differed 
between RB1 wildtype and deficient tumour cell line models was performed to determine 
if they were also differentially expressed. Seven genes (RB1, ERG1C1, WD Repeat 
Domain 60 (WDR60), TBC1 Domain Family Member 9B (TBC1D9B), Ubiquitin Specific 
Peptidase 53 (USP53), Keratin 8 (KRT8), and Caspase 10 (CASP10)), were differentially 
expressed in U2OS 4.2, and five genes (RB1, KRT8, Chromosome 17 Open Reading 
Frame 75 (C17orf75), Coatomer Protein Complex Subunit Beta 2 (COPB2), and USP53), 
as differentially expressed in U2OS 4.5. Interestingly in addition to RB1, differential 
expression was seen in both daughter tumour cell lines in KRT8, and USP53, an ubiquitin 
specific peptidase.  
 




Table 15 Alterations identified by exome sequencing of the RB1 deficient clones U2OS 4.2 
and 4.5 and parental 9.1 
Gene  U2OS 9.1 U2OS 4.2 U2OS 4.5 
RB1  CCTGAGGAGGA>C C>CT 
ERG1C1 G>GT  G>GT 
TBC1D9B G>GTA  G>GTA 
TTC6  GGGCCCTGCAT>G  
NOS2 AG>A   
GLT6D1  CA>C  
EFCAB13 CAGTG>C  CAGTG>C 
C8orf34   TCCGGCTCTCAGCGC>T 
PHACTR1   CTCTTT>C 
GLT6D1   CA>C 
NUDT1 G>T   
KLK12 C>T   
ECSCR  C>T  
WIPF2 T>G  T>G 
PYROXD1 C>A  C>A 
DMGDH G>T  G>T 






CCL25 G>A  G>A 
FAM98A C>A   
KRT8 G>A   
 
 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































U2OS 4.2 U2OS 4.5 
	 
Figure 28 MA plots to visualise the relationship between log fold change in expression and 
mean expression of each gene for the RB1 isogenic pairs.  
Scatter plots of differentially expressed genes between U2OS 4.2 and 4.5 compared to the 
parental clone U2OS 9.1 were defined using a False Discovery Rate (FDR) p-value of < 0.05 and 
are shown in red. RNA was extracted from the OS tumour cell lines U2OS 4.2, 4.5 and 9.1. 
Members of the TPU (ICR) performed mRNA sequencing and James Campbell and Aditi Gulati 
aligned the reads and performed a differential expression analysis in R using the Bioconductor 
package, DESeq2 (v1.14.1) which was used to generate the MA plots by Aditi Gulati. Triplicates 









4.2.1.4 Protein Expression of RB1 in the RB1 isogenic models 
Profiling of the clones by western blot confirmed that both 4.2 and 4.5 had lost expression 
of RB1 at both the N and C-termini (Figure 29).  
 
As another layer of annotation to further categorise the tumour cell lines into RB1 and 
CDKN2A deficient or wildtype groups, proteomic profiling was undertaken. Proteomic 
abundance of RB1 demonstrated the U2OS mutants clustered with tumour cell lines 




At the commencement of this thesis, no human isogenic models of loss of RB1 in 
osteosarcoma had been described. Therefore, a panel of tumour cell lines was used to 
describe the genetic dependencies in osteosarcoma with the aim of identification of 
candidate synthetic lethalities, while an isogenic model was created using CRISPR-Cas9 
mediated mutagenesis.  
 
The advantages and disadvantages of isogenic versus non-isogenic models have already 
been discussed. Employment of both types of models has the potential to increases the 
success of generating candidate genetic dependencies which are synthetically lethal with 
RB1 loss, but which can also be extrapolated across a wider panel of tumour cell lines.  
 
Two RB1 deficient models of OS were engineered using CRISPR-Cas9, which were both 
confirmed to have homozygous loss of function mutations by both Sanger and whole 
exome sequencing, and loss of expression of both the N and C terminus of RB1 by 
western blotting. Proteomic profiling provided further annotation, which demonstrated that 
the level of abundance of RB1 was comparable with the OS tumour cell lines known to 
harbour homozygous deletions of RB1. In order to investigate the transcriptional changes 
associated with RB1 deficiency, whole transcriptome analysis was performed in the RB1 
isogenic U2OS models. RB1 mRNA levels were significantly reduced (false discovery 
rate ≤ 0.05) in both the RB1 deficient models. Therefore, these models were robustly 
determined to suitable models to investigate the phenotype of RB1 deficiency in OS.


















































































Figure 29 U2OS RB1 mutant clones (4.2 and 4.5) generated by CRISPR-Cas9 do not express 
RB1 unlike RB1 wildtype parental U2OS 9.1. 
Western blotting of RB1 using antibodies to both the N and C termini for U2OS clones 4.2, 4.5, 
4.10, 4.15, 5.1 and 5.12 and the Cas9 only control 9.1. Lysates of U2OS collected 48 hours post 
transfection with siRNA targeting RB1 and the non-targeting siAllstar were used as positive and 
negative controls. Molecular weight of protein markers (ladder) shown in kilodaltons. Whole cell 
lysates were collected from untreated tumour cells, electrophoresed and immunoblotted as 
described in Methods. Immunoblotting of actin was used as the loading control. 




5 Identifying genetic dependencies in osteosarcoma  
5.1 INTRODUCTION 
This chapter describes the use of a high-throughput cell-based screen using a custom 
library of short interfering RNA (siRNA) oligonucleotides to identify candidate genetic 
dependencies in osteosarcoma. This system offers a relatively unbiased and rapid 
approach to systematically assessing the genetic contribution to a particular cellular 
phenotype. Although whole genome RNAi screens are possible, a focused screening 
using a subset of the most tractable genes was chosen to generate genetic dependency 
profiles of multiple models of osteosarcoma.  
 
RNA interference (RNAi) enables post-transcriptional gene silencing and has been 
performed using either small interfering RNA (siRNA) or small hairpin RNA (shRNA) 
(Willingham, Deveraux, Hampton, et al., 2004; Lord, Martin & Ashworth, 2009; Brough, 
Frankum, Sims, et al., 2011; Iorns, Lord, Turner, et al., 2007) to identify novel genes 
involved in biological processes.  
 
Non-protein coding miRNAs are transcribed from the genome and then processed in the 
nucleus into shorter RNA species bearing a hairpin structure (shRNAs) (Lord, Martin & 
Ashworth, 2009). shRNAs are exported from the nucleus and further processed into small 
RNA duplexes (siRNAs), which are loaded into the RNA-induced silencing complex 
(RISC) which facilitates binding between one of the siRNA strands and protein-coding 
mRNAs that have nucleotide sequence complementary to the siRNA (Lord, Martin & 
Ashworth, 2009).  Once siRNA/mRNA binding has occurred, and the target mRNA 
transcript recognised, a nuclease in RISC degrades the mRNA, thereby ultimately 
reducing the amount of mRNA that is available for translation and protein production 
(Lord, Martin & Ashworth, 2009). These steps are summarised in Figure 30. 
 
Small or short hairpin RNA (shRNA) comprise approximately 65 nucleotide sequences 
that are cloned into a viral vector backbone, enabling production of viral particles capable 
of transduction of the cell of choice. shRNA libraries can be classified by the type of 
vector used; such as non-viral (plasmid), retroviral, adenoviral or lentiviral (Iorns, Lord, 
Turner, et al., 2007). Screens based on shRNA vectors can provide long-term gene 
silencing since the vectors used are able to integrate into genomic DNA and are thus 
copied along with cellular DNA (Iorns, Lord, Turner, et al., 2007). One of the main 




limitations of shRNA is the inherent instability of some of the viral systems used to 
express them, limiting their wider exploitation. In contrast, siRNA are approximately 20 
base pairs in length and do not require a vector for transfer, but do require the target cells 
to be transfectable (Lord, Martin & Ashworth, 2009). Synthetic synthesis of siRNA results 
in consistent quality of reagents (Lord, Martin & Ashworth, 2009). siRNA only provide a 
relatively short period of silencing, as they are most likely degraded by the target cell, and 
not replicated with the genomic DNA (Lord, Martin & Ashworth, 2009).   
 
Analysis of siRNA screen data demonstrates a wide range of effects across cell lines. It 
has been reasoned that siRNAs causing significant loss of cell viability in all cell lines 
assayed are likely to target genes that have an essential ubiquitous function in both 
normal and tumour cells (Brough, Frankum, Sims, et al., 2011). Similarly, siRNAs with no 
major effect on viability in any of the cell lines either are not functional or target 
nonessential genes (Brough, Frankum, Sims, et al., 2011). Therefore, Brough et al. 
postulated that siRNAs causing significant lethality in the majority, but not all, cell lines 
most likely identify genes that represent tumour-specific dependencies and candidate 
therapeutic targets (Figure 31) (Brough, Frankum, Sims, et al., 2011). This approach 
generated a measure of viability for each of the siRNAs in the cell lines, expressed as Z 
scores, to allow comparison of data across the panel of cell lines, and to minimise the 
impact of variation caused by transfection efficiency between cell lines (Brough, Frankum, 
Sims, et al., 2011). 
 





Figure 30: Schematic describing RNA interference. 
Non-protein coding miRNAs are transcribed from the genome and then processed in the nucleus 
into shorter RNA species bearing a hairpin structure (shRNAs). shRNAs are exported from the 
nucleus and further processed into small RNA duplexes (siRNAs), which are loaded into the RNA-
induced silencing complex (RISC) which facilitates binding between one of the siRNA strands and 
protein-coding mRNAs that have nucleotide sequence complementary to the siRNA. Once 
siRNA/mRNA binding has occurred, and the target mRNA transcript recognised, a nuclease in 
RISC degrades the mRNA, thereby ultimately reducing the amount of mRNA that is available for 
translation and protein production. (Reproduced from Lord et al. (Lord, Martin & Ashworth, 2009)).  
 
 







































































































































Candidate Tumour Specific GeneA B C
 
Figure 31 Example of discrimination of essential and non-essential genes via waterfall plot 
of Z-scores.  
(A) siRNAs with no major effect on viability in any of the cell lines are either not functional or target 
nonessential genes.  
(B) siRNAs causing significant loss of cell viability in all cell lines assayed are more likely to target 
genes that have an essential ubiquitous function.  
(C) siRNAs causing significant lethality in the majority, but not all, cell lines are most likely to 
identify genes representing tumour-specific dependencies and candidate therapeutic targets 
(Brough, Frankum, Sims, et al., 2011).  
Adapted from Brough et al. (Brough, Frankum, Sims, et al., 2011). 
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Figure 32 Schematic of overview of high-throughput siRNA screen.  
First, transfection conditions for the panel of characterised OS tumour cell lines were optimised for 
each cell line. Cells were arrayed in triplicate and reverse transfected in 384-well plate format in 
variable densities and transfection reagents. After seven days, cell viability was measured using a 
luminescence assay that measures the metabolic activity of the cell using CellTiter-Glo (Promega). 
Optimal conditions were chosen which demonstrated the greatest dynamic range between 
negative and positive controls, with high reproducibility between the replicates. Secondly, the 
siRNA screens were performed in triplicate in 384 well plate format using an in-house library 
containing 720 kinases, 80 tumour suppressor genes and 480 genes from the Cancer Gene 
Census (Futreal, Coin, Marshall, et al., 2004). Thirdly, each screen was subjected to rigorous 
quality control measures to ensure reproducibility, and a sufficient dynamic range. Only screens 
that passed these pre-define criteria were analysed further. Cell viability scores were plate centred 
and transformed to Z scores, for further analysis. The median permutation test was used to 
identify candidate genetic dependencies associated with gene alterations.  




In order to maximise the potential for identification of candidate genetic dependencies 
specific to OS, a siRNA screen was performed in the panel of 18 OS tumour cell lines 
described in Chapter three. A schematic of the steps performed is shown in Figure 32. 
Optimisation of high-efficiency reverse transfection was performed for all of the tumour 
cell lines. Optimal conditions were chosen which demonstrated the greatest dynamic 
range between negative and positive controls, with high reproducibility between the 
replicates. Secondly, the siRNA screens were performed in triplicate in 384 well plate 
format using an in-house library containing 720 kinases, 80 tumour suppressor genes 
and 420 genes from the Cancer Gene Census (Futreal, Coin, Marshall, et al., 2004). A 
complete list of the genes included in each RNA sub-library is provided in Appendix 
Tables 1-3. Thirdly, each screen was subjected to rigorous quality control measures to 
ensure reproducibility, and a sufficient dynamic range. Only screens that passed these 
pre-define criteria were analysed further. Cell viability scores were plate centred and 
transformed to Z scores, for further analysis. The median permutation test and T-tests 




5.2.1 Screen optimisation 
Eighteen osteosarcoma tumour cell lines (described previously in Chapter three), to be 
used for subsequent screening, were reversed transfected in 384-well plate format to 
determine the optimal cell density and transfection reagent. The ideal transfection 
reagent would permit efficient entry of the siRNA following membrane permeabilisation 
without any toxicity to the cell in the absence of siRNA since non-specific toxicity to the 
cell could reduce the screen specificity. To allow efficient transfection, the density of cells 
was titrated such that the cells did not reach confluence at the end point of the 
experiment (day seven). Cells were seeded at 250 and 500 cells per well, and three 
transfection reagents (Lipofectamine 2000, Dharmafect 4, and RNAMax) were tested to 
determine the optimal cell density and transfection reagent for each cell line. As a positive 
control to ensure successful transfection, an siRNA targeting Polo-like kinase (siPLK), 
which is essential for viability was used (Strebhardt & Ullrich, 2006). Three non-targeting 
controls (siControl1, siControl2, and siAllstar) were used as negative controls. Cell 
density and transfection reagent was decided on the basis of which produced the 




maximum separation difference between survival fraction in the positive and negative 
controls. Within each plate 16 “mocks” at each cell density consisting of the same volume 
of media (35µL) with the addition of 10µL optimem to reach the same final volume (45µL) 
as the samples were plated. The survival fraction (SF) was calculated by the division of 
each sample by the median of the negative controls (non-targeting siRNA): 
 
Survival fraction = sample / median of the ‘mocks’ 
 
Selected optimisation conditions for each of the OS tumour cell line panel, determined by 
comparison of the survival fractions for each siRNA condition (siCON1, siCON2, Allstar, 
and PLK) are demonstrated in Figure 33 and summarised in Table 16. Optimal conditions 
were considered to be: (i) viability of <30% in siPLK wells; and (ii) viability relative to the 
‘mocks’ (wells without siRNA reagents) of >60% in two or more negative controls 
(Brough, Frankum, Sims, et al., 2011). Two cell lines (G292 Clone A141B1 and KPD) 
initially failed this first optimisation stage because of survival fractions of less than 50% in 
the negative controls and so were repeated successfully at higher cell densities of 750 
and 1000 cells per well. For 15 of the tumour cell lines the SF for the positive control 
(siPLK) was less than 30% and greater than 60% in at least two of the three negative 
controls (siCON1, siCON2 and allstar). Three (U2OS, KPD and OSA) had a SF of less 
than 50% in two of the three negative controls. However, all PLK values for these tumour 
cell lines were all less than 10%, thus deemed to have adequate separation of controls 
and resulting dynamic range for screening. 
 
5.2.2 siRNA screen overview 
A siRNA library targeting 720 known and putative human protein kinases, 80 tumour 
suppressor genes and 480 genes included in the Cancer Gene Census (Futreal, Coin, 
Marshall, et al., 2004) was obtained in 384-well plates from Dharmacon (GE, 3135 
Easton Turnpike, Fairfield, CT 06828, United States of America). A complete list of the 
genes included in each RNA sub-library provided in Appendix Tables 1-3. Each well 
contained 5µL (200nM) of a SMART pool of four distinct siRNA species targeting different 
sequences of the single target transcript. Additional positive (siRNA targeting PLK1) and 
negative (non-targeting siRNA: siControl1, siControl2 and siAllstar (Qiagen)) controls 
were added to the edges of each plate (8 wells of each control) (Figure 34), with an 




internal well of siPLK within the first plate (each screen consists of three 384 well plates). 
Each siRNA screen was carried out in triplicate. 
 
5.2.3 Osteosarcoma siRNA screen quality control 
To determine that the screening process was robust and reproducible, specific 
parameters were used as measures of quality control. Calculation of the Spearman’s rank 
correlation coefficient was used as a measure of the reproducibility between the 
replicates of each screen (Table 17). A Spearman’s rank value of one represented strong 
correlation, and zero no correlation. All tumour cell lines passed the stringent quality 
control with a mean Spearman's Rank correlation of all three replicates approaching 1 
(>0.7) (Turner, Lord, Iorns, et al., 2008; Iorns, Turner, Elliott, et al., 2008). 
 
A measure of the quality of the screen, the Z prime, based on the dynamic range of 
negative and positive controls was calculated (Figure 35). The dynamic range of each 
screen was determined by calculating Z prime values (Zhang, Chung & Oldenburg, 
1999), based on positive (siPLK) and negative (siCON1, siCON2 and allstar) control wells 
in each plate, which were used as a marker of quality (Figure 35). A minimum of two 
negative controls and one positive control was used for each analysis. Z prime values 
greater than >0.3 have been shown to be representative of reproducible data (Zhang, 
Chung & Oldenburg, 1999), and were considered acceptable, with a Z prime 0.5 – 1 
demonstrating a robust and powerful screen (Brough, Frankum, Sims, et al., 2011). 
Spearman Rank Correlation (as described above) determined the reproducibility between 
the replicates. 
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Figure 33 Selected optimisation conditions for high efficiency reverse transfection of the 
panel of osteosarcoma tumour cell lines.  
Bar charts illustrate the effect of siRNA non-targeting negative (siControl1, siControl2, and 
siAllstar) and positive control (siPLK) on viability. Viability was calculated relative to mock 
transfection, where mock refers to treatment with lipid transfection mix only, with no addition of 
siRNA. Each graph represents the optimal transfection reagent and cell density for each cell line in 
384-well plate format. For the majority (15/18) of the tumour cell lines, the siPLK reduced the 
surviving fraction to <30%, while the negative control siRNA (siCON1, siCON2, or siAllstar), 
resulted in a surviving fraction of >60% in two out of three controls. Error bars represent standard 
error of mean (SEM). [LF2000; Lipofectamine 2000; DF4: Dharmafect 4; Max: RNAmax] 




Table 16 Summary of optimised reverse transfection conditions for each tumour cell line 
screened in the RNAi viability profiling 
Cell Line Lipid Number of cells per well (384 
well plate) 
CAL72 Dharmafect 4 250 
HU03N1 RNA max 250 
HOSMNNG Dharmafect 4 500 
OSA/SJSA-1 Dharmafect 4 500 
NOS-1 RNA max 500 
MG63 Dharmafect 4 250 
SAOS2 RNA max 500 
U2OS RNA max 500 
HOS RNA max 500 
OHS-N RNA max 500 
MHM RNA max 500 
OS25-HAL RNA max 500 
LM7 RNA max 500 
KPD RNA max 750 
HU09 RNA max 500 
NY RNA max 500 
G292 clone A141B1 Lipofectamine 2000 1000 
143B RNA max 250 
 





Figure 34: Illustrative example of luminosity read-out as a measure of viability for a 384 well 
siRNA screening plate.  
Graphic illustrating cellular viability where blue represented loss of viability, orange represented 
some loss of viability, while red represented no loss of viability. Graphical representation of 
viability enables easy recognition of any edge effects or plating errors, and preliminary 
confirmation of successful controls. Cell lines were transfected with SMART pool siRNA using 
RNAiMax (Invitrogen), Lipofectamine 2000 (Invitrogen) or Dharmafect4 (Dharmacon) as per the 
results of prior optimisation described in section 5.2.1. After the addition of 35µL cell suspension to 
each well, the final concentration of siRNA was 20nM. Each cell line was screened in triplicate on 
the same day. After seven days cell viability was quantified via a highly sensitive luminescent 
assay measuring cellular ATP levels (CellTiter Glo; Promega). [Controls plated in Columns 2 and 
23 (siCON1: rows A-D; siCON2: rows E-H; siALLSTAR: rows I-L; siPLK1: rows M-P). N= negative 
control, P = positive control.] 
 
  




A Z prime of less than 0.3 was calculated in five tumour cell lines (KPD, HU09, NY, 
CAL72, and OSA/SJSA-1), because of reduced impact on viability by siPLK and/or more 
effect on viability by the negative controls. Using a subset of other cell lines that had 
undergone the same screening process by other members of the laboratory (n=99: 27 
breast; 19 ovary; 19 lung; 14 oesophagus; 5 pancreas; 5 head and neck; 4 cervical; 4 
central nervous system; 2 endometrium)(Campbell, Ryan, Brough, et al., 2016), I was 
able to compare the magnitude of effects on viability of siRNA directed against PLK and 
other mitotic check points such as Aurora Kinase A (AURKA) and WEE1 G2 Checkpoint 
Kinase (WEE1) in a wider panel of tumour cell lines (Figure 36). From the non-
osteosarcoma tumour cell line panel dataset four mitotic cell-cycle checkpoint kinases 
(PLK1, AURKA, WEE1, Chekpoint Kinase 1 (CHEK1)), Cyclin Dependent Kinase 11A 
(CDK11A), and Guanylate Cyclase 2D (GUCY2D) represented candidate genetic 
dependencies in more than 70% of the tumour cell lines screened (Campbell, Ryan, 
Brough, et al., 2016). Therefore, comparison of loss of viability for these genes was 
deemed a robust alternative method of confirming dynamic range. Comparison of the 
viability by silencing these additional genes (AURKA, WEE1 and GUCY2D) demonstrated 
that these OS screens were similar to those with a Z prime greater than 0.3 (Figure 36). 
This suggested that siPLK did not have a uniform effect on viability in all tumour cell lines 
but for tumour cell lines with a Z prime of greater than 0.3, siPLK was usually the most 
negative Z score. Whereas for the five tumour cell lines with a Z prime of less than 0.3, 
this was not the case, since hits from the screening library had a greater effect on 
viability. These five screens were therefore determined to be valid, and included in the 
panel, resulting in all 18 screens with robust viability profiles.  
 
5.2.4 Analysis of Raw data 
To account for the plate-to-plate variation common in high-throughput screens, raw 
luminescence readings from each well were log2 transformed and centred by the plate 
median. The data was normalised in this way, to also adjust for systemic errors of the 
screen for example variations in incubation time, differences in time when measuring 
luminescence values, or reagent evaporation, whilst preserving biologically relevant 
variation (Boutros, Brás & Huber, 2006). To allow data comparison between siRNA 
screens from individual tumour cell lines, the data was standardised by the use of a Z-
score statistic; the plate-centred data was standardised to median effects of the library 
and the median absolute deviation (MAD). A Z score of zero represented no effect on 




viability, while negative Z-scores represented loss of viability (Brough, Frankum, Sims, et 
al., 2011). All three replicates for each cell line were combined in the final analysis; the 
median Z-score for each individual siRNA was calculated using the median normalised 
value of each siRNA and the MAD in order to account for the variance within each screen 
(Boutros, Brás & Huber, 2006). The Z score statistic assumes a normal distribution, with 
the assumption that the majority of siRNA tested would have little or no effect on viability. 
The distribution of each screen was assumed to approximate to normal, allowing 
comparison of the individual siRNA effects in multiple tumour cell lines. A schematic 
detailing data analysis from raw luminescence values to Z scores is shown in Figure 37. 
 
5.2.5 Compilation of the dataset 
There are a number of possible methods to align multiple distributions of data sets to aid 
comparison of the Z scores of screens with a large difference in magnitude. Normalised 
percentage inhibition (NPI), is one such method which has been used in a similar high-
throughput RNAi screen (Mendes-Pereira, Lord & Ashworth, 2012). Calculation of NPI 
requires limits to be defined, usually as the maximal inhibitory effect as that caused by 
siRNAs targeting PLK, and the minimal effect as that caused by non-targeting control 
siRNAs. Since, siPLK did not have uniform effects on viability in the tumour cell lines, 
quantile normalisation (QN) (Bolstad, Irizarry, Astrand, et al., 2003; Qiu, Wu & Hu, 2013) 
of the data set was chosen instead. QN enables alignment of multiple distributions with 
consideration of rank and magnitude.   
 




Table 17 RNAi screen quality control: spearman's rank correlation coefficient for 
correlation of replicates and Z prime. 
All OS tumour cell lines had Spearman’s rank correlation coefficients approaching one (>0.7) and 
therefore, deemed to be reproducible (Turner, Lord, Iorns, et al., 2008; Iorns, Turner, Elliott, et al., 
2008). 
Cell Line Spearman’s Rank Correlation Coefficient Z Prime 
R1 v. R2 R2 v. R3 R1 v. R3 R1 R2 R3 
CAL72 0.8977 0.9087 0.8917 0.06 0.18 0.06 
HU03N1 0.7340 0.7888 0.7563 0.43 0.26 0.35 
HOSMNNG 0.9216 0.9108 0.9119 0.81 0.81 0.80 
OSA/SJSA-1 0.9512 0.9515 0.9478 -0.09 -0.29 -0.45 
NOS-1 0.8650 0.8524 0.8239 0.55 0.50 0.59 
MG63 0.8880 0.8830 0.8101 0.64 0.65 0.71 
SAOS2 0.7914 0.6632 0.6623 0.35 0.56 0.52 
U2OS 0.9203 0.9018 0.8644 0.36 0.34 0.39 
HOS 0.7899 0.8079 0.9470 0.68 0.67 0.72 
OHS-N 0.8776 0.8740 0.8900 0.37 0.45 0.39 
MHM 0.8511 0.8557 0.8072 0.66 0.59 0.57 
OS25-HAL 0.7983 0.8073 0.7316 0.61 0.59 0.61 
LM7 0.8570 0.8319 0.7772 0.69 0.64 0.60 
KPD 0.8784 0.9105 0.8916 0.24 0.16 0.25 
HU09 0.8023 0.7806 0.7147 0.02 -0.16 -0.41 
NY 0.8882 0.8774 0.8123 0.14 0.01 0.09 
G292 clone 
A141B1 
0.9243 0.9120 0.8898 0.45 0.48 0.49 
143B 0.9052 0.9045 0.8911 0.76 0.75 0.79 
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Figure 35 Clear separation of positive and negative controls confirmed by a Z prime of 
greater than 0.3. 
Distribution plot illustrating Z score values for positive and negative controls, which show clear 
separation, for one replicate of the siRNA screen performed in the OS tumour cell line HOS. 
Negative controls (siCON1, siCON2, siALLSTAR) shown in blue, positive controls (siPLK1) shown 
in red. The dynamic window shown by calculation of the separation of negative and positive 
controls, was termed Z prime. Cells were reverse transfected, and after seven days viability 
estimated using CellTiter Glo as described in the Methods. Raw luminescence values were 
processed using the CellHTS package of the R software suit (BioConductor), used to generate this 
distribution plot and calculate the Z prime. [plk: siPLK positive control; neg: non-targeting siRNA 
species used as negative controls] 
 
 











































































































































































































































































































































































Figure 36 Comparison of Z scores from RNAi screens in osteosarcoma, bladder and breast 
tumour cell lines highlighted the variance of Z scores and effects on viability by the mitotic 
check-point kinases (siPLK, siAURKA, siWEE1) and siGUCY2D.  
Violin plot of Z scores for each RNAi screen in OS, bladder and breast tumour cell lines to 
compare the magnitude of effects of viability of siRNA targeting GUCY2D (orange) and the mitotic 
check-point kinases PLK (red), AURKA (pink), and WEE1 (brown). Tumour cell lines with Z prime 
of less than 0.3 were highlighted in red. Comparison of the viability by silencing (AURKA, WEE1 
and GUCY2D) demonstrated that these OS screens were similar to those with a Z prime greater 
than 0.3 and deemed to be valid. From the RNAi data set of 117 tumour cell lines (including OS), a 
set of six kinase-coding genes (PLK1, AURKA, WEE1, CHEK1, CDK11A, and GUCY2D) has been 
determined to represent candidate genetic dependencies in greater than 70% of the tumour cell 
lines screened (Campbell, Ryan, Brough, et al., 2016). Cells were arrayed in triplicate 384 well 
plates, reverse transfected, and after seven days viability estimated using CellTiter Glo as 
described in the Methods. Raw luminescence values were converted to Z score statistics to 
enable comparison between screens. CAL72 had identical Z scores (-2.8) for PLK1 and AURKA. 
[Red: siPLK; orange: Guanylate Cyclase 2D (GUCY2D); pink: Aurora Kinase A (AURKA); brown: 
WEE1 G2 Checkpoint Kinase (WEE1)]
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Figure 37 Schematic of data analysis from raw luminescence values to generation of Z 
scores. 
Raw luminescence values from the siRNA screens performed in triplicate were first log2 
transformed and then plate centred by the plate median to account for plate-to-plate variation. To 
allow data comparison between siRNA screens from individual tumour cell lines, the data was 
standardised by the use of a Z-score statistic; the plate-centred data was standardised to median 
effects of the library and the median absolute deviation (MAD). A Z score of zero represented no 
effect on viability, while negative Z-scores represented loss of viability (Brough, Frankum, Sims, et 
al., 2011). Each replicate of the screen for each tumour cell line was used in the analysis and the 
median Z-score for each individual siRNA was calculated using the median normalised valued of 
each siRNA and the MAD, to account for the variance within the screen. Illustrative examples of 
triplicate raw luminosity read-outs as a measure of viability for 384 well siRNA screening plates 
are shown. Box and whisker plots of median and range of Log2 transformed data for each 
replicate of the screen shown in pink, and in blue after plate centred by the plate median 
(normalised data). Scatter plot illustrating range of the median Z scores for an individual RNAi 
screen in an OS tumour cell, with the positive controls (siPLK) highlighted in red and genes of 
interest (samples) in black. 




Quantile normalisation of the Z scores was kindly performed by James Campbell using 
the preProcessCore package (Bioconductor). This method (originally described by 
Bolstad et al. (Bolstad, Irizarry, Astrand, et al., 2003)) adjusts the distribution of z-scores 
for each cell line so as to make each of them identical whilst maintaining the approximate 
magnitude of the original z-scores. The principle of quantile normalisation is to first rank 
order (sort) z-scores for each cell line, average the values across each rank and then 
return the averaged values to the original order. The effect of QN on alignment of the 
distribution of the Z scores across the panel of 18 tumour cell lines can be seen in Figure 
38 and Figure 39. A Z score threshold of <-1.5 representing 1.5 median absolute 
deviation (MAD) effects from the median effect was used to define significant loss of 
viability. 
 
From this data set, it was possible to determine the genes whose depletion by siRNA 
caused loss of viability with a QN Z score less than minus 1.5 for each cell line (Figure 
39). This analysis shows the predominant genetic dependencies for each cell line, and 
the QN Z scores were used as a basis for all further comparisons. 
 
5.2.6 Identification of candidate genetic dependencies 
The median permutation test and Student’s t-tests were used to identify candidate 
genetic dependencies associated with gene alterations between groups of tumour cell 
lines. The Student’s t test was calculated using Microsoft Excel or GraphPad Prism. 
James Campbell, at the ICR, performed the median permutation test (MPT) using a 
custom script on R. The MPT is a random sampling test to calculate the median 
difference between two groups. One million random samples for the two groups are 
performed. A false discovery rate (FDR) was set at 0.1. The median permutation test 
does not assume that both data sets have a normal distribution, unlike the T-test, and so 
is a more rigorous selection method for identification of candidate genetic dependencies.  
 
 




















































































Figure 38 Range of Z scores for each RNAi screen for 18 OS tumour cell lines.  
Dot plot of range of Z scores for each OS tumour cell line, where each line represented a median 
Z score for each individual siRNA within the RNAi library, and the median Z score for the entire 
screen shown by a wider line. It was apparent that the range of Z scores varied between OS 
tumour cell lines. Cells were arrayed in triplicate 384 well plates, reverse transfected and after 
seven days viability was estimated using CellTiter Glo as described previously. Raw luminescence 
values were log2 transformed, plate centred to the plate median, and standardised to median 
effects of the library and MAD into Z scores. Each replicate of the screen for each tumour cell line 
was used in the analysis, and the median Z score for each individual siRNA was calculated using 
the median normalised value of each siRNA and the MAD to account for variance within the 
screen.  


































































































































































Figure 39 Effects of quantile normalisation on Z scores for each RNAi screen performed on 
the OS tumour cell line panel.  
Dot plot of range of quantile normalised (QN) Z scores for each OS tumour cell line, where each 
line represented a QN median Z score for each individual siRNA within the RNAi library, and the 
median QN Z score for the entire screen shown by a wider line. Cells were arrayed in triplicate 384 
well plates, reverse transfected and after seven days viability was estimated using CellTiter Glo as 
described in the Methods. Raw luminescence values were transformed into Z scores as previously 
described. Quantile normalisation of the Z scores for each screen was then used to align the 
multiple distributions of data and aid comparison of Z scores of screens with a large difference in 
magnitude, without loss of consideration of rank and magnitude of each screen. QN adjusts the 
distribution of z-scores for each cell line so as to make each of them identical whilst maintaining 
the approximate magnitude of the original z-scores (Bolstad, Irizarry, Astrand, et al., 2003). The 
principle of quantile normalisation is to first rank order (sort) z-scores for each cell line, average 
the values across each rank and then return the averaged values to the original order. Quantile 
normalisation of the Z scores was kindly performed by James Campbell using the preProcessCore 
package (Bioconductor).  




5.2.7 Unsupervised hierarchical clustering of osteosarcoma replicates 
To confirm reproducibility of the data set, unsupervised hierarchal clustering of a subset 
of the viability data for 15 of the 18 osteosarcoma tumour cell lines that were available at 
the time, all screened using the same library, was undertaken using Gene-e 
(http://www.broadinstitute.org/cancer/software/GENE-E/) (Figure 40). These results 
demonstrated that the biological replicates for each cell line cluster together except 
SAOS2, which was likely due to an edge effect on one of the replicates and hence was 
excluded from the analysis and final data set. Edge effects cause a larger degree of loss 
of viability around the edge of the plate, which has the potential to skew that data-set 
leading to a greater risk of identifying false positive effects. Hence, to mediate against this 
risk, low profile lids were used on the 384 well plates to reduce evaporation, and the 
screens performed in triplicate so that outlying replicates can be identified and discarded. 
SAOS2 and LM7 (which was cycled through the lungs of mice to form a metastatic cell 
line) clustered together. Tumour cell lines did not cluster according to date of experiment. 
 
5.2.8 Identification of skeletal system morphogenesis pathway as osteosarcoma-
specific genetic dependencies  
In order to identify genetic dependencies specific to osteosarcoma, supervised 
hierarchical cluster analysis of all 18 osteosarcoma tumour cell lines compared to the 99 
non-osteosarcoma tumour cell lines (Campbell, Ryan, Brough, et al., 2016) was 
performed and a heatmap generated as a visual measure of the differences of the two 
groups (Figure 41 and Figure 42). A significant difference in quantile normalised Z scores 
reflecting viability was seen in 163 genes between the two groups (OS and the non-
osteosarcoma tumour cell line panel). In addition, a heatmap of the most profound 
genentic dependencies seen in the OS panel alone is shown in Figure 43. No genetic 




























































































     
 
Figure 40 Unsupervised hierarchical clustering of the triplicate replicates for each siRNA 
screen in 15 OS tumour cell lines confirm reproducibility of the data set. 
Unsupervised hierarchical clustering of a subset of the viability data for 15 of the 18 OS tumour 
cell lines that were available at the time, all screened using the same RNAi library was performed. 
All biological replicates for each tumour cell line clustered together except SAOS2, which was 
likely due to an edge effect on one replicate and so was excluded from this analysis and final data 
set. SAOS2 and LM7 (which was cycled through the lungs of mice to form a metastatic cell line) 
clustered together. Tumour cell lines did not cluster according to date of experiment. Gene-e 
software (http://www.broadinstitute.org/cancer/software/GENE-E/) was used to perform this 
analysis.  
 





Figure 41 Heatmap of osteosarcoma tumour cell lines and 99 non-osteosarcoma tumour 
cell lines, by comparison of the QN Z scores in each group.  
Only significant (p<0.05) genetic dependencies are shown. Each row represents viability effects of 
silencing of a target gene, while each column represents a tumour cell line. Dark blue represents 
loss of viability, whereas white represents no effect on viability. James Campbell (ICR) used a 
custom script in R to perform this analysis and generate the heatmap. The 20 most significant 
candidate genetic dependencies are highlighted by a red box and shown in Figure 42. P values 
calculated by median difference permutation test. 





Figure 42 Heatmap of osteosarcoma tumour cell lines and 99 non-osteosarcoma tumour 
cell lines, by comparison of the QN Z scores in each.  
Each row represents viability effects of silencing of a target gene, while each column represents a 
tumour cell line. Dark blue represents loss of viability, whereas white represents no effect on 
viability. James Campbell (ICR) used a custom script in R to perform this analysis and generate 
the heatmap. The twenty most significant candidate genetic dependencies are shown (p<0.05). p 
values calculated by the median difference permutation test. 
 



















































































































Figure 43 Heatmap of osteosarcoma tumour cell lines by comparison of the QN Z scores in 
each. 
Each row represents viability effects of silencing of a target gene, while each column represents a 
tumour cell line. Turquoise represents loss of viability, whereas black represents no effect on 
viability, and yellow positive effects on viability. Aditi Agulati (ICR) used a custom script in R to 
perform this analysis and generate the heatmap. The eighteen significant candidate genetic 
dependencies are shown (p<0.05). p values calculated by the median difference permutation test. 




The heatmap demonstrated a number of genes which caused significant lethality 
amongst the osteosarcoma models, but minimal effect on viability in the non-
osteosarcoma tumour cell line panel models, which were considered most likely to 
represent tumour-specific dependencies and candidate therapeutic targets (Brough, 
Frankum, Sims, et al., 2011). Two of the most significant genes were mitogen-activated 
protein kinase kinase kinase 6 (MAP3K6) and mitogen-activated protein kinase kinase 
kinase 3 (MAP4K3) which are shown in Figure 44. Both of these genes code for proteins 
that are part of the mitogen-activated protein kinase (MAPK) family which link 
extracellular signals to the intracellular processes such as growth, proliferation, and 
differentiation (Dhillon, Hagan, Rath, et al., 2007). Additionally, a reliance on genes 
involved in ‘skeletal system morphogenesis’ including PDGFRA, ACVR2B, TGFBR2, 
DLG1, FGFR1 and FGFR2 was identified (Campbell, Ryan, Brough, et al., 2016) (Figure 
45 and Figure 46). 
 
The FGFR1 and FGFR2 kinase genetic dependencies suggested that osteosarcoma 
models might be especially sensitive to small molecule FGFR inhibitors, and these 
associations are shown in the next chapter. Another of the genes identified in ‘skeletal 
system morphogenesis’ was Platelet derived growth factor receptor alpha (PDGFRA).  
Olaratumab is a new antibody targeting PDGFRA, currently undergoing Phase 1b clinical 




This chapter described the steps to the generation of the first kinome-wide genetic 
dependency maps of multiple OS tumour cell line models on this scale. This data-set was 
made a publically available resource for the identification of OS genetic dependencies by 
the inclusion in Cancer GD www.cancergd.org which provides a searchable collection of 
genetic vulnerabilities associated with the alteration of driver genes in cancer cell lines as 
part of a collaboration between the Institute of Cancer Research, Systems Biology 
Ireland, University College Dublin and the Health Research Board.   
 




















































Figure 44 OS tumour cells demonstrated a candidate genetic dependency on 
MAP3K6/ASK2 and MAP4K6/MEK6 genes when compared to non-osteosarcoma tumour cell 
lines (n=99).  
Dot plots of quantile normalised Z scores for MAP3K6/ASHK2 and MAP4K6/MEK6 in 18 
osteosarcoma tumour cell lines and 99 non-osteosarcoma tumour cell lines (n=99: 27 breast; 19 
ovary; 19 lung; 14 oesophagus; 5 pancreas; 5 head and neck; 4 cervical; 4 central nervous 
system; 2 endometrium). Tumour cell lines were arrayed in triplicate 384 well plates, and reverse 
transfected using the siRNA library described in Appendix Tables 1-3. After seven days, cell 
viability was estimated by CellTiter Glo reagent as described in the methods. A custom script on R 
was used to quantile normalise the Z scores across the non-osteosarcoma tumour cell line panel 
by James Campbell (ICR). Tumour cell lines were clustered into two groups, Osteosarcoma and 
non-osteosarcoma. Median and interquartile range highlighted. P values calculated by Median 
Permutation Test. 





Figure 45 Radar plot (generated by James Campbell), summarizing the candidate genetic 
dependencies associated with the osteosarcoma histotype.  
The concentric circles indicate the statistical significance and the depth of colour indicates the 
separation of Z scores between the osteosarcoma histotype (n = 18) and the non-osteosarcoma 
group of tumour cell lines (n=99: 27 breast; 19 ovary; 19 lung; 14 oesophagus; 5 pancreas; 5 head 
and neck; 4 cervical; 4 central nervous system; 2 endometrium). A set of six kinases annotated as 
involved in skeletal system morphogenesis in the Gene Ontology are annotated with asterisks 
(Campbell, Ryan, Brough, et al., 2016). A custom R script was used by James Campbell to 
generate this radar plot. 
 
 















































































































































p = 0.00055 
 
Figure 46 Six candidate genetic dependencies annotated as involved in skeletal system 
morphogenesis in the Gene Ontology, associated with the osteosarcoma histotype. 
Dot plots of quantile normalised Z scores for six genes involved skeletal system morphogenesis, in 
18 osteosarcoma tumour cell lines and 99 non-osteosarcoma tumour cell lines (n=99: 27 breast; 
19 ovary; 19 lung; 14 oesophagus; 5 pancreas; 5 head and neck; 4 cervical; 4 central nervous 
system; 2 endometrium). Tumour cell lines were arrayed in triplicate 384 well plates, and reverse 
transfected using the siRNA library described in Appendix Tables 1-3. After seven days, cell 
viability was estimated using the CellTiter Glo reagent as described in the methods. A custom 
script on R was used to quantile normalise the Z scores across the non-osteosarcoma tumour cell 
line panel. Tumour cell lines were clustered into two groups, Osteosarcoma and non-
osteosarcoma. Median and interquartile range highlighted. P values calculated by MPT. 




This analysis was based on unbiased RNAi screening of a panel of tumour cell lines, and 
it is therefore particularly interesting that a reliance on this skeletal morphogenesis 
pathway was identified in osteosarcoma, given that osteosarcoma derives from primitive 
bone-forming mesenchymal stem cells (MSC) (Gorlick, 2009). MSC are pluripotent cells 
that via the complex process of osteogenic differentiation and the appropriate stimuli, can 
give rise to multiple lineages including osteocytes, myocytes, adipocytes, and 
chondrocytes (Tang, Song, Luo, et al., 2008). Although the exact mechanisms of 
pathogenesis of OS is unknown, it is postulated that disruption of differentiation of these 
MCS (Tang, Song, Luo, et al., 2008) leads to cellular arrest as undifferentiated 
precursors, supported by the many similarities seen between OS and primitive 
osteoblasts (Wagner, Luther, Zhu, et al., 2011). 
 
Genetic dependencies specific to osteosarcoma were identified, with a reliance of genes 
involved in ‘skeletal system morphogenesis’ including FGFR1 (Campbell, Ryan, Brough, 
et al., 2016). ‘Skeletal system morphogenesis’ is a Gene Ontology term (Ashburner, Ball, 
Blake, et al., 2000) which encompasses four subcategories; cartilage condensation; 
embryonic skeletal system morphogenesis; bone trabecular formation; and bone 
morphogenesis. Platelet-derived growth factor receptor A (PDGFRA) is a cell surface 
tyrosine-protein kinase receptor that is required for normal skeletal development, and 
plays an important role in the differentiation of bone marrow-derived mesenchymal stem 
cells (Uezumi, Fukada, Yamamoto, et al., 2014). It mediates activation of the MAP 
kinases (MAPK1/ERK2 and MAPK3/ERK1), and the Signal Transducer And Activator Of 
Transcription (STAT) family (STAT1, STAT3, and STAT5A/B). Actin A Receptor Type 2B 
(ACVR2B) is a member of the transforming growth factor-beta (TGF-beta) superfamily, 
and is a growth and differentiation factor involved in cell surface to cytoplasmic signalling 
(Olsen, Wader, Hella, et al., 2015). Olaratumab a novel antibody targeting PDGFRA, has 
recently been seen to improve overall survival for patients with metastatic soft tissue 
sarcoma in combination with doxorubicin compared to doxorubicin alone (Tap, Jones, 
Van Tine, et al., 2016). As a result olaratumab is now licenced for this indication. 
Olaratumab demonstrates anti-tumour activity in models of paediatric sarcoma including 
osteosarcoma (May, Loizos, Novosiadly, et al., 2015). The observation of increased 
reliance on PDGFRA in osteosarcoma provides further rationale to support a clinical trial 
in this disease.   
 




Transforming Growth Factor Beta Receptor 2 (TGFBR2), another member of the TGF-
beta receptor superfamily, regulates transcription of a subset of genes related to cell 
proliferation and is involved in control of mesenchymal cell proliferation and differential, 
and extracellular matrix production (Wu, Chen & Li, 2016). A paralog of this gene is 
ACVR2A, which has very similar roles to ACVR2B (Olsen, Wader, Hella, et al., 2015). 
Discs Large MAGUK Scaffold Protein 1 (DLG1) encodes a scaffolding protein required for 
normal development, with a possible role in cell proliferation, signal transduction, and 
adherens junction assembly. Fibroblast Growth Factor Receptor 1 (FGFR1) and 2 
(FGFR2) are members of the fibroblast growth factor receptor (FGFR) family of trans-
membrane catalytic receptors with intracellular tyrosine kinase activity. FGFR1 and 
FGFR2 play an essential role in the regulation of embryonic development, cell 
proliferation, differentiation and migration. Both are also required for normal skeletal 
genesis, and function upstream of the MAP kinase and phosphoinositide 3-kinase (AKT1) 
signalling pathways (Su, Jin & Chen, 2014). FGFR2 also plays a role in regulation of 
osteogenesis, osteoblast differentiation, and promotes apoptosis in differentiated 
osteoblasts (Su, Jin & Chen, 2014). Although there is a possibility of any given 
dependency being the result of off-target siRNA effects (Jackson & Linsley, 2010), the 
likelihood of an entire pathway being identified through off-target effects is likely to be 
much lower.  
 
Genes identified as essential for viability in osteosarcoma but not in the non-
osteosarcoma tumour cell line panel may represent key drivers of cellular survival in 
osteosarcoma. Two FGFR chemical inhibitors AZD4547 and PD173074 were both found 
to be more selective for osteosarcoma than a panel of 58 non-osteosarcoma tumour cell 
lines, described in the next chapter.  
 
In the next chapter, I will demonstrate how the RNAi profiling of this OS tumour cell line 
panel enabled identification of candidate genetic dependencies specific to loss of RB1 
and CDKN2A deficiency. 
 




6 Identification of genetic dependencies associated with driver 
mutations in osteosarcoma 
6.1 INTRODUCTION 
6.1.1 Identification of candidate genetic dependencies  
In the previous chapter, the genetic dependencies of the panel of OS tumour cell lines 
were compared to that of 99 non-osteosarcoma cell lines, which identified a particular 
reliance on genes involved in skeletal system morphogenesis. To identify genetic 
dependencies associated with specific driver mutations, the data set viability scores 
described in Chapter 5, were integrated with the molecular profiling of the tumour cell 
lines, to enable identification of genetic vulnerabilities associated with driver alterations in 
osteosarcoma. As stated in Chapter 2, in addition to TP53, RB1 and CDKN2A are the 
most common recurrent mutational events in sporadic osteosarcomas (Gorlick, 
Anderson, Andrulis, et al., 2003). Loss of function of RB1 is reported in many cancer 
types (Knudsen & Wang, 2010). Furthermore, germ-line mutations of RB1 have been 
associated with occurrence of osteosarcoma and structural alterations of the RB1 gene 
have been reported in up to 30% of sporadic cases (Araki, Uchida, Kimura, et al., 1991). 
Thus genetic dependencies associated with loss of function of RB1 and CDKN2A were 
worthy of further investigation. Chapter three described the characterisation of the tumour 
cell line panel into ‘deficient’ and ‘wildtype’ groups for both of these genes (CDKN2A and 
RB1), which were used as the basis for class analysis in this Chapter. The most 
significant and reproducible differential effect identified between the RB1 mutant and 
wildtype tumour cell lines in the high-throughput siRNA screen, was seen with siRNA 
targeting DYRK1A (dual-specificity tyrosine-regulate kinase 1A). 
 
6.2 RESULTS 
6.2.1 Identification of genetic dependencies associated with loss of function of 
CDKN2A in osteosarcoma 
To identify candidate genetic dependencies associated with loss of function of CDKN2A, 
osteosarcoma tumour cell lines were clustered into ‘deficient’ and ‘wildtype’ groups, 
described in Chapter 3. A Z score threshold of < -1.5, representing 1.5 Median Absolute 
Deviation (MAD) effects from the median effect was used to define significant loss of 




viability. To exclude any genes which had an effect on all tumour cell lines, and therefore 
more likely to represent an essential gene, a Z score of > -1.0 was used in the CDKN2A 
wildtype cohort. Therefore, the following criteria were used to select genes for 
revalidation: (i) median Z score in the CDKN2A deficient cells lines of < - 1.5; (ii) median 
Z score in the CDKN2A wildtype group of > -1.0; (iii) probability of the difference between 
the Z scores in both the CDKN2A deficient and wildtype groups seen by chance of 
p<0.05. Using these criteria, 99 genes demonstrated significant differential effects in the 
two groups (Figure 47 and Figure 48), and those with the most significant effects are 
shown in Figure 49.  
 
Serine/Threonine-Protein Kinase 22C (STK22C) is a kinase involved in germ cell 
differentiation and mature sperm function. Fucokinase (FUK) mediates the fucose 
salvage pathway and FUK may have a role in metastasis, with a reduced expression in 
advanced murine melanomas observed (Lau, Feng, Claps, et al., 2015). Two members of 
the Cyclin Dependent Kinase Family, PCTK3 and CDKN1C were also identified. Cyclin 
Dependent Kinase 18 (PCTK3) controls actin cytoskeleton dynamics by negatively 
regulating the FAK/Rho signalling pathway, and silencing of PCTK3 by siRNA has been 
associated with increased cell motility (Matsuda, Kawamoto, Miyamoto, et al., 2017). 
Cyclin Dependent Kinase Inhibitor 1C, also known as p57KIP2, inhibit G1 cyclin-dependent 
kinases thereby negatively regulating cell proliferation (Riccio & Cubellis, 2012). CDKN1C 
is part of a cluster of imprinted genes on Chromosome 11p15.5, reduced expression or 
activity is associated with the overgrowth syndrome Beckwith-Wiedermann Syndrome 
and a range of sporadic cancers (Riccio & Cubellis, 2012; Borriello, Caldarelli, 
Bencivenga, et al., 2011). Branched Chain Ketoacid Dehydrogenase Kinase (BCKDK) is 
a rate-limiting enzyme in branched-chain amino acids catabolism and expression has 
been negatively correlated with survival in patients with colorectal cancer (Xue, Zeng, 
Duan, et al., 2017). N-Acetylglucosamine Kinase (NAGK) is a salvage enzyme that is 
involved in mammalian amino-sugar metabolism and a member of the Heat Shock 
Protein 70 family (Islam, Sharif, Lee, et al., 2015). Mitogen-Activated Protein Kinase 
Kinase Kinase 3 (MAP3K3), is a serine/threonine protein kinase within the MAP3K family 
(Fan, Ge, Wang, et al., 2014). Amplification of MAP3K3 has been observed in 20% of 
breast cancers although the exact role of MAP3K3 is still unknown (Fan, Ge, Wang, et 
al., 2014). Pyrroline-5-Carboxylate Synthetase (Glutamate Gamma-Semialdehyde 
Synthetase) (PYCS) is a member of the aldehyde dehydrogenase family. Further 
validation of these effects, and mechanistic understanding was not prioritised.   




6.2.2 Identification of candidate genetic vulnerabilities associated RB1 deficiency 
To identify candidate genetic dependencies associated with loss of function of RB1, the 
siRNA data-set from osteosarcoma tumour cell lines was clustered according to the 
status of RB1 (described in Chapter 3), demonstrating differences in gene dependency 
between RB1 deficient and wildtype groups by comparison of the QN Z scores in each 
group (Figure 50). The same criteria, described in 6.2.1 were used to select genes for 
revalidation. Based on these criteria eight genes (CDKL4, JAK2, DYRK1A, NEK7, 
PRKCN, MYLK, GALK1 and LAK) were identified (Figure 51). 
 
6.2.3 Revalidation of siRNA high-throughput screen candidate genetic 
dependencies  
Limitations of siRNA screening are well known, and of primary significance are the off-
target effects which occur when using siRNA particularly in mammalian systems (Iorns, 
Lord, Turner, et al., 2007; Echeverri & Perrimon, 2006). Silencing of genes through the 
siRNA pathway requires the species to be highly complementary to the target mRNA, 
while off-target effects may require less in a similar manner to microRNA machinery 
(Iorns, Lord, Turner, et al., 2007). At the 5’ end of the anti-sense strand, a seven to eight 
‘seed’ nucleotide region is most critical in generating off-target effects, particularly when 
this ‘seed’ region occurs in the 3’ un-translated region of a potential off-target gene 
(Birmingham, Anderson, Reynolds, et al., 2006). It is therefore important to perform 
‘redundancy’ or rescue experiments to confirm the observed phenotype is due to a 
specific on-target effect of silencing the gene of interest (Echeverri & Perrimon, 2006). 
Therefore, robust revalidation was performed using deconvolution with four distinct siRNA 
species targeting different regions of the target gene, as well as the SMARTpool used in 
the original screen. 
 
 





Figure 47 Heatmap of osteosarcoma tumour cell lines demonstrating the differences in 
gene dependency between CDKN2A deficient and wildtype groups by comparison of QN Z 
scores of each group.  
Each row represents viability effects of silencing of a target gene, while each column represents a 
tumour cell line. Dark blue represents loss of viability, whereas white represents no effect on 
viability. Only significant (p<0.05) genetic dependencies are shown. The 20 most significant 
candidate genetic dependencies are highlighted by a red box and shown in Figure 48. P values 
calculated by median difference permutation test. James Campbell (ICR) used a custom script in 
R to perform this analysis and generate the heatmap. 




















































































































































































































































































































































































Figure 48 Heatmap of osteosarcoma tumour cell lines demonstrating the differences in 
gene dependency between CDKN2A deficient and wildtype groups by comparison of QN Z 
scores of each group.  
Each row represents viability effects of silencing of a target gene, while each column represents a 
tumour cell line. Dark blue represents loss of viability, whereas white represents no effect on 
viability. James Campbell (ICR) used a custom script in R to perform this analysis and generate 
the heatmap. Only the 20 most significant candidate genetic dependencies are shown (p<0.05). P 
values calculated by median difference permutation test. 
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Figure 49 Candidate genetic dependencies associated with CDKN2A deficiency in 
osteosarcoma  
Dot plots showing comparison of QN Z scores grouped by CDKN2A status. OS tumour cell lines 
were arrayed in triplicate 384 well plates and reverse transfected using the siRNA library 
described in Appendix Tables 1-3. After seven days, cell viability was estimated using the CellTiter 
Glo via a luminescence assay. A custom script on R was used to quantile normalise the Z scores 
across OS tumour cell line panel. Median and interquartile range represented by bars. CDKN2A 
wildtype shown in black, and CDKN2A deficient OS tumour cell lines shown in red. Median and 











Figure 50 Heatmap of osteosarcoma tumour cell lines demonstrating differences in gene 
dependency between RB1 deficient and wildtype groups by comparison of the QN Z scores 
in each group.  
Only significant (p<0.05) genetic dependencies are shown. Each row represents viability effects of 
silencing of a target gene, while each column represents a tumour cell line. Dark blue represents 
loss of viability, whereas white represents no effect on viability. James Campbell (ICR) used a 
custom script in R to perform this analysis and generate the heatmap. P values calculated by 
median difference permutation test [QN: quantile normalised] 
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Figure 51 Candidate genetic dependencies chosen for revalidation according to RB1 status 
in osteosarcoma tumour cell line models.  
Dot plots showing comparison of QN Z scores grouped by RB1 status with median and 
interquartile range. Tumour cell lines were arrayed in triplicate 384 well plates and reverse 
transfected using the siRNA library described in Appendix Tables 1-3. After seven days, cell 
viability was estimated using the CellTiter Glo via a luminescence assay. A custom script on R 
was used by James Campbell (ICR) to quantile normalise the Z scores across the non-
osteosarcoma tumour cell line panel. Revalidation criteria were (i) median Z score in the RB1 
deficient cells lines of < - 1.5; (ii) median Z score in the RB1 wildtype group of > -1.0; (iii) 
probability of the difference between the Z scores in both the RB1 deficient and wildtype groups 












Based on these criteria 8 genes (CDKL4, JAK2, DYRK1A, NEK7, PRKCN, MYLK, 
GALK1 and LAK) were selected for validation in the panel of non-isogenic osteosarcoma 
tumour cell lines. These genes were included in a custom 384-well plate of 231 other 
siRNA chosen for revalidation in other histologies (data not shown). It was assumed that 
the majority of these siRNA would not have an effect on viability in OS, and thus 
generation of Z scores were deemed valid. Observation of a phenotype caused by two 
different siRNA oligonucleotide species is considered unlikely that to be the result of an 
off-target effect (Echeverri & Perrimon, 2006). Therefore, validation of the effect was 
deemed successful if two out of the four individual oligonucleotides passed the above 
criteria. DYRK1A was the only candidate genetic dependency where these criteria were 
met (Figure 52 and Figure 53).  
 
6.2.4 Investigation of the extent of the genetic dependency on DYRK1A in non-
osteosarcoma tumour cell lines 
To investigate the extent of the genetic dependency on DYRK1A, data from the non-
osteosarcoma tumour cell line dataset (n=99 tumour cell lines derived from 10 cancer 
types) (Campbell, Ryan, Brough, et al., 2016), and the 18 osteosarcoma tumour cell 
lines, was clustered according to RB1 status. RNAi targeting DYRK1A resulted in a 
significant difference in viability between RB1 wildtype and deficient osteosarcoma and 
breast tumour cell lines (Figure 54).  
 
To further validate this observation in an independent data set, the publically available 
‘Achilles’ data-set from the Broad Institute https://portals.broadinstitute.org/achilles which 
used lenti-virus to deliver 54,000 shRNA library in a panel of 216 cancer cell lines 
(Cowley, Weir, Vazquez, et al., 2014) was used. Non-osteosarcoma tumour cell lines 
were annotated for RB1 using a combination of protein expression by western blotting 
performed by Rachel Brough, publically available sequencing and mRNA expression data 
from COSMIC and CCLE using the same methodology to classify the OS tumour cell 
lines described in Chapter three. Only one osteosarcoma cell line, SJAS1/OSA was 
included in this data set. A similar significant difference of loss of viability in RB1 deficient 
tumour cell lines compared to wildtype was seen with silencing of DYRK1A (Figure 55).  
 




















































































































































Figure 52 Revalidation of DYRK1A by deconvolution.  
Dot plots of quantile normalised Z scores for DYRK1A clustered according to RB1 in 
osteosarcoma tumour cell lines. (A) Data from the high-throughput screen of osteosarcoma 
tumour cell lines (RB1 deficient: n = 6; RB1 wildtype: n = 12), using a DYRK1A siRNA smartpool. 
(B) Validation using a DYRK1A smartpool and subset of OS tumour cell lines (RB1 deficient: n = 6; 
RB1 wildtype: n = 8). (C-F) Deconvolution using four different individual siRNAs targeting differing 
regions of DYRK1A. Tumour cell lines were reverse transfected using siRNA targeting DYKR1A. 
After seven days, cell viability was estimated using the CellTiter Glo via a luminescence assay. A 
custom script on R was used to quantile normalise the Z scores across the OS tumour cell line 
panel. Median and interquartile range highlighted. P values calculated by Student’s t test. 

























































































































































































































































































































































Figure 53 Waterfall plots of quantile normalised Z scores for DYRK1A revalidation using 
RB1 deficient (red), and RB1 wildtype (black) osteosarcoma tumour cell lines.  
Each OS tumour cell line was ranked from least to most sensitive to DYRK1A silencing by siRNA, 
as measured by cell viability (Z score). (A) Data from the high-throughput screen of 18 
osteosarcoma tumour cell lines using a DYRK1A siRNA smartpool. (B) Re-validation using a 
DYRK1A smartpool. (C-F) Deconvolution using four different individual siRNAs targeting differing 
regions of DYRK1A. A subset of the OS tumour cell lines (RB1 deficient: n = 6; RB1 wildtype: n = 
8) was used for revalidation (B - F). Tumour cells were arrayed in triplicate 384 well plates, reverse 
transfected and viability was estimated after seven days using CellTiter Glo reagent as described 
in the methods.






























Figure 54 RB1 deficient OS and breast tumour cell lines exhibit genetic vulnerability to 
silencing DYRK1A 
Dot plot of quantile normalised Z scores for DYRK1A dependency with median and interquartile 
range clustered according to RB1 status. OS and breast tumour cell lines were arrayed in triplicate 
348 well plates, and reverse transfected using the siRNA library described in Appendix Tables 1-3. 
After seven days, cell viability was estimated using the CellTiter Glo via a luminescence assay. A 
custom script on R was used to quantile normalise the Z scores across the panel of breast and OS 
tumour cell lines. Tumour cell lines were clustered into two groups, RB1 deficient (OS: n = 6; 



























RB1 deficient RB1 wildtype 
p = 0.0016 
 
Figure 55 DYRK1A confirmed as a candidate genetic dependency in RB1 deficient tumour 
cell lines using viability data from the independent publically available ‘Achilles’ data-set 
from the Broad Institute.  
Dot plot of Z scores for DYRK1A using the ‘Achilles’ data set from the Broad Institute 
(https://portals.broadinstitute.org/achilles), which was comprised of a panel of 216 cancer cell lines 
with lenti-virally delivered genome-wide shRNA. Only one osteosarcoma cell line, SJAS1/OSA 
(RB1 wildtype) was included in this data set. Silencing of DYRK1A resulted in a significantly 
decreased loss of viability in RB1 deficient tumour cell lines compared toRB1 wildtype. Non-
osteosarcoma tumour cell lines were annotated for RB1 using a combination of protein expression 
by western blotting performed by Rachel Brough, and publically available sequencing and mRNA 
expression data from COSMIC and CCLE using the same methodology to classify the OS tumour 
cell lines in Chapter 3. Median and interquartile range highlighted. P values calculated by the 
MPT. 




In addition, Mittnacht et al. performed a siRNA screen of the kinome using a colon cancer 
derived cell line, which was irradiated to induce phosphorylation and activation of RB1 
(Stockwell, Li, Aherne, et al., 2012). DYRK1A was found to a be a candidate genetic 
dependency from this screen, with silencing in the absence of active RB1 associated with 
loss of viability (Stockwell, Li, Aherne, et al., 2012). 
 
6.3 INVESTIGATION OF THE DYRK1A AND RB1 SYNTHETIC LETHALITY  
6.3.1.1 Inhibitors of DYRK1A 
There are a number of inhibitors of DYRK1A of varying efficacy, which can be broadly 
divided according to their action against Class I (DYRK1A and DYRK1B) and Class II 
(DYRK2, DYRK3, and DYRK4) targets (Ashford, Oxley, Kettle, et al., 2014). Harmine, a 
plant alkaloid beta-carboline compound and the benzothiazole indy (INhibitor of 
DYRK1A), both exhibit selectivity to Class I over Class II, and have been co-crystallised 
with DYRK1A, bonding within the ATP binding-pocket (Ionescu, Dufrasne, Gelbcke, et al., 
2012). Harmine has an IC50 of 0.03-0.4µM for DYRK1A while 0.2-0.3µM for DYRK1B 
(Ionescu, Dufrasne, Gelbcke, et al., 2012; Göckler, Jofre, Papadopoulos, et al., 2009). 
Harmine also inhibits monoamine oxidase (MAO) A at a lower dose (IC50 5nM) than that 
required for inhibition of DYRK1A, which negatively impacts the side-effect profile 
(Ionescu, Dufrasne, Gelbcke, et al., 2012; Ogawa, Nonaka, Goto, et al., 2010). Indy has 
an IC50 of 0.01-0.9µM for DYRK1A while 0.24µM for DYRK1B (Ionescu, Dufrasne, 
Gelbcke, et al., 2012; Ogawa, Nonaka, Goto, et al., 2010). Indy has not been shown to 
have any action on MAO A (Ogawa, Nonaka, Goto, et al., 2010). AZ191 also selectively 
targets Class I over Class II, and despite a lower IC50 for DYRK1B (0.017µM) than 
DYRK1A (IC50 0.08µM), it compairs to the IC50s for DYRK1A seen with harmine and 
indy (Ashford, Oxley, Kettle, et al., 2014). There are no reports of use of AZ191 or indy in 
vivo, while harmine is reportedly well tolerated in mice with only side effects of tremble, 
twitching and jumping (Chen, Chao, Chen, et al., 2005; Wang, Alvarez-Perez, Felsenfeld, 
et al., 2015). A Phase I/II clinical trial (NCT02914769) of ayahuasca, an Amazonian 
botanical containing both harmine and a 5HT2A agonist in 17 patients with recurrent 
depression, demonstrated that the drug was well tolerated, with the only adverse effect 
reported as vomiting in 47% (Sanches, de Lima Osório, Santos, et al., 2016). These three 
drugs (harmine, indy, and AZ191) were chosen because they demonstrate inhibition of 
DYRK1A in vitro with the least recorded off-target effects.  





6.3.2 Effects of silencing DYRK1A by siRNA  
To further confirm the revalidation of DYRK1A, siRNA smart-pools targeting RB1 and 
DYRK1A separately with non-targeting controls, and together, were used in the RB1 
wildtype OS tumour cell line U2OS (Figure 56). A significant difference in viability 
between silencing of either RB1, or DYRK1A in combination with negative controls, 
compared to silencing of both RB1 and DYRK1A together was observed, confirming the 
genetic vulnerability. From this experiment silencing of RB1 lead to an increase in cell 
viability compared to mock (tumour cells treated with lipid transfection mix alone), while 
silencing of DYRK1A had the opposite effect. Silencing of both RB1 and DYRK1A 
demonstrated greater loss of viability than silencing DYRK1A alone. 
 
6.3.3 Orthogonal validation of the DYRK1A and RB1 genetic vulnerability using 
inducible expression of DYRK1A 
To further revalidate the DYRK1A and RB1 genetic vulnerability, an orthogonal system 
was sought which enabled silencing of DYRK1A using an alternative to siRNA to confirm 
the observed phenotype was not an off-target effect of siDYRK1A. In the absence of an 
isogenic model of deficient and wildtype DYRK1A, exogenous kinase inactive DYRK1A 
known to have a dominant negative effect on endogenous DYRK1A (Yang, Ahn & Chung, 
2001) (Litovchick, Florens, Swanson, et al., 2011) was used. Three tumour cell lines (a 
generous gift from DeCaprio et al. (Litovchick, Florens, Swanson, et al., 2011)) generated 
in OS tumour cell line U2OS with a tetracycline-on plasmid expression of empty vector 
(pRev), wildtype (WT), and kinase-inactive (KR) DYRK1A-K188R (created by site-
directed mutagenesis using QuikChange: Aglient), were used. Kinase inactivation of 
DYRK1A by conversion of a critical Lys-188 residue in the catalytic domain to Arg-188 
has been shown to have a dominant negative effect on wildtype DYRK1A (Yang, Ahn & 
Chung, 2001) (Litovchick, Florens, Swanson, et al., 2011). Suppression of endogenous 
DYRK1A via the dominant negative effect of expression of exogenous kinase inactive 
DYRK1A was associated with a significant difference in fold change colony formation 
when RB1 was silenced. No loss of viability with kinase inactive DYRK1A expression 
when RB1 was not silenced was seen (Figure 57 and Figure 58). 
 




Protein levels of DYRK1A were confirmed by western blot (Figure 59), and demonstrated 
endogenous expression of DYRK1A in pRev, increased expression of DYRK1A in both 
kinase inactive and wild-type exogenous DYRK1A expression. However, increased 
DYRK1A expression was observed in both the kinase inactive and wild-type conditions 
even when grown in tetracycline free media, suggesting expression of the target gene in 
the absence of the inducing agent, a frequent issue encountered in these systems 
(Pham, Moretti, Goodall, et al., 2008). Despite this ambiguity, a difference in viability was 
still observed with this genetic vulnerability. This provided evidence that the genetic 
dependency observed is dependent on the kinase activity of DYRK1A. 
 
6.3.4 Validation of the DYRK1A and RB1 genetic vulnerability using a breast 
TCL with isogenic RB1 deficiency 
To provide a robust model to further investigate specific genetic lethalities associated with 
loss of RB1 function, an isogenic model of RB1 loss was developed. In the absence of an 
available RB1 deficient isogenic model in osteosarcoma at the time, a breast cancer cell 
line model (MDAMB231) created by shRNA-mediated silencing of RB1 was used. 
Reverse transfection in a 96-well plate format was used with 3000 cells per well. siRNA 
smart-pools targeting DYRK1A, with PLK as a positive control, and non-targeting 
negative controls (siCON1, siCON2, and siAllstar) were used. Cell viability was assessed 
using a CTG assay at seven days post reverse transfection. This experiment 
demonstrated that silencing of DYRK1A in a RB1 deficient setting was associated with a 
significant increase in loss of viability, confirming the genetic vulnerability in an additional 
tissue type (Figure 60).  
 
6.3.5 High-throughput siRNA screen in isogenic RB1 deficient and wildtype 
U2OS osteosarcoma models 
After generation of a two isogenic RB1 deficient and wildtype U2OS osteosarcoma 
tumour cell line models by CRISPR-Cas9, as detailed in Chapter four the models were 
screening using the same RNAi library as described previously (Appendix Tables 1-3). 
The screen was performed in triplicate using the same optimised transfection conditions 
already described for U2OS in Chapter 5. All three screens passed the same robust 
measures of quality control as previously set (5.2.3); U2OS 4.2: mean r2 (Spearman’s 
rank correlation coefficient) = 0.87, mean Z prime = 0.65; U2OS 4.5: mean r2 = 0.93; 




mean z prime = 0.66; U2OS 9.1: mean r2 = 0.91; mean z prime = 0.68 (Figure 61 and 
Figure 62). 
 













































































Figure 56 Silencing of both RB1 and DYRK1A simultaneously by siRNA using the RB1 
wildtype OS tumour cell line U2OS confirmed the genetic vulnerability.  
Bar chart illustrating survival fraction compared to ‘mock’. Tumour cells were plated in 96 well 
format. Reverse transfection with siRNAs targeting the following combinations were undertaken: 
RB1 and three different non-targeting controls (siAllstar, siCON1 and siCON2); DYRK1A and three 
different non-targeting controls (siAllstar, siCON1 and siCON2); RB1 and DYRK1A; and PLK. 
Cells only treated with lipid transfection media without siRNA were termed ‘mock’. After incubation 
for seven days, cell viability was assessed using CellTiter Glo reagent as described in the 
methods. A significant difference in viability (*p<0.05) between silencing of either RB1, or DYRK1A 
with negative controls, compared to silencing of both RB1 and DYRK1A together was observed. P 
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Figure 57 A significant difference between colony formation post silencing of RB1 
compared to non-targeting control (siAllstar) in the kinase inactive DYRK1A-K188R (KR) 
tumour cell line in the presence of doxycycline was observed.  
Histogram of quantitation of colony formation post reverse transfection with siRNA targeting RB1 
using U2OS tumour cell lines with tetracycline inducible empty vector (pRev), kinase inactive 
DYRK1A-K188R (KR), and wildtype DYRK1A (WT). Fold change in colony formation from the 
tetracycline free condition normalised to the doxycycline treated non-targeting siRNA control 
(siAllstar) is shown. All three tumour cell lines were grown for one week in tetracycline free media, 
before division and the addition of doxycycline at 5µg/ml to half of the cells. After four days, cells 
were reverse transfected with a siRNA smart-pools targeting RB1, PLK and a non-targeting control 
(Allstar). At 24 hours, cells were then seeded in triplicate at low density (500 cells per well of six 
well plate), and after two weeks, the cells were fixed and stained. P values calculated using 
Student’s t test. Error bars represent SEM (standard error of the mean) from three replicates. p = 
0.0065 kinase inactive DRYK1A-K188R reverse transfected with siAllstar versus kinase inactive 
DRYK1A-K188R reverse transfected with siRB1. 
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Figure 58 Colony formation post reverse transfection with siRNA targeting RB1 
Three U2OS tumour cell lines were used with either a tetracycline inducible empty vector (pRev), 
kinase inactive DYRK1A-K188R (KR), or wildtype DYRK1A (WT). Each U2OS tumour cell line was 
expanded for a week in tetracycline free media, split and half were treated with doxycycline 
(5µg/ml) for five days. Cells were then reverse transfected with siRNA targeting RB1, Allstar 
(negative control), and PLK (positive control), and after 24 hours plated at low density (500 cells 
per well) for colony formation. After two weeks the colonies were fixed and stained. [- Dox: 
tetracycline free media; + Dox: doxycycline (5µg/ml); CON: siAllstar; RB1; siRB1; PLK; siPLK] 
 







































































































Figure 59 Increased exogenous levels of DYRK1A seen in both KR and WT DYRK1A 
vectors, both in the presence and absence of doxycycline, suggest some leakiness of the 
vector. 
Western blot is shown. The OS tumour cell lines U2OS pRev, kinase inactive (KR) exogenous 
DYRK1A-K188R, and wild-type exogenous DYRK1A were exposed to tetracycline doxycycline 
(5µg/ml) for five days or grown in tetracycline free media. Total cell lysates isolated after drug 
exposure were electrophoresed and immunoblotted as described in the methods. Immuoblotting of 






























































Knock-down of DYRK1A using MDAMB231 







Figure 60 Genetic vulnerability to silencing of DYRK1A observed in the isogenic RB1 
deficient and wildtype breast cancer cell line MDMAMB231.  
Bar chart illustrating survival fraction relative to ‘mock’. Tumour cells that were only transfected 
with lipid transfection mix, but without siRNA were termed ‘mock’, and demonstrated no effect on 
viability of transfection mix alone. RB1 deficient (shRB1) and wildtype (shNS) MDAMB231 tumour 
cell lines were arrayed in 96 well plates, and reverse transfected with non-targeting controls 
(siControl 1, siControl 2, and siAllstar), positive control siPLK, and siDYRK1A. After seven days, 
cell viability was assessed using CellTiter Glo reagent as described in the methods. Error bars 
represent SEM. P values calculated by Student’s t test. Reverse transfection with the non-
targeting controls had a minimal effect on viability, while siPLK demonstrated a profound loss of 
viability in both tumour cell lines. p = 0.0007 MDAMB231 shRB1 reverse transfected with 
siDYRK1A versus MDAMB213 shNS reverse transfected with siDYRK1A. [*: p<0.05; **: p<0.01; 










































Figure 61 Spearman's rank correlation coefficient for each replicate of the siRNA screen 
performed using the isogenic RB1 deficient U2OS 4.2 and 4.5 and RB1 wildtype U2OS 9.1 
tumour cell lines were >0.7. 
Raw luminescence data from the RNAi screens was correlated using GraphPad Prism to 




























Figure 62 Z prime for each replicate of the siRNA screen performed using the isogenic RB1 
deficient U2OS 4.2 and 4.5 and RB1 wildtype U2OS 9.1 tumour cell lines were >0.3. 
Raw luminescence data from the RNAi screens was processed and Z prime values for each 
screen calculated using the CellHTS2 package of the R software suit (BioConductor). 
 




The same criteria as previously described in section 6.2.1 were used to identify candidate 
genetic dependencies associated with RB1 deficiency: (i) median Z score in both the RB1 
deficient tumour cells lines combined of < - 1.5; (ii) median Z score in the RB1 wildtype 
parental line of > -1.0; (iii) probability of the difference between the Z scores in both the 
RB1 deficient and wildtype groups seen by chance of <0.05. Twenty-seven genes met 
these criteria (Rho GTPase Activating Protein 26 (ARHGAP26), Heterogeneous Nuclear 
Ribonucleoprotein A2/B1 (HNRNPA2B1), Werner syndrome helicase (WRN), Calmodulin 
Binding Transcription Activator 1 (CAMTA1), Ras-Related C3 Botulinum Toxin Substrate 
1 (RAC1), ERCC Excision Repair 3 TFIIH Core Complex Helicase Subunit (ERCC3), 
IKAROS Family Zinc Finger 1 (IKZF1), Motor Neuron And Pancreas Homeobox 
1(MNX1), Programmed Cell Death 1 Ligand 2 (PDCD1LG2), Heat Shock Protein 90 
Alpha Family Class A Member 1 (HSP90AA1), RecQ Like Helicase 5 (RECQL5), 
Cytochrome C Oxidase Subunit 6C (COX6C), Acyl-CoA Synthetase Long-Chain Family 
Member 3 (ACSL3), PALB2, Clathrin Heavy Chain (CLTC), Homeobox A13 (HOXA13), 
Ras Homolog Family Member H (RHOH), GATA Binding Protein 3 (GATA3), Epidermal 
Growth Factor Receptor Pathway Substrate 15 (EPS15), HRas Proto-Oncogene GTPase 
(HRAS), RAD50 Double Strand Break Repair Protein (RAD50), 8-Oxoguanine DNA 
Glycosylase (OGG1), Cyclin D3 (CCND3), WW Domain Containing Transcription 
Regulator 1 (WWTR1), Homeobox D13 (HOXD13), MYC Associated Factor X (MAX), 
and Solute Carrier Family 45 Member 3 (SLC45A3)), and the most profound are shown in 
Figure 63.  
 
Network analysis demonstrated a number of connections between these candidate 
genetic dependencies (Figure 64). Of particular interest are the connections with DNA 
metabolism and damage repair (WRN, RECQL5, RAD50, ERCC3, OGG1 and PALB2). In 
addition, mutations of WRN cause Werner Syndrome, also known as adult progeria, 
characterised by premature aging, short stature and distinctive skin changes, is also 
associated with an increased risk of OS and other malignancies (Calvert, Randall, Jones, 
et al., 2012). Other DNA helicase disorders, Bloom Syndrome and Rothmund-Thomson 
Syndrome (RTS) are associated with germ-line mutations of RECQL3 and RECQL4 
respectively (Vogelstein, Papadopoulos, Velculescu, et al., 2013; Kansara & Thomas, 
2007). Although mutations of RECQL5 do not cause a monogenic disease, 
polymorphisms in this gene have been associated with an increased prevalence of OS in 
the Chinese Han population (Zhi, Ma, Zhang, et al., 2014) and overexpression in the OS 
tumour cell line MG63 was associated with decreased viability (Wu, Zhi, Dai, et al., 2015).  




Analysis of the data generated by screening the RB1 isogenic U2OS models separately 
identified one of the candidate genetic dependencies (GALK1) already selected for 
revalidation by the siRNA screen performed in the panel of OS tumour cell lines (Figure 
65). Two other candidate genetic dependencies selected for revalidation including 
DYRK1A met one out of three of the criteria (Figure 66).  
 
Further overlap of the genetic dependencies identified in this isogenic screen with those 
of the osteosarcoma tumour cell line panel, in particular DYRK1A were not observed. 
This could be due to other molecular characteristics of the tumour cell line U2OS that 
mitigate the genetic vulnerability of loss of DYRK1A.  
 
6.3.6 DYRK1A expression in the panel of OS tumour cell lines 
To determine if vulnerability to silencing of DYRK1A correlated with protein expression, 
expression of DYRK1A in the panel of OS tumour cell lines was determined by rtPCR, 
western blotting, and proteomic abundance. Levels of expression of DYRK1A by rtPCR 
(Figure 67), western blotting (Figure 68) and proteomic abundance of DYRK1A (Figure 
69) varied across the tumour cell line panel with no discernable pattern with relation to 
RB1 or CDKN2A deficiency.  
 
A positive correlation was observed between DYRK1A mRNA expression delta delta 
cycle threshold levels by rtPCR and DYRK1A Z scores amongst the RB1 deficient OS 
tumour cell lines (Figure 70). Delta delta cycle threshold levels are inversely correlated 
with mRNA, meaning increasing delta delta cycle threshold levels equates to decreased 
mRNA expression. Spearman’s rank correlation coefficient (r2) = 0.735 demonstrated that 
in the context of RB1 deficiency, increased mRNA expression levels (decreased delta 
delta cycle threshold) of DYRK1A was associated with a greater loss of viability when 
DYRK1A was silenced by siRNA (more negative Z score). 










RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 

























RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 
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RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 
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RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 
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RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 
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RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 
























RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 
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RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 
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RB1 isogenic deficient (4.2 and 4.5) and wildtype (9.1) 



















Figure 63 The most profound candidate genetic dependencies according to RB1 status in 
isogenic RB1 deficient and wildtype isogenic U2OS OS tumour cell lines.  
Dot plots are shown illustrating the median effects on viability. U2OS 4.2 and 4.5 are RB1 deficient 
mutant clones created by CRISPR-Cas9 mutagenesis, and U2OS 9.1 was the parental line 
(reverse transfected with Cas9 alone). Tumour cell lines were arrayed in triplicate 384 well plates, 
and reverse transfected using the siRNA library described in Appendix Tables 1-3. After seven 
days, cell viability was estimated using the CellTiter Glo reagent as described in the methods. A 
custom script on R was used to quantile normalise the Z scores across the tumour cell lines. P 
values calculated by the MPT. [QN: quantile normalised]





Figure 64 Protein-protein network analysis using String (string-db.org) highlights a reliance 
on genes involved in DNA metabolism and damage repair (WRN, RECQL5, RAD50, ERCC3, 
OGG1 and PALB2 highlighted by red boxes) associated with a RB1 deficient phenotype. 
 
 











RB1 isogenic deficient (4.2) and wildtype (9.1) 



















Figure 65 RB1 deficient U2OS model demonstrates genetic dependency on GALK1. 
Dot plot is shown illustrating viability. This candidate genetic dependency was previously selected 
from data generated by RNAi screen of the panel of 18 OS tumour cell lines for revalidation. In 
both screens, the median Z score in the RB1 deficient cells lines was < - 1.5; median Z score in 
the RB1 wildtype group was > -1.0; and the probability of the difference between the Z scores in 
both the RB1 deficient and wildtype groups seen by chance of <0.05. Tumour cell lines (U2OS 4.2 
and 9.1) were arrayed in triplicate in 384 well plates, and reverse transfected using the siRNA 
library described in Appendix Tables 1-3. After seven days, cell viability was estimated using 
CellTiter Glo reagent as described in the methods. A custom script on R was used to quantile 
normalise the Z scores across the non-osteosarcoma tumour cell line panel. Median and 















RB1 isogenic deficient (4.5) and wildtype (9.1) 
























RB1 isogenic deficient (4.5) and wildtype (9.1) 



















Figure 66 RB1 deficient U2OS model demonstrates genetic dependency on PDPK1 and 
DYRK1A.  
Dot plot is shown illustrating viability. These candidate genetic dependencies were previously 
selected from data generated by RNAi screen of the panel of 18 OS tumour cell lines for 
revalidation. In this screen these genes met one of the three criteria set for selection for 
revalidation described previously. Tumour cell lines (U2OS 4.5 and 9.1) were arrayed in triplicate 
384 well plates, and reverse transfected using the siRNA library described in Appendix Tables 1-3. 
After seven days, cell viability was estimated using CellTiter Glo reagent as descripted in the 
methods. A custom script on R was used to quantile normalise the Z scores across the non-
osteosarcoma tumour cell line panel. Median and interquartile range highlighted P values 

















































































Endogenous expression of DYRK1A by rtPCR
 
Figure 67 Endogenous mRNA expression levels of DYRK1A expression in the panel of OS 
tumour cell lines.  
Bar chart illustrating delta delta cycle threshold levels for DYRK1A relative to endogenous 
expression of the control GAPDH. Delta delta cycle threshold levels are inversely correlated with 
mRNA, meaning increasing delta delta cycle threshold levels equates to decreased mRNA 
expression. RB1 deficient tumour cell lines are shown in red, and RB1 wildtype in black. cDNA 
was prepared from untreated tumour cells using the Supercript III First Strand Synthesis System 
for rt-PCR. Quantitive rtPCR was performed using Taqman Universal mastermix II with UNG using 
probes for DYRK1A and GAPDH. mRNA expression was detected using a 7900 HT Fast Real-
Time PCR system RT-PCR. Target gene expression was calculated as expression relative to the 
expression of control cDNA after adjusting for expression of GAPDH as the endogenous control.  




































































































Figure 68 Heterogeneity of DYRK1A, RB1 and p16 (CDKN2A) protein expression in 18 
osteosarcoma tumour cell lines.  
Western blot is shown. Total cell lysates were collected from untreated cells, electrophoresed and 
immunoblotted as described in the methods. Immunoblotting of actin was used as the loading 
control. Levels of expression of DYRK1A varied across the tumour cell line panel with no 
discernable pattern with relation to RB1 or CDKN2A deficiency. DYRK1A expression was seen in 
all RB1 deficient tumour cell lines but did not correlate with genetic vulnerability.  
 








































































































Figure 69 Proteomic abundance of DYRK1A in osteosarcoma tumour cell lines was not 
associated with RB1 status.  
Bar chart illustrating proteomic abundance of DRRK1A quantified by mass spectroscopy 
proteomic profiling performed by Colm Ryan (Systems Biology, Dublin, Ireland). Following lysis, 
protein purification, and tryptic digest, peptides were separated by liquid chromatography and 
measured by mass spectrometer. Label-free proteome quantification was performed using the 
MaxQuant software environment (Coscia, Watters, Curtis, et al., 2016; Cox, Hein, Luber, et al., 
2014) to determine the quantitative abundance of 6696 peptides with a false discovery rate of less 
than one percent. Red columns indicate tumour cell lines classified as RB1 deficient (Chapter 3). 
Isogenic RB1 wildtype (U2OS 9.1) and RB1 deficient U2OS tumour cell lines (U2OS 4.2 and 
U2OS 4.5) generated by CRISPR-Cas9 mediated mutagenesis (described in Chapter 4) are 
shown as contrasts. DYRK1A expression was seen in all RB1 deficient tumour cell lines but did 
not correlate with genetic vulnerability to silencing of DYRK1A. 
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Figure 70 DYRK1A mRNA expression and siDYRK1A viability amongst the RB1 deficient OS 
tumour cell lines are negatively correlated.  
Scatter plot of DYRK1A quantile normalised Z scores and delta delta cycle threshold levels of 
DYRK1A using RB1 deficient OS tumour cell lines only. cDNA was prepared from untreated 
tumour cells using the Supercript III First Strand Synthesis System for rt-PCR. Quantitive rtPCR 
was performed using Taqman Universal mastermix II with UNG using probes for DYRK1A and 
GAPDH. mRNA expression was detected using a 7900 HT Fast Real-Time PCR system RT-PCR. 
Target gene expression was calculated as expression relative to the expression of control cDNA 
after adjusting for expression of GAPDH as the endogenous control. Delta delta cycle threshold 
levels are inversely correlated with mRNA, meaning increasing delta delta cycle threshold levels 
equated to decreased mRNA expression. Spearman’s rank correlation coefficient (r2) = 0.735 
demonstrated that in the context of RB1 deficiency, increased mRNA expression levels 
(decreased delta delta cycle threshold) of DYRK1A were associated with a greater loss of viability 
when DYRK1A was silenced by siRNA (more negative Z score). [r2: Spearman’s rank correlation 
coefficient; QN: quantile normalised] 
 




To determine if DYRK1A protein expression by western blotting correlated with genetic 
dependency, densitometry of DYRK1A relative to actin was performed prior to correlation; 
no significant correlation was observed (Figure 71). DYRK1A expression was seen in all 
RB1 deficient tumour cell lines but did not correlate with genetic vulnerability. Proteomic 
abundance of DYRK1A defined by mass spectroscopy proteomic profiling did not 
correlate with genetic dependency to DYRK1A (Figure 72).  
 
A positive correlation between a genetic dependency to DYRK1A and mRNA expression 
levels of DYRK1A but not protein levels was observed; this could be due to the linear 
relationship between binding of siDYRK1A via the RNA-induced silencing complex 
(RISC) which facilitates binding between one of the siRNA strands and protein-coding 
mRNAs that have nucleotide sequence complementary to the siRNA leading to mRNA 
degradation (Lord, Martin & Ashworth, 2009). Hence if a tumour cell has a high 
expression level of mRNA, silencing would require a high number of siDYRK1A. Given 
that there is the opportunity for considerable post-translational modification of protein 
expression level it is not unsurprising that no direct correlation was observed.   
 
6.3.7 Small molecule inhibition of DYRK1A 
To determine if small molecule inhibition of DYRK1A in an RB1 deficient setting could 
recapitulate the genetic effects observed, a short-term five day assay was performed on a 
limited panel of osteosarcoma tumour cell lines (five RB1 deficient and eight RB1 
wildtype), using two inhibitors of DYRK1A, harmine and indy (Ogawa, Nonaka, Goto, et 
al., 2010; Ionescu, Dufrasne, Gelbcke, et al., 2012). Of the two inhibitors, the greatest 
difference in loss of viability in the RB1 deficient group was observed with Indy, although 
the effect was modest.  
 
Median survival fractions were calculated for RB1 wildtype and RB1 deficient, with a 
significant difference between the two groups post exposure to indy (ANOVA plus 
Bonferroni post hoc test p = 0.0028) (Figure 73) but no significant difference in viability 
seen with harmine (ANOVA plus Bonferroni post hoc test p = 0.83) (Figure 74). After 
short-term exposure to indy, AUC for the range 0.05-50µM when grouped according to 
RB1 status, demonstrated a statistically significant difference in median AUC shown in 
Figure 75. No significant difference in AUC was observed with harmine between the two 
groups (Figure 76).  
























Figure 71 No significant correlation was observed between the density of DYRK1A 
expression and genetic dependency to DYRK1A  
Scatter plot of DYRK1A expression by western blotting, relative to actin, and DYRK1A viability. 
Total cell lysates from untreated cells were electrophoresed and immunoblotted as described in 
the methods. Immunoblotting of actin was used as the loading control. Densitometry of DYRK1A 
expression relative to actin was calculated for each OS tumour cell line using ImageJ software. 
Spearman’s rank correlation coefficient calculated using GraphPad Prism. No significant 
correlation between DYRK1A expression and quantile normalised Z score for DYRK1A was 
observed (Spearman’s rank correlation coefficient 0.2024). [r2: Spearman’s rank correlation 
coefficient; QN: quantile normalised] 
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Figure 72 No significant correlation was observed between proteomic abundance of 
DYRK1A and genetic dependency to DYRK1A 
Scatter plot of proteomic abundance of DYRK1A and viability in RB1 deficient OS tumour 
cell lines only. Proteomic profiling of the OS tumour cell lines was performed by Colm 
Ryan (Systems Biology, Dublin, Ireland). Following lysis, protein purification, and tryptic 
digest, peptides were separated by liquid chromatography and measured by mass 
spectrometer. Label-free proteome quantification was performed using the MaxQuant 
software environment (Coscia, Watters, Curtis, et al., 2016; Cox, Hein, Luber, et al., 
2014) to determine the quantitative abundance of 6696 peptides with a false discovery 
rate of less than one percent. Spearman’s rank correlation coefficient (r2) = 0.1635 did not 
demonstrate an association between DYRK1A quantile normalised Z score and 
proteomic abundance of DYRK1A in the setting of RB1 deficient osteosarcoma tumour 
cell lines. Spearman’s rank correlation coefficient calculated using GraphPad Prism. [r2: 
Spearman’s rank correlation coefficient; QN: quantile normalised]


























Figure 73 RB1 deficient osteosarcoma tumour cell lines (TCLs) exhibit enhanced sensitivity 
to the DYRK1A small molecule inhibitor, indy. 
Dose response curves are shown illustrating the median effects in a panel of five RB1 deficient OS 
TCLs (LM7, HU03N1, HU09, OHSN, SAOS2) compared to the median effect in eight RB1 wildtype 
OS TCLs (CAL72, KPD, U2OS, MHM, OSA/SJSA1, G292 clone A141B1, HOS, MG63). TCLs 
were arrayed in triplicate 384 well plates, and after twenty-four hours, were exposed to indy (0.05-
50µM titration) for five continuous days as described in the methods, at which point cell viability 
was estimated by CellTiter Glo Reagent. Median survival fraction for RB1 deficient tumour cell 
lines shown in red, and median survival fraction for RB1 wildtype tumour cell lines shown in black. 
Error bars represent standard error of the mean (SEM). ANOVA plus Bonferroni post hoc test, p = 
0.0028 RB1 deficient versus RB1 wildtype. 
 


























Figure 74 RB1 deficient osteosarcoma tumour cell lines did not exhibit profound sensitivity 
to the DYRK1A small molecule inhibitor, harmine. 
Dose response curves are shown illustrating the median effects in a panel of five RB1 deficient OS 
TCLs (LM7, HU03N1, HU09, OHSN, SAOS2) compared to the median effect in eight RB1 wildtype 
OS TCLs (CAL72, KPD, U2OS, MHM, OSA/SJSA1, G292 clone A141B1, HOS, MG63). TCLs 
were arrayed in triplicate 384 well plates, and after twenty-four hours, were exposed to harmine 
(0.05-50µM titration) for five continuous days as described in the methods, at which point cell 
viability was estimated by CellTiter Glo Reagent. Median survival fraction for RB1 deficient tumour 
cell lines shown in red, and median survival fraction for RB1 wildtype tumour cell lines shown in 
black. Error bars represent standard error of the mean (SEM). ANOVA plus Bonferroni post hoc 
test, p = 0.89 RB1 deficient versus RB1 wildtype. 
 
 


















Figure 75 RB1 deficient osteosarcoma tumour cell lines exhibit greater sensitivity to the 
DYRK1A small molecule inhibitor, indy. 
Dot plot is shown illustrating AUC for indy, in a panel of five RB1 deficient OS TCLs (LM7, 
HU03N1, HU09, OHSN, SAOS2) compared to the median effect in eight RB1 wildtype OS TCLs 
(CAL72, KPD, U2OS, MHM, OSA/SJSA1, G292 clone A141B1, HOS, MG63). TCLs were arrayed 
in triplicate 384 well plates, and after twenty-four hours, were exposed to indy (0.05-50µM titration) 
for five continuous days as described in the methods, at which point cell viability was estimated by 
CellTiter Glo Reagent. AUC calculated from dose response curves using GraphPad Prism and p 
values calculated by Student’s t test. Median and interquartile range shown. Median survival 
fraction for RB1 deficient tumour cell lines shown in red, and median survival fraction for RB1 
wildtype tumour cell lines shown in black. Error bars represent standard error of the mean (SEM). 
P = 0.0377 RB1 deficient versus RB1 wildtype. [AUC: area under the curve] 
 
 



















Figure 76 RB1 deficient osteosarcoma tumour cell lines did not exhibit a profound 
sensitivity to the DYRK1A small molecule inhibitor harmine. 
Dot plot is shown illustrating AUC for harmine, in a panel of five RB1 deficient OS TCLs (LM7, 
HU03N1, HU09, OHSN, SAOS2) compared to the median effect in eight RB1 wildtype OS TCLs 
(CAL72, KPD, U2OS, MHM, OSA/SJSA1, G292 clone A141B1, HOS, MG63). TCLs were arrayed 
in triplicate 384 well plates, and after twenty-four hours, were exposed to harmine (0.05-50µM 
titration) for five continuous days as described in the methods, at which point cell viability was 
estimated by CellTiter Glo Reagent. AUC calculated from dose response curves using GraphPad 
Prism and p values calculated by Student’s t test. Median and interquartile range shown. Median 
survival fraction for RB1 deficient tumour cell lines shown in red, and median survival fraction for 
RB1 wildtype tumour cell lines shown in black. Error bars represent standard error of the mean 
(SEM). P = 0.7830 RB1 deficient versus RB1 wildtype. [AUC: area under the curve] 




To establish if a greater difference in viability seen with inhibition of DYRK1A in the 
absence of RB1 would be seen with multiple dosing, a longer-term assay over two weeks 
was performed. Although greater sensitivity to Indy was seen in the RB1 deficient group, 
harmine was chosen for longer-term drug assay because it has previously been used in 
humans. No difference in sensitivity was seen with RB1 deficiency (Figure 77). From 
these dose-response experiments it was possible to conclude that exposure to the 
DYRK1A inhibitors indy and harmine, were not able to clearly replicate the genetic effects 
already observed, potentially because of the inadequacy of the inhibitors. To determine if 
the synthetic lethality can be replicated using small molecule inhibition, other newer 
inhibitors of DYRK1A such as newer inhibitor GNF4877 (DYRK1A IC50 6nM) (Shen, 
Taylor, Jin, et al., 2015) should be investigated.  
 
6.3.8 Exposure to DYRK1A inhibitor harmine increased apoptosis in RB1 
deficient tumour cell line 
To determine if the observed cellular inhibition phenotype seen post silencing of DYRK1A 
in RB1 deficient OS tumour cell lines was due to cellular death via the role of DYRK1A as 
a negative regulator of apoptosis, or cell cycle exit into a quiescent G0 state, the role of 
apoptosis was investigated by measuring caspase 3/7 activation post exposure to small 
molecule inhibition of DYRK1A. In the absence of more potent chemical inhibitors of 
DYRK1A at the time, harmine was used. Two OS tumour cell lines both CDKN2A 
wildtype, one with wildtype RB1 (G292 clone A141B1), and one with a homozygous 
deletion of RB1 (HU09) were chosen as models. Exposure to 30µM of harmine caused a 
three-fold increase in apoptosis as measured by caspase 3/7 activity in the RB1 deficient 
tumour cell line HU09 at both 24 and 48 hours, not observed in the RB1 wildtype tumour 
cell line G292 clone A141B1 (Figure 78).  In addition, a replicate experiment was used to 
assess viability at the same time points using CTG, which demonstrated a concomitant 
reduction in cell viability in the RB1 deficient tumour cell line HU09, which was most 
notable at 48 hours (Figure 79). These experiments suggest that cellular inhibition 
observed in the RB1 and DYRK1A synthetic lethality is due to the loss of DYRK1A as a 
negative regulator of apoptosis and thus more therapeutically attractive. Therefore, to 
determine if harmine had any synergistic effect in combination with cisplatin and 
doxorubicin, agents that already form part of the standard of care, combination 
experiments were performed. 
























Figure 77 RB1 deficient osteosarcoma tumour cell lines did not exhibit profound sensitivity 
to long term (two week) exposure to the DYRK1A small molecule inhibitor, harmine. 
Dose response curves illustrating survival fractions for HU09 (RB1 deficient) in red, and G292 
clone A141B1 (RB1 wildtype) in black. G292 clone A141B1 and HU09 cells were plated at a 
density of 500 cells/ml in 24 well plates and after 24 hours cells were drugged with five 
concentrations of harmine (0.1µM, 0.5µM, 1µM, 5µM and 10µM). Cells were drugged twice per 
week. After two weeks, cell viability was estimated using CellTiter Glo as described in the 
methods. Error bars represent standard error of the mean (SEM). ANOVA, p = 0.18 HU09 (RB1 
deficient) versus G292 clone A141B1 (RB1 wildtype). 






























































Figure 78 Harmine sensitivity in RB1 deficient tumour cell line HU09 was characterised by 
an apoptotic response.  
Bar charts illustrating caspase 3/7 activity relative to DMSO at (A) 24 and (B) 48 hours of exposure 
to harmine. Cells were plated at high density (10,000 cells per well) and exposed to harmine 
(10µM and 30µM) or drug vehicle, DMSO. At (A) 24 and (B) 48 hours post drug exposure, a 
luminogenic caspase 3/7 substrate was added, which resulted in cell lysis and caspase cleavage 
of the substrate with luminescence readout proportional to the caspase activity. P values 
calculated using Student’s t test. Error bars represent SEM. Exposure to 30µM of harmine caused 
a two-fold increase in apoptosis as measured by caspase 3/7 activity in the RB1 deficient tumour 
cell line HU09, not seen in the RB1 wildtype tumour cell line G292 clone A141B1 (p = 0.0002852 
at 24 hours and p = 0.00045122 at 48 hours). 
 























































Figure 79 Harmine exposure in RB1 deficient tumour cell line HU09 was characterised by 
decreased viability at 48 hours in the RB1 deficient tumour cell line HU09.  
Bar charts illustrating luminescence relative to DMSO as a measure of viability at (A) 24 hours and 
(B) 48 hours of exposure to harmine. Cells were plated at high density (10,000 cells per well) and 
exposed to DMSO, 10µM harmine or 30µM harmine. At (A) 24 and (B) 48 hours post drug 
exposure, a CTG was used to assess viability. Error bars represent SEM. P values calculated 
using Student’s t test. Viability post exposure to harmine was significantly decreased in HU09 
compared toG292 clone A141B1 at 48 hours (p = 0.0015712) but not 24 hours (p = 0.403186). 




6.3.9 Combination of DYRK1A inhibitor and chemotherapeutic agents cisplatin 
and doxorubicin  
MacDonald et al. suggested that targeting DYRK1A, and other members of the DREAM 
complex in ovarian tumour cell line spheroids causes cell death instead of increased 
proliferation, and is therefore a possible attractive therapeutic approach (MacDonald, 
Ramos-Valdes, Perampalam, et al., 2016). They combined 30µM indy with 100-150µM 
carboplatin, an alkylating agent used in the treatment of ovarian malignancy, and 
demonstrated that after 48 hours, viability was decreased when these agents were 
combined (MacDonald, Ramos-Valdes, Perampalam, et al., 2016). Furthermore in those 
tumour types where cells evade the effects of cytotoxic therapy by quiescence, inhibition 
of DREAM complex formation and resultant increase in cell cycling, may make them 
more susceptible to cytotoxic therapy.  
 
Cisplatin and doxorubicin are two of the main chemotherapeutic modalities used to treat 
osteosarcoma. Cisplatin causes DNA cross-links which cause DNA damage and prohibit 
replication, subsequently inducing apoptosis (Dasari & Tchounwou, 2014). Doxorubicin 
also causes intercalation, DNA strand breakage and inhibition of topoisomerase II. ATR is 
activated during replication stress, by regions of single-stranded DNA and functions as 
part of the DNA damage response (Williamson, Miller, Pemberton, et al., 2016).  
 
To investigate if inhibition of DYRK1A by harmine or indy increased the sensitivity of the 
RB1 deficient tumour cell line HU09 to exposure with cisplatin, doxorubicin or the ATR 
inhibitor VX970, short-term combination dose response experiments were performed. 
The ATR inhibitor VX970 was chosen as it has shown to be both a chemo-sensitiser to 
DNA damaging agents, and observed to increase the proportion of cells in non-replicating 
S phase (Figure 85 and Figure 86) and therefore might act synergistically with inhibition 
of DYRK1A. Two OS tumour cell lines both CDKN2A wildtype, one with wildtype RB1 
(G292 clone A141B1), and one with a homozygous deletion of RB1 (HU09) were chosen 
as models. After incubation for five days, cell viability was assessed using a CTG 
luminescence assay. Dose response curves for harmine and cisplatin alone and in 
combination are shown in Figure 80. Moderate synergy was seen with both combinations 
of DYRK1A inhibitor and cisplatin and require further investigation using both longer-term 
exposure and use of one of the new agents with greater potency of inhibition to DYRK1A 
such as GNF4877 (DYRK1A IC50 6nM) (Shen, Taylor, Jin, et al., 2015) instead of 
harmine and indy.  





The RB1 deficient tumour cell line HU09 was more sensitive to doxorubicin, but this effect 
was not potentiated by the addition of harmine or indy. Dose response curves to harmine 
and indy alone, and in combination with doxorubicin are shown in Figure 81. Using these 
short-term assays, no synergistic effect was seen with the addition of either harmine or 
indy to the ATR inhibitor VX90 (Figure 82).  
 
6.3.10 Silencing of DYRK1A and cell cycle profiling 
DYRK1A has a number of roles within cell cycle control, which lead to G1 arrest via both 
direct and downstream interactions with Cyclin D1, p27Kipl and p21; cell cycle exit via 
DREAM complex formation, and repression of apoptosis via inhibition of Caspase 9 
summarised in Figure 94. To determine if the loss of viability seen with the genetic 
vulnerability observed between DRYK1A and RB1 was also mediated by the role of 
DYRK1A in the cell cycle, fluorescence activated cell sorting (FACS) was performed. 
 
DYRK1A silencing has previously been associated with a shortened G1 duration (Chen, 
Lin, Tsai, et al., 2013) and increased proportion of cells in S phase (Litovchick, Florens, 
Swanson, et al., 2011). Therefore, I hypothesised that loss of DYRK1A could have 
multiple effects on the cell cycle; loss of DREAM complex formation could increase cell 
signalling and reduce senescence and quiescence; or degradation of Cyclin D1 or 
stabilisation of p27Kip1 (and resultant decrease in Cyclin E), could decrease 
phosphorylation of RB1 and therefore stall cells in G1. However, in an RB1 deficient 
setting, the role of cyclins D1 and E are unknown, since their main substrate is lost. 
Therefore, the effects of silencing DYRK1A in an RB1 deficient setting could lead to 
increased cell cycling with loss of the DREAM complex and the RB dependent restriction 
point, leading to rapid unchecked-cycling and loss of viability (MacDonald, Ramos-
Valdes, Perampalam, et al., 2016).  
 












































































































































Figure 80 A modest synergistic effect was seen with the combination of harmine or indy 
with cisplatin in both tumour cell lines (G292 clone A141B1 and HU09).  
Dose response curves illustrating survival fraction relative to DMSO. (A) Exposure to harmine 
alone. (B) Exposure to cisplatin alone. (C and E) Exposure to cisplatin and harmine in 
combination, (E and F) exposure to cisplatin and indy in combination using the RB1 wildtype 
tumour cell line G292 clone A141B1 and RB1 deficient tumour cell line HU09. HU09 and G292 
clone A141B1 tumour cells were plated in triplicate 384 well plates, and after twenty four hours, 
were exposed to harmine (0.1-100µM titration) or indy (0.01-10µM titration) in combination with 
cisplatin (0.1-100µM titration) or drug vehicle, DMSO, for five continuous days, at which point cell 
viability was estimated using CellTiter Glo reagent as described in the methods. Error bars 
represent SEM.


























































































































Figure 81 The RB1 deficient tumour cell line HU09 was more sensitive to doxorubicin than 
the RB1 wildtype tumour cell line G292 clone A141B1 but no synergistic effect with the 
addition of harmine or indy was seen.  
Dose response curves illustrating survival fraction relative to DMSO. (A) Exposure to doxorubicin 
alone. (B and C) Exposure to doxorubicin and harmine in combination, (D and E) exposure to 
doxorubicin and indy in combination using the RB1 wildtype tumour cell line G292 clone A141B1 
and RB1 deficient tumour cell line HU09. HU09 and G292 clone A141B1 tumour cells were plated 
in triplicate 384 well plates, and after twenty four hours, were exposed to harmine (0.1-100µM 
titration) or indy (0.01-10µM titration) in combination with doxorubicin (0.001-1µM titration) or drug 
vehicle, DMSO, for five continuous days, at which point cell viability was estimated using CellTiter 
Glo reagent as described in the methods. Error bars represent SEM.







































































































Figure 82 No synergistic effect was observed between the DYRK1A inhibitors harmine and 
indy in combination with VX970. 
Dose response curves illustrating survival fraction relative to DMSO. (A and B) Exposure to VX970 
and harmine in combination, (C and D) exposure to VX970 and indy in combination using the RB1 
wildtype tumour cell line G292 clone A141B1, and RB1 deficient tumour cell line HU09. HU09 and 
G292 clone A141B1 tumour cells were plated in triplicate 384 well plates, and after twenty four 
hours, were exposed to harmine (0.1-100µM titration) or indy (0.01-10µM titration) in combination 
with VX970 (0.01-10µM titration) or drug vehicle, DMSO, for five continuous days, at which point 
cell viability was estimated using CellTiter Glo reagent as described in the methods. Error bars 
represent SEM. 
 




Two osteosarcoma tumour cell lines both CDKN2A wildtype, one with wildtype RB1 
(G292 clone A141B1) and one with homozygous deletion of RB1 (HU09) were chosen as 
models. Asynchronous cells were used for siRNA targeting and exposure to the DYRK1 
inhibitor harmine at 10 and 30µM. Cells were collected 48 hours after reverse transfection 
with RNAi or exposure to inhibitor and fixed. Cells were stained with EDU and DAPI to 
identify replicating cells with the addition of an anti-phospho-histone H3 antibody 
identifying those in active mitosis. Silencing of S Phase Kinase-associated protein (SKP2) 
a genetic vulnerability associated with deficient RB1 (Zhao, Wang, Bauzon, et al., 2016) 
which leads to G0/G1 arrest (Lu, Gan, Cao, et al., 2014), and ATR inhibitor VX970, 
known to target cells in S phase, were used as positive controls. FACS plots of siRNA 
transfection in both tumour cell lines are shown in Figure 83 and Figure 84. To further 
highlight these changes, percentage change from control (siControl1 or DMSO) for each 
phase of the cell cycle was calculated and shown in Figure 87 and Figure 88. 
 
The cell cycle changes post reverse transfection were of low amplitude, particularly when 
compared to the positive control siSKP2. Cell cycling profiling of HU09 post reverse 
transfection with siDYRK1A resulted in increased S phase and G2, with a decrease in 
sub G1 and G1. This suggests that when DYRK1A is silenced, a decreased proportion 
enter the subG1 state, most likely via failure of formation of the DREAM complex, which 
is dependent on phosphorylation of LIN52 on serine 28 by DYRK1A (Litovchick, Florens, 
Swanson, et al., 2011). In the absence of a functioning RB restriction point in G1, the 
RB1 deficient tumour cells are able to proceed through G1, with increased cell numbers 
in S and G2 phases. These changes are concordant with an increase in S phase 
(Litovchick, Florens, Swanson, et al., 2011) and decrease in G1 phase (MacDonald, 
Ramos-Valdes, Perampalam, et al., 2016) observed previously although of lower 
amplitude. MacDonald et al. used transfected shDYRK1A in ovarian spheroids which 
potentially have a different phenotype compared to adherent cells, and they also 
observed a large increase in subG1 which was not seen here (MacDonald, Ramos-
Valdes, Perampalam, et al., 2016). Reverse transfection of siDYRK1A increased the 
percentage of RB1 wildtype G292 clone A141B1 cells in G1 and S phase. In contrast to 
the effects seen with HU09, the proportion of RB1 wildtype tumour cells in G1 increases, 
concordant with failure of formation of the DREAM complex, resulting in fewer cells 
exiting to subG1, and actions of the RB restriction point, stalling cells in G1. The changes 
observed here are not profound. 
 




As expected, silencing of SKP2 leads to G0/G1 arrest and decreased S phase (Lu, Gan, 
Cao, et al., 2014), seen in both HU09 and G292 clone A141B1. In G292 clone A141B1, 
an additional increase in the proportion of cells in G2 was also observed. 
 
Exposure to harmine at 10µM and 30µM concentrations resulted in a profound decrease 
in cells in G1 in both tumour cell lines, most noticeable in the RB1 deficient tumour cell 
line HU09; a profound increase in cell in G2 was seen in both tumour cell lines, 
particularly HU09. A compensatory increase in active mitosis was only seen in the RB1 
wildtype tumour cell line G292 Clone A141B1. Some of the features seen are concordant 
with silencing of DYRK1A by siRNA, namely a decrease in G1 and increase in G2 was 
seen in HU09 for both conditions. In contrast, siDYRK1A caused an increase in G1 in 
G292 clone A141B1, whereas a decrease was seen post exposure to harmine, and 
instead the proportion of cells in G2/M increased. It is possible that these effects are due 
to off-target effects of harmine. Harmaline, another β-carboline alkaloid very similar 
harmine, has been shown to induce G2/M arrest via induction of p21, and activation of 
the Fas/FasL pathway (Wang, Wang, Jiang, et al., 2015). Exposure to VX970 resulted in 
HU09 and G292 clone A141B1 tumour cells stalling in subG1 and non-replicating S 
phase, with compensatory decreases in other phases of the cell cycle, concordant with 
disruption of replication in S phase as predicted (Williamson, Miller, Pemberton, et al., 
2016). 
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Figure 83 Increase in RB1 wildtype OS tumour cells in G1 and S phase when DYRK1A is 
silenced. 
FACS plots illustrating cell cycle fractions labelled with EDU, DAPI and anti-phospho-histone H3 
antibody. G292 clone A141B1 tumour cells were fixed 48 hours post reverse transfection as 
described in the methods with (A) non-targeting control (siCON2), (B) ‘mock’, (C) siDYRK1A and 
(D) siSKP2. Reverse transfection of siDYRK1A in the RB1 wildtype tumour cell line G292 clone 
A141B1 increased the percentage of cells in G1 and S phase, while decreased non-replicating S 
phase. Silencing of SKP2 demonstrated an increase of tumour cells in G1 and G2 phases, with a 
compensatory decrease in S phase. [NR S: non-replicating S phase] 
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Figure 84 Increase in RB1 deficient OS tumour cells in G2 and S phase when DYRK1A is 
silenced. 
 FACS plots illustrating cell cycle fractions labelled with EDU, DAPI and anti-phospho-histone H3 
antibody. HU09 tumour cells were fixed 48 hours post reverse transfection as described in the 
methods with (A) non-targeting control (siCON2), (B) ‘mock’, (C) siDYRK1A and (D) siSKP2. 
Reverse transfection of siDYRK1A in the RB1 deficient tumour cell line HU09 increased the 
percentage of cells in G2 and S phase, while decreased non-replicating S phase. Silencing of 
SKP2 stalled the tumour cells in G1, with a compensatory decrease in all other phases of the cell 
cycle. [NR S: non-replicating S phase] 
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Figure 85 Profound increase in RB1 wildtype OS tumour cells in G2 post exposure to the 
DYRK1A small molecule inhibitor, harmine. 
FACS plots illustrating cell cycle fractions labelled with EDU, DAPI and anti-phospho-histone H3 
antibody. G292 clone A141B1 tumour cells were fixed 48 hours post exposure to (A) DMSO, (B) 
harmine 10µM, (C) harmine 30µM and (D) 1µM VX970 as described in the methods. Exposure to 
harmine at both concentrations resulted in a profound decrease in cells in G1 and increase in G2, 
which was observed in both tumour cell lines. A compensatory increase in active mitosis was also 
seen. Exposure to VX970 resulted in stalling in subG1 and non-replicating S phase, with 
compensatory decreases in other phases of the cell cycle. [NR S: non-replicating S phase] 
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Figure 86 Profound increase in RB1 deficient OS tumour cells in G2 post exposure to the 
DYRK1A small molecule inhibitor, harmine. 
FACS plots illustrating cell cycle fractions labelled with EDU, DAPI and anti-phospho-histone H3 
antibody. HU09 tumour cells were fixed 48 hours post exposure to (A) DMSO, (B) harmine 10µM, 
(C) harmine 30µM and (D) 1µM VX970 as described in the methods. Exposure to harmine at both 
concentrations resulted in a profound decr ase in cells in G1, and increase in G2. A compensatory 
increase in active mitosis was not seen in HU09. Exposure to VX970 resulted in stalling in subG1 
and non-replicating S phase, with compensatory decreases in other phases of the cell cycle. [NR 
S: non-replicating S phase] 
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Figure 87 Percentage changes of the cell cycle post reverse transfection with siDYRK1A 
and siSKP2 are dependent on RB1 status.   
Bar charts illustrating percentage change of the cell cycle relative to control at 28 hours post 
reverse transfection. (A) Small changes in cell cycle were observed post reverse transfection with 
siDYRK1A; siDYRK1A increased the percentage of cells in S phase and decreased non-
replicating S phase in both tumour cell lines. However, it also resulted in an increase in G2, with 
compensatory decrease in G1 in the RB1 deficient tumour cell line HU09, while an increase in G1 
in the RB1 wildtype tumour cell line G292 Clone A141B1. (B) siSKP2 stalled RB1 deficient HU09 
tumour cells in G1, with a compensatory decrease in all other phases of the cell cycle. siSKP2 
increased G292 clone A141B1 RB1 wildtype tumour cells in G1 and G2 phases, with a 
compensatory decrease in S phase. 
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Figure 88 Exposure to the DYRK1A small molecule inhibitor, harmine, is associated with a 
profound increase in G2 independent of RB1 context, and compensatory rise in active 
mitosis only seen in the RB1 wildtype tumour cell line. 
Bar charts illustrating percentage change of the cell cycle relative to DMSO after 48 hours 
exposure to (A) harmine (10µM and 30µM) and (B) VX970 (1µM) using the RB1 deficient tumour 
cell line HU09, and RB1 wildtype tumour cell line G292 Clone A141B1. (A) Harmine resulted in a 
profound decrease in cells in G1 and increase in cells in G2 in both tumour cell lines. A 
compensatory increase in active mitosis was only seen in the RB1 wildtype tumour cell line G292 
Clone A141B1. (B) Exposure to VX970 resulted in HU09 and G292 clone A141B1 tumour cells 
stalling in subG1 and non-replicating S phase, with compensatory decreases in other phases of 
the cell cycle. 




6.3.11 Protein expression changes by western blotting associated with silencing 
DYRK1A 
To further investigate the nature of cell cycle profile changes post silencing by RNAi or 
inhibition of DYRK1A, protein expression of some of the Cyclins and known key 
substrates of DYRK1A were investigated. One of the key substrates of DYRK1A is 
p27Kipl, known to play a role in cell cycle transition from G0 to S phase transition, by a 
decrease in translation of p27Kipl during G1 progression (Chu, Hengst & Slingerland, 
2008). DYRK1A phosphorylates p27Kipl at Serine10, leading to enhanced stability, and 
supressed levels of Cyclin E, thereby maintaining RB1 in its active, unphosphorylated 
state causing cell cycle arrest (Ishida, Kitagawa, Hatakeyama, et al., 2000). SKP2 
negatively regulates expression of p27Kipl, hence silencing of SKP2, leads to increase 
p27Kipl with stalling in G1/0 and decreased S phase (Lu, Gan, Cao, et al., 2014). Active 
RB1 in an unphosphorylated form, negatively regulates SKP2 to maintain cells in G1/0 
(Lu, Bauzon, Fu, et al., 2014). To establish if p27Kipl levels decrease with silencing of 
DYRK1A, western blotting was undertaken using lysates collected 48 hours post reverse 
transfection (Figure 89). To highlight these changes densitometry of p27Kipl expression 
was performed, and corrected to actin, relative to siAllstar at each time point (Figure 90). 
Only the time points at 48 and 72 hours post reverse transfection are shown here, as they 
likely represent maximal effect of the siRNA prior to dilution with cell expansion.  
 
In G292 clone A141B1, expression of p27Kipl was high at 48 hours, but decreased with 
time. Expression of p27Kipl did not rise in HU09, in keeping with diminished stability in the 
absence of phosphorylation by DYRK1A, and absence of active RB1. In both tumour cell 
lines p27Kipl increased with silencing of SKP2 as expected. The increased expression of 
p27Kipl at 48 hours in tumour cell line G292 clone A141B1 could relate to the presence of 
wildtype active un-phosphorylated RB1, and it’s regulation of p27Kipl via SKP2. Since 
levels of p27Kipl are controlled by phosphorylation and stabilisation by DYRK1A, but also 
negative inhibition by SKP2, silencing of DYRK1A may lead to a change in balance of 
p27Kipl regulation in tumour cell lines with active RB1. Whereas, in the RB1 deficient 
tumour cell line HU09, in the absence of inhibitory regulation of SKP2 by active un-
phosphorylated RB1, baseline p27Kipl levels are low compared to the RB1 wildtype 
tumour cell line. Increased p27 expression was not maintained at 72 hours in G292 clone 
A141B1 post reverse transfection with either siDYRK1A or siSKP2. This could reflect a 
faster growth characteristic than HU09, and therefore greater dilution of the siRNA, and 
therefore earlier return to baseline expression levels. 





To further understand the cell cycle changes seen by FACS profiling when DYRK is 
silenced, western blots examining the cyclins A2, D1 and E1 were performed using 
lysates 48 hours post reverse transfection with siCON2 (non-targeting control), siSKP2, 
siDYRK1A and mock (untreated) (Figure 91). Silencing of DYRK1A by siRNA caused a 
decreased expression of DYRK1A in both tumour cell lines. Baseline Cyclin D1 levels 
were high in G292 clone A141B1 with a slight increase in cyclin D1 with silencing of 
DYRK1A. Baseline expression of Cyclin D1 was absent in HU09, but detectable post 
silencing of DYRK1A. This is accordant with loss of negative regulation of Cyclin D1 by 
DYRK1A, leading to increased levels of Cyclin D1.  
 
Decreased expression of Cyclin E1 was seen in the RB1 wildtype tumour cell line G292 
clone A141B1, in keeping with the increase in p27Kipl levels seen at 48 hours (Figure 89). 
Levels of p27Kipl were low in the RB1 deficient tumour cell line HU09, and hence no 
significant change of expression of Cyclin E1 was seen. Cyclin A1 expression levels were 
low for both tumour cell lines, without significant changes to expression levels. DYRK1A 
is known to phosphorylate and activate Sirtuin1 (SIRT1), which deacetylates p53, a 
negative regulator of p21 activation (Guo, Williams, Schug, et al., 2010). Silencing of 
DYRK1A, would therefore be expected to increase p21 activation, however, increased 
expression of p21 is seen in neither tumour cell line. This is perhaps because p21 
expression is also negatively regulated by SKP2 expression, and therefore other 
homeostatic control measures prevent a significant increase.  
 
Silencing of SKP2, used as a positive control, lead to loss of inhibitory control of p27Kipl 
with resultant increase in p27Kipl expression (Figure 90), and subsequent decrease in 
Cyclin E1, seen in both tumour cell lines. Furthermore, p21 expression was significantly 
increased in both tumour cell lines, in keeping with loss of inhibitory control by SKP2. 
Resultant increase in the proportion of cells in G1 and decreased S phase was seen in 
both cell lines by FACS as expected.   






















































































































































































































































Figure 89 DYRK1A expression when targeted by siDYRK1A in both G292 clone A141B1 
(RB1 wildtype), and HU09 (RB1 deficient) tumour cell lines decreased.  
Western blotting of DYRK1A and p27 expression in G292 clone A141B1 and HU09. Both tumour 
cell lines were reverse transfected with siRNA targeting siDYRK1A, siAllstar (non-targeting 
control) and siSKP2, whole cell fractions collected after 48, 72 and 96 hours, electrophoresed and 
immunoblotted as described in the methods. Immunoblotting of actin was used a loading control. 
In G292 clone A141B1, expression of p27Kipl was high at 48 hours, and decreased with time. 
Expression of p27Kipl did not rise in HU09 and expression was absent at 96 hours, in keeping with 
diminished stability in the absence of phosphorylation by DYRK1A. In both tumour cell lines p27Kipl 
increased with silencing of SKP2 as expected. 
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Figure 90 Densitometry of p27Kipl expression corrected to actin, relative to siAllstar at 48 
and 72 hours post reverse transfection.  
Bar chart of corrected p27 expression levels relative to siAllstar by western blotting. G292 clone 
A141B1 and HU09 were reverse transfected with siRNA targeting siDYRK1A, siAllstar (non-
targeting control) and siSKP2, whole cell fractions collected after 48, 72 and 96 hours, 
electrophoresed and immunoblotted as described in the methods. Immunoblotting of actin was 
used a loading control. Densitometry of DYRK1A expression relative to actin was calculated for 
each OS tumour cell line using ImageJ software. In G292 clone A141B1, expression of p27Kipl was 
high at 48 hours, and decreased with time. Expression of p27Kipl did not rise in HU09. In both 
tumour cell lines p27Kipl increased with silencing of SKP2 as expected. Increased p27 expression 
was not maintained at 72 hours in G292 clone A141B1 post reverse transfection with either 
siDYRK1A or siSKP2. This could reflect a faster growth characteristic than HU09, and therefore 
greater dilution of the siRNA. [p27: p27Kipl]




In conclusion, the most profound changes seen post silencing of DYRK1A in RB1 
deficient tumour cells are decreased p27Kipl and an increase in Cyclin D1 at this time 
point. Expression of p21 and Cyclin E1 did not change. On inspection of the known 
targets of DYRK1A, at this time point, it is possible to exclude Cyclin E1 and p21 from the 
mechanism of synthetic lethality. It is most likely the following changes occur: firstly, 
reduction of phosphorylation of Cyclin D1 by DYRK1A leads to stabilisation, reflected in 
increased protein expression in both cell lines. In the RB1 wildtype context, loss of 
repression of Cyclin D1 leads to activation of RB1 (Soppa, Schumacher, Florencio Ortiz, 
et al., 2014; Ashford, Oxley, Kettle, et al., 2014). Secondly, reduction of phosphorylation 
of p27Kipl at Serine10 by DYRK1A, leads to decreased stability (Ishida, Kitagawa, 
Hatakeyama, et al., 2000), reflected in decreased p27Kipl expression in HU09. However, 
with decreased expression of p27Kipl, no compensatory rise in Cyclin E1 was seen, but 
this could be because 48 hours was too early for this to be observed, or because of 
redundancy of regulation of Cyclin E1, for example by p21 acting via Cyclin D1. The cell 
cycle profile changes identified by FACS were not profound, and so it is possible that 
some of the expected increase of Cyclin A2 with the tumour cell line HU09, was too small 
to observe.  
 
Lysates collected 48 hours post exposure to 3µM harmine and 3µM AZ191 were also 
used to investigate cyclin and DYRK1A substrate expression (Figure 92). AZ191 had 
become available from Astra Zenica on a material transfer agreement, and given its 
nanomolar IC50 inhibition of DYRK1A and DYRK1B, was used in addition to harmine. 
Decreased expression of DYRK1A was seen post inhibition of DYRK1A using both 
agents in both cell lines. After exposure to harmine and AZ191, no significant changes in 
Cyclin D1, Cyclin E1 or Cyclin A2 were seen. It is possible that the profound changes 
seen in cell cycling by FACS after exposure to 30µM harmine are off target effects given 
that no profound changes in Cyclin profiles were seen with a lower drug dose or silencing 
by siRNA.  
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Figure 91 Expression of DYRK1A substrates and markers of the cell cycle at 48 hours post 
reverse transfection with siDYRK1A and siSKP2. 
Western blotting is shown. Tumour cells were reverse transfected with siRNA (siAllstar, 
siDYRK1A, and siSKP2). After 48 hours, total cell lysates were collected, electrophoresed and 
immunoblotted Immunoblotting of actin was used as the loading control. Silencing of DYRK1A by 
siRNA caused a decreased expression of DYRK1A in both tumour cell lines. Baseline Cyclin D1 
levels were high in G292 clone A141b1 with an increase in cyclin D1 with silencing of DYRK1A. 
Baseline expression of Cyclin D1 was absent in HU09, but detectable with silencing of DYRK1A. 
This is accordant with loss of negative regulation of Cyclin D1 by DYRK1A, leading to increased 
levels of Cyclin D1. Decreased expression of Cyclin E1 was seen in the RB1 wildtype tumour cell 
line G292 clone A141B1, in keeping with the increase in p27Kipl levels seen at 48 hours. Silencing 
of DYRK1A leads to decreased phosphorylation of p27Kipl and therefore decreased stability. Levels 
of p27Kipl were low in the RB1 deficient tumour cell line HU09, and hence no significant change of 
expression of Cyclin E1 was seen. Cyclin A1 expression levels were low for both tumour cell lines, 
without significant changes to expression levels. Levels of expression of p21 were unchanged in 
both tumour cell lines. Silencing of SKP2, used as a positive control, leads to loss of inhibitory 
control of p27Kipl (shown previously) and p21, with subsequent decrease in Cyclin E1, seen in both 
tumour cell lines.  
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Figure 92 Expression of DYRK1A substrates and markers of the cell cycle responses to 
inhibition of DYRK1A by 3µM harmine and 3µM AZ191 in OS tumour cell lines.  
Western blot is shown. G292 clone A141B1 and HU09 were exposed to 3µM harmine or 3µM 
AZ191 or drug vehicle, DMSO or untreated. After 48 hours, total cell lysates were isolated after 
drug exposure, electrophoresed and immunoblotted as described in the methods. Immunoblotting 
of actin was used as a loading control. Decreased expression of DYRK1A is seen post inhibition of 
DYRK1A using both agents in both tumour cell lines. After exposure to harmine and AZ191, no 
significant changes in Cyclin D1, Cyclin E1 or Cyclin A2 were seen. A decrease in expression of 
p21 was seen in both tumour cell lines, reflecting progression through G1 into S and beyond to 
G2.  
 





This chapter descried the results of two parallel cell-based siRNA screens (OS panel of 
18 tumour cell lines, and isogenic RB1 deficient OS models) to identify genetic 
vulnerabilities associated with the recurrent driver mutations of RB1 and CDKN2A.  
 
Genetic vulnerabilities associated with CDKN2A deficiency were identified and 
revalidation of these genes could form the basis for future work. Genetic dependencies 
associated with RB1 deficiency were also identified, and eight genes underwent 
revalidation by deconvolution. High-throughput cell-based screening has the advantage 
of allowing multiple individual genes to be targeted simultaneously, although type I and II 
errors may occur (Martis & Radhakrishnan, 2011). The incidence of false positive (Type I) 
errors can be reduced by performing multiple parallel screens with subsequent validation 
of generated hits. As discussed previously, both isogenic and non-isogenic models have 
inherent limitations, and thus in an attempt to overcome these limitations both models 
were screened to increase the likelihood of identifying a clinically relevant RB1 synthetic 
lethal effect.  
 
Twenty-seven genes were selected using the criteria set to identify candidate genetic 
dependencies associated with RB1 deficiency using the isogenic RB1 deficient U2OS 
models. Network analysis demonstrated a number of connections between these 
candidate genetic dependencies and reliance on DNA metabolism and damage repair 
(WRN, RECQL5, RAD50, ERCC3, OGG1 and PALB2). Revalidation of these genes 
could provide the basis for future work. Of eight candidate genetic dependencies 
associated with RB1 deficiency in the OS tumour cell line panel chosen for revalidation by 
deconvolution, only DYRK1A met the stringent criteria set for revalidation. To investigate 
the robustness of this synthetic lethal observation, combination of both the osteosarcoma 
and breast tumour cell line panels identified DYRK1A as a candidate genetic dependency 
associated with RB1 deficiency. This observation was also seen in an independent 
publically available data set called ‘Achilles’ created by the Broad Institute using lenti-viral 
delivered genome-wide shRNA in a panel of 216 cancer cell lines (Cowley, Weir, 
Vazquez, et al., 2014). A further independent data set derived from siRNA screening 
using a colon cancer cell line, which was irradiated to induce phosphorylation and 
inactivation of RB1 also demonstrated a genetic dependency on DYRK1A (Stockwell, Li, 
Aherne, et al., 2012). 




Further overlap of the genetic dependencies identified in isogenic RB1 deficient U2OS 
cell line models with those of the osteosarcoma tumour cell line panel, in particular 
DYRK1A was not observed. This could be that other molecular characteristics of the 
tumour cell line U2OS mitigate the genetic vulnerability of loss of DYRK1A. Deficiency of 
CDKN2A (p16) was found in this panel of tumour cell lines to be mutually exclusive with 
deficiency of RB1. U2OS, although CDKN2A wildtype, p16 expression is not detectable 
by western blot, and mRNA expression and proteomic abundance levels are comparable 
with other tumour cell lines with homozygous deletion of CDKN2A, and so previously 
classified as CDKN2A deficient (described in Chapter three). It is possible that a 
deficiency of CDKN2A abrogates genetic vulnerabilities specific to acquired deficiencies 
associated with deficiency of RB1. Absence of p16 (CDKN2A) leads to loss of repression 
of Cyclin D1, and therefore phosphorylation and inactivation of RB1. CRISPR-Cas9 
mediated mutagenesis of RB1 was attempted in a number of osteosarcoma tumour cell 
lines (G292 clone A141B1, KPD, MHM and OS25-HAL) before success in U2OS. These 
tumour cell lines all had wildtype CDKN2A, and post reverse transfection, all CRISPR-
Cas9 transfected clones demonstrated rapid loss of viability. It is possible that acquired 
deficiency of RB1 is only possible in tumour cells with concomitant deficiency of 
CDKN2A, and have therefore adapted to a cellular state in which RB1 is inactivated, 
which could impact on possible genetic vulnerabilities. Given that CRISPR-Cas9 
mutagenesis was attempted in a number of other CDKN2A wildtype tumour cell lines 
without success, it is possible sudden acquired complete deficiency of RB1 is lethal 
without prior deficiency of CDKN2A, and that a deficiency of CDKN2A abrogates genetic 
vulnerabilities specific to acquired deficiencies associated with deficiency of RB1.  
 
All of these models have their limitations. Isogenic models that derive from a single 
progenitor cell line, with minimal genetic differences between the daughter and parental 
cell lines, so that any observed differences are more likely to be due to the gene of 
interest (Rehman, Lord & Ashworth, 2010), were sought. However, given the 
heterogeneity of osteosarcoma in vivo, a panel of representative tumour cell lines was 
attractive, but does make isolation of genetic vulnerabilities with a molecular deficiency 
such as RB1 more difficult.  
 
Kinase inactivation of DYRK1A by conversion of a critical Lys-188 residue in the catalytic 
domain to Arg-188 has been shown to have a dominant negative effect on wildtype 
DYRK1A (Yang, Ahn & Chung, 2001; Litovchick, Florens, Swanson, et al., 2011). Using a 




tetracycline inducible model of kinase inactivated and wildtype DYRK1A, colony formation 
assay post reverse transfection with siRNA targeting RB1, demonstrated suppression of 
colony formation. This confirmed that the genetic dependency observed was dependent 
on the kinase activity of DYRK1A.  
 
Many different roles for DYRK1A have been recorded, with those in the DREAM complex 
and the cell cycle most annotated. DYRK1A is a critical component of the DREAM 
complex. Litovchick et al. established that the DREAM complex controls cell cycle exit 
into G0, and is composed of RB Transcriptional Co-repressor Like 2 (p130), E2F 
Transcription Factor 4 (E2F4), dimerization protein 1 (DP), and a stable core complex of 
five MuvB-like proteins which form the multi-vulval class B (MuvB) core: LIN9, LIN37, 
LIN52, LIN54 and RB Binding Protein 4, Chromatin Remodelling Factor (RBBP4); the 
MuvB core binds p130-E2F4 dimerisation partner (DP) to form the DP, RB like E2F and 
MuVB (DREAM) complex in G0 to repress all cell cycle-dependent gene expression 
(Litovchick, Florens, Swanson, et al., 2011; Sadasivam & Decaprio, 2013), totalling more 
than 800 human promoters and is required for repression of E2F target genes (Litovchick, 
Sadasivam, Florens, et al., 2007).  
 
Formation of the MuvB core with p130 and E2F4 is dependent on phosphorylation of 
Serine28 on LIN52 by DYRK1A. Silencing or kinase inactivation (DYRK1A-K188R) of 
DYRK1A, or mutagenesis of Serine28 on LIN52, prevents DREAM complex formation, 
reducing the ability of the cell to enter quiescence or undergo Ras-induced senescence 
(Litovchick, Florens, Swanson, et al., 2011). DRYK1B has also been shown to 
phosphorylate LIN52 in vitro, but no specific role for endogenous DYRK1B in vivo has 
been established, however, exogenous overexpression does rescue the effects of 
depletion of DYRK1A (Litovchick, Florens, Swanson, et al., 2011). 
 
If RB1 is active, cells are arrested at the restriction point. The activator E2Fs, (E2F1, 
E2F2, and E2F3) contribute to the control of early cell cycle gene expression and G1 to S 
phase transition. Cyclins D and E in complex with the cyclin-dependent kinases (CDKs) 
mitigate repression of E2F by phosphorylation of active RB1 to its inactive form. In the 
absence of DREAM complex formation, the MuvB core recruits BMYB during S phase 
and then forkhead box protein M1 (FOXM1) to the promoters of the G2/M phase-
expressed genes (Sadasivam & Decaprio, 2013). The MuvB core is essential for 
targeting each of the three complexes (DREAM, BMYB and FOXM1) to specific sets of 




cell cycle gene promoters (Sadasivam & Decaprio, 2013). A schematic of the DREAM 
complex and it’s role in the cell cycle is shown in Figure 93. 
 
The balance between the quiescent DREAM complex and the proliferative phase BMYB–
MuvB–FOXM1 complex is frequently disrupted in cancer (Sadasivam & Decaprio, 2013). 
Disruption of the DREAM complex and RB1 by deregulated cyclin and cyclin dependent 
kinase (CDK) activity leads to decreased expression of the E2F-dependent cell cycle 
genes and instead activation of the late cell cycle genes (Sadasivam & Decaprio, 2013). 
Increased DREAM formation by over expression of DRYK1A or decreased levels of 
BMYB may result in cancer cells exiting the cell cycle and remaining dormant. It is 
unknown if the loss of RB1 and the perturbation of the DREAM complex can be 
distinguished in cancer, and thus whether there are separate roles during quiescence and 
senescence (Sadasivam & Decaprio, 2013).  
 
Defective DREAM complex assembly, results in the loss of transcriptional repression of 
cell cycle genes (MacDonald, Ramos-Valdes, Perampalam, et al., 2016). Loss of 
endogenous expression of DYRK1A appears to result in two fates, either proliferation or 
cell death; chemical silencing of DYRK1A in non cancerous pancreatic beta-cells 
increases proliferation (Shen, Taylor, Jin, et al., 2015; Wang, Alvarez-Perez, Felsenfeld, 
et al., 2015). Conversely, retention of the MuvB-BYMB complex, after loss of DYRK1A in 
epithelial ovarian cancer spheroids, leads to increased DNA synthesis that is concomitant 
with cell death (MacDonald, Ramos-Valdes, Perampalam, et al., 2016). Ovarian tumour 
cell lines induced to produce spheroids enter G0, with DYRK1A acting as the primary 
kinase responsible for DREAM complex assembly (MacDonald, Ramos-Valdes, 
Perampalam, et al., 2016). DYRK1A depleted ovarian tumour cell line spheroids, created 
by lentiviral shRNA infection, resulted in a significantly increased level of DNA synthesis 
at 6 hours post transfer to non-adherent conditions (MacDonald, Ramos-Valdes, 
Perampalam, et al., 2016). Although this effect was abrogated by 24 hours, extensive 
subG1 death was observed and spheroid viability was reduced (MacDonald, Ramos-
Valdes, Perampalam, et al., 2016). Exposure of ovarian spheroids to a DYRK1A inhibitor, 
Indy in combination with carboplatin resulted in greater loss of viability than with either 
agent alone (MacDonald, Ramos-Valdes, Perampalam, et al., 2016). Targeting DYRK1A, 
and other members of the DREAM complex, in such a setting instead of leading to 
proliferation, caused cell death, suggesting a possible attractive therapeutic approach 




(MacDonald, Ramos-Valdes, Perampalam, et al., 2016). Furthermore in those tumour 
types where cells evade the effects of cytotoxic therapy by quiescence, inhibition of 
DREAM complex formation and resultant increase in cell cycling, may make them more 
susceptible to cytotoxic therapy. One example is with Imatinib, the primary treatment of 
gastrointestinal stromal tumours (GIST), which has been shown to induce DREAM 
mediated quiescence in vivo. Inhibition of the DREAM complex formation by depletion of 
DYRK1A or LIN52 by siRNA or treatment with harmine, reduced quiescence and 
increased imatinib induced apoptosis (Boichuk, Parry, Makielski, et al., 2013).  
 
DYRK1A is also pro-survival with a role as a negative regulator of the intrinsic apoptotic 
pathway in the mouse retina (Laguna, Aranda, Barallobre, et al., 2008). DYRK1A 
phosphorylates caspase-9 on threonine residue 125, which is crucial in protecting cells in 
the retina from apoptosis (Laguna, Aranda, Barallobre, et al., 2008). DYRK1A also 
phosphorylates and activates Sirtuin1 (SIRT1), which deacetylates p53 leading to cell 
survival despite DNA damage (Guo, Williams, Schug, et al., 2010). Deacetylation of p53 
by SIRT1 leads to transcriptional inactivation and repression of the p53-mediated cell 
growth arrest and apoptosis in response to DNA damage and oxidative stress (Brooks & 
Gu, 2011). In addition, SIRT1 mediated deacetylation process has been associated with 
increased cellular senescence (Brooks & Gu, 2011). The p53-dependent transactivation 
of p21 is also prevented by this deacetylation (Brooks & Gu, 2011). p21 negatively 
regulates CDK1 activation, a promoter of cell cycle progression from G2 to mitosis 
(Ronco, Martin, Demange, et al., 2017). Silencing of endogenous DYRK1A and DYRK3 
leads to hypo-phosphorylation of SIRT1, and sensitisation of cells to DNA damage-
induced cell death (Guo, Williams, Schug, et al., 2010). DYRK1A also selectively binds 
and phosphorylates huntingtin-interacting protein 1 (Hip-1) during the neuronal 
differentiation of embryonic hippocampal neuro-progenitor cells, which results in the 
blockade of Hip-1 mediated neuronal cell death (Kang, Choi, Park, et al., 2005).  
 
The diverse roles of DYRK1A are summarised in Figure 94. 
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Figure 93 Schematic of the DREAM complex and role in the cell cycle adapted from 
Sadasivam et al. (Sadasivam & Decaprio, 2013). 
The DREAM complex is composed of p130, E2F4, dimerization protein 1 (DP), and a stable core 
complex of five MuvB-like proteins which form the multi-vulval class B (MuvB) core: LIN9, LIN37, 
LIN52, LIN54 and RBBP4 (Litovchick, Florens, Swanson, et al., 2011). Formation of the DREAM 
complex (multi-vulval class B (MuvB) core with p130 and E2F4) is dependent on phosphorylation 
of LIN52 by DYRK1A (Litovchick, Florens, Swanson, et al., 2011). MuvB binds p130-E2F4 
dimerisation partner (DP) to form the DP, RB-like E2F and MuVB (DREAM) complex in G0 to 
repress all cell cycle-dependent gene expression. If RB1 is active, cells are arrested at the 
restriction point. The activator E2Fs, (E2F1, E2F2, and E2F3) contribute to the control of early cell 
cycle gene expression and G1 to S phase transition (represented by the green arrow). Cyclins D 
and E in complex with the cyclin-dependent kinases (CDKs) mitigate repression of E2F by 
phosphorylation of active RB1 to its inactive form. In the absence of DREAM complex formation, 
the MuvB core recruits BMYB during S phase and then forkhead box protein M1 (FOXM1) to the 
promoters of the G2/M phase-expressed genes (Sadasivam & Decaprio, 2013). The MuvB core is 
essential for targeting each of the three complexes (DREAM, BMYB and FOXM1) to specific sets 
of cell cycle gene promoters (Sadasivam & Decaprio, 2013). Reproduced with alteration from 
Sadasivam et al (Sadasivam & Decaprio, 2013). [P: phosphorylation; DP: dimerization partner] 
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Figure 94 Schematic summarising the multiple reported roles of dual-specificity tyrosine-
regulate kinase 1A (DYRK1A).  
The formation of the DREAM complex is dependent on the phosphorylation of Serine28 on LIN52 
by DYRK1A, which promotes cell cycle exit into G0 (Litovchick, Florens, Swanson, et al., 2011; 
Sadasivam & Decaprio, 2013); DYRK1A phosphorylates Cyclin D1 leading to protosomal 
degradation, meaning RB1 remains in an un-phosphorylated active state (Soppa, Schumacher, 
Florencio Ortiz, et al., 2014); DYRK1A phosphorylates p27Kipl at Serine10, leading to enhanced 
stability, and supressed levels of Cyclin E, thereby maintaining RB1 in its active, unphosphorylated 
state causing cell cycle arrest (Ishida, Kitagawa, Hatakeyama, et al., 2000);  DYRK1A 
phosphorylates caspase-9 on threonine residue 125, preventing apoptosis (Laguna, Aranda, 
Barallobre, et al., 2008); DYRK1A phosphorylates and activates Sirtuin1 (SIRT1), which 
deacetylates p53 leading to cell survival despite DNA damage (Guo, Williams, Schug, et al., 
2010). Deacetylation of p53 by SIRT1 leads to transcriptional inactivation and repression of the 
p53-mediated cell growth arrest and apoptosis in response to DNA damage and oxidative stress 
(Brooks & Gu, 2011). In addition, this SIRT1 mediated deacetylation process has been associated 
with increased cellular senescence (Brooks & Gu, 2011). The p53-dependent transactivation of 
p21 is also prevented by this deacetylation (Brooks & Gu, 2011). p21 negatively regulates CDK1 
activation, a promoter of cell cycle progression from G2 to mitosis (Ronco, Martin, Demange, et 
al., 2017). pRb2/ p130 also induces p27Kipl levels by impeding cyclin E/CDK2 phosphorylation of 
p27Kipl, which in turn generates the proteolytic degradation of p27 Kipl (Neganova & Lako, 2008). 




In addition to roles in both cell cycle exit to G0 via formation of the DREAM complex 
(Litovchick, Florens, Swanson, et al., 2011; Sadasivam & Decaprio, 2013), DYRK1A also 
represses Cyclin D1 and E1, both directly via proteosomal degradation of Cyclin D1 
(Chen, Lin, Tsai, et al., 2013; Soppa, Schumacher, Florencio Ortiz, et al., 2014), and 
indirectly via enhanced stability of p27Kipl which negatively controls Cyclin E1 (Ishida, 
Kitagawa, Hatakeyama, et al., 2000). Repression of Cyclin D1 and E1 leads to 
maintenance of RB1 in an active unphosphorylated stated, and stalling of cells in G1 
(Figure 95). It is logical therefore, that inhibition of DYRK1A would lead to decreased cell 
cycle exit into G0, and increased cell cycling through G1 and beyond depending on the 
function of the RB restriction point. 
 
Litovchick et al. identified a link between DYRK1A and LIN52, one of the components of 
the DREAM complex which regulates quiescence and senescence (Litovchick, Florens, 
Swanson, et al., 2011). They performed similar cell cycle experiments in both serum 
positive (10% FBS) and serum starved (0% FBS) conditions using T98G cells of 
glioblastoma origin, that have previously been shown to have cell cycle control that is 
dependent on functional pRB1 (Paggi, Felsani & Giordano, 2003). Forty-eight hours post 
reverse transfection with siDYRK1A and 20 hours post exposure to 10µM harmine, cell 
cycle profiling using FACS showed that S phase was increased in both treatment and 
serum conditions (Litovchick, Florens, Swanson, et al., 2011). From this they concluded 
that DYRK1A must be essential to DREAM complex assembly and entry into 
G0/quiescence (Litovchick, Florens, Swanson, et al., 2011). Notably Litovchick et al. only 
used EDU and DAPI stains, and so without the addition of a phospho-histone H2 
antibody were unable to identify active mitosis. Concordant with these observations, in 
both tumour cell lines regardless of RB1 context, there was a modest increase in S phase 
post exposure to siDYRK1A. However, the observations of Litovchick et al. did not 
correspond with the dramatic decrease of S phase seen in the RB1 wildtype tumour cell 
line G292 clone A14B1 post exposure to 30µM harmine from 3% as compared to 11% in 
the control (DMSO). It is possible that at higher doses of harmine off-target effects such 
as G2/M arrest via induction of p21, and activation of the Fas/FasL pathway (Wang, 
Wang, Jiang, et al., 2015) mask the on-target effects of increased S-phase or temporal 
effects of a later time point used (48 hours not 20 hours as per Litovchick et al.). 
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Figure 95 Schematic of RB pathway in a non-manipulated cell adapted from Mittnacht et al. 
(Mittnacht, 2005).  
RB1 in its active state is hypo-phosphorylated and binds E2F. Cyclins D1 and E lead to hyper-
phosphorylation and inactivation of RB1, and dissociation of the E2F transcription factors, enabling 
the cell to proceed through the cell cycle. DYRK1A phosphorylates Serine10 of p27Kip1 leading to 
enhanced stability and suppression of levels of Cyclin E (Ishida, Kitagawa, Hatakeyama, et al., 
2000). Phosphorylation at Thr286 by DYRK1A and DYRK1B induces proteosomal degradation of 
Cyclin D1 during G1 phase (Soppa, Schumacher, Florencio Ortiz, et al., 2014) meaning RB1 
remains in an un-phosphorylated active state.  
 




Chen et al. also demonstrated that silencing of DYRK1A by siRNA or by harmine, 
decreased the duration of G1 phase (Chen, Lin, Tsai, et al., 2013). MacDonald et al. 
observed a decrease in G1, and an increase in subG1 population 20 hours post spheroid 
formation in ovarian tumour cell lines which stably expressed shDYRK1A (MacDonald, 
Ramos-Valdes, Perampalam, et al., 2016). Although I do not see an increase in the 
subG1 population, this could be a function of the time point analysed. It is also important 
to note that these experiments (MacDonald, Ramos-Valdes, Perampalam, et al., 2016) 
were performed in spheroid systems, not adherent cells which are likely to have different 
cell cycle profiles, and clinical implications for future extrapolation. 
 
In accordance with the hypothesis that inhibition of DYRK1A decreases the proportion of 
cells exiting the cell cycle into G0, it appeared from the FACS experiments that inhibition 
of DYRK1A by harmine increased the proportion of cells in G2. In the RB1 wildtype 
tumour cell line, cells continued to undergo mitosis, with a corresponding increase in 
mitosis (1% DMSO; 4% 10µM harmine; 10% 30µM harmine). However, in the RB1 
deficient tumour cell line, an increase in mitosis was not seen (1% DMSO; 2% 10µM 
harmine; 2% 30µM harmine), consistent with stalling in G2. It is possible that these 
effects are due to off-target effects of harmine. Harmaline, another β-carboline alkaloid 
very similar harmine, has been shown to induce G2/M arrest via induction of p21, and 
activation of the Fas Cell Surface Death Receptor (Fas/FasL) pathway (Wang, Wang, 
Jiang, et al., 2015), since these profound changes were not seen with lower 
concentrations of harmine, or post silencing of DYRK1A by siRNA. In addition, the 
increase in apoptosis seen post exposure to harmine at 10µM and 30µM concentrations 
may partially be explained by off target-effects of activation of the Fas/FasL pathway, 
which have been shown to activate Caspase-8 and Caspase-3 (Wang, Wang, Jiang, et 
al., 2015). However, this would not explain the statistically significant difference in levels 
of apoptosis seen between the two tumour cell lines. Tumour cells deficient in RB1 have 
been shown to be resistant to apoptosis induced via the Fas/FasL pathway, because of a 
deficiency in caspase-8 expression secondary to epigenetic gene silencing by over 
methylation (Poulaki, Mitsiades, McMullan, et al., 2005). It is therefore unlikely that 
potential off-target effects of harmine explain this observation.  
 
Exposure to harmine was associated with a decreased viability and increased level of 
apoptosis at 48 hours in the RB1 deficient tumour cell line HU09, compared to the RB1 
wildtype tumour cell line G292 clone A141B1. Although single agent DYRK1A inhibitors 




have shown little selectivity towards tumour cells with RB1 deficiency, a modest 
synergistic effect was observed with the combination of harmine and cisplatin in 
combination in the RB1 deficient tumour cell line HU09. To further establish any possible 
synergistic relationship, a longer-term assay with multiple dosing could be performed. 
Furthermore, combination of harmine or one of the new agents with greater potency of 
inhibition to DYRK1A such as GNF4877 (DYRK1A IC50 6nM) (Shen, Taylor, Jin, et al., 
2015) could be screened in combination with other cytotoxic agents, in particular anti-
mitotic agents such as paclitaxel or vinblastine to look for synergy. 
 
Interpretation of the protein expression data is complicated by the many roles of DYRK1A 
and unknown consequences of an RB1 deficient context. As predicted, silencing of 
DYRK1A leads to reduction of phosphorylation of Cyclin D1 and subsequent stabilisation, 
reflected in increased protein expression in both tumour cell lines. In the RB1 wildtype 
context, loss of repression of Cyclin D1 leads to activation of RB1 (Soppa, Schumacher, 
Florencio Ortiz, et al., 2014; Ashford, Oxley, Kettle, et al., 2014). In addition, p27Kipl levels 
were increased and Cyclin E1 decreased, which could explain the increase in proportion 
of RB1 wildtype G292 clone A141B1 tumour cells in G1 post reverse transection with 
siDYRK1A, but why despite an increase in Cyclin D1, the RB1 deficient HU09 tumour 
cells progress past the non-functional RB restriction point.  
 
Therefore, it is likely that a combination of increase in Cyclin D1, together with loss of 
formation of the DREAM complex increases the number of cells actively cycling. Cell 
cycle progression past G1 is determined by the cellular context and presence of 
functioning RB restriction point. Cyclin profiles, p27Kipl and members of the Fas/FasL 
pathway expression after exposure to 30µM harmine could be performed to confirm the 
findings seen by flow cytometry and determine if these were more likely off-target effects. 
Further investigation of the effects of blockade of DYRK1A by other small molecule 
inhibitors could be undertaken using the newer inhibitor GNF4877 (DYRK1A IC50 6nM) 
(Shen, Taylor, Jin, et al., 2015). Unlike harmine and harmaline, which are beta-carboline 
compounds, GNF4877 is based on an aminopyrazine scaffold and structurally different. 
Therefore, cell cycle analysis after exposure to GNF4877 has the potential to confirm the 
effects of silencing DYRK1A without the potential for off-target effects seen with harmine.  
 
Deficiency of active RB1 has been associated with mis-regulation of E2F targets leading 
to RB1 pathway defects which have been associated with over expression of mitotic 




checkpoint protein (MAD2), and mitotic defects (Hernando, Nahlé, Juan, et al., 2004), 
increasing the incidence of multipolar spindles, anaphase bridges, lagging chromosomes 
and micronuclei harbouring whole chromosomes (Amato, Schillaci, Lentini, et al., 2009), 
preventing progression through mitosis (Manning & Dyson, 2012). It is therefore 
conceivable that RB1 deficient tumour cells are stalled in G2, because RB1 deficiency 
affects progression through mitosis (Dyson, 2016) forming the basis of the genetic 
vulnerability to loss of DYRK1A. Increased apoptosis observed in the RB1 deficient cell 
line, could be mediated by decreased phosphorylation of caspase-9 on threonine residue 
125 by DYRK1A, with resultant increase in apoptosis (Laguna, Aranda, Barallobre, et al., 
2008) or from mitotic catastrophe. To further confirm these changes the following 
experiments could be performed: firstly, silencing of LIN52 by siRNA or CRIPSR-Cas9 
mutagenesis of the Serine28, critical for formation of the DREAM complex, should lead to 
the same phenotype observed, if failure of DREAM complex formation occurs. Secondly, 
expression of functional RB1 should reverse the phenotype and decrease apoptosis. 
Thirdly a DNA fibre assay could be performed to identify fork stalling, while γH2AX assay 
could investigate for increased DNA damage. A schematic summarising the proposed 
hypothesis for the DYRK1A and RB1 synthetic lethality is shown in Figure 96. 
 
To further confirm this genetic vulnerability, a solution would be a rescue experiment, by 
silencing of endogenous expression of DRYK1A by CRISPR mutagenesis in an RB1 
deficient OS tumour cell line, and then controlled expression of exogenous wild type 
DYRK1A or kinase inactive (K188R) DYRK1A using a cre:lox system (Figure 97). This 
would enable further robust investigation of the mechanism without using siRNA.
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Figure 96 Schematic of the proposed hypothesis for the DYRK1A and RB1 synthetic 
lethality  
It is likely that a combination of increase in Cyclin D1, together with loss of formation of the 
DREAM complex increases the number of cells actively cycling. Deficiency of active RB1 has 
been associated with mis-regulation of E2F targets leading to firstly up-regulation of the spindle-
assembly checkpoint component MAD2 and resultant hyper-activated checkpoint with impaired 
cleavage of cohesion, leading to lagging chromosomes, chromosome breaks, deletions 
(Hernando, Nahlé, Juan, et al., 2004; Manning & Dyson, 2012),double strand DNA breaks, 
compromised centromere structure and function (Manning & Dyson, 2012). It is therefore 
conceivable that RB1 deficient tumour cells are stalled in G2, because deficient RB1 affects 
progression through mitosis (Dyson, 2016) forming the basis of the genetic vulnerability to loss of 
DYRK1A. Increased apoptosis observed in the RB1 deficient cell line, could be mediated by 
decreased phosphorylation of caspase-9 on threonine residue 125 by DYRK1A, with resultant 
increase in apoptosis (Laguna, Aranda, Barallobre, et al., 2008) or from mitotic catastrophe. [Red 
text: highlights outcomes; dashed red arrows: proposed effects; solid red arrows: observed effects] 
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Figure 97 Schematic of future rescue experiment to further confirm the DYRK1A and RB1 
synthetic lethality. 
A: Transfection of Cas9 plasmid and guide DNA targeting Exon 1 of DYRK1A or Cas9 alone into a 
RB1 deficient OS tumour cell line; B: Transfection efficiency monitored using a EGFP control. 
Cells selected by blastocydin, and seeded for colony formation. 100 colonies were picked and 
expanded. Generation of DYKR1A mutant and control (Cas9 alone) clones. C: Manufacture of 
genomic DNA from single colony clones, and subsequent amplification of target region of DYRK1A 
by PCR. Selection of mutant clones with the Surveyor Assay performed using the DYRK1A PCR 
product of all clones by identification of multiple DNA bands; sub-clone mutant clones, and sanger 
sequence for comparison with Cas9 control (parental) clone. Confirmation of expression of loss of 
DYRK1A expression by western blot of both N and C-termini of DYRK1A; D: Codon optimise 
genomic DYRK1A within the CRISPR guide target region only. Generation of plasmids for both 
wildtype and kinase inactive (K188R) DYRK1A; E: viral infection of DYRK1A plasmids into 
DYRK1A silenced CRISPR mutants; F: generation of stable tumour cell lines with cre:lox control of 
exogenous expression of wildtype and K188R DYRK1A. G: In the RB1 deficient setting, does 
expression of wildtype DYRK1A rescue the synthetic lethality? Is rescue of the synthetic lethality 
by exogenous expression of DYRK1A dependent on the activity of the kinase domain or will 
kinase inactive K188R DYRK1A also rescue the synthetic lethality?  




7 Identifying drug dependencies in osteosarcoma using a 
focused high-throughput cell based drug screen 
7.1 INTRODUCTION 
Unfortunately despite international collaboration, there has been little improvement in 
survival for patients with OS over the past two decades (Kempf-Bielack, Bielack, Jürgens, 
et al., 2005; Janeway, Barkauskas, Krailo, et al., 2012; Mirabello, Troisi & Savage, 2009; 
Luetke, Meyers, Lewis, et al., 2014) with 5 year survival remaining in the order of 70% for 
young patients with localised disease. For those with metastatic disease at diagnosis, 
outcome is poor with only 20-30% surviving for 5 years (Koboldt, Fulton, McLellan, et al., 
2012), and remains even more dismal for those with recurrence (Luetke, Meyers, Lewis, 
et al., 2014). There is a paucity of early phase clinical trials available for these patients 
and unfortunately results from these have generally been disappointing. Therefore, new 
or repositioned agents are needed for improvement of outcome. Currently no means of 
stratification of drugs for treatment of osteosarcoma or biomarkers of efficacy or 
sensitivity to treatment exist in the clinic. Targeting RB1 deficiency in osteosarcoma 
represents a novel therapeutic approach and is attractive as up to 35% have structural 
rearrangements of RB1 (Araki, Uchida, Kimura, et al., 1991).  
 
The aim of the parallel drug screen using a customised drug library was (i) to identify 
drugs with novel activity in osteosarcoma, (ii) further investigate drugs with known activity 
in osteosarcoma, (iii) more specifically to identify agents with sensitivity in RB1 deficient 
models, (iv) validate potential therapeutic targets identified from the siRNA screens and 
(v) investigate the relative sensitivity of OS to PARP inhibition compared to HR deficient 
tumour cell lines. High-throughput approaches offer the benefit of rapidly examining the 
effects of multiple drugs or genes simultaneously (Boutros, Brás & Huber, 2006; Lord, 
Martin & Ashworth, 2009). Performing parallel screens with siRNA provided potential 
synergy whereby drugs and siRNA against the same target were identified to cause 
similar phenotypes and thus provide cross-validation. Chapter 3 described the rationale 
behind the models chosen for this thesis and the potential advantages and disadvantages 
of using isogenic and non-isogenic systems. In order to maximise the potential of 
identifying potential therapeutics for osteosarcoma, and RB1 deficient tumours in 
particular, high-throughput drug screens were performed in the panel of OS tumour cell 
lines, and also isogenic RB1 wildtype and deficient U2OS models.  




The DNA damage response (DDR) is critical to genomic stability (Lord & Ashworth, 
2012). DDR pathways encompass an analogous group of coordinated processes: 
detection of DNA damage; accumulation of DNA repair factors at the site of damage; and 
physical repair of the lesion (Lord & Ashworth, 2012). Ataxia-Telangiectasia Mutated 
(ATM), ATM-Rad3-related protein kinase (ATR) and the DNA-dependent protein kinase 
(DNA-PK) are kinases which transduce the DDR signals (Lord & Ashworth, 2012). 
Double strand breaks (DSB) in DNA are primarily repaired by homologous recombination 
(HR) and the more error prone non-homologous end joining (NHEJ) (Lord & Ashworth, 
2012). HR involving resection of the sequence surrounding the DSB, and synthesis of 
replacement DNA using the homologous sister chromatid as a template, is primarily 
undertaken in the S and G2 phases of the cell cycle (Lord & Ashworth, 2012). Genes that 
encode proteins crucial to this process are BRCA1, BRCA2, RAD51 and PALB2 (Lord & 
Ashworth, 2012). In contrast to HR, NHEJ is active through-out the cell cycle and 
mediates repair by directly ligating the ends of a DSB together, which can lead to deletion 
or mutation of DNA sequences at or around the DSB site (Lord & Ashworth, 2012). The 
most well characterised role of DNA-PK is direct ligation of DNA double-strand breaks in 
NHEJ (Goodwin & Knudsen, 2014).  
 
RB1, through its amino terminal (RB1N) domain, has been shown to bind to KU70, KU80 
and DNA-PK, all components of the NHEJ machinery (Huang, Cook & Mittnacht, 2015). 
Furthermore, RB1 deficient cells displayed an increased frequency of chromosomal 
aberrations after irradiation, a characteristic of defective NHEJ (Huang, Cook & Mittnacht, 
2015). In addition, decreased NHEJ in RB1 deficient cells and concomitant loss of the G1 
checkpoint would lead to an increased reliance on the HR pathway. In tumour cells with a 
deficiency of RB1 and loss of the G1 checkpoint, cells enter S phase with more 
unrepaired DNA damage. Therefore, RB1 deficient cells would have a greater reliance on 
functional ATR to delay mitotic entry until all DNA damage repairs have been performed, 
and the DNA replicated (Nghiem, Park, Kim, et al., 2001). Tumour suppressor genes, for 
example RB1, which when inactivated drive replication stress (Huang, Cook & Mittnacht, 
2015) could potentially be therapeutically targeted with agents that disrupt the DNA 
damage repair, such as inhibitors of ATR.  
 
DSBs activate primarily ATM and DNA-PK, while ATR responds to a wide spectrum of 
DNA damage, including DSBs, regions of single-stranded DNA and a variety of DNA 
lesions that interfere with replication (Goodwin & Knudsen, 2014; Maréchal & Zou, 2013; 




Williamson, Miller, Pemberton, et al., 2016). Replication stress leads to an increased 
proportion of single-stranded DNA, and a reliance upon an ATR checkpoint function 
(Williamson, Miller, Pemberton, et al., 2016). Chemotherapeutic agents such as platinum 
salts (carboplatin and cisplatin) have a long history of clinical use by exploitation of DDR 
defects through DNA inter and intra-strand crosslinks repaired by nucleotide excision 
repair (NER) and HR (Lord & Ashworth, 2012). Recently new potent and specific 
inhibitors of ATR have been developed, VX970 (Vertex) and VE821 (Vertex) (Williamson, 
Miller, Pemberton, et al., 2016); VE821 is a tool box compound while VX970 is currently 
in Phase I/II clinical trials in combination with topotecan (NCT02487095). In pre-clinical 
studies, in tumour cells with defects in the ATM/p53 pathway, VE821 has been shown to 
enhance the cytotoxic effects of DNA damaging agents suggesting a potential role for 
ATR inhibition as a chemo-sensitising agent (Williamson, Miller, Pemberton, et al., 2016).  
 
Inhibition of DNA-PK has been shown to sensitise tumour cells that depend on NHEJ for 
survival after induced DSB formation by chemotherapeutic agents such as doxorubicin 
and etoposide (Boucher, Hillier, Newsome, et al., 2016; Tang, Yuan & Guo, 2014). 
VX984 (Vertex) a DNA-PK inhibitor has been shown to act synergistically with 
doxorubicin and etoposide in tumour cell lines and limited patient derived xenografts, 
leading to increased phosphorylated histone H2AX (gamma-H2AX), consistent with failed 
DSB repair (Boucher, Hillier, Newsome, et al., 2016). An early phase Clinical Trial of 
VX984 in combination with pegylated liposomal doxorubicin is currently in progress 
(NCT02644278). In view of this evidence, an additional focused screen looking to 
determine if enhanced sensitivity to ATR and DNA-PK inhibition was observed in RB1 
deficient compared to RB1 wildtype tumour cell lines was performed. 
 
The concept of a BRCAness phenotype and potential applicability to osteosarcoma was 
discussed in 1.1.4.1 of Chapter 1. Given the great general interest amongst the OS 
community with regards the potential for clinical trial of PARP inhibitors in OS, this 
provided the rationale to investigate the representation of a ‘BRCAness’ phenotype in the 
OS tumour cell line panel and degree of sensitivity to PARP inhibition in relation to 
validated BRCA models.  
 
 





7.2.1 Screen overview 
To identify therapeutically activate agents in osteosarcoma, and also inhibitor 
dependencies specific for RB1 deficiency, all cell lines were profiled using a customised 
in-house drug library containing 80 drugs (Table 2, described in Chapter 2). These agents 
have either been licenced for clinical use in cancer or are in early phase clinical trials and 
were selected because of their potential for rapid clinical translation (17 under preclinical 
investigation, 24 in Phase I-III clinical trials, and 39 approved for use in cancer therapy). 
The library was chosen to cover a wide variety of proteins and biological processes 
relevant to cancer, including DNA repair, metabolism, cell cycle, DNA damaging 
chemotherapeutics, receptor and cytoplasmic tyrosine kinases, serine/threonine kinase 
and cytoskeleton assembly. Previous efforts within the Lord / Ashworth laboratory have 
screened a total of 99 tumour cell lines from a range of other ten other histologies 
(Campbell, Ryan, Brough, et al., 2016), using the same screening format, making 
contextual comparison of relative drug sensitivity possible.  
 
An additional library consisting of 395 drugs (Table 3, described in Chapter 2), which 
have either been licenced for clinical use in cancer or are in early phase clinical trials at 4 
different concentrations (0.5, 5, 50, and 500nM) was also used to screen the isogenic 
RB1 deficient U2OS models. This additional library was advantageous compared to the 
previous library, because it contained a wider selection of drugs, with redundancy of 
targets and pathways for example, three different Heat Shock Protein 90 (HSP90) 
inhibitors 17AAG, ganetesipib and geldanamycin providing additional internal validation. 
However, only 4 concentrations of each inhibitor were used compared to eight 
concentrations in the previous library. This additional library was a new addition to the 
laboratory and only available after the panel of OS tumour cell lines had been screened, 
and additional screening of the panel was not possible.  
 
This methodology was described in Chapter 2 and summarised in Figure 98.  
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Figure 98 Schematic of high-throughput cell-based drug sensitivity screen overview.  
The panel of 18 OS tumour cell lines and isogenic RB1 deficient U2OS models were screened in 
triplicate. Cells were arrayed in 384-well plates, and after 24 hours the drug library was added. 
After five days of continuous drug exposure, cellular viability was estimated using CellTiter Glo 
reagent via a luminescence assay that measures cellular ATP, described in the methods. The raw 
data was processed using the CellHTS2 package of the R software suite (BioConductor), plate 
normalised, and subjected to robust quality control assessment by Spearman’s Rank correlation 
and calculation of Z prime values to determine the dynamic range. 




7.2.2 Screen quality control 
The quality of the data was examined in a similar way to that of the data generated by 
siRNA screening already described in section 5.2.3 of Chapter 5. For the drug screen the 
Z prime (Zhang, Chung & Oldenburg, 1999), was based on positive (100% DMSO 
treated) and negative (0.2% (v/v) DMSO-treated) control wells in each plate to determine 
the dynamic range of the screen. 
 
Spearman's Rank Correlation was performed to determine the reproducibility between the 
plates and was calculated on excel for the 3 combinations of pairs of replicates for each 
of the 2 drug plates for the main drug screen (Table 2), where a value of one represented 
strong correlation, and zero no correlation. All cell lines passed the stringent quality 
control with Spearman's Rank correlation approaching 1 (>0.7) and Z prime >0.3 (Turner, 
Lord, Iorns, et al., 2008; Iorns, Turner, Elliott, et al., 2008) (Figure 99, Table 18 and Table 
19). The main drug library used to screen all 18 OS tumour cell lines and RB1 deficient 
isogenic U2OS models, while an additional library (Table 3), was used as an additional 
screen for the RB1 deficient isogenic U2OS models. It was possible to identify special 
abnormalities such as dispensing errors or edge effects using heatplots of CellTiter Glo 
values using CellHTS (Figure 100). 
  
7.2.3 Raw data analysis 
Raw luminescence values were first log2 transformed and normalised to eliminate the 
effects of plate-plate variation and adjust for unavoidable errors while maintain 
biologically relevant variation. Reagent evaporation, edge effects, time differences in the 
measurement of luminescence, and variation in incubation time could introduce systemic 
errors (Boutros, Brás & Huber, 2006; Makarenkov, Zentilli, Kevorkov, et al., 2007). Three 
main approaches could have been employed for data analysis following normalisation: 
firstly calculation of a Z score statistic, which is a measure of the number of standard 
deviations from the mean. This was deemed inappropriate since calculation assumes a 
normal distribution and that the majority of drugs tested have little or no effect on viability. 
Secondly, normalised percent inhibition (NPI) allows for differential responses to the 
positive and negative controls between the models. Since 100% DMSO (positive control) 
lead to an almost complete loss of viability and 0.2% (v/v) DMSO (negative control) had 
no effect on viability in all models, this approach was not employed. Therefore calculation 
of the median survival fractions of the three replicates were chosen to identify both 




osteosarcoma specific and RB1 deficient selective effects. The Survival Fraction 50 
(SF50), the drug concentration required to elicit a 50 percent inhibition of the cell 
population, and the SF80 (concentration required to elicit an 80 percent inhibition of the 
cell population) were calculated from the dose response curves using GraphPad Prism. 
The Area Under the Curve (AUC) for each dose response curve was also calculated 
using GraphPad Prism. Comparison of SF50 and AUC was by a two-sided Student’s t-
test.  
 
7.2.4 Identification of drug effects in a panel of osteosarcoma tumour cell lines 
High-throughput drug screens in the panel of 18 osteosarcoma tumour cell line models 
demonstrated that the majority of the agents screened had a heterogeneous effect on the 
viability of osteosarcoma (at a dose of <1000nM thought to be most clinical relevant) with 
only a couple of OS tumour cell lines showing particular sensitivity or resistance, while 
the viability of the majority of tumour cell lines was not profoundly affected. Since there is 
no agreed definition of cellular sensitivity to a drug, an arbitrary cut-off of two or more 
tumour cell lines with an AUC <0.5 was used to identify drugs to which OS was most 
sensitive (Figure 101). 
 
Out of these 11 drugs, six were cytotoxic (camptothecin, doxorubicin, gemcitabine, 
methotrexate, paclitaxel and vinorelbine). Methotrexate and doxorubicin are already 
incorporated within standard MAP chemotherapy in the treatment of OS. Cisplatin, one of 
the other standard therapeutic agents using in the treatment of OS, was not included in 
the drug screen. A number of chemotherapeutics are used for the treatment of advanced 
OS. Gemcitabine combined with docetaxel is commonly used as treatment for patients 
with relapsed disease as a study found that 13% of patients had a partial response to the 
combination, and 43% had stable disease (Palmerini, Jones, Marchesi, et al., 2016). 
Although docetaxel was not included in this drug screen, the OS tumour cell lines did 
show sensitivity to another taxane, paclitaxel. Paclitaxel, a microtubule inhibitor, in the 
form of protein-bound nab paclitaxel is currently in Phase I/II study in children with 
advanced solid tumours including OS (NCT01962103). Nab-paclitaxel also in 
combination with gemcitabine is in currently in Phase II trial for patients with advanced 
sarcoma (NCT02945800).  
















































































































Figure 99 Drug screen quality control: Spearman's R2 values for both plates of the drug 
library. 
Dot plot illustrating Spearman’s rank correlation coefficient values for both drug plates of the drug 
screen for all OS tumour cell lines including the isogenic RB1 models engineered by CRISPR-
Cas9 mutagenesis in U2OS (4.2, 4.5 and 9.1). All tumour cell lines passed the stringent quality 
control with Spearman's Rank correlation approaching 1 (>0.7). Mean and range for triplicate 
replicates are shown. Spearman’s Rank Correlation coefficient calculated using GraphPad Prism. 








Table 18 Drug screen quality control: Z prime scores for main drug screen.  
All tumour cell lines passed the threshold of Z prime greater than 0.3. 

















G292 clone A141B1 0.61 
143B 0.75 
U2OS 4.2 0.71 
U2OS 4.5 0.71 
U2OS 9.1 0.85 
 	 
 
Table 19 Drug screen quality control: Z prime scores for additional drug screen for the 
isogenic RB1 deficient U2OS tumour cell line models.  
All tumour cell lines passed the threshold of Z prime greater than 0.3. 
Cell Line Mean Z Prime  
U2OS 4.2 0.8266 
U2OS 4.5 0.7340 

























































Figure 100 Quality control examples for OS tumour cell line MG63. 
(A) Plate plots of raw luminescence intensities of CellTiter Glo values, generated by CellHTS for 
main drug screen performed in triplicate. These graphical representations provided easy 
identification of spatial abnormalities due to edge effect or dispensing errors. High cell viability was 
shown in red, while blue reflected loss of viability.  
(B) Distribution blots for each replicate of the separation between negative (0.2% (v/v) DMSO) 
shown in blue and positive (100% DMSO) controls shown in red, demonstrating a good dynamic 
range and Z prime values of 0.64, 0.65 and 0.71 respectively. 


























1: 17AAG (HSP90 inhibitor)
2: camptothecin (Topoisomerase inhibitor)
3: dasatinib (Bcr-Abl/Src inhibitor)
4: doxorubicin (Anthracyline)
5: everolimus (mTOR inhibitor)
6: gemcitabine (Anti-metabolite)
7: methotrexate (Anti-metabolite)
8: paclitaxel (microtubule poison)
9: PF-03758309 (PAK inhibitor)
10: vinorelbine (Anti-mitotic)
11: YM155 (Survivin- suppressant)
P 2 4 63 5 7 8 9 1110
P: BI2536 (PLK inhibitor)
 
Figure 101 Drugs to which OS tumour cell lines demonstrated the greatest sensitivity. 
Scatter plot of AUC (area under the curve) for each OS tumour cell line. Cells were arrayed in 
triplicate 384 well plates, and after 24 hours exposed to eighty drugs (0.5-1000nM titration). After 
five days of continuous exposure, cellular viability was estimated using CellTiter Glo reagent as 
described in the methods. Highlighted in red are the drugs to which OS tumour cell lines 
demonstrated the greatest sensitivity (two or more OS tumour cell lines with AUC < 0.5). The 
internal positive control, BI2536 (PLK inhibitor) was highlighted in blue. AUC were calculated using 
R. [P: internal positive control] 




A number of the agents identified in the screen have already been investigated in OS. 
Dasatinib an inhibitor of the BCR-ABL fusion gene and SRC previously demonstrated 
sensitivity in three OS tumour cell lines (143b, HOS and SAOS2) (Hingorani, Zhang, 
Gorlick, et al., 2009). These tumour cell lines were also represented in this panel and 
among the most sensitive in this screen. However, no effects on primary or metastatic 
tumour growth were observed in orthotopic mouse models using an oral dose of 
50mg/kg/dose twice daily or intra-peritoneal administration of 25mg/kg/dose daily for four 
weeks (Hingorani, Zhang, Gorlick, et al., 2009) and so potential clinical translation is 
unlikely.  
 
Whole-exome sequencing of 59 OS tumour samples, whole genome sequencing of 13 
tumour samples, and RNA-sequencing of 35 of the samples identified alterations in the 
Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide / Mechanistic Target Of 
Rapamycin (PI3K/mTOR) pathway in 24% of patients with OS (Perry, Kiezun, Tonzi, et 
al., 2014). Perry et al. therefore hypothesised that the PI3K/mTOR pathway was a 
unifying vulnerability required for OS tumour proliferation, which could be exploited 
therapeutically; they demonstrated sensitivity in four OS tumour cell lines to the dual 
PIK3CA/mTOR inhibitors GSK2126458 and BEZ235, comparable with the breast cancer 
cell line MCF7 known to harbour a PIK3CA p.E545K mutation previously established to 
undergo apoptosis in response to treatment with these inhibitors (Perry, Kiezun, Tonzi, et 
al., 2014). BEZ235 was included in the drug screen, but a statistically significant 
difference between AUC for the OS panel compared to the non-osteosarcoma tumour cell 
line panel was not observed (Figure 102). MCF7 was used as a positive control for 
sensitivity to BEZ235.  
 
OS tumour cell lines did demonstrate some sensitivity to everolimus, a first generation 
inhibitor of mTOR (Figure 101), but was not statistically significant compared to the non-
osteosarcoma tumour cell line panel (Figure 103). Everolimus in combination with 
sorafenib, a multi-targeted kinase inhibitor, in Phase II study demonstrated an increased 
progression free survival time in 17 out of 35 (45%) patients with advanced OS (Grignani, 
Palmerini, Ferraresi, et al., 2014). Another Phase II trial combined the mTOR inhibitor 
rapamycin with gemcitabine, and demonstrated a progression free survival rate of 28% in 
patients with advanced OS (Broto, Redondo, Valverde, et al., 2015). Second generation 
mTOR inhibitors such as ridaforolimus have demonstrated efficacy in a Phase II study in 
212 patients with advanced sarcomas (54 bone sarcomas), with a clinical benefit rate of 




28.8%, four patients (two with OS) achieved partial remission (Chawla, Staddon, Baker, 
et al., 2012). This lead to a Phase III study of maintenance therapy in 702 patients with 
metastatic sarcomas randomised to receive ridaforolimus or blinded placebo, which found 
a modest improvement in progression free survival rate (Hazard Ratio 0.72; p = 0.001) 
(Demetri, Chawla, Ray-Coquard, et al., 2013).  
 
OS tumour cell lines were sensitive to Heat shock protein 90 (HSP90), an evolutionarily 
conserved molecular chaperone, p-21 activated kinase 4 (PAK4) inhibitor PF-03758309, 
and the survivin inhibitor YM155. Assessment of these HSP90 inhibitors in OS tumour 
cell lines and limited mouse models have demonstrated limited efficacy (Hu, Bobb, He, et 
al., 2015). A Phase I clinical trial of PAK4 inhibitor PF-03758309 in patients with 
advanced solid tumours was terminated due to pharmokinetic concerns (NCT00932126) 
and other inhibitors have yet to be studied. Limited in vitro studies using the OS tumour 
cell line MG63, demonstrated that doxorubicin resistant daughter clones had increased 
expression of survivin compared to the parental tumour cell line, and increased sensitivity 
to the combination of doxorubicin and YM-155 which was also replicated using a mouse 
model (Zhang, Zhang, Lv, et al., 2015). Hence, survivin inhibition in pre-treated patients 
with advanced OS could be therapeutically attractive, but requires confirmation of efficacy 
in mouse models prior to clinical translation. Confirmation of increased survivin 
expression could be performed using immunohistochemistry of tumour samples from 
biobanks such as SARC Biospecimen Bank and at the Royal National Orthopaedic 
Hospital. BI2536 a PLK (Polo like Kinase 1) inhibitor was used as an internal positive 
control and demonstrates considerable loss of viability in this screen.  
 
7.2.5 Identification of drugs that selectively target OS tumour cell lines 
To investigate the relative sensitivity of the OS tumour panel to these drugs, comparison 
was made with identical drug screen data from non-osteosarcoma tumour cell lines (n=99 
tumour cell lines derived from 10 cancer types) described previously (Figure 104). 
Although OS tumour cell lines may appear sensitive to an agent in isolation, comparison 
with the non-osteosarcoma tumour cell line panel highlights the utility of such a data set 
for contextual comparison, since agents that are universally toxic to all tumour cell lines 
are most likely to be toxic to non-malignant cells as well. OS tumour cell lines were 
demonstrated to be significantly more sensitive to the CHK1 inhibitor PF-004477736, and 




FGFR1 inhibitors AZD4547 and PD173074 when compared to the non-osteosarcoma 
tumour cell line panel (Figure 104).  
 
7.2.5.1 OS tumour cell line sensitivity to CHK1 inhibition  
The cell cycle checkpoint kinase 1 (CHK1) is a serine/threonine-protein kinase that 
regulates S and G2/M phases of the cell cycle. It is highly expressed in OS tumours that 
demonstrate a poor response to neo-adjuvant chemotherapy (Man, Chintagumpala, 
Visvanathan, et al., 2005) and has a role in the regulation of the DNA damage response 
and is essential for the repair of double-strand breaks by HR (Dai & Grant, 2010). The 
CHK1 inhibitor LY2606368 (Prexasertib) and siRNA targeting CHK1 were observed to 
cause cell cycle arrest in G1/S and apoptosis (Strauss, Mistry, Mendoza, et al., 2014) in 
OS tumour cell lines. In addition, sub-toxic concentrations in vitro potentiated the effect of 
methotrexate and doxorubicin and caused significantly more γH2AX than either agent 
alone concordant with increased DNA damage (Strauss, Mistry, Mendoza, et al., 2014). 
While single agent LY2606368 significantly delayed tumour growth in a subcutaneous 
HOSMNNG mouse model (Strauss, Mistry, Mendoza, et al., 2014) and a pulmonary 
adenocarcinoma xenograft tumour model using the tumour cell line Calu6 (King, Diaz, 
McNeely, et al., 2015). Replication stress may increase sensitivity to CHK1 inhibition but 























Figure 102 OS tumour cell lines did not exhibit profound sensitivity to BEZ235.  
Dot plot illustrating AUC for BEZ235 for osteosarcoma (n = 18), non-osteosarcoma (n = 99) 
tumour cell lines and MCF7. Cells were arrayed in triplicate 384 well plates, and after 24 hours 
exposed to the drug library (0.5-1000nM titration). After five days of continuous exposure, cellular 
viability was estimated using CellTiter Glo reagent as described in the methods. AUC for BEZ235 
were calculated using a custom script in R by Aditi Gulati and clustered into OS and non-OS 
groups. MCF7 used as a positive control with known sensitivity to this agent was shown for 
comparison. Median and interquartile ranges were shown. P values calculated by the MPT. 
Osteosarcoma tumour cell lines versus non-osteosarcoma tumour cell lines (p = 0.609). 
 















Figure 103 OS tumour cell lines did not exhibit profound sensitivity to everolimus.  
Dot plot illustrating AUC for everolimus for osteosarcoma (n = 18), non-osteosarcoma (n = 99) 
tumour cell lines and MCF7. Cells were arrayed in triplicate 384 well plates, and after 24 hours 
exposed to the drug library (0.5-1000nM titration). After five days of continuous exposure, cellular 
viability was estimated using CellTiter Glo reagent as described in the methods. AUC for BEZ235 
were calculated using a custom script in R by Aditi Gulati and clustered into OS and non-OS 
groups. MCF7 used as a positive control with known sensitivity to this agent was shown for 
comparison. Median and interquartile ranges were shown. P values calculated by the MPT. 
Osteosarcoma tumour cell lines versus non-osteosarcoma tumour cell lines (p = 0.679). 
 
 





Figure 104 Comparison of sensitivity to the drug library between OS and non-osteosarcoma 
tumour cell lines. 
Scatter plot of AUC for osteosarcoma tumour cell lines (n = 18: red circles), and non-
osteosarcoma tumour cell lines (n = 99: black circles). Highlighted by red boxes are the drugs to 
which OS tumour cell lines demonstrated the greatest sensitivity, but were not shown to be 
significantly different from the non-OS panel. Green boxes highlight two FGFR1 inhibitors 
AZD4547 and PD173074, which were found to be more selective for OS models independent of 
amplification status, when compared to a subset of the non-OS panel. Also highlighted in green is 
the CHK1 inhibitor PF-004477736, which was found to be more selective for OS models. The 
internal positive control, BI2536 (PLK inhibitor) was highlighted in blue. Tumour cells were arrayed 
in triplicate 384-well plates, and after 24 hours eighty drugs (0.05-1000nM titration) were added. 
After five days of continuous exposure, cellular viability was estimated using CellTiter Glo reagent 
as described in the methods. A custom script in R was used by Aditi Gulati to calculate the AUC 
and generate this scatter plot. 




Therefore, the AUC for the CHK1 inhibitor PF-004477736 for the OS and non-
osteosarcoma tumour cell line panels were compared to the BRCA1 deficient breast 
tumour cell line SUM149, and the BRCA1 secondary mutant SUM149.B1*.S (c.2288delT, 
p.N723fsX13) known to restore BRCA1 function and HR (Dréan, Williamson, Brough, et 
al., 2017). SUM149 demonstrated considerable sensitivity to the agent, while 
SUM149.B1*.S was more resistant, suggesting a possible role for HR deficiency in CHK1 
inhibitor sensitivity. One of the OS tumour cell lines, NY, was as sensitive as the BRCA1 
deficient SUM149. Two of the OS tumour cell lines LM7 and parental SAOS2 were 
assessed for an HR defect by assessment of nuclear RAD51 foci formation post IR, 
described in 7.2.9.1.1. LM7 cells exhibited significantly lower RAD51 foci formation than 
SAOS2, suggestive of an acquired HR defect. Therefore, to identify if the acquired HR 
defect of LM7 also predisposed to greater sensitivity to CHK1, tumour cell lines were 
ranked according to the AUC for the CHK1 inhibitor PF-004477736 (Figure 106). No 
significant difference in sensitivity was seen between LM7 and SAOS2 and suggests that 
HR deficiency may not be used as a robust biomarker for CHK1 inhibitor sensitivity. 
 
To identify if the OS tumour cell lines also demonstrated a genetic dependency to CHK1, 
comparison of quantile normalised Z scores from RNAi was made with the non-
osteosarcoma tumour cell line panel. A significant difference was not observed (Figure 
107). This could reflect the possibility of a false negative within the siRNA screen, or 
possible off-target effects of PF-004477736 and could be confirmed using small-scale 
deconvolution with multiple individual siRNA targeting CHK1, and drug screen with a 
structurally different inhibitor of CHK1 such as LY2606368.  
 
7.2.5.2 OS tumour cell line sensitivity to FGFR1 inhibition 
The FGFR1 and FGFR2 kinase genetic dependencies described in the previous chapter, 
suggested that osteosarcoma models might be particularly sensitive to small molecule 
FGFR inhibitors. A sub-set of the non-osteosarcoma tumour cell line panel, consisting of 
58 tumour cell lines, that included cell lines with FGFR1/2 amplification were tested for 
FGFR inhibitor sensitivity, using two FGFR1 inhibitors AZD4547 (Gavine, Mooney, 
Kilgour, et al., 2012) and PD173074 (Gavine, Mooney, Kilgour, et al., 2012). These 
agents were found to be more selective for osteosarcoma models independent of 
amplification status (AZD4547, p = 7.6x10-3, PD173074 p = 3.9x10-2) (Figure 108). 




The cBioPortal was used to access Comparative Genomic Hybridisation (CGH) data from 
the Broad Institute CCLE, scored via the GISTIC algorithm to define amplification (score 
+2) of FGFR1 (Mermel, Schumacher, Hill, et al., 2011). Amplification data for five OS 
tumour cell lines (143b, HOS, G292 clone A141B1, U2OS and MB63) was available 
using this method, and only G292 Clone A141B1 was found to harbour amplification of 
FGFR1. Additionally Fluorescent in situ hybridisation (FISH) was performed by Fernanda 
Amary on fixed pellets of five OS tumour cell lines, and G292 Clone A141B1, CAL72 and 
NOS-1 were identified as positive for amplification for FGFR1 while HU09 and NY were 
scored as polysomy (Fernanda Amary, Ye, Berisha, et al., 2014). Using data from both 
these sources, the OS tumour cell line panel was clustered into four groups: (i) positive 
for amplification; (ii) polysomy (three to five copies); (iii) not amplified; and (iv) unknown 
amplification status (Table 20). On this basis median dose response curves were plotted 
(Figure 109) which demonstrated that OS tumour cell lines positive for FGFR1 
amplification were significantly more sensitive to both FGFR1 inhibitors (AZ547 and 
PD173074) than unknown or non-amplified (ANOVA plus Bonferroni post hoc test 
p<0.0001).  
 
While FGFR1 amplification in OS tumour cell lines has previously been determined to be 
a marker of sensitivity to FGFR inhibition by the pan-FGFR inhibitor NVP-BGJ398 
(Guagnano, Kauffmann, Wöhrle, et al., 2012), the finding that OS tumour cell lines with 
FGFR1 polysomy were also more sensitive to FGFR1 inhibition by two different FGFR1 
inhibitors (ANOVA plus Bonferroni post hoc test p < 0.0001), suggests that an additional 
cohort of patients may benefit and adds further weight to the importance of the role of 
FGFR in OS.




































p = 0.0498 
 
Figure 105 OS tumour cell lines exhibit enhanced sensitivity to CHK1 inhibition by 
PF004477736.  
Dot plot of AUC for PF004477736 for OS (n = 18), non-OS (n = 99), SUM149 and SUM149.B1*.S 
tumour cell lines. Cells were arrayed in triplicate 384 well plates, and after 24 hours exposed to the 
drug library (0.5-1000nM titration). After five days of continuous drug exposure, cellular viability 
was estimated using CellTiter Glo reagent as described in the methods. Comparison was also 
made with the BRCA1 deficient breast cancer cell line SUM19 and the BRCA1 secondary mutant 
SUM149.B1*.S. The secondary BRCA1 mutant SUM149.B1*.S (c.2288delT, p.N723fsX13) was 
engineered by CRISPR Cas9 mutagenesis, which restored the open reading frame of BRCA1, 
restoring BRCA1 function and HR (Dréan, Williamson, Brough, et al., 2017). Aditi Gulati used a 
custom script in R to calculate the AUC for PF-004477736. Median and interquartile ranges were 
shown. P values calculated by the MPT. OS tumour cell lines versus non-osteosarcoma cell lines 
(p = 0.0498). 










































Figure 106 Comparison of CHK1 inhibition in OS tumour cell lines, BRCA1 deficient 
SUM149 and secondary BRCA1 mutant SUM149.B1*.S. 
Waterfall plot of AUC for PF004477736 for OS (n = 18), non-OS (n = 99), SUM149 and 
SUM149.B1*.S tumour cell lines. Cells were plated in 384-well plate format in triplicate, and after 
24 hours the drugs (0.5-1000nM titration) were added. After five days of continuous drug 
exposure, cellular viability was estimated using CellTiter Glo (Promega), as described previously. 
LM7 the daughter of SAOS2 did not demonstrate acquired sensitivity to PF-04477736 despite an 
acquired HR defect. The secondary BRCA1 mutant SUM149.B1*.S (c.2288delT, p.N723fsX13) 
was engineered by CRISPR Cas9 mutagenesis, which restored the open reading frame of 
BRCA1, restoring BRCA1 function and HR were highlighted in red (Dréan, Williamson, Brough, et 
al., 2017). Aditi Gulati used a custom script in R to calculate the AUC for PF-004477736.  





























p = 0.08 
 
Figure 107 OS tumour cell lines do not exhibit enhanced genetic vulnerability to CHK1. 
Dot plot of quantile normalised Z score for CHK1 silencing by siRNA in osteosarcoma (n = 18) and 
non-osteosarcoma tumour cell lines (n = 99). Tumour cell lines were reverse transfected using the 
siRNA library described in Appendix Tables 1-3. After seven days, cell viability was estimated 
using the CellTiter Glo reagent as described in the methods. A custom script on R was used to 
quantile normalise the Z scores across the entire tumour cell line panel by James Campbell (ICR). 
Tumour cell lines were clustered into two groups, Osteosarcoma and non-osteosarcoma. Median 
and interquartile ranges were shown. P values calculated by the MPT. OS tumour cell lines versus 
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Figure 108 OS tumour cell lines exhibited enhanced sensitivity to FGFR1 inhibitors.  
Box plots of AUC for the FGFR1 inhibitors AZD4547 and PD173074 for osteosarcoma (n = 18), 
and non-osteosarcoma (n = 58) tumour cell lines. Cells were arrayed in triplicate 384-well plates 
and after 24 hours the drug library (0.5-1000nM titration) was added. After five days of continuous 
drug exposure, cellular viability was estimated using CellTiter Glo reagent as described in the 
methods. FGFR1 and FGFR2-amplifed tumour cell lines are indicated with black and green 
circles, respectively. Grey arrows indicate the non-tumour epithelial cell lines MCF10A and 
MCF12A. FGFR1 amplification status was described using GISTIC comparative genomic 
hybridisation values from Broad Institute CCLE only. James Campbell (ICR) calculated AUC, and 
generated these box plots using a custom script in R. James Campbell (ICR) aslo used the 
cBioPortal to access the Comparative Genomic Hybridisation data, scored via the GISTIC 
algorithm to define FGFR1 in a subset of the cell lines for which the data was available. The top 
and bottom of each box represents the median and interquartile range, while the whiskers extend 
to 1.5 times the interquartile distance from the box. P values calculated by use of a one-sided 
Mann Whitney U test on AUC values. AZD4547 and PD173074 were found to be selective for 
osteosarcoma models compared to other cancer cell line (AZD4547, p = 7.6x10-3, PD173074 p = 
3.9x10-2). [osteo: osteosarcoma] reproduced from Campbell et al. (Campbell, Ryan, Brough, et al., 
2016). 




Table 20 FRF1 amplification status using GISTIC data from the Broad Institute CCLE and 










G292 Clone A141B1 HU09 U2OS LM7 
NOS1 NY MG63 SAOS2 
CAL72  HOS MHM 
  143b HU03N1 
   KPD 
   HOSMNNG 
   OSA/SJSA-1 
   OS25HAL 
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Figure 109 FGFR1 amplification and polysomy are associated with enhanced sensitivity to 
FGFR1 inhibition by AZ4547 and PD173074.  
Dose response survival curves are shown illustrating the median effects for two FGFR1 inhibitors 
(A) AZ4547 and (B) PD173074 for OS tumour cell lines (n = 18). OS tumour cell lines (TCL) were 
clustered into groups according to FGFR1 amplification status using GISTIC CGH data from the 
Broad Institute and FISH performed by Fernanda Amary. Cells were arrayed in triplicate 384 well 
plates, and after 24 hours the drug library (0.5-1000nM titration) was added. After five days of 
continuous drug exposure, cellular viability was estimated using CellTiter Glo reagent as described 
in the methods. Error bars represent SEM. OS tumour cell lines positive for amplification exhibited 
enhanced sensitivity to AZ4547 and PD173074 compared to those with an unknown (ANOVA plus 
Bonferroni post hoc test, p<0.0001), or negative amplification status (ANOVA plus Bonferroni post 
hoc test, p<0.0001). OS tumour cell lines positive for polysomy exhibited enhanced sensitivity to 
AZ4547 and PD173074 compared to those with an unknown (ANOVA plus Bonferroni post hoc 
test, p<0.0001), or negative amplification status (ANOVA plus Bonferroni post hoc test, p<0.0001).  




Lenvatinib, a multi-targeted kinase inhibitor, is currently in Phase I/II clinical investigation 
alone and in combination with ifosfamide and etoposide in children and young adults with 
osteosarcoma (NCT02432274) and although marketed as a VEGFR inhibitor, also 
inhibits FGFR1 (IC50 = 46nmol/L) (Cabanillas & Habra, 2016). Therefore, the relative 
sensitivity of OS tumour cell lines to lenvatinib, compared to the non-osteosarcoma 
tumour cell line panel was investigated, but determined to be non-significant (p=0.06) 
(Figure 110). However, it was apparent that there was a spectrum of sensitivity to 
lenvatinib amongst the OS tumour cell line panel. To determine if sensitivity to lenvatinib 
was determined by FGFR1 amplification, the OS tumour cell lines were clustered 
according to the same classification outlined in Table 20 and AUC for lenvatinib 
compared. Neither OS tumour cell lines with FGFR1 amplification nor polysomy were 
significantly more sensitive to lenvatinib than tumour cell lines known to be not amplified 
(Figure 111). In the absence of a specific inhibitor for vascular endothelial growth factor 
receptor (VEGFR), a similar analysis was performed using the AUC for cabozantinib, 
another multi-tyrosine kinase inhibitor with preferential activity against VEGFR2 (IC50 
0.035nM), c-MET Proto-Oncogene (c-MET) (IC50 1.3nM), Ret Proto-Oncogene (RET) 
(IC50 4nM), KIT Proto-Oncogene Receptor Tyrosine Kinase (KIT) (IC50 4.6nM), Fms 
Related Tyrosine Kinase 1/3/4 (FLT-11/3/4) (IC50 12/11.3/6nM), TEK Receptor Tyrosine 
Kinase (TIE2) (IC50 14.3nM) and AXL Receptor Tyrosine Kinase (AXL) (7nM), was used 
to further determine the role of VEGFR inhibition in OS. OS tumour cell lines were not 
preferentially sensitive to cabozantinib compared to the non-osteosarcoma tumour cell 
line panel (Figure 110), and FGFR1 amplification or polysomy did not predict sensitivity 
(Figure 111). These results are potentially confounded by the multi-tyrosine kinase 
inhibition of this agent, and further clarification of the role of VEGFR inhibition in OS could 
be determined using a more specific inhibitor with fewer off target effects. Sorafenib, a 
multi-kinase inhibitor of Raf1 (IC50 6nM), B-Raf (IC50 22nM) and VEGFR-2 (ICF50 
90nM) has already demonstrated some activity in OS in phase II trial (Grignani, 






























Figure 110 OS tumour cell lines did not exhibit enhanced sensitivity to mulit-targeted 
kinase inhibitors with preferential activity against VEGFR.  
Dot plots are shown illustrating AUC for lenvatinib and cabozantinib clustered into osteosarcoma 
(n = 18) and non-osteosarcoma tumour cell lines (n = 99). Tumour cells were arrayed in triplicate 
384 well plates, and after 24 hours the drug library (0.5-1000nM titration) was added. After five 
days of continuous drug exposure, cellular viability was estimated using CellTiter Glo reagent as 
described in the methods. AUC for lenvatinib and cabozantinib were calculated using a custom 
script in R by Aditi Gulati. Median and interquartile ranges were shown. OS tumour cell lines did 
not exhibit enhanced sensitivity to lenvatinib (p = 0.158) or carbozantinib (p = 0.08) compared to 
non-OS tumour cell lines. P values calculated by the MPT. 






















































































p = 0.252 
p = 0.204 
 
Figure 111 OS tumour cell lines harbouring amplification or polysomy of FGFR1 did not 
exhibit enhanced sensitivity to lenvatinib or cabozantinib. 
Dot plots are shown illustrating AUC for lenvatinib and cabozantinib. OS tumour cell lines were 
clustered into groups according to FGFR1 amplification status using GISTIC CGH data from the 
Broad Institute and FISH performed by Fernanda Amary. OS tumour cells were arrayed in 
triplicate 384 well plates and after 24 hours the drug library (0.5-1000nM titration) was added. After 
five days of continuous drug exposure, cellular viability was estimated using CellTiter Glo reagent 
as described in the methods. AUC for lenvatinib and cabozantinib were calculated by Aditi Gulati 
using a custom script in R and clustered according to FGFR1 amplification and polysomy. Median 
and interquartile ranges were shown. OS tumour cell lines with FGFR1 amplification did not exhibit 
enhanced sensitivity to lenvatinib (p = 0.133) or carbozantinib (p = 0.252) compared to non-
amplified OS tumour cell lines. OS tumour cell lines with FGFR1 polysomy did not exhibit 
enhanced sensitivity to lenvatinib (p = 0.142) or carbozantinib (p = 0.204) compared to non-
amplified OS tumour cell lines. P values calculated by MPT. 
 




7.2.5.3 IGF-1R/IR inhibition in OS tumour cell lines  
Dependency on insulin like growth factor 1 receptor (IGF-1R) signalling and activation of 
IGF-1R by IGF-1 leading to stimulation of the growth of OS tumour cells both in vitro 
(Kappel, Velez-Yanguas, Hirschfeld, et al., 1994) and in vivo (Kolb, Gorlick, Houghton, et 
al., 2008) has been described. Recent findings of insulin like growth factor (IGF) 
signalling pathway alterations (focal amplification of IGF1R (n=3) and IGF1 (n=2); 
frameshift indels in IGF2R (n=2) and Insulin like growth factor binding protein 5 (IGFBP5) 
(n=1)) in eight out of 112 tumour OS samples which were either whole genome or exome 
sequenced (Behjati, Tarpey, Haase, et al., 2017), has provided a rationale to further 
explore this pathway again as a therapeutic target. In targeted blockade of IGR-1R alone, 
the Insulin Receptor (IR) has been shown to activate the same downstream signalling 
pathways as IGF-1R (Kuijjer, Peterse, van den Akker, et al., 2013), therefore, targeting 
both IGF-1R and IR might have greater effect. Given this interest, sensitivity to two dual 
inhibitors of IGR-1R and IR in the OS tumour cell line panel was investigated. OS tumour 
cell lines did not show significant sensitivity to the dual IGF-1R and IR inhibitors linsitinib 
(OSI-906) or GSK1904529A compared to the non-osteosarcoma tumour cell line data 
(Figure 112). However, a considerable range of sensitivity in the OS tumour cell line 
panel was observed with exposure to OSI-906 (range AUC 0.701-1). 
 
Two OS tumour cell lines (LM7 and KPD) demonstrated particular sensitivity to linsitinib; 
LM7 did not harbour mutations or amplification of the IGF pathway members but KPD 
harbours a missense mutation of unknown significance of IGFBP4 (p.A161V). Therefore, 
mutation status of all the OS tumour cell lines was used to determine if mutation status of 
IGF pathway way members predicted sensitivity to linsitinib and GSK1904529A. In the 
OS tumour cell line panel, point substitution missense mutations of IGF1R (n=2: 
HU03N1, G292 clone A141B1), IGFBP4 (n=1; KPD), IGF2R (n=1; SAOS2), IGFBP6 
(n=1: G292 clone A141B1) and Insulin Like Growth Factor Binding Protein Like 1 
(IGFBPL1) (n=1; G292 clone A141B1) were identified and are of unknown significance 
but did predict sensitivity to linsitinib (p = 0.0286) but not GSK1904529A (Figure 113). No 
frameshift, or in/del mutations were identified. Only G292 clone A141B1 was found to 
have IGF1R amplification and was amongst the most sensitive to linsitinib (AUC 0.772) 
but this observation was not replicated with GSK1904529A.  
 



























Figure 112 OS tumour cell lines did not exhibit enhanced sensitivity to dual IGF-1R / IR 
inhibitors. 
Dot plots are shown illustrating AUC for OSI-906 and GSK1904592A for OS (n = 18) and non-
osteosarcoma (n = 99) tumour cell lines. Tumour cells were arrayed in triplicate 384 well plates, 
and after 24 hours the drug library (0.5-1000nM titration) was added. After five days of continuous 
drug exposure, cellular viability was estimated using CellTiter Glo reagent as described previously. 
Two OS tumour cell lines (LM7 and KPD) demonstrated particular sensitivity to linsitinib; LM7 did 
not harbour mutations or amplification of the IGF pathway members but KPD harboured a 
missense mutation of unknown significance of IGFBP4 (p.A161V). AUC for OSI-906 and 
GSK1904529A were calculated by Aditi Gulati using a custom script in R and clustered into OS 
and non-OS groups. Median and interquartile ranges were shown. OS tumour cell lines versus 
non-osteosarcoma tumour cell lines, OSI-906 (p = 0.567) and GSK1904592A (p = 0.592). P 
values calculated by the MPT. 
 































p = 0.201 
 
Figure 113 Mutations of the IGF pathway were associated with enhanced sensitivity to OSI-
906 but not GSK1904529A. 
Dot plots are shown illustrating the AUC for OSI-906 and GSK1904529A for 18 OS tumour cell 
lines that were clustered according to known mutation status of IGF pathway genes (substitution 
mutations of IGF1R (n=2: HU03N1, G292 clone A141B1), IGF2R (n=1; SAOS2), IGFBP4 (n=1; 
KPD), IGFBP6 (n=1: G292 clone A141B1) and Insulin Like Growth Factor Binding Protein Like 1 
(IGFBPL1) (n=1; G292 clone A141B1). Tumour cells were arrayed in triplicate 384 well plates, and 
after 24 hours the drug library (0.5-1000nM titration) was added. After five days of continuous drug 
exposure, cellular viability was estimated using CellTiter Glo reagent as described in the methods. 
AUC for OSI-906 and GSK1904529A were calculated by Aditi Gulati using a custom R script. 
Median and interquartile ranges were shown. OS tumour cell lines with mutation of the IGF 
pathway versus OS tumour cells without known mutation of the IGF pathway, OSI-906 (p = 0.049) 
and GSK1904592A (p = 0.201). P values calculated by the MPT. 
 
 




7.2.6 Identification of CDKN2A selective drug effects 
In order to identify CDKN2A deficient selective effects, the median survival fraction (SF) 
of the CDKN2A deficient OS tumour cell lines (n=6) and CDKN2A wildtype OS tumour 
cell lines (n=12) were compared at each drug and concentration. Drugs were ranked 
according to the difference in median SF between the two cohorts, to identify drugs that 
had a selective effect on viability in the CDKN2A deficient cohort only. CDKN2A 
deficiency was associated with increase sensitivity to methotrexate (ANOVA plus 
Bonferroni post hoc test p = 0.0109) (Figure 114).  
 
MTAP deficiency is a known sensitiser to methotrexate sensitivity, and is co-located on 
Chromosome 9 with CDKN2A. Cells deficient in Methylthioadenosine Phosphorylase 
(MTAP) by deletion or inactivation via methylation of the MTAP promoter are more 
sensitive to methotrexate (Bertino, Waud, Parker, et al., 2011). Therefore, I hypothesised 
that CDKN2A deficiency in OS tumour cell lines could be used as a surrogate marker for 
methotrexate sensitivity. To categorise the tumour cell lines into MTAP deficient or 
wildtype groups, proteomic profiling was undertaken (Figure 115). It was possible to 
segregate the level of MTAP abundance by proteomic profiling into two groups. All cell 
lines with homozygous deletion of CDKN2A (HOS, CAL72, HOSMMNG, 143b, and 
MG63) had low levels of MTAP and clustered together, except for CAL72. This likely 
represents the partial loss of MTAP, and expression of shorter isoforms of MTAP. It must 
also be noted that HOSMNNG and 143b are isogenic derivates of the same cell line 
HOS, and so would be expected to cluster together. As described in section 3.2.4 of 
Chapter 3, although U2OS was not known to harbour mutations of CDKN2A, and had a 
normal copy number, protein expression of CDKN2A was absent by western blot, and 
proteomic expression clustered with the other tumour cell lines known to harbour 
homozygous deletions of CDKN2A and hence it was categorised previously as CDKN2A 
deficient. It is therefore, not unsurprising that given that U2OS has wildtype MTAP, that 
out of the CDKN2A group, U2OS had the largest AUC for methotrexate. 
































































p = 0.041  
 
Figure 114 CDKN2A deficiency is associated with enhanced sensitivity to methotrexate 
Tumour cells were arrayed in triplicate 384 well plates, and after 24 hours the drug library (0.5-
1000nM titration) was added. After five days of continuous drug exposure, cellular viability was 
estimated using CellTiter Glo reagent as described in the methods.  
(A) Dose response survival curves illustrating the median effects for CDKN2A deficient (n = 5) and 
CDKN2A wildtype (n = 13) OS tumour cell lines. Error bars represent SEM. ANOVA plus 
Bonferroni post hoc test p = 0.0109 CDKN2A deficient versus CDKN2A wildtype. 
(B) Dot plot illustrating the AUC for methotrexate clustered according to CDKN2A deficiency for 
CDKN2A deficient (n = 5) and CDKN2A wildtype (n = 13) OS tumour cell lines. Median and 
interquartile ranges were shown. AUC for methotrexate was calculated using a custom script on R 
by Aditi Gulati. p=0.0193 CDKN2A deficient versus CDKN2A wildtype. P values calculated by the 
MPT. 





























































































Figure 115 Proteomic abundance of MTAP in osteosarcoma tumour cell lines was 
significantly lower in CDKN2A deficient OS tumour cell lines.  
Bar chart illustrating proteomic abundance of MTAP defined by mass spectroscopy performed by 
Colm Ryan, (Systems Biology, Dublin, Ireland) in the OS tumour cell line panel. Following lysis, 
protein purification, and tryptic digest, peptides were separated by liquid chromatography and 
measured by mass spectrometer. Label-free proteome quantification was performed using the 
MaxQuant software to determine the quantitative abundance of 6696 peptides with a false 
discovery rate of less than one percent. Red columns indicate tumour cell lines classified as 
CDKN2A deficient by a combination of western blotting, copy number and mRNA expression 
levels. It was possible to segregate the level of MTAP abundance by proteomic profiling into two 
groups. All cell lines with homozygous deletion of CDKN2A (HOS, CAL72 HOSMMNG, 143b, and 
MG63) had low levels of MTAP and clustered together, except for CAL72. This likely represented 
the partial loss of MTAP, and expression of shorter isoforms of MTAP. Although U2OS was not 
known to harbour mutations of CDKN2A, and had a normal copy number, protein expression of 
CDKN2A was absent, and hence it was categorised as CDKN2A deficient. No mutations of MTAP 
in the tumour cell line U2OS were recorded. p=0.0036 proteomic abundance of MTAP in 
osteosarcoma tumour cell lines was significantly lower in CDKN2A deficient and CDKN2A wildtype 
OS tumour cell lines. P values calculated by Student’s t test. 




7.2.7 Identification of RB1 selective drug effects 
7.2.7.1 OS tumour cell line panel 
In order to identify RB1 deficient selective effects, the median survival fraction (SF) of the 
RB1 deficient OS tumour cell lines (n=6) and RB1 wildtype OS tumour cell lines (n=12) 
were compared at each drug and concentration. Drugs were ranked according to the 
difference in median SF between the two cohorts, to identify drugs that had a selective 
effect on viability in the RB1 deficient cohort only. Paclitaxel, vinorelbine and 
camptothecin were the only drugs with a significant difference (p<0.05) at 2 or more 
concentrations and are shown in Figure 15 and Figure 117. OS RB1 deficient tumour cell 
lines were significantly more sensitive to paclitaxel, vinorelbine and camptothecin than 
those with wildtype RB1 (ANOVA plus Bonferroni post hoc test p<0.0001). To ensure 
clinical relevance and ascertain relative sensitivity compared to other cancer types, 
comparison of the AUC for these drugs was made with the data from the non-
osteosarcoma tumour cell line panel (Figure 116 and Figure 117). RB1 deficient OS 
tumour cell lines all demonstrated relative sensitivity to paclitaxel, vinorelbine and 
camptothecin when compared to other cancer types. In addition, publically available data 
from COSMIC drug sensitivity in cancer, 
(http://www.cancerrxgene.org/translation/Gene/1330) confirmed that a diverse panel of 
tumour cell lines with a mutation in RB1 were more sensitive to paclitaxel.  
 
Perturbation of the RB1 pathway is well recognised in small-cell lung cancer (Knudsen & 
Knudsen, 2008), and increased paclitaxel sensitivity has been correlated with increased 
E2F3 expression, consistent with deregulation of E2F secondary to deficient RB1 and 
absence of un-phosphorylated RB1 which bind the E2Fs (Kurtyka, Chen & Cress, 2014). 
 
Sensitivity to camptothecin in the RB1 deficient OS tumour cell line SAOS2, has 
previously been demonstrated due to increased apoptosis (Lauricella, Calvaruso, 
Carabillò, et al., 2001); expression of exogenous wildtype RB1 rescued sensitivity, via an 
anti-apoptotic influence through the control of c-Jun N-terminal kinase (JNK) activity 
(Lauricella, Calvaruso, Carabillò, et al., 2001). Sensitivity to both paclitaxel and 
camptothecin demonstrate the mechanistic relevance of these findings in the drug 
screen.  
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Figure 116 RB1 deficiency was associated with increased sensitivity to paclitaxel and 
vinorelbine. 
Tumour cells were arrayed in triplicate 384 well plates, and after 24 hours the drug library (0.5-
1000nM titration) was were added. After five days of continuous drug exposure, cellular viability 
was estimated using CellTiter Glo reagent as described in the methods. (A and B) Dose response 
survival curves illustrating median effects for RB1 deficient (n = 6) and RB1 wildtype (n = 12) OS 
tumour cell lines. Error bars represent SEM. RB1 deficient versus RB1 wildtype, paclitaxel 
(ANOVA plus Bonferroni post hoc test p<0.0001) and vinorelbine (ANOVA plus Bonferroni post 
hoc test p<0.0001). (B and C) Dot plots illustrating AUC for paclitaxel and vinorelbine for the OS 
tumour cell line panel. Median and interquartile ranges are shown. RB1 deficient versus RB1 
wildtype, paclitaxel (p = 0.0062) and vinorelbine (p = 0.0019). P values calculated by Student’s t 
test. (E and F) Dot plots illustrating AUC for paclitaxel and vinorelbine for the OS tumour (n = 18) 
and non-osteosarcoma (n = 99) tumour cell line panels to demonstrate relative context of 
sensitivity. Median and interquartile ranges were shown. P values calculated by the MPT.
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Figure 117 RB1 deficiency was associated with enhanced sensitivity to camptothecin. 
Tumour cells were arrayed in triplicate 384 well plates, and after 24 hours the drug library (0.5-
1000nM titration) was added. After five days of continuous drug exposure, cellular viability was 
estimated using CellTiter Glo reagent as described in the methods. (A) Dose response survival 
curves illustrating median effects for RB1 deficient (n = 6) and RB1 wildtype (n = 12) OS tumour 
cell lines. Error bars represent SEM. ANOVA plus Bonferroni post hoc test, p<0.0001 RB1 
deficient versus RB1 deficient. (B) Dot plots illustrating AUC for camptothecin for the OS tumour 
cell line panel clustered into RB1 deficient and wildtype groups. Median and interquartile ranges 
were shown. p = 0.0055 RB1 deficient versus RB1 wildtype. (C) Dot plots illustrating AUC for 
camptothecin (0.5-1000nM range) for the OS tumour (n = 18) and non-osteosarcoma (n = 99) 
tumour cell line panels to demonstrate relative context of sensitivity. Median and interquartile 
ranges were shown. P values calculated by the MPT. 




7.2.7.2 Isogenic models of RB1 deficiency in osteosarcoma  
Given the molecular heterogeneity of the panel of OS tumour cell lines, to determine the 
drugs with greatest sensitivity in an RB1 deficient setting, the isogenic RB1 deficient 
U2OS models were used. Isogenic RB1 deficient U2OS models generated by CRISPR-
Cas9 mutagenesis and described in Chapter 4 were screened using both drug libraries 
described in section 2.1.2 of Chapter 2. Statistically significant increased sensitivity in the 
RB1 deficient models compared to RB1 wildtype model, to vinorelbine, camptothecin and 
paclitaxel were not seen in this screen (data not shown). Similar to limited overlap 
between the siRNA screens performed on the OS tumour cell line panel and isogenic 
RB1 deficient U2OS models, drug sensitivity might be mediated by the other molecular 
characteristics of the tumour cell U2OS such as CDKN2A deficiency, not seen in the OS 
tumour cell lines with endogenous RB1 deficiency.  
 
Three groups of inhibitors in the additional drug screen, targeting Heat Shock Protein 90 
(HSP90) (Figure 118), kinesin spindle protein (Figure 119), and Nicotinamide adenine 
dinucleotide (NAD) biosynthesis (Figure 120) showed the greatest difference in sensitivity 
according to RB1 status. Unfortunately, because these agents were in the additional drug 
library, it was not possible to compare these results with the non-osteosarcoma tumour 
cell line panel data. 
 
 
7.2.8 DNA damage repair 
7.2.8.1 Investigation of sensitivity to small molecule inhibition of ATR and DNA-
PK depending on RB1 context 
RB1 deficient tumour cells are known to have defective NHEJ, which combined with 
concomitant loss of the G1 checkpoint leads to an increase reliance on the HR pathway 
(Huang, Cook & Mittnacht, 2015). RB1 deficient tumour cells therefore enter S phase with 
more unrepaired damage, and could have a greater reliance on functional ATR to delay 
mitotic entry until all DNA damage repairs have been performed, and the DNA replicated 
(Nghiem, Park, Kim, et al., 2001). Therefore, RB1 deficient models of OS were used to 
determine if RB1 deficiency is associated with increased sensitivity to ATR and DNA-PK 
inhibition.  





































































Figure 118 RB1 deficiency was associated with enhanced sensitivity to HSP90 inhibitors. 
Dose response survival curves illustrating the effects of the HSP90 inhibitors (17-AAG, ganetespib 
and geldanamycin) in the isogenic RB1 deficient (4.2 and 4.5) and wildtype (9.1) U2OS models. 
Tumour cells were arrayed in triplicate 384 well plates, and after 24 hours the drug library (0.5-
500nM titration) was added. After five days of continuous drug exposure, cellular viability was 
estimated using CellTiter Glo reagent as described in the methods. Error bars represent SEM. 
RB1 deficient versus RB1 wildtype, 17-AAG (ANOVA, p<0.0001), ganetespib  (ANOVA, p<0.0001) 
and geldanamycin (ANOVA, p<0.0001). [U2OS 4.2 and 4.5 are RB1 deficient created by CRISPR-
Cas9 mediated mutagenesis. U2OS 9.1: RB1 wildtype parental cell line] 














































Figure 119 RB1 deficiency was associated with enhanced sensitivity to kinesin spindle 
protein inhibitors. 
Dose response survival curves illustrating the effects of the kinesin spindle protein inhibitors 
(ispinesib and SB743921), in the isogenic RB1 deficient (4.2 and 4.5) and wildtype (9.1) U2OS 
models. Tumour cells were arrayed in triplicate 384 well plates, and after 24 hours the drug library 
(0.5-500nM titration) was added. After five days of continuous drug exposure, cellular viability was 
estimated using CellTiter Glo reagent as described in the methods. Error bars represent SEM. 
RB1 deficient versus RB1 wildtype, ispinesib (ANOVA, p<0.0001) and SB743921 (ANOVA, 
p<0.0001). [U2OS 4.2 and 4.5 are RB1 deficient created by CRISPR-Cas9 mediated mutagenesis. 













































Figure 120 RB1 deficiency was associated with enhanced sensitivity to NAD biosynthesis 
inhibitors. 
Dose response survival curves illustrating the effects of the NAD biosynthesis inhibitors (APO-886 
and FK866), in the isogenic RB1 deficient (4.2 and 4.5) and wildtype (9.1) U2OS models. Tumour 
cells were arrayed in triplicate 384 well plates, and after 24 hours the drug library (0.5-500nM 
titration) was added. After five days of continuous drug exposure, cellular viability was estimated 
using CellTiter Glo reagent as described in the methods. Error bars represent SEM. RB1 deficient 
versus RB1 wildtype, APO-886 (ANOVA, p<0.0001) and FK866 (ANOVA, p<0.0001). [U2OS 4.2 
and 4.5 are RB1 deficient created by CRISPR-Cas9 mediated mutagenesis. U2OS 9.1: RB1 
wildtype parental cell line]




As described previously, inhibitors of ATR, have been shown in pre-clinical studies to 
enhance the cytotoxic effects of DNA damaging agents (Williamson, Miller, Pemberton, et 
al., 2016). Cisplatin, a well recognised chemotherapeutic agent which is part of 
established therapy for OS (Bacci, Longhi, Fagioli, et al., 2005) that causes DNA 
crosslinks, which activate several signal transduction pathways including ATR (Siddik, 
2003) thus was chosen for combination experiments to investigate whether RB1 
deficiency was associated with increased sensitivity to combination therapy with ATR 
inhibitors. Inhibitors of DNA-PK have already been shown to sensitise tumour cells that 
depend on NHEJ for survival after induced DSB formation by chemotherapeutic agents 
such as doxorubicin (Boucher, Hillier, Newsome, et al., 2016; Tang, Yuan & Guo, 2014). 
As doxorubicin is part of established therapy for OS, it was therefore chosen for 
combination experiments with DNA-PK inhibition. The clinical aim was to establish if OS 
tumour cells deficient in RB1 could be sensitised to cisplatin and doxorubicin by ATR and 
DNA-PK inhibition respectively. 
 
Generation of an isogenic RB1 deficient and wildtype model in osteosarcoma by 
CRIPSR-Cas9 mutagenesis (described in Chapter 4), enabled investigation of the effects 
of ATR and DNA-PK inhibition in osteosarcoma in an isogenic system. The tumour cell 
lines were exposed to the ATR inhibitor VX970 and cisplatin, alone and in combination 
(Figure 121). Exposure to VX970 demonstrated that both RB1 deficient clones were more 
sensitive than the RB1 wildtype parental tumour cell line (ANOVA p<0.001). Although 
RB1 context did not determine sensitivity to cisplatin, VX970 was found to potentiate the 
therapeutic effect of cisplatin in both RB1 deficient clones compared to the parental RB1 
wildtype tumour cell line (ANOVA p<0.001).  
 
The isogenic U2OS tumour cell lines were also exposed to the DNA-PK inhibitor VX984 
alone and in combination with doxorubicin (Figure 122). No synergy was observed or 
increased sensitivity depending on RB1 context.  
 
Using the data generated from siRNA screen of the isogenic RB1 deficient U2OS models 
to identify genetic dependencies associated with RB1 deficiency, the same revalidation 
criteria as previously were used (median Z score in the group 1 of < - 1.5; median Z score 
in group 2 of > -1.0; probability of the difference between the Z scores in both groups 
seen by chance of <0.05), PRKDC, also known as DNA-PK, was isolated (Figure 123).  


































































Figure 121 RB1 deficiency was associated with enhanced sensitivity to VX970 alone and in 
combination with cisplatin. 
Dose response survival curves for (A) VX970 (B) cisplatin (C) cisplatin in combination with 0.1µM 
VX970.  
Cells were arrayed in 384 well plates and after 24 hours the drugs were added. Sixteen replicates 
for each drug dose were used. After five days of continuous drug exposure, cellular viability was 
estimated using CellTiter Glo (Promega), as described previously. Error bars represent SEM. RB1 
deficient versus RB1 wildtype, VX970 (ANOVA p<0.001) and VX970 in combination with cisplatin 
(ANOVA p<0.001). RB1 context did not determine sensitivity to cisplatin in these OS tumour cell 
lines. [U2OS 4.2 and 4.5 are RB1 deficient created by CRISPR-Cas9 mediated mutagenesis. 
U2OS 9.1: RB1 wildtype parental cell line]
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Figure 122 RB1 deficiency did not determine sensitivity to the DNA-PK inhibitor VX984, 
doxorubicin, or in combination.  
Dose response survival curves for (A) VX984 (B) doxorubicin (C) doxorubicin in combination with 
1µM VX970. Cells were arrayed in 384-well plate format, and after 24 hours the drugs were 
added. Sixteen replicates for each drug dose were used. After five days of continuous drug 
exposure, cellular viability was estimated using CellTiter Glo reagent as described in the methods. 
Error bars represent SEM. RB1 deficient tumour cell lines (U2OS 4.2 and 4.5) did not exhibit 
enhanced sensitivity to VX984, nor VX984 in combination with doxorubicin, nor doxorubicin alone 
compared to the RB1 wildtype (U2OS 9.1) parental tumour cell line. [U2OS 4.2 and 4.5 are RB1 
deficient created by CRISPR-Cas9 mediated mutagenesis. U2OS 9.1: RB1 wildtype parental cell 
line] 
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p = 0.03 
 
Figure 123 RB1 deficiency is associated with decreased genetic dependency on PRKDC 
than RB1 wildtype.  
Dot plot illustrating quantile normalised Z scores for PRKDC for the isogenic RB1 
deficient (4.2 and 4.5) wildtype (9.1) U2OS tumour cell lines. Loss of PRKDC has little 
effect on viability in the absence of RB1. This could be because in the absence of active 
RB1, NHEJ is defective, so further silencing of PRKDC has little additional effect. p = 0.03 
RB1 deficient versus RB1 wildtype Median and interquartile range shown. P values 
calculated by the MPT. 




Although this effect has yet to be revalidated using deconvolution, it does suggest that 
silencing of PRKDC has little effect on viability in the absence of RB1. This could be 
because in the absence of active RB1, NHEJ is defective, so further silencing of PRKDC 
has little additional effect, concordant with no loss of viability seen with DNA-PK inhibition 
by VX984.  
 
7.2.9 Investigation of ‘BRCAness’ in osteosarcoma in cellular models 
7.2.9.1 Identification of an isogenic model of PARP sensitivity in osteosarcoma 
As described previously in sections 1.1.4.1 and 7.1, given the recent interest in the 
potential ‘BRCAness’ phenotype in OS (Kovac, Blattmann, Ribi, et al., 2015; Engert, 
Kovac, Baumhoer, et al., 2016) the sensitivity of OS tumour cell lines to PARP inhibition 
was determined. From the drug screen described in 7.2.1 it was apparent that some of 
the OS tumour panel showed outlying sensitivity to inhibitors of PARP. Tumour cell lines 
with loss of functions of BRCA1/2 are associated with an increased sensitivity to PARP 
inhibition (Bryant, Schultz, Thomas, et al., 2005; Farmer, McCabe, Lord, et al., 2005). To 
investigate the scale of sensitivity of the OS tumour cell line panel, and provide context 
for comparison, the OS tumour cell line panel was compared to tumour cell lines with loss 
of function of BRCA1/2 as described in Table 18. The triple negative breast tumour cell 
line SUM149, which harbours a loss of function mutation of BRCA1 (p.P724fs*12 
homozygous), and mutant clones of SUM149 generated by CRISPR-Cas9 mutagenesis 
with loss of function mutations of REV7, 53BP1, PARP1 and gain of function of BRCA2, 
which have acquired resistance to PARP inhibition were used as a negative controls for 
comparison (Table 21). In addition, the pancreatic ductal adenocarcinoma cell line 
CAPAN1, known to be sensitive to PARP inhibition (Edwards, Brough, Lord, et al., 2008), 
which harbours a BRCA2 mutation and mutant daughter clone (CAPAN1.B2*.S), with a 
secondary mutation of BRCA2, which restored the native open reading frame and BRCA2 
function were also used as controls. CAPAN1.B2.S* and SUM149.B1.S* have been 
shown to be profoundly less sensitive to PARP inhibition by olaparib than their isogenic 
parental cell lines (Figure 124), demonstrated BRCA expression by western blotting, and 
both demonstrate the ability to form RAD51 foci in response to ionising radiation (Dréan, 
Williamson, Brough, et al., 2017). Using these tumour cell lines as controls, a good 
dynamic range was seen in all three PARP inhibitors demonstrating the utility of 
comparison with the isogenic SUM149 models (Figure 125).  




Comparison of the OS tumour cell lines with tumour cell lines derived from 78 other tissue 
types comprised of breast (n = 42), head and neck (n = 11), synovial sarcoma (n = 5), 
prostate (n = 4), lung (n= 4), cervical (n = 4), soft tissue (n = 3), large intestine (n = 3), 
autonomic ganglion (n = 1), and haematological (n = 1), demonstrated a spectrum of 
sensitivities to PARP inhibition by rucaparib (Figure 126), talazoparib (Figure 127), and 
olaparib (Figure 128). LM7, daughter of SAOS2, created by repeated passage of SAOS2 
through the lungs of nude mice (Jia, Worth & Kleinerman, 1999), demonstrated profound 
acquired sensitivity to short-term exposure to PARP inhibition, similar to that of triple 
negative breast tumour cell lines with known loss of function of BRCA1 such as 
MDAMB436 and HCC1395. The other OS tumour cell lines demonstrated a spectrum of 
sensitivity to PARP inhibition (Figure 129).  
 
To further investigate the sensitivity of LM7 and SAOS2, compared to BRCA1 and 
BRCA2 isogenic breast tumour models, longer term drug exposure was performed. The 
PARP inhibitors olaparib and talazoparib were refreshed twice per week. After two weeks 
of continuous drug exposure, cellular viability was estimated using CellTiter Glo 
(Promega), and the survival fractions calculated relative to DMSO (Figure 130). LM7 
exhibited comparable olaparib sensitivity to CAPAN1 (ANOVA p=0.587) and SUM149 
(ANOVA p=0.183) but significantly greater sensitivity than CAPAN1.B2*.S cells with a 
secondary gain of function BRCA2 mutation (ANOVA p<0.0001) and SUM149.B1*.S 
(ANOVA p<0.0001) with secondary BRCA1 mutation. In addition, LM7 exhibited 
comparable talazoparib sensitivity compared to SUM149 (ANOVA p=0.326), but 
significantly greater sensitivity than CAPAN1 (ANOVA p=0.007), SUM149.B1*.S cells 
with a secondary BRCA2 mutation (ANOVA p<0.0001) and CAPAN1.B2*.S (ANOVA 
p<0.0001) with secondary BRCA1 mutation.  




Table 21 BRCA1 or BRCA2 mutant tumour cells used in PARP inhibitor sensitivity profiling 
studies.  
To assess the scale and context of OS PARP inhibitor sensitivity, breast or pancreatic tumour cell 
lines with defects in either BRCA1 or BRCA2 as positive controls were used. 
Tumour cell line Histology BRCA gene alteration  
MDAMB436 Triple negative breast cancer BRCA1 c.5277+1G>A splice 
site, homozygous mutation 
SUM149 Triple negative breast cancer BRCA1 p.P724fs*12, 
homozygous mutation 
(Dréan, Williamson, Brough, 
et al., 2017) 
HCC1395 Triple negative breast cancer BRCA1 p.R1751*, 
homozygous mutation 
HCC38  Triple negative breast cancer BRCA1 promoter 
hypermethylation 




(Dréan, Williamson, Brough, 








Table 22 Secondary mutant tumour cells used in PARP inhibitor sensitivity profiling 
studies.  
To assess the scale and context of PARP inhibitor resistance in the OS tumour cell line panel, 
tumour cell lines generated from BRCA1 or BRCA2 mutant tumour cells, with secondary mutations 
engineered by CRISPR-Cas9 mutagenesis, that caused PARP inhibitor resistance were used as 
negative controls. 
Tumour cell line Secondary mutation 
SUM149.B1*.S (BRCA1 revertant) Intragenic mutation in BRCA1 that restored 
the native open reading frame (Dréan, 
Williamson, Brough, et al., 2017) 
SUM149 REV7 mutant Truncating mutation in REV7 (MAD2L2) 
that causes PARPi resistance (Inga 
Brandsma, ICR) 
SUM149 PARP1 mutant Missense mutation in PARP1 that causes 
PARPi resistance (Stephen Pettitt, ICR) 
SUM149 53BP1 mutant Truncating mutation in 53BP1 that causes 
PARPi resistance (Inga Brandsma, ICR) 
CAPAN1.B2*.S (BRCA2 revertant) Intragenic mutation in BRCA1 that 
restored the native open reading frame 













































Figure 124 Secondary mutation of BRCA2 or BRCA1, which lead to restoration of function 
were associated with a significant decrease in sensitivity to PARP inhibition. 
Dose response survival curves for olaparib in the isogenic tumour cell lines CAPAN1 and SUM149 
were generated by Amy Dréan (ICR). CRISPR-Cas9 mutagenesis by Amy Dréan of the pancreatic 
ductal adenocarcinoma cell line CAPAN1 (BRCA2 defective: c.6174delT, p.S1982fs*22) and 
BRCA1 deficient breast tumour cell line SUM149 BRCA1 mutant c.2288delT, p.N723fsX13) was 
used to restore BRCA2 and BRCA1 function respectively, profoundly decreasing sensitivity to 
olaparib (Dréan, Williamson, Brough, et al., 2017). Cells were arrayed by Amy Dréan in triplicate 
384 well plates, and after 24 hours olaparib (0.001-10µM titration) was added. After five days of 
continuous exposure, cellular viability was estimated using CellTiter Glo reagent as described in 
the methods. CAPAN1.B2.S* tumour cells exhibited enhanced resistance to olaparib compared to 
CAPAN1 (ANOVA p<0.0001). SUM149.B1.S* tumour cells exhibited enhanced resistance to 
olaparib compared to SUM149 (ANOVA p<0.0001). [Bx.S*: BRCA secondary mutation] 


































































































Figure 125 PARP inhibitor sensitivity in tumour cell lines derived from OS, breast cancer or 
head and neck cancers.  
Dot plots illustrating AUC for three different inhibitors of PARP (rucaparib, talazoparib, and 
olaparib), for the OS tumour cell line panel (n = 18), breast tumour cells (n = 36), and head and 
neck (n = 11) tumour cell lines. Tumour cell lines were arrayed in triplicate 384 well plates, and 
after 24 hours exposed to the drug library (0.5-1000nM titration). After five days, cell viability was 
estimated using CellTiter Glo reagent as described in the methods. Raw luminescence values 
were plate normalised to account for plate to plate variation and then used to calculate AUC 
values for each drug in each cell line. Aditi Gulati used a custom script in R to calculate AUC. 
Median and interquartile range shown.  
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Figure 126 Rucaparib sensitivity in 96 tumour cell lines.  
Waterfall plot illustrating rucaparib AUC is shown. Breast tumour cell lines with BRCA1 alterations 
are shown, as are SUM149 daughter clones with mechanisms of PARP inhibitor resistance 
(SUM149 REV7 mutant, PARP1 mutant, 53BP1 mutant and SUM149.B1*.S). Ewing’s sarcoma 
tumour cell lines are also annotated. Osteosarcoma tumour cell lines are highlighted (red dots and 
bold). Tumour cell lines were arrayed in triplicate 384 well plates, and after 24 hours exposed to 
the drug library (0.5-1000nM titration). After five days, cell viability was estimated using CellTiter 
Glo reagent as described in the methods. Raw luminescence values were plate normalised to 
account for plate to plate variation and then used to calculate AUC values for each drug in each 
cell line. Aditi Gulati (ICR) used a custom script in R to calculate AUC. Ilirjana Bajrami and Chris 
Lord (ICR) determined the BRCA1/2 mutations in the non-osteosarcoma tumour cell line panel.  
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Figure 127 Talazoparib sensitivity in 96 tumour cell lines.  
Waterfall plot illustrating talazoparib AUC is shown. Breast tumour cell lines with BRCA1 
alterations are shown, as are SUM149 daughter clones with mechanisms of PARP inhibitor 
resistance (SUM149 REV7 mutant, PARP1 mutant, 53BP1 mutant and SUM149.B1*.S). Ewing’s 
sarcoma tumour cell lines are also annotated. Osteosarcoma tumour cell lines are highlighted (red 
dots and bold). Tumour cell lines were arrayed in triplicate 384 well plates, and after 24 hours 
exposed to the drug library (0.5-1000nM titration). After five days, cell viability was estimated using 
CellTiter Glo reagent as described in the methods. Raw luminescence values were plate 
normalised to account for plate to plate variation and then used to calculate AUC values for each 
drug in each cell line. Aditi Gulati (ICR) used a custom script in R to calculate AUC. Ilirjana Bajrami 
and Chris Lord (ICR) determined the BRCA1/2 mutations in the non-osteosarcoma tumour cell line 
panel.  
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Figure 128 Olaparib sensitivity in 96 tumour cell lines.  
Waterfall plot illustrating olaparib AUC is shown. Breast tumour cell lines with BRCA1 alterations 
are shown, as are SUM149 daughter clones with mechanisms of PARP inhibitor resistance 
(SUM149 REV7 mutant, PARP1 mutant, 53BP1 mutant and SUM149.B1*.S). Ewing’s sarcoma 
tumour cell lines are also annotated. Osteosarcoma tumour cell lines are highlighted (red dots and 
bold). Tumour cell lines were arrayed in triplicate 384 well plates, and after 24 hours exposed to 
the drug library (0.5-1000nM titration). After five days, cell viability was estimated using CellTiter 
Glo reagent as described in the methods. Raw luminescence values were plate normalised to 
account for plate to plate variation and then used to calculate AUC values for each drug in each 
cell line. Aditi Gulati (ICR) used a custom script in R to calculate AUC. Ilirjana Bajrami and Chris 
Lord (ICR) determined the BRCA1/2 mutations in the non-osteosarcoma tumour cell line panel. 













































































































































Figure 129 Comparison of PARP inhibitor sensitivity in OS tumour cell lines and SUM149-
derived positive and negative controls.   
Waterfall plot illustrating AUC for (A) talazoparib, (B) rucaparib, and (C) olaparib. Tumour cells 
were arrayed in triplicate 384 well plates, and after 24 hours the drug library (0.5-1000nM titration) 
was added. After five days of continuous drug exposure, cellular viability was estimated using 
CellTiter Glo reagent as described in the methods. Aditi Gulati used a custom script in R to 
calculate AUC. LM7 the daughter of SAOS2 demonstrated acquired sensitivity to PARP inhibition 
by talazoparib, rucaparib and olaparib. 























































Figure 130 Fourteen day PARP inhibitor survival characteristics in SAOS2 and LM7 
compared to BRCA2 mutant CAPAN1 cells, BRCA1 mutant SUM149 cells and PARP 
inhibitor resistant daughter clones.  
Tumour cells were plated in a 6-well plate format and continuously exposed to PARP inhibitor for a 
two-week period at which point cell survival was estimated. Dose response curves from triplicate 
experiments are shown. Error bars represent SEM.  
A. LM7 exhibited comparable olaparib sensitivity to CAPAN1 (ANOVA p=0.587) and SUM149 
(ANOVA p=0.183) but significantly greater sensitivity than CAPAN1.B2*.S cells with a secondary 
BRCA2 mutation (ANOVA p<0.0001) and SUM149.B1*.S (ANOVA p<0.0001) with secondary 
BRCA1 mutation. 
B. LM7 exhibited comparable talazoparib sensitivity to SUM149 (ANOVA p=0.326) but significantly 
greater sensitivity than CAPAN1 (ANOVA p=0.007), SUM149.B1*.S cells with a secondary BRCA2 
mutation (ANOVA p<0.0001) and CAPAN1.B2*.S (ANOVA p<0.0001) with secondary BRCA1 
mutation. [BMN673: talazoparib]




Neither LM7 nor SAOS2 harbour a BRCA1 or BRCA2 mutation. Given that SAOS2, the 
parent of LM7 did not demonstrate the same sensitivity to PARP inhibition, and in the 
absence of any OS tumour cell lines with loss of function of BRCA, this was conceived to 
have the potential to be an isogenic model for the investigation of PARP sensitivity in 
osteosarcoma. NOS-1 was reported to have a homozygous missense mutation of BRCA1 
(c.154C>T) but this mutation was not postulated to cause loss of function. 
 
Comparison of the relative sensitivity of the panel of OS by use of AUC for talazoparib 
with data from three OS tumour cells (MG63, SAOS2, and HOSMNNG) reported by 
(Engert, Kovac, Baumhoer, et al., 2016) did not demonstrate a particular sensitivity to this 
agent for these tumour cell lines (Figure 129). The AUC for HOSMNNG was very similar to 
that seen for the SUM149 PARP1 and 53BP1 mutants, and greater than SUM149.B1*.S, 
which were used markers of resistance to PARP inhibition.  
 
7.2.9.1.1 Marked decrease in RAD51 foci in LM7 
To investigate if the LM7 had an acquired HR defect that could explain increased 
sensitivity to PARP, γH2AX and RAD51 foci formation were performed in both SAOS2 
and LM7. Deficiency of formation of RAD51 foci is known to be a mechanistic 
determinant of PARP-inhibitor sensitivity (Lord & Ashworth, 2012). CAPAN1 (BRCA2 
deficient) and CAPAN1.B2*.S (BRCA2 proficient) were used as positive and negative 
controls. 10Gray of irradiation was used to induce γH2AX foci. Four hours post irradiation 
the cells were fixed and stained. Confocal microscopy was used to visualise and score 
the γH2AX and RAD51 foci (Figure 131). After irradiation, γH2AX foci formation was 
increased in all cell lines, reflecting DSBs consistent with genotoxic stress. RAD51 foci, 
critical to HR (Tarsounas, Davies & West, 2004) were observed post irradiation only in 
SAOS2 and CAPAN1.B2*.S. BRCA2 acts as a co-factor for RAD51, and is critical to HR, 
in accordance with the absence of RAD51 foci seen in the CAPAN1 tumour cells. LM7 
also failed to form RAD51 foci in the presence of γH2AX foci post irradiation, suggestive 
of an HR defect. 
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Figure 131 LM7 cells exhibit a defect in nuclear RAD51 foci formation.  
Bar chart illustrating quantitation of nuclear RAD51 foci after exposure to ionising radiation. Cells 
were plated in triplicate in 6 well plates on coverslips. After 24 hours, tumour cells were irradiated 
(10 Gray) and cultured for a subsequent four hours, at which point cells were fixed and 
immunostained. Confocal microscopy was used to visualise and score the nuclear γH2AX and 
RAD51 foci. Cells containing more than 5 foci were considered positive. Mean ± SEM for three 
independent experiments are shown. LM7 cells exhibited significantly decreased nuclear RAD51 
foci formation compared to SAOS2 (p = 0.0005). p values were calculated using Student’s t test. 
 





Figure 132 LM7 cells exhibited a defect in nuclear RAD51 foci formation, suggestive of an 
acquired HR defect. 
Representative confocal images for nuclear RAD51 foci formation in LM7 and SAOS2 cells 
following IR exposure with staining to demonstrate γH2AX (pink) and RAD51 foci (green). Cells 
were plated in triplicate in 6 well plates on coverslips. After 24 hours, tumour cells were irradiated 
(10 Gy) and cultured for a subsequent four hours, at which point cells were fixed and 
immunostained. Confocal microscopy was used to visualise and score the nuclear gH2AX and 
RAD51 foci. Cells containing more than five foci were considered positive. Scale bar = 30 µm. [-IR: 
not exposed to irradiation; +IR: exposed to 10Gy radiation] 
 




7.2.9.1.2 siRNA screen in combination with olaparib 
To investigate the mechanism of sensitivity to PARP inhibition in osteosarcoma, the cell 
lines LM7 and SAOS2 were screened using the same siRNA library as described in 
Chapter 5 with the addition of continuous exposure to DMSO or 500nM of olaparib (SF50 
for LM7) for five days. The Drug Effect (DE) on each gene was calculated (described in 
2.3.1.4 section of Chapter 2), where scores of -2 < or > 2 were considered significant for 
sensitising and resistance causing effects. The Delta Drug Effect was calculated as the 
difference between the DE for each tumour cell line.  
 
Selection criteria for candidate genetic dependencies that caused selective loss of 
viability in the presence of olaparib were set as follows: statistically significant (p<0.05) 
difference between viability in the presence of DMSO or olaparib; drug effect < - 2 in 
either cell line. Using these criteria, for LM7 the following 24 genes were identified: 
BRCA1, BRCA2, FANCM, RAD51, SHFM1, PALB2, Essential Meiotic Structure-Specific 
Endonuclease Subunit 2 (EME2), Tight Junction Protein 2 (TJP2), Homeobox C13 
(HOXC13), X-ray repair cross-complementing 3 (XRCC3), Glypican 3 (GPC3), Rho 
Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2), FGFR3, Serine/Threonine 
Kinase 40 (STK40) (MGC4796), Calcium/Calmodulin Dependent Protein Kinase IV 
(CAMK4), Pyruvate Kinase Muscle (PKM2), MUTYH, Membrane Palmitoylated Protein 3 
(MPP3), Advanced Glycosylation End-Product Specific Receptor (RAGE), Vaccinia 
Related Kinase 2 (VRK2), DNA Polymerase Gamma, Catalytic Subunit (POLG), 
MAP4K2, Protein Kinase N1 (PRKCL1), and Protein Kinase C Delta (PRKCD); and for 
SAOS2 the following ten genes were identified: BRCA1, FANCM, SHFM1, Cyclin E1 
(CCNE1), RAD51, Eukaryotic Translation Initiation Factor 4A2 (EIF4A2), Replication 
Protein A3 (RPA3), Transcription Factor 7 Like 2 (TCF7L2), Nuclear Receptor 
Coactivator 4 (NCOA4), and X-Ray Repair Cross Complementing 1 (XRCC1). Protein-
protein network analysis using String (string-db.org) highlighted a reliance on nine genes 
involved in DNA damage repair associated with a phenotype sensitive to PARP inhibition 
(Figure 133). Some genes for example BRCA1 and BRCA2 were in the siRNA library 
twice, and therefore provide further internal revalidation. To attempt to determine a 
mechanism of sensitivity to olaparib in LM7, candidate genetic dependencies that cause 
loss of viability of SAOS2 (Z score < -1.5) in the presence of olaparib, but without an 
effect on viability of LM7 (Z score > - 1.0), were sought. No candidate genetic 
dependencies were identified.  




7.2.9.1.3 Exome sequencing and Transcriptome profiling of LM7 and SAOS2 
Given the evidence of an acquired sensitivity to PARP and HR defect in LM7, exome 
sequencing and mRNA transcriptome profiling of LM7 and SAOS2 was performed by the 
Tumour Profiling Unit at the Institute of Cancer Research, London. Differences were 
sought between the two tumour cell lines to further understand the acquired sensitivity to 
PARP inhibition by LM7. The focus was set on genes known to be involved in DNA 
repair. Mutations, copy number changes and mRNA expression changes that were seen 
in both cell lines were excluded, since it is likely these effects do not cause a differential 
sensitivity to PARP. Therefore, only changes seen in either LM7 or SAOS2 are 
described.  
 
122 protein-altering mutations present in either SAOS2 or LM7 were identified; 104 were 
missense; four (Autophagy Related 4A Cysteine Peptidase (ATG4A), Complement Factor 
H Related 2 (CFHR2), Ring Finger Protein 20 (RNF20), Tectonic Family Member 3 
(TCTN3)) were found in splice sites; eight (Kelch Like Family Member 29 (KLHL29), 
Meiotic Double-Stranded Break Formation Protein 1 (MEI1), ATP Binding Cassette 
Subfamily A Member 12 (ABCA12), Churchill Domain Containing 1 (CHURC1), 
Complement C7 (C7), EH Domain Containing 1 (EHD1), Protocadherin Alpha 1 
(PCDHA1), Protocadherin Beta 5 (PCDHB5)) were nonsense mutations (stop gained); 
and six (Contactin Associated Protein-Like 2 (CNTNAP2), Insulin Receptor Substrate 4 
(IRS4), H2B Histone Family Member W Testis Specific (H2BFWT), RP4-724E16.2, 
Serpin Family B Member 10 (SERPINB10), Protein Tyrosine Phosphatase, Receptor 
Type C (PTPRC)) were frame shift mutations. Three missense mutations in LM7 in three 
genes (HUS1 Checkpoint Clamp Component (HUS1), INTS3 And NABP Interacting 
Protein (INIP), and EYA Transcriptional Coactivator And Phosphatase 4 (EYA4)) 
encoding proteins involved in DNA repair and HR were identified. HUS1 has a critical role 
in the S-phase checkpoint in leading to cell cycle arrest in response to DNA damage 
(Weiss, Leder & Vaziri, 2003). INIP is a component of the sensor of single strand DNA 
(SOSS) complex, which functions to promote DNA repair and plays a critical role in the 
repair of DSB by HR (Huang, Gong, Ghosal, et al., 2009). EYA4 promotes DNA repair by 
the recruitment of DNA repair complexes and dephosphorylation of H2AX (Wilson, Vucic, 
Enfield, et al., 2014). EYA4 was found to also have very low transcript expression in LM7.  
 





Figure 133 Protein-protein network analysis using String (string-db.org) highlighted a 
reliance on nine genes involved in DNA damage repair associated with a phenotype 
sensitive to PARP inhibition (LM7). 
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Figure 134 Silencing of BRCA1 and BRCA2 was associated with loss of viability in the 
presence of olaparib in both OS tumour cell line, but particularly LM7. 
Bar charts illustrating viavility are shown for LM7 and SAOS2 in the presence of DMSO or 
olaparib. Tumour cell lines were reverse transfected using the siRNA library described in Appendix 
Tables 1-3. After 24 hours, cells were exposed to DMSO or 500nM olaparib. Post a further six 
days, cell viability was estimated using the CellTiter Glo reagent as described in the methods. The 
effect of each siRNA on olaparib (500nM) sensitivity was determined by calculation of a drug effect 
(DE) score for each siRNA. DE scores were calculated by the difference between the median of 
replicate wells with drug and median of replicate corresponding wells with no drug for each siRNA. 
The median absolute deviation (MAD) was used to account for variance of the DE data. Delta drug 
effect was calculated as the difference between the DE for each tumour cell line. Some genes 
such as BRCA1 and BRCA2 were in the siRNA library twice, and therefore provide further internal 
revalidation. Box and whisker plots showing mean and standard deviation. Bar represents mean 
value and error bars standard deviation. P values calculated by the Student’s t test. [DE: drug 
effect; Δ DE: Delta drug effect] 
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Figure 135 Candidate genetic dependencies associated with sensitivity to PARP inhibition 
by olaparib.  
Bar charts illustrating viavility are shown for LM7 and SAOS2 in the presence of DMSO or 
olaparib. Tumour cell lines were reverse transfected using the siRNA library described in Appendix 
Tables 1-3. After 24 hours, cells were exposed to DMSO or 500nM olaparib. Post a further six 
days, cell viability was estimated using the CellTiter Glo reagent as described in the methods. The 
effect of each siRNA on olaparib sensitivity was determined by calculation of a drug effect (DE) 
score for each siRNA. DE scores were calculated by the difference between the median of 
replicate wells with drug and median of replicate corresponding wells with no drug for each siRNA. 
The median absolute deviation (MAD) was used to account for variance of the DE data. Delta drug 
effect was calculated as the difference between the DE for each tumour cell line.  Some genes 
such as PALB2 were in the siRNA library twice, and therefore provide further internal revalidation. 
Bars represent mean and error bars standard deviation. P values calculated by the Student’s t 
test. [DE: drug effect; Δ DE: Delta drug effect] 




There were 14 genes with copy number changes only seen in LM7 (SLX1 Homolog A, 
Structure-Specific Endonuclease Subunit (SLX1A), PARP1 Binding Protein (PARPBP), 
CHEK2, EYA2, Ubiquitin C (UBC), Mortality Factor 4 Like 2 (MORF4L2), Ubiquitin 
Conjugating Enzyme E2 A (UBE2A), Acyl-CoA Synthetase Long-Chain Family Member 4 
(ACSL4), Cullin 4B (CUL4B), Iduronate 2-Sulfatase (IDS), Nuclear Receptor Coactivator 
6 (NCOA6), RUNX1, 1-Acylglycerol-3-Phosphate O-Acyltransferase 3 (AGPAT3), Solute 
Carrier Family 19 Member 1 (SLC19A1)) involved in DNA repair. Of these, three genes 
(SLX1A, PARPBP and CHEK2) were known to be involved in HR-mediated DNA repair. 
There was no evidence of differential mRNA expression of these 14 DNA repair genes. 
Loss of homozygosity regions were identified in six genes (FANCM, Ring Finger Protein 
168 (RNF168), 3-Hydroxybutyrate Dehydrogenase 1 (BDH1), NIMA Related Kinase 1 
(NEK1), WBSCR22 and WBSCR27) in LM7, with known involvement in DNA repair 
pathways. Two out of these six genes (FANCM and RNF168) have known involvement in 
HR dependent DNA repair. 
 
7.2.9.1.4 Investigation of differences in expression of proteins known to be 
involved in DNA damage repair pathways 
To investigate if proteins known to be sensitisers to PARP inhibition were expressed at 
differential levels between LM7 and SAOS2 and therefore potential biomarkers of 
sensitivity to PARP inhibition, western blotting of selected proteins was undertaken. To 
identify changes in phosphorylated CHK1, tumour cells were exposed to DMSO or 10µM 
olaparib for 24 hours. No difference in levels of expression was seen between the two 
tumour cell lines for BRCA1, BRCA2, CHK1, phosphorylated CHK1 (Serine 345), 
phosphorylated CHK2 (Threonine 68), ATM or ATR (Figure 136, Figure 137 and Figure 
138). Total CHK2 expression was slightly decreased in SAOS2. However, no obvious 
differential expression of known sensitisers to PARP inhibition that could explain the 
acquired sensitivity to PARP inhibition by LM7 was observed. 
 
7.2.9.1.5 Investigation of differences in abundance of proteins known to be 
involved in DNA damage repair pathways 
To further identify differences in protein expression between the two tumour cell lines that 
could explain the acquired sensitivity to PARP inhibition by LM7, proteomic profiling was 
kindly undertaken by Colm Ryan using the methodology described in section 2.2.3.2 of 




Chapter 2. Proteins with the greatest differential abundance between LM7 and SAOS2, 
with lowest abundance in LM7, were selected. SWI/SNF Related Matrix Associated Actin 
Dependent Regulator Of Chromatin Subfamily A Member 1 (SMARCA1), Fanconi 
Anaemia Complementation Group D2 (FANCD2) and Histone Cluster 2 H2B Family 
Member A (HIST2H2AB) exhibited the greatest difference (Figure 139). Protein 
abundance values for BRCA1, BRCA2, SHFM1, XRCC3, and PALB2 were not available 
and therefore likely represent low abundance.  
 
SMARCA1 is a member of the SWI/SNF family of proteins that contribute to the 
chromatin remodelling of transcription. These complexes also function in HR, NHEJ and 
DNA damage associated signalling (Lans, Marteijn & Vermeulen, 2012). Inhibition of 
SMARCA1, has been shown to selectively activate the DNA damage response, leading to 
inhibition of growth and apoptosis of tumour cells (Aydin, Vermeulen & Lans, 2014). 
Potentially decreased expression of SMARCA1 leading to constitutive activation of the 
DNA damage response could increase sensitivity to PARP inhibition. HIST2H2AB is a 
pseudo-gene of the histone family of proteins primarily responsible for nucleosome 
structure of the chromosomal fibre. As a pseudo-gene its relevance is unknown. FANCD2 
co-localises with BRCA1 and is directly involved in HR and cell cycle checkpoint 
response to DNA damage (Bogliolo & Surrallés, 2013).  
 
Although, there are no supportive genomic correlates of SMARCA1, FANCD2 or 
HIST2H2AB, seen in the whole exome sequencing, or mRNA transcriptome profiling, loss 
of heterozygosity (LOH) for FANCM was identified in LM7 but not SAOS2. FANCD2 
controls FANCM, and the combination of LOH of FANCM and decreased abundance of 
FANCD2, both key proteins in DDR may explain the acquired sensitivity to PARP by LM7. 
 
Unfortunately, siRNA targeting SMARCA1 and HIST2H2AB were not part of the RNAi 
library used in 7.2.9.1.2, and could not be used to cross-reference and validate these 
findings. Small-scale revalidation to test the hypothesis that silencing of SMARCA1 or 
HIST2H2AB in SAOS2 could increase sensitivity to PARP inhibition could be 
investigated, or if over expression using a plasmid could rescue the sensitivity to PARP 
inhibition, and increase the resistance in LM7. Silencing of FANCD2 in this screen did not 
cause a loss of viability (median Z score < -1.5) in LM7 or SAOS2. This could be because 
of redundancy of the protein or a false negative in the screen. 
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Figure 136 LM7 and SAOS2 exhibit similar expression levels of BRCA2, total CHK2 and 
phospho threonine 65-CHK2.  
Western blot is shown. Total cell lysates were collected from untreated cells, electrophoresed, and 
immunoblotted as described in the methods. Immunoblotting of actin was used as the loading 
control. No difference in expression levels of BRCA2 or phosphorylated CHK2 (Threonine 68) was 
observed between the two tumour cell lines. Expression of total CHK2 was slightly decreased in 
SAOS2.  
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Figure 137 LM7 and SAOS2 exhibit similar protein expression levels of phosphor serine 
345-CHK1 and total CHK1.  
Western blot is shown. Tumour cells were exposed 10µM olaparib or DMSO for 24 hours. Total 
cell lysates isolated after drug exposure were electrophoresed, and immunoblotted as described in 
the methods. Immunoblotting of actin was used as the loading control. [-: 24 hour exposure to 
DMSO; +: 24 hour exposure to 10µM olaparib; pCHK1: phosphorylated CHK1 (Serine 345)]. 
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Figure 138 LM7 and SAOS2 exhibit similar protein expression of ATM and ATR by western 
blotting. 
Western blot is shown. Total cell lysates were collected from untreated cells, electrophoresed, and 
immunoblotted as described in the methods. Immunoblotting of DNA-PK was used as the loading 
control. 
 



























































































































































































































































































































Figure 139 Proteomic abundance of (A) SMARCA1, (B) FANCD2, and (C) HIST2H2AB in LM7 
and SAOS2, exhibited large differential in abundance.  
Bar charts of protein abundance of (A) SMARCA1, (B) FANCD2, and (C) HIST2H2AB in LM7 and 
SAOS2 defined by mass spectrometry that was performed Colm Ryan (Systems Biology, Dublin, 
Ireland). Following lysis, protein purification, and tryptic digest, peptides were separated by liquid 
chromatography and measured by mass spectrometer. Label-free proteome quantification was 
performed using the MaxQuant software environment to determine the quantitative abundance of 
6696 peptides with a false discovery rate of less than one percent.  





This chapter describes high-throughput screening of the panel of 18 OS tumour cell lines 
and isogenic RB1 deficient and wildtype U2OS tumour cell line generated by CRISPR-
Cas9 mutagenesis, with the aim of identification of drugs with novel activity in OS that 
may facilitate development of clinical trials and or stratification of patients for clinical trials. 
The heterogeneity of the molecular landscape of OS makes finding new molecular targets 
challenging, and the overall resistance of OS to the majority of small molecule inhibitors 
and chemotherapeutics compared to other cancer types makes identification of novel 
agents also difficult. It is therefore imperative to have a range of useful models for 
studying this disease further, and context for comparison of sensitivity. The small 
molecule screens described in this chapter demonstrate that sensitivity to most inhibitors 
was seen only in a minority of models, thus diminishing the statistical power and possible 
clinical relevance. Due to the heterogeneity of the disease, appropriate patient selection 
using biomarkers of sensitivity will be critical. For a disease that is not common, further 
division of the patient population into a number of minority subsets, could present 
challenges with trial recruitment nationally, and necessitate international collaboration.  
 
The drug screen demonstrated that OS tumour cell lines exhibit sensitivity to 
chemotherapeutics that already form the standard of care (methotrexate and doxorubicin) 
(Marina, Smeland, Bielack, et al., 2016), and are frequently used in the advanced setting 
(gemcitabine) (Palmerini, Jones, Marchesi, et al., 2016). Others such as mTOR inhibitors 
have demonstrated clinical activity in OS but not sufficient to be incorporated into 
treatment protocols (Chawla, Staddon, Baker, et al., 2012; Demetri, Chawla, Ray-
Coquard, et al., 2013). Whole-exome sequencing, whole genome sequencing, and RNA-
sequencing of OS tumour samples, identified alterations in the PI3K/mTOR pathway in 
24% of patients with OS (Perry, Kiezun, Tonzi, et al., 2014). Mutations of PTEN and 
PIK3CA were found in by multivariable analysis of clinical trial data to be predictive of 
response to rapamycin in advanced cancer (Janku, Hong, Fu, et al., 2014). However, no 
mutations of PI3K/mTOR pathway members (PI3K, PTEN, PDPK1, AKT1 and EIF4B) 
were observed in the panel of OS tumour cell lines, and so make these models less 
attractive for further study in this area.   
 
Recent findings of IGF signalling pathway mutations or amplification in eight out of 112 
tumour OS samples which were either whole genome or exome sequenced (Behjati, 
Tarpey, Haase, et al., 2017), has provided a novel insight into the pathway as a potential 




avenue worthy of investigation once again. Response to robatumumab, a fully human 
antibody that binds and inhibits IGF-1R, was found in Phase II trial to be related to 
disease burden, imparting a complete or partial response in three of 31 patients with 
resectable osteosarcoma metastases, but not in patients with un-resectable metastases 
(Anderson, Bielack, Gorlick, et al., 2016), while a monoclonal antibody targeting IGF-1R, 
R1507, showed limited activity in OS with only two of 38 patients with advanced OS, 
achieving partial remission, as part of a larger study (Pappo, Vassal, Crowley, et al., 
2014). However, all clinical trials in sarcoma have been closed or halted due to perceived 
lack of activity and no biomarker to stratify patients for therapy. In blockade of IGR-1R 
alone, the IR has been shown to activate the same downstream signalling pathways as 
IGF-1R (Kuijjer, Peterse, van den Akker, et al., 2013). Therefore, targeting both IGF-1R 
and IR might have greater effect. A phase II study of linsitinib (NCT02546544) in patients 
with relapsed or refractory advanced Ewing’s sarcoma has closed and the results are 
awaited. The OS tumour cell lines did not show significant sensitivity to the dual IGF-1R 
and IR inhibitors linsitinib (OSI-906) or GSK1904529A compared to the non-
osteosarcoma tumour cell line data. However, a considerable range of sensitivity in the 
OS tumour cell line panel was observed with exposure to linsitinib (OSI-906), and 
mutation of the IGF pathway genes (IGF1R, IGF2R, IGFBP4, IGFBP6 and IGFBPL1) 
were found to correlate with sensitivity. One of the tumour cell lines harboured IGF1R 
amplification and was amongst the most sensitive to linsitinib, however, these results 
were not replicated with GSK1904529A. Further validation of these observations using 
tumour samples is needed to determine applicability of any IGF pathway mutation as a 
potential biomarker for linsitinib, and IGF pathway inhibitors in general, since these 
observations were not replicated with GKS1904529A. A robust biomarker for sensitivity to 
IGF1R/IR inhibition could be therapeutically attractive but as yet has proven illusive. 
 
An OS specific dependency to the CHK1 inhibitor PF-004477736 was identified, although 
an OS specific genetic dependency on CHK1 was not observed. This could be a false 
negative from the siRNA screen described in Chapter 5, or an off-target effect of the drug 
leading to a false positive. To further establish the role of CHK1 in this panel of OS 
tumour cell lines, a small-scale deconvolution reverse transfection using multiple siRNA 
species each targeting a different region of CHK1 could be performed. In addition, a drug 
screen using other structurally different inhibitors of CHK1, and also confirmation of cell 
cycle arrest in G2/M. Interestingly, the BRCA1 deficient breast cancer cell line SUM149 
was particularly sensitive to PF-004477736, while the secondary BRCA1 mutant 




SUM149.B1*.S demonstrated acquired resistance. However, acquired sensitivity to this 
agent was not observed in LM7 compared toSAOS2, despite an acquired HR defect. 
 
A number of CHK1 inhibitors are currently in development and early clinical trials. A 
Phase I trial of PF-004477736 was commenced in combination with gemcitabine in 
patients with advanced solid tumours, but was terminated for financial reasons 
(NCT00437203). A phase I trial of LY2606368 to determine the safety and toxicity profile 
in patients with advanced solid tumours has been performed (no patients with OS were 
enrolled) (Hong, Infante, Janku, et al., 2016). Grade 4 neutropenia occurred in 73% of 
patients but was transient, and otherwise well tolerated; two of 45 patients had a partial 
response, while 15 had stable disease (Hong, Infante, Janku, et al., 2016). A number of 
clinical trials of LY2606368 in patients with advanced solid tumours are currently 
recruiting. The potential for CHK1 inhibitor use is likely to be limited by absence of a 
sufficient biomarker of sensitivity. It will be interesting to observe if a relationship between 
HR deficiency and CHK1 sensitivity is established in a clinical trial setting 
(NCT02873975).  
 
The previous chapter described a reliance on genes involved in ‘skeletal system 
morphogenesis’ including FGFR1 (Campbell, Ryan, Brough, et al., 2016). Two FGFR 
inhibitors AZD4547 and PD173074, were found to be selective for osteosarcoma models 
independent of amplification status. In addition, amplification and polysomy of FGFR1 in 
this panel of OS tumour cell lines was shown to be associated with significantly greater 
sensitivity to the FGFR1 inhibitors than OS tumour cell lines for which FGFR1 
amplification was unknown or negative. Using 145 tumour cell lines of lineages which for 
which Guagnano et al. reported FGFR1 amplification, in breast, lung and OS, they 
demonstrated that FGFR1 amplification was significantly associated with sensitivity to the 
FGFR inhibitor NVP-BGJ398 (Guagnano, Kauffmann, Wöhrle, et al., 2012). Validation of 
these findings in OS tumour samples, identified one of 17 samples with FGFR1 
amplification (defined as log2 ratio ≥1: equal to ≥4 normalized DNA copies) (Guagnano, 
Kauffmann, Wöhrle, et al., 2012). A c-Fos oncogene-induced orthotopic mouse model of 
OS was used to demonstrate that treatment with the FGFR inhibitor AZD4547 lead to a 
reduction of the number and size of pulmonary nodules (Weekes, Kashima, Zandueta, et 
al., 2016). In addition, silencing of FGFR1 by use of shRNA targeting FGFR prior to 
injection, decreased the number of spontaneous pulmonary metastases (Weekes, 
Kashima, Zandueta, et al., 2016).  




Recently a study analysed FGFR1 amplification using interphase fluorescence in situ 
hybridisation (FISH) in 352 OS tumour samples from 288 patients. FGFR1 amplification 
was defined as positive if ≥10% of the cells showed (a) FGFR1/Centromere 8 (CEN8) 
ratio >2, (b) clusters of FGFR1 signals, or (c) >15 copies of FGFR1 per cell. Amplification 
of FGFR1 was observed in 18.5% of patients in whose tumours revealed a poor response 
to chemotherapy (<90% necrosis) (Fernanda Amary, Ye, Berisha, et al., 2014) and 
present disproportionally higher in the rarer histological variants of OS such as 
fibroblastic and pleomorphic subgroups (Fernanda Amary, Ye, Berisha, et al., 2014). 
Patients with a good response to chemotherapy did not harbour FGFR1 amplification 
(Fernanda Amary, Ye, Berisha, et al., 2014). Nearly 10% of OS tumour samples from 288 
patients exhibited FGFR1 amplification, while approximately 50% of tumour samples 
were observed to have polysomy (Fernanda Amary, Ye, Berisha, et al., 2014). It was not 
possible to establish if FGFR1 amplification increased the risk of metastatic disease 
because of relatively small data set (Fernanda Amary, Ye, Berisha, et al., 2014). Thus, 
from the results of the drug screen, there are indications of possible treatment 
opportunities of a significant proportion of OS patients with FGFR1 amplification and/or 
polysomy. Given that FGFR1 amplification was seen in patients who had a poorer 
response to chemotherapy, and associated with rarer histological variants (Fernanda 
Amary, Ye, Berisha, et al., 2014), finding an association that FGFR1 amplification in this 
panel of OS tumour cell lines was associated with significantly greater sensitivity to the 
FGFR1 inhibitors provides further rationale for finding inhibitors.  
 
There are a number of monoclonal antibodies and specific tyrosine kinase inhibitors that 
target the FGFR receptor family that are currently in Phase I/II clinical trials. One such 
study, of the inhibitor AZD4547, added a basket cohort to explore efficacy of the agent in 
FGFR amplified osteosarcoma (NCT01795768). Unfortunately the study is currently “on 
hold” due to unexpected side effects identified. Lenvatinib, a multi-targeted kinase 
inhibitor was investigated in osteosarcoma in a phase I study initially developed by the 
Innovative Therapies for Children with Cancer (ITCC), and identified 14mg/m2/day as the 
recommended dose (Gaspar, Melcon, Venkatramani, et al., 2017). The efficacy of this 
agent is currently being explored in a phase II expansion of the single agent in 
osteosarcoma and Phase Ib study in combination with ifosfamide and etoposide in 
osteosarcoma (NCT02432274). Although marketed as a VEGFR inhibitor, it is also an 
FGFR1 inhibitor with an IC50 of 46nmol/L (Cabanillas & Habra, 2016). However, data 
from the drug screen in this thesis cautions the clinical translation of lenvatinib, since no 




significant sensitivity was seen in OS compared to non-OS tumour cell lines, and 
sensitivity did not correlate with FGFR1 amplification status. A more specific FGFR1 
inhibitor might be more effective.  
 
While FGFR1 amplification in OS tumour cell lines has previously been determined to be 
a marker of sensitivity to FGFR inhibition by the pan-FGFR inhibitor NVP-BGJ398 
(Guagnano, Kauffmann, Wöhrle, et al., 2012), the finding that OS tumour cell lines with 
FGFR1 polysomy are also sensitive to FGFR1 inhibition by two different FGFR1 
inhibitors, in addition to a panel wide reliance on genes involved in ‘skeletal system 
morphogenesis’ including FGFR1 (Campbell, Ryan, Brough, et al., 2016), suggests that 
an additional cohort of patients may benefit from FGFR1 inhibition. These findings add 
further weight to the importance of the role of FGFR in OS and rationale for a clinical trial 
of FGFR1 inhibitors in an enriched patient population with FGFR1 amplification or 
polysomy. In addition, it would be valuable to measure FGFR status in patients on current 
clinical trials to determine whether there is any correlation with response to the therapy.  
 
Sensitivity to drugs depending on deficiency of CDKN2A and RB1 were identified. 
CDKN2A deficiency was demonstrated to be predictive of methotrexate sensitivity, as 
MTAP, a known sensitiser to methotrexate is collocated on Chromosome 9 with 
CDKN2A. Cells deficient in MTAP by deletion or inactivation via methylation of the MTAP 
promoter are more sensitive to methotrexate (Bertino, Waud, Parker, et al., 2011). Cells 
deficient in MTAP, have a defective salvage pathway for adenine and methionine, 
increasing sensitivity to inhibitors of de novo purine synthesis such as methotrexate, and 
methionine deprivation (Bertino, Waud, Parker, et al., 2011).  Interestingly, four out of the 
five of the OS tumour cell line panel (HOS, HOSMMNG, 143b and MG63) with 
homozygous deletions of CDKN2A also had homozygous deletions of MTAP. CAL72 has 
a region of loss from 21894035 – 22183163 base pairs on chromosome 9. This included 
CDKN2A (21967751 – 21995300 base pairs), but only part of MTAP (21802543 – 
21937651 base pairs), meaning that some isoforms of MTAP are still possible. 
Methotrexate is one of the three principal chemotherapeutics used for the treatment of 
OS. At present there is no biomarker for determining potential response to therapy, 
however, deficiency of CDKN2A or MTAP could have the potential for use as a 
biomarker. It would be valuable to measure CDKN2A or MTAP status by 
immunohistochemistry in patients on current clinical trials to determine whether there is 
any correlation with response to the therapy. However, this is confounded by likely co-




treatment with doxorubicin and cisplatin in addition to methotrexate. Determining if 
patients whose tumours harbour CDKN2A or MTAP deficiency would have a similar 
outcome post dose-reduction of methotrexate as compared to standard therapy would be 
limited by the need for a large phase III trial. Given the toxicity of high-dose methotrexate 
at the standard doses, combined with that of doxorubicin and cisplatin, it would be difficult 
to envisage increasing the dose of methotrexate in those patients who were CDKN2A or 
MTAP wildtype. Therefore, possible benefit would be most likely if an additional agent 
could be used in combination with or instead of methotrexate in this potential cohort.  
 
Given the heterogeneity of OS in vivo, a panel of representative tumour cell lines is 
attractive, but does make isolation of drug dependencies associated with a molecular 
deficiency such as RB1 more challenging. Isogenic models that derive from a single 
progenitor cell line, with minimal differences between the daughter and parental cell lines, 
so that any observed differences are more likely to be due to the gene of interest 
(Rehman, Lord & Ashworth, 2010) have the potential to make isolation of drug 
dependencies more accessible. However, these isogenic models also have their 
limitations, since the observed dependency may be specific to the molecular landscape of 
the model, with limited wider applicability and require further validation in a panel of 
representative tumour cell lines. Hence, both methodologies were employed, with drug 
screens in both the panel of OS tumour cell lines, and the isogenic RB1 deficient U2OS 
models. Similar to the observed genetic dependencies described in the previous chapter, 
different drug dependencies were found using the different models. As discussed in the 
previous chapter, RB1 and CDKN2A deficiency were found to be mutually exclusive in 
the OS tumour cell line panel. The OS tumour cell line U2OS was classified in Chapter 
three as CDKN2A deficient. Given that CRISPR-Cas9 mutagenesis was attempted in a 
number of other CDKN2A wildtype OS tumour cell lines without success, it is possible 
sudden acquired complete deficiency of RB1 is lethal without prior deficiency of CDKN2A, 
and that a deficiency of CDKN2A abrogates vulnerabilities specific to acquired 
deficiencies associated with deficiency of RB1. This presents future challenges for the 
isolation of both genetic and drug dependencies associated with RB1 deficiency, given 
the heterogeneity of the panel and difficulty of creation of an isogenic model 
representative of the disease.  
 
Paclitaxel, vinorelbine and camptothecin were the only drugs that demonstrated 
increased sensitivity with RB1 deficiency in the panel of OS tumour cell lines and could 




be avenues for future investigation using mouse models prior to clinical translation. 
Although paclitaxel and camptothecin appear mechanistically relevant to tumour cells 
harbouring RB1 deficiency (Kurtyka, Chen & Cress, 2014; Lauricella, Calvaruso, 
Carabillò, et al., 2001), and statistically significant, the scale of effect observed was 
modest, and is unlikely to be a priority.  
 
The isogenic RB1 deficient U2OS models generated by CRISPR-Cas9 mutagenesis 
demonstrated sensitivity to HSP90, kinesin spindle protein and NAD biosynthesis 
inhibitors. HSP90 is recognised as a crucial facilitator of oncogene addiction and cancer 
cell survival, via its protection of an array of mutated and overexpressed oncoproteins 
from mis-folding and degradation (Trepel, Mollapour, Giaccone, et al., 2010). Despite 
over twenty clinical trials, only moderate single agent activity has been observed in 
diseases such as HER-2 amplified breast cancer and ALK rearranged and EGFR mutant 
lung cancer where the tumour cells are addicted to a HSP90 client protein (Neckers & 
Workman, 2012). Assessment of efficacy of HSP90 in osteosarcoma has been on in vivo 
tumour cell lines (Hu, Bobb, He, et al., 2015) and limited mouse models (Hu, Bobb, He, et 
al., 2015) that have shown limited efficacy. 
 
Kinesin spindle protein (KSP) inhibitors are a family of molecular motors that travel uni-
directionally along tracks to support cell division (Rath & Kozielski, 2012). In RB1 
deficient tumour cell lines, decreased ϒ-tubulin, an important regulator of microtubule 
formation, has been demonstrated to induce cell death (Lindström, Villoutreix, Lehn, et 
al., 2015). Mechanistically an increased reliance on KSP might also be explained in RB1 
deficient tumour cells by an increase in cell cycling, due to the loss of inhibitory control of 
RB1. Unfortunately, they have also shown limited efficacy in the clinic, with frequent 
mutation of the binding pocket (Jiang & You, 2013). Relatively recent discovery of an ATP 
competitive KSP inhibitor which has the potential to overcome mutation-mediated 
resistance to the allosteric inhibitors, or combination with chemotherapeutic agents, could 
provide increased efficacy for these agents (Jiang & You, 2013; El-Nassan, 2013). 
 
These RB1 deficient models also demonstrated increased sensitivity to a NAD 
biosynthesis inhibitor and the potential for combination treatment with PARP inhibition 
could be explored by combination experiments in the OS tumour cell line panel. The 
PARP family of enzymes add ADP-ribose moieties onto proteins, using b-NAD+ as 
substrate termed PARylation (De Vos, Schreiber & Dantzer, 2012). Nicotinamide 




phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme involved in the generation 
of the PARP substrate b-NAD+ from the natural precursor nicotinamide essential for 
cellular survival (Bajrami, Kigozi, Van Weverwijk, et al., 2012; Nahimana, Attinger, Aubry, 
et al., 2009). Inhibition of NAMPT has a negative impact on the catalytic activity of PARP 
enzymes (Bajrami, Kigozi, Van Weverwijk, et al., 2012). PARP inhibitors are selective for 
tumour cells with homologous recombination (HR) gene defects (Bajrami, Kigozi, Van 
Weverwijk, et al., 2012). Two inhibitors of PARP, rucaparib and olaparib also part of the 
same screen were not found to be selective for RB1 deficiency in these models, nor in 
the wider OS tumour cell line panel. However, inhibition of NAMPT has been shown to 
increase the tumour cell inhibitor effect of the clinical PARP inhibitor olaparib both in vitro 
and an in vivo model of triple-negative breast cancer (Bajrami, Kigozi, Van Weverwijk, et 
al., 2012). It is therefore possible, that inhibition of NAMPT might sensitise osteosarcoma 
tumour cells to PARP inhibition. These effects were not prioritised for smaller scale 
revalidation and confirmation of effects, but are potential avenues for further investigation. 
RB1 has been reported to have a role DNA damage repair, predominantly by NHEJ 
(Huang, Cook & Mittnacht, 2015; Cook, Zoumpoulidou, Luczynski, et al., 2015), but also 
regulation of HR (Yang, Tian, Brown, et al., 2013) with RB1 deficiency associated with 
chromosomal instability (CIN) (Huang, Cook & Mittnacht, 2015; Manning, Longworth & 
Dyson, 2010). It is therefore possible to postulate that RB1 deficient tumour cells might 
have a dependency on NAMP and PARP inhibitors because of increased reliance on HR, 
but this dependency would be conditional on the level of deregulation of HR, and unless 
significant, unlikely to translate to the clinic.  
 
A targeted drug screen of the ATR inhibitor VX970 in combination with cisplatin, using the 
isogenic RB1 deficient U2OS model generated by CRISPR-Cas9 mutagenesis 
demonstrated a synergistic effect in both RB1 deficient clones compared to the parental 
RB1 wildtype tumour cell line. VX970 has already been demonstrated to increase 
sensitivity to DNA damaging agents such as cisplatin in lung xenograft models (Hall, 
Newsome, Wang, et al., 2014). In a trial to identify biomarkers of response to neo-
adjuvant cisplatin in patients with bladder cancer, genomic alterations of ATM, RB1 and 
FANCC predicted response and clinical benefit (Plimack, Dunbrack, Brennan, et al., 
2015). As discussed in section 7.1, RB1 deficient cells have defective NHEJ (Huang, 
Cook & Mittnacht, 2015), an increased reliance on the HR pathway, a greater reliance on 
the DNA damage G2 checkpoint, and functional ATR to delay mitotic entry (Nghiem, 
Park, Kim, et al., 2001; Eguchi, Takaki, Itadani, et al., 2007). Cell cycling could be 




investigated by FACS, presence of pan-nuclear γH2AX in response to replication fork 
stress, and presence of DSB by nuclear γH2AX foci (Ward & Chen, 2001), and both 
speed of replication forks, and also replication fork collapse, which is associated with 
ATR inhibition in combination with cisplatin (Reaper, Griffiths, Long, et al., 2011). Further 
investigation into the mechanism of ATR and cisplatin inhibition in RB1 deficient tumour 
cell lines, using some of the models described in this thesis is planned and supports the 
potential relevance of RB1 in OS (personal correspondence Sybille Mittnacht, UCL). 
Further investigation of the combined activity of VX970 and cisplatin could be performed 
using colony formation assays to establish the presence of a longer-term effect, and 
effect on cellular inhibition. In addition, exposure to the combination of VX970 and 
cisplatin in the panel of 18 osteosarcoma cell lines would provide a measure of efficacy 
given the heterogeneity of the panel. Prior to clinical translation, confirmation of efficacy 
using RB1 deficient and wildtype mouse models with treatment arms comprised of 
vehicle, VX970, cisplatin, and VX970 in combination with cisplatin, would need to be 
performed. If successful a clinical trial to compare the efficacy of standard MAP 
chemotherapy compared to addition of VX970. Given that cisplatin is one of the 
established therapeutic agents in OS, and VX970 is already in Phase I/II development in 
other tumour types, VX970 has the potential to be used as a biomarker driven chemo-
sensitiser in a molecularly defined population.  Although VX970 has reportedly been well 
tolerated, most frequently reported toxicities are of myelo-suppression, and given that 
cisplatin and doxorubicin in combination are already significantly myelo-suppressive, the 
practicalities of addition to the current schedule could be challenging, and possibly 
require a longer duration between cycles for count recovery or dose reduction of cisplatin. 
Any benefit would need to be balanced with possible deleterious effect on outcome due 
to reduction of dose-intensity and explored in a trial setting. 
 
In view of recent interest in exploring the role of PARP inhibitors in OS, a comprehensive 
analysis of OS tumour cell line sensitivity was undertaken. A minority of OS tumour cell 
lines were determined to be sensitive to PARP inhibition by talazoparib, rucaparib and 
olaparib. Comparison with tumour cell lines with BRCA1/2 deficiency such as SUM149 
and CAPAN1 demonstrated that LM7, the daughter of SAOS2 had acquired increased 
sensitivity to PARP inhibition, in both short and longer-term exposure. The panel of OS 
tumour cell lines demonstrated a spectrum of sensitivity to PARP inhibition. Determinants 
of sensitivity to PARP inhibition are known to primarily be genes encoding proteins which 
modulate HR (Lord & Ashworth, 2012). It was not surprising that the top candidate 




genetic dependencies seen from the siRNA screen with the addition of olaparib using 
LM7 and SAOS2 were involved in DNA damage repair. The most profound candidate 
genetic dependencies with greatest drug effect were BRCA1 and BRCA2. Silencing of 
BRAC1 and BRCA2 in both LM7 and SAOS2 caused loss of viability in the presence of 
olaparib but not DMSO. Other genetic dependencies involved in DNA damage repair 
were isolated in LM7. PALB2 (partner and localizer of BRCA2) is involved in stability and 
nuclear localization, and required for some functions of BRCA2 in double-strand break 
repair and homologous recombination (Rahman, Seal, Thompson, et al., 2007). MUTYH 
(MutY DNA Glycosylase) is a DNA glycosylase involved in oxidative DNA damage repair, 
and functions to remove inappropriately paired adenine bases from the DNA backbone 
(Torrezan, da Silva, Santos, et al., 2013). XRCC3 is RAD51 paralog that functions as part 
of a PALB2-scaffolded HR complex containing BRCA2 and RAD51, involved in HR repair 
of DNA DSBs (Brenneman, Weiss, Nickoloff, et al., 2000). Split Hand/Foot Malformation 
(Ectrodactyly) Type 1 (SHFM1) is a component of the Three Prime Repair Exonuclease 2 
(TREX-2) complex which binds and stabilizes BRCA2 (Huen & Chen, 2008). Tumour 
cells depleted of SHFM1 do not form RAD51 foci in response to DNA damage (Huen & 
Chen, 2008). Fanconi Anaemia Complementation Group M (FANCM) is one the 19 
proteins which comprise the Fanconi anaemia (FA) pathway which repair DNA inter-
strand cross-links (ICLs) (Ceccaldi, Sarangi & D'Andrea, 2016). Essential Meiotic 
Structure-Specific Endonuclease Subunit 2 (EME2) functions as a DNA structure-specific 
endonuclease in DNA repair (Ciccia, Ling, Coulthard, et al., 2007). Although, it might be 
expected that any tumour cell line in the presence of PARP inhibition would exhibit 
genetic dependencies to these genes involved in DNA damage repair, different genetic 
dependencies were observed between LM7 and SAOS2, which suggests some residual 
reliance on HR by LM7. Although the RAD51 assay demonstrated the presence of an HR 
defect in LM7, this screen in the presence of olaparib suggested that HR has not been 
completely abrogated, since silencing of BRCA1 and BRCA2 still leads to a decrease in 
viability in the presence of PARP inhibition. In addition, silencing of SHFM1 (DDS), 
required for DNA damage induced RAD51 foci formation and PALB2, the partner and 
localiser of BRCA2, both had the same effect. Small-scale revalidation of these candidate 
genetic dependencies by deconvolution could be performed. Silencing of proteins 
involved in the HR response such as XRCC3 and RAD52, by targeted siRNA in U2OS 
tumour cells induced a HR defect, PARP hyper-activation and increased sensitivity to 
PARP inhibitors (Michels, Vitale, Saparbaev, et al., 2014). Therefore, further experiments 
to determine if exogenous expression of the genetic dependencies observed in LM7 




rescue sensitivity to PARP inhibition, might help both with further understanding of the 
biology and could also be used as a biomarker for sensitivity to PARP inhibition. 
Tractable genetic dependencies of both LM7 and SAOS2, for example RAD51 and FANC 
proteins, in the presence of olaparib could also be used to explore possible combination 
therapies with PARP inhibition, although these drugs are still in pre-clinical investigation.  
 
Deficiency of formation of RAD51 foci is known to be a mechanistic determinant of 
PARP-inhibitor sensitivity (Lord & Ashworth, 2012). At present, determination of RAD51 
foci formation is an ex vivo assay that requires either treatment of in vitro cells with 
ionising radiation, or the patient to have had radiotherapy prior to tumour biopsy. 
Therefore, using RAD51 foci formation to determine potential sensitivity to PARP 
inhibition in a clinical trial setting is problematic. However, new techniques that do not 
have these requirements are in development and could provide a useful biomarker for 
patient selection and inclusion in clinical trials of PARP inhibitors.  
 
Comparison of exome sequencing and mRNA transcriptome data of LM7 and SAOS2 
was performed to identify any molecular differences between the two cells that could 
explain the sensitivity of LM7 to PARP inhibition. A number of molecular differences were 
observed, focussed on DNA damage repair such as missense mutations in LM7 of HUS1, 
INIP, and EYA4, and copy number changes in SLX1A, PARPBP and CHEK2; these could 
be investigated further to identify if these changes can explain the increased sensitivity to 
PARP by LM7 and therefore, if silencing could impart PARP sensitivity on SAOS2. 
Further confirmation could be investigated by a rescue experiment to determine if over 
expression of these genes impart PARP resistance on LM7. At a protein level, no 
significant changes in a subset (BRCA2, CHK1, pCHK1, ATR and ATM) of the known 
sensitisers to PARP inhibition were seen, but further work to clarify all sensitisers such as 
RAD51, ATRX, SHFM1, RPA1, NBN, miR-182, CDK1, SWI5–SFR1, USP1/ UAF1 and 
the Fanconi anaemia proteins could be performed. Proteomic profiling of LM7 and 
SAOS2 was performed and identified 11 proteins with the greatest differential abundance 
between the two tumour lines. Of these proteins, SMARCA1 involved in the DNA damage 
response and HIST2H2AB, a pseudo-gene of the histone family of proteins primarily 
responsible for nucleosome structure of the chromosomal fibre, and FANCD2 that co-
localises with BRCA1 and directly involved in HR, were identified as having lower 
abundance in LM7 than SAOS2. These findings merit further investigation, to identify if 
silencing the genes encoding these proteins confers an increased sensitivity to PARP 




inhibition on SAOS2, and if over expression using cDNA in a plasmid, rescues the PARP 
sensitivity seen with LM7. Potential differences of molecular or gene expression or 
proteomic abundance could lead to a biomarker for PARP sensitivity ensuring an 
enriched population for subsequent trials. At present, only mutations of BRCA1/2 have 
been established as robust markers of PARP sensitivity (Brown, Kaye & Yap, 2016), or 
the use of a surrogate marker such as deficiency of RAD51 foci, which using the current 
methodology has considerable limitations. Increased expression of PARPBP, observed in 
LM7, and reported in pancreatic cancers, leads to PARP hyper-activation which may 
reflect DNA damage repair, and has already been postulated as a potential biomarker of 
PARP sensitivity (Michels, Vitale, Saparbaev, et al., 2014). Further understanding of this 
relationship is required by investigation of PARPBP expression status and PARP 
sensitivity in tumour cell lines, or primary tumour models, with potential utility as an 
attractive biomarker. The LM7 and SAOS2 models could be used to determine the 
comparative status of other postulated biomarkers of PARP inhibitor sensitivity such 
increased 53BP1, PAR, EMSY. HER2, NF-kB and AURKA, or decreased expression of 
POLB, MRE11, XRCC1, CDK5, PLK3 and MAPK12 (Michels, Vitale, Saparbaev, et al., 
2014). 
 
Clarification of the protein expression status of phosphorylated CHK2 post exposure to 
olaparib, and also BRCA1 could be sought by western blotting. Expression of other 
molecular features characteristic of BRCAness such as BAP1, BARD1, and FANCD2 
could be investigated (Engert, Kovac, Baumhoer, et al., 2016) along with other known 
determinants of sensitivity to PARP inhibition for example RAD51, ATRX, SHFM1, RPA1, 
NBN, miR-182, CDK1, SWI5–SFR1, USP1/ UAF1 and the Fanconi anaemia proteins 
(Lord & Ashworth, 2012). Homozygous deletion of ATRX was observed in the OS tumour 
cell lines NOS-1 and U2OS that both exhibited moderate sensitivy to PARP inhibition. 
Whole genome sequencing of 34 OS tumour samples identified structural variants and 
point mutations of ATRX in 10 tumours (29%) (Chen, Bahrami, Pappo, et al., 2014). 
ATRX mutations were observed in 11/31 (35%) OS tumour samples which were exome 
sequenced (Kovac, Blattmann, Ribi, et al., 2015). Point mutations and structural variants 
of ATRX were also identified by whole genome and exome sequencing in another 
sequencing study of 112 OS tumour samples (Behjati, Tarpey, Haase, et al., 2017). 
Determination of the potential utility of ATRX as a biomarker would require further 
correlation of precise mutation status with PARP sensitivity in a wider tumour panel.  
 




The molecular phenotype of ‘BRCAness’ (Turner, Tutt & Ashworth, 2004) was described 
in section 1.1.4.1 of Chapter 1. As discussed above, a recent publication revealed a 
significant proportion of OS to potentially have a ‘BRCAness’ phenotype (Kovac, 
Blattmann, Ribi, et al., 2015). There has been much recent debate as to the applicability 
of this phenotype in OS. On the basis of Kovac et al.’s findings investigation of the 
potential therapeutic opportunity in OS was undertaken using four OS tumour cell lines 
(MG63, ZK58, SAOS2, and HOSMMNG) which they reported to have disruptive gains in 
PTEN and FANCD2 and / or losses of ATM, BAP1, BARD1, FANCA or CHK2 and 
therefore functionally analogous to BRCA mutations, were observed to be susceptible to 
PARP inhibition by talazoparib (BMN-673) (Engert, Kovac, Baumhoer, et al., 2016). 
However, very large doses of talazoparib (0.01-100µM), were needed to demonstrate 
sensitivity to the OS cell lines (Engert, Kovac, Baumhoer, et al., 2016), which are unlikely 
to be clinically relevant, with no comparison of context by use of BRCA 1/2 deficient cell 
lines for scale of sensitivity. Inspection of the screen data after short-term exposure to 
talazoparib (range 0.5-1000nM) did not demonstrate a profound sensitivity to PARP 
inhibition in the OS tumour cell line panel. In addition, data from the Wellcome Trust 
Sanger Institute demonstrated that of the whole-genome sequencing performed on 37 
osteosarcoma tumour samples, only one, a radiation-induced OS, harboured evidence of 
HR deficiency using HRdetect methodology (mutation signature three) (Behjati, Tarpey, 
Haase, et al., 2017; Davies, Glodzik, Morganella, et al., 2017). From this series, nine 
different mutational signatures were represented, the most prevalent were signatures five 
(age-related mutational process), and eight (unknown origin) (Behjati, Tarpey, Haase, et 
al., 2017). It was determined from that analysis that detection of the BRCAness molecular 
phenotype should only be performed on whole genome sequencing, not the whole-exome 
sequencing performed by Kovac et al. (Kovac, Blattmann, Ribi, et al., 2015).  
 
It is therefore likely that the degree of BRCAness of OS has been overstated by Kovac et 
al. due to differences in methodology (Kovac, Blattmann, Ribi, et al., 2015). Nevertheless, 
exploiting the BRCAness phenotype in a subset of OS tumours could be therapeutically 
attractive. LM7 demonstrated differential sensitivity to PARP inhibition in both short and 
longer-term multi-dosing experiments. In addition, a marked deficiency in RAD51 foci 
formation after ionising radiation compared to SAOS2 was observed, suggestive of an 
HR defect that could explain the increased sensitivity seen with this tumour cell line. To 
further investigate a BRCAness phenotype in OS, LM7 the “daughter” of SAOS2, has the 




potential to be an attractive model for investigation of mechanisms and potential 
biomarkers for patient selection for OS and more widely.  
 
A number of PARP inhibitors are licenced for the treatment of cancer (Brown, Kaye & 
Yap, 2016), for example rucaparib and niraparib have been granted approval by the 
American Food and Drug Administration (FDA) for patients with BRCA mutant ovarian 
cancer, there are a number of Phase II Clinical trials of talazoparib, and olaparib has 
been licenced for use in BRCA mutant ovarian cancer by the National Institute of Clinical 
Excellence (NICE). These agents could be easily repositioned for use in OS, and their 
oral bioavailability with relatively fewer toxicity effects than traditional chemotherapy 
agents makes them attractive. Finding the appropriate subset of patients with OS that 
could benefit from these agents, by use of a biomarker, is therefore paramount for the 
translation of these pre-clinical findings into the clinic. Confirmation of an in vivo 
differential sensitivity to PARP inhibition using orthotopic mouse models of LM7 and 
SAOS2 that are already available (Jia, Worth & Kleinerman, 1999) is required. 
Considering the role of PARP inhibition is OS is challenging, not least due to the need for 
a biomarker for appropriate selection, but also determining the best combination therapy, 
and timing of PARP inhibitor treatment. Standard MAP chemotherapy is particularly toxic, 
and it is unlikely that addition of PARP therapy alongside MAP would be acceptable to 
the patient population, and delays to the current treatment schedule caused by any 
increase in toxicity profile could worsen outcomes. Consideration of PARP inhibition as a 
maintenance therapy after MAP chemotherapy therefore appears most plausible, similar 
to the approval of olaparib maintenance for ovarian carcinoma (Ledermann, Harter, 
Gourley, et al., 2016), but PARP inhibitor monotherapy is unlikely to be effective in OS. 
For the addition of PARP inhibitor combination maintenance therapy to be successful, a 
balance must be struck between providing a sufficient survival extension with acceptable 
drug-related toxicity profile, to warrant use in an already heavily treated patient who 
would otherwise have an asymptomatic, treatment-free interval before progression 
(Graybill, Pothuri, Chase, et al., 2017). One option would therefore be to perform a 
double-blinded clinical trial with randomisation at the end of MAP to PARP inhibitor 
combination therapy or placebo. In the absence of an appropriate biomarker to enrich the 
study population, parallel molecular characterisation of tumour samples could be 
undertaken in an attempt to determine a clinical biomarker.  
 




An important consideration is the noticeable challenge of translating a drug from 
promising pre-clinical studies into the clinic. One example is the discovery that Ewing 
sarcoma cell lines that harboured the EWS-FLI1 rearrangement were particularly 
sensitive to single agent PARP inhibition by olaparib and rucaparib (Garnett, Edelman, 
Heidorn, et al., 2012). Given strong pre-clinical data with a mechanistically plausible 
explanation, there was great enthusiasm in the community, which resulted in a Phase II 
clinical trial of olaparib in patients with refractory Ewing sarcoma following failure of 
chemotherapy (Choy, Butrynski, Harmon, et al., 2014). However, it was closed at the 
interim analysis for lack of activity (Choy, Butrynski, Harmon, et al., 2014). Unfortunately 
the profound responses seen both in vitro and in vivo were not replicated by this study. 
There are a number of possible explanations for this; (i) confirmation of EWS-FLI1 
rearrangement was not confirmed in patients enrolled in the study; (ii) the preclinical 
tumour cell line models might not be representative of the disease, for example might be 
chemotherapy naïve compared to patients with chemo-refractory disease; (iii) unknown 
secondary genomic or epigenomic alterations or tumour environment interactions leading 
to PARP inhibitor resistance (Choy, Butrynski, Harmon, et al., 2014). There is however, 
also strong preclinical evidence of synergy of PARP inhibition given in combination with 
alkylating agents and topoisomerase inhibitors such as temozolomide or irinotecan which 
might prove more successful, and a phase I clinical trial to determine the safety of the 
PARP inhibitor niraparib in combination with temozolomide or irinotecan in patients with 
advanced Ewing sarcoma is currently in progress (NCT02044120). This example 
highlights the many challenges of drug translation into the clinic, confirming the need for 
reproducible models that are representative of the disease, and provides greater 
understanding of why so few agents are successful in the journey from bench to bedside.  
 
This chapter has described a number of potential drugs for further validation for which are 
selective for RB1 deficient OS tumour cells using the OS isogenic models. The drug 
screens presented are limited by both their potential applicability depending on the 
models used, and also by potential false positives and negatives via off-target effects and 
practicalities such as human error, reinforcing the need for robust revalidation. Further 
experiments to understand if these observations are confirmed firstly in the wider panel of 
OS tumour cell lines, and then in vivo, needs to be established prior to any further clinical 
translation. The challenges of identification of therapeutically relevant targets given the 
heterogeneity of the tumour, and difficulty of establishing a representative isogenic model 
of RB1 deficiency in OS have been discussed; the synergy observed between VX970 and 




cisplatin may be confined to the molecular background of U2OS, and will need further 
investigation in the tumour cell line to determine potential wider applicability.  
 
The complexity of drug screens and challenge of validation in OS was confirmed in this 
chapter, however possible targets were identified which have therapeutic potential. 
However, what appears statistically significant in a drug screen may not necessarily be 
clinically relevant. Comparison of activity with appropriate models to determine context is 
very important, and thus highlights the investigation of PARP sensitivity in OS, where 
comparison was possible with models that are known to be reflective of sensitive disease 
in clinic. The most promising targets from this Chapter are FGFR1 inhibition in OS 
patients with FGFR1 polysomy in addition to amplification, the use of CDKN2A or MTAP 
as a potential biomarker for methotrexate sensitivity, VX9070 in combination with cisplatin 
in RB1 deficient tumours and PARP combination maintenance therapy in OS. The recent 
establishment of patient derived xenograph (PDX) models in osteosarcoma which more 
closely resemble the human disease on a morphological, histological and genomic level 
(Blattmann, Thiemann, Stenzinger, et al., 2015) than previously used orthotopic models 
are well placed to investigate further the potential of PARP combinations. These agents 
are well positioned for clinical translation, methotrexate is already included in standard 
therapy, PARP inhibitors are licenced for use in other malignancies, and VX970 is in early 
Phase I/II trials. Specific inhibition of FGFR1 might prove more challenging, after one of 
the more promising agents (AZD4547) was withdrawn due to unwanted side effects. The 
data presented here supports the hypothesis that the multi-kinase inhibitor lenvatinib 
might be less effective in this population than a specific inhibitor of FGFR1. A more 
specific FGFR1 inhibitor has the potential for a better side effect profile, without 
hypertension and proteinuria associated with VEGFR blockade (Lewin & Siu, 2015). JNJ-
42756493 an oral, selective pan-FGFR inhibitor that is reported to exhibit minimal activity 
against other kinases has completed Phase I trial in advanced solid tumours (Tabernero, 
Bahleda, Dienstmann, et al., 2015), and due to start Phase II trial in paediatric patients 
with advanced solid malignancies (NCT03210714) and could be repositioned in OS.  




8 General Discussion 
8.1 RATIONALE FOR PROJECT 
Since the introduction of MAP (methotrexate, doxorubicin and cisplatin) therapy, despite 
international collaboration, there has been little improvement in survival over the past two 
decades (Kempf-Bielack, Bielack, Jürgens, et al., 2005; Janeway, Barkauskas, Krailo, et 
al., 2012; Mirabello, Troisi & Savage, 2009) with five year survival remaining in the order 
of 70% for young patients with localised disease. For those with metastatic disease at 
diagnosis, outcome is poor with only 20-30% surviving for five years (Koboldt, Fulton, 
McLellan, et al., 2012), and remains even more dismal for those with recurrence (Luetke, 
Meyers, Lewis, et al., 2014). Therefore, identification of new therapeutic targets is critical. 
 
8.2 SUMMARY OF WORK PRESENTED WITHIN THIS THESIS 
8.2.1 Characterisation of osteosarcoma tumour cell line panel 
Firstly, described in this thesis are a panel of OS tumour cell lines. Although a number of 
these OS tumour cell lines had already been genetically characterised by EuroBoNeT, a 
European Network of Excellence on bone tumours (http://www.eurobonet.eu) (Ottaviano, 
Schaefer, Gajewski, et al., 2010) (Mohseny, Machado, Cai, et al., 2011) further genetic 
characterisation of the remainder of the panel was undertaken at the Wellcome Trust 
Sanger Institute and Tumour Profiling Unit of the Institute of Cancer Research (ICR). 
Using the whole exome sequencing for the panel of 18 OS tumour cell lines, I was able to 
confirm that although a considerable degree of heterogeneity was observed, the 
spectrum of recurrent somatic mutations identified was reflective of those seen in recent 
sequencing of the clinical samples, and the panel was therefore a suitable model for 
further investigation of genetic dependency profiling of OS.  
 
8.2.2 Generation of isogenic RB1 deficient osteosarcoma tumour cell line models 
To date, no stable isogenic model of RB1 deficiency in OS had been described. Using 
CRISPR-Cas9 mutagenesis I was able to generate two stable models of RB1 deficiency 
using the OS tumour cell line U2OS. These models were extensively characterised by 
transcriptome profiling, whole exome sequencing and proteomics and were robustly 
determined to suitable models to investigate the phenotype of RB1 deficiency in OS. 




They have the potential to be used to create an isogenic orthotopic mouse model of RB1 
deficiency that could be used for revalidation. The advantages and limitations of isogenic 
and non-isogenic models have been discussed, and provided the rationale for use of both 
systems in this thesis as a complementary approach.  
 
8.2.3 Identification of candidate genetic dependencies in osteosarcoma 
This thesis described the production of the first kinome-wide genetic dependency maps of 
multiple OS tumour cell line models on this scale. This data-set was made a publicly 
available resource for the identification of OS genetic dependencies by the inclusion in 
Cancer GD www.cancergd.org which provides a searchable collection of genetic 
vulnerabilities associated with the alteration of driver genes in cancer cell lines as part of 
a collaboration between the Institute of Cancer Research, Systems Biology Ireland, 
University College Dublin and the Health Research Board. Comparison of this data set 
with the non-osteosarcoma tumour cell line panel, demonstrated a reliance on the 
skeletal morphogenesis pathway in osteosarcoma (Campbell, Ryan, Brough, et al., 
2016). This was a particularly interesting finding given, the unbiased nature of the 
screening, and that OS derives from primitive bone-forming mesenchymal stem cells 
(MSC) (Gorlick, 2009). Further interrogation of this data set and integration with additional 
molecular characterisation such as transcriptome profiling for the entire OS tumour cell 
line panel could provide a powerful basis for future pre-clinical and clinical investigation. 
 
8.2.4 DYRK1A and RB1 synthetic lethality 
In Chapter 5 I described the genetic vulnerabilities associated with the recurrent driver 
mutations of RB1 and CDKN2A. Results from this thesis have established DYRK1A as a 
specific vulnerability for RB1 deficient OS tumour cell lines, an observation also seen in 
two independent data sets comprised of multiple histologies (Cowley, Weir, Vazquez, et 
al., 2014; Stockwell, Li, Aherne, et al., 2012). Interpretation of the mechanism of synthetic 
lethality between DYRK1A and RB1, was complicated by the many roles of DYRK1A and 
unknown consequences of an deficient RB1 context. Of greatest clinical relevance was 
the synergistic effect seen between harmine and cisplatin, however, further work is 
required to understand the mechanism. The lack of potency of the available DYRK1A 
inhibitors such as harmine was also challenging. A new small molecule inhibitor, 
GNF4877, with lower IC50 than harmine and potential for fewer/different off-target effects 




(Shen, Taylor, Jin, et al., 2015) has the potential to overcome some of these challenges. 
The work presented in this thesis established that the selectivity of silencing DYRK1A in 
RB1 deficient OS tumour cells is due to an increase in apoptosis, but clarification is 
needed to confirm that this observation is independent of activation of the Fas/FasL 
pathway by off-target effects of harmine.   
 
8.2.5 Identification of tractable targets in osteosarcoma  
In Chapter 6 I described the results from a high-throughput cell-based drug screen 
performed in a panel of OS tumour cell lines. These agents have either been licenced for 
clinical use in cancer or are in early phase clinical trials and were selected because of 
their potential for rapid clinical translation. The heterogeneity of molecular landscape of 
OS makes finding new molecular targets challenging, this was highlighted by only a 
minority of tumour cell lines demonstrating sensitivity to the majority of drugs. Given that 
osteosarcoma is not a common tumour, further subdivision of the patient population into a 
number of minority subsets, makes biomarker patient selection a priority and necessitates 
international collaboration for trial recruitment.  
 
Further to demonstrating a reliance on genes involved in ‘skeletal system morphogenesis’ 
including FGFR1, two FGFR inhibitors AZD4547 and PD173074, were found to be 
selective for osteosarcoma models independent of amplification status (Campbell, Ryan, 
Brough, et al., 2016). In addition, both FGFR1 amplification and polysomy in this panel of 
OS tumour cell lines were shown to be associated with significantly greater sensitivity to 
the FGFR1 inhibitors than cell lines unknown or negative for amplification. Since nearly 
10% of OS tumour samples from 288 patients exhibited FGFR1 amplification, while 
approximately 50% of tumour samples were observed to have polysomy (Fernanda 
Amary, Ye, Berisha, et al., 2014), these findings provide further rationale for investigation 
of FGFR inhibition as a therapy in OS and the use of FGFR1 amplification and/or 
polysomy as molecular biomarkers to target specific patient groups, which are predicated 
to include a significant proportion of patients. 
 
Another of the genes identified in ‘skeletal system morphogenesis’ was Platelet derived 
growth factor receptor alpha (PDGFRA). Olaratumab a novel antibody targeting 
PDGFRA, has recently been seen to improve overall survival for patients with metastatic 
soft tissue sarcoma in combination with doxorubicin compared to doxorubicin alone (Tap, 




Jones, Van Tine, et al., 2016) and olaratumab is now licenced for this indication. 
Olaratumab demonstrates anti-tumour activity in models of paediatric sarcoma including 
osteosarcoma (May, Loizos, Novosiadly, et al., 2015). However, in a phase II study, the 
multi-kinase inhibitor imatinib, which has an IC50 of 100nM against PDGFR, did not 
exhibit sufficient activity in soft tissue sarcoma to warrant further investigation (Chugh, 
Wathen, Maki, et al., 2009) and at present no suitable biomarkers for patient selection 
have been identified. Therefore, caution as to the clinical applicability of PDGFR inhibition 
in OS in the absence of a biomarker for patient selection must be noted.  
 
Additionally, using the isogenic RB1 deficient U2OS model, the ATR inhibitor VX970 was 
observed to potentiate the therapeutic effect of cisplatin in both RB1 deficient clones 
compared to the parental RB1 wildtype tumour cell line. Further validation of this effect is 
required in both longer-term assays in a wider tumour cell line panel, as well as studies to 
understand the mechanism, but given that cisplatin is one of the established therapeutic 
agents in OS, VX970 has the potential to be used as a biomarker driven chemo-
sensitising agent. This will form part of a recently awarded Children with Cancer Grant, 
exploring RB1 deficiency as an actionable target in paediatric bone and soft tissue 
sarcoma, led by Sybille Mittnacht at the UCL Cancer Institute.  
 
MTAP and CDKN2A were identified as potential biomarkers for sensitivity to 
methotrexate. Further validation using tumour samples is now required and there are now 
a growing number of biobanks containing OS tumour samples such as the SARC 
Biospecimen Bank and at the Royal National Orthopaedic Hospital, where clinical 
information on chemotherapeutics and outcome is also available. Using these samples 
CDKN2A and MTAP status by immunohistochemistry could be retrospectively assessed, 
and correlated with response to therapy. However, this is confounded by likely co-
treatment with doxorubicin and cisplatin in addition to methotrexate. This evidence could 
provide rationale for a clinical biomarker driven trial to establish if patients with defective 
MTAP or CDKN2A could achieve the same outcome with dose-reduction of methotrexate 
or preferentially identify patients for whom methotrexate is not useful. However, both of 
these options are limited by either the need for a costly phase III trial to identify if dose 
reduction of methotrexate, or a different agent in CDKN2A/MTAP wildtype patients could 
achieve the same or better outcome than current standard therapy. It would be difficult to 
envisage dose reduction of methotrexate, since even in patients with localised, resectable 
disease and a ‘good’ histological response (>90% necrosis) to neo-adjuvant 




chemotherapy, event free survival is only 70% whilst those with a ‘poor’ response this lies 
below 50% (Bielack, 2002). Given the toxicity of high-dose methotrexate at the standard 
doses, combined with that of doxorubicin and cisplatin, it would be difficult to envisage 
increasing the dose of methotrexate in those patients who were CDKN2A or MTAP 
wildtype. Possible benefit would be most likely if an additional agent could be used in 
combination with or instead of methotrexate in this potential cohort. 
 
8.2.6 ‘BRCAness’ in osteosarcoma 
After the drug screen was performed in the panel of OS tumour cell lines, two 
manuscripts were published which suggested that the majority of OS tumours harbour a 
BRCAness molecular phenotype due to HR deficiency, with sensitivity to PARP inhibition 
identified in a subset of OS tumour cell lines (Kovac, Blattmann, Ribi, et al., 2015; Engert, 
Kovac, Baumhoer, et al., 2016). On the basis of this evidence, a PARP inhibitor trial is 
currently being considered in patients with OS. However, using the HRdetect 
methodology (Davies, Glodzik, Morganella, et al., 2017) to assess the mutational 
signatures of whole genome sequencing data from 37 OS tumour samples at the WTSI, 
only one, which was radiation induced, has shown evidence of HR deficiency (Behjati, 
Tarpey, Haase, et al., 2017). From this series, nine different mutational signatures were 
represented, the most prevalent were signatures five (age-related mutational process), 
and eight (unknown origin) (Behjati, Tarpey, Haase, et al., 2017). Kovac et al. classified 
the molecular phenotype using whole-exome sequencing not whole-genome, and thus 
potentially over stated any effect observed. In addition, very large doses of talazoparib 
(0.01-100µM), which are unlikely to be clinically relevant, were needed to demonstrate 
sensitivity to the OS cell lines (Engert, Kovac, Baumhoer, et al., 2016), with no 
comparison of context by use of BRCA 1/2 deficient cell lines for scale of sensitivity. In 
Chapter 6, short-term exposure to talazoparib did not demonstrate a profound sensitivity 
to PARP inhibition in the OS tumour cell line panel. Instead, the OS tumour cell lines 
demonstrated a spectrum of sensitivity to the PARP inhibitors talazoparib, rucaparib, and 
olaparib, with only a minority harbouring sensitivity comparable to other tumour cell lines 
with a ‘BRCAness’ phenotype. 
 
Exploiting the BRCAness phenotype in a subset of OS tumours could be therapeutically 
attractive since inhibitors such as olaparib are already approved for the treatment of 
BRCA mutant ovarian cancer by NICE, rucaparib is FDA approved for BRCA mutant 




ovarian cancer, and talazoparib is in Phase II clinical trial. These agents could be easily 
repositioned for use in OS, and their oral bioavailability with relatively fewer toxicity 
effects than traditional chemotherapy agents makes them attractive. However, from the 
data presented in this thesis, demonstrating that only a minority of OS tumour cell lines 
harbour sensitivity to PARP inhibition at clinically relevant doses, and data from the WTSI 
described above (Behjati, Tarpey, Haase, et al., 2017), it is likely that the degree of 
BRCAness of OS has been overstated by Kovac et al. and Engert et al. (Kovac, 
Blattmann, Ribi, et al., 2015; Engert, Kovac, Baumhoer, et al., 2016). Therefore, single 
agent PARP inhibition is unlikely to have a significant impact in the therapy of OS, but 
there could be potential for biomarker driven PARP inhibitor combination studies in a 
subset of patients with OS. Although the majority of OS tumour cell lines do not exhibit 
the profound PARP inhibitor sensitivity associated with BRCAness, one OS tumour cell 
line, LM7, clearly demonstrates this phenotype. The absence of RAD51 foci in LM7 
identifies this as a suitable, mechanistically relevant, tool for studying BRCAness in this 
cancer histology. SMARCA1, HIST2H2AB, or FANCD2, were found to have the greatest 
differential proteomic abundance between LM7 and parental SAOS2 tumour cell lines. 
Further comparison of molecular features in LM7 versus the parental SAOS2 cell line 
might inform the identification of molecular drivers of PARP inhibitor sensitivity in LM7. 
Therefore, there are many unanswered questions regarding the degree of BRCAness 
seen in OS. Further investigation of the cell lines using a RAD51 assay to determine if 
any OS tumour cell lines in addition to LM7 harbour an HR defect would be interesting 
and informative. Given the sensitivity to PARP inhibition seen in the small molecule 
screen performed in Chapter 6, it is likely that only a small minority possess such a 
defect. Determining the BRCAness phenotype of a tumour sample requires either the 
application of HRdetect (Davies, Glodzik, Morganella, et al., 2017) on whole-genome 
sequencing or the use of an ex vivo RAD51 assay on sample material that has been 
exposed to DNA damage in vivo. New technology that could circumvent these challenges 
and make rapid assessment of an HR defect and thus potential sensitivity to PARP 
inhibition would improve real-time patient selection for clinical trials of PARP inhibitors in 
tumours such as OS, where no simple genetic marker of sensitivity as been isolated, 
unlike BRCA1/2 deficiency in breast and ovarian malignancies. 
 
 




8.3 OVERALL CONTEXT OF THIS STUDY 
8.3.1 Clinical advances in immunotherapy in osteosarcoma 
Recent advances in molecular profiling over the last decade have lead to increasing 
availability of large-scale genetic profiling, driving towards truly personalised medicine. 
Clinical trials are increasingly looking at the molecular as well as clinical phenotypes of 
disease, and patient selection is increasingly biomarker driven. A large number of 
molecularly targeted cancer drugs have now gained regulatory approval. However, 
despite considerable unmet need in OS, and increased understanding of the molecular 
landscape of OS, this is only just beginning to translate into specific therapies. During this 
thesis, immunotherapies emerged as the latest trend in cancer therapies, and appear 
therapeutically attractive with fewer side effects than conventional cytotoxic agents. 
These agents stimulate the innate and adaptive immune system to inhibit the tumour 
tolerance usually seen. A number of agents are currently in early Phase trials including 
aerosolised proleukin (Interleukin 2) (NCT01590069), avelumab (anti-Programmed cell 
death ligand 1 (PD-L1) antibody) (NCT03006848), pembrolizumab (anti-PD-L1 antibody) 
(NCT03013127) and anti-ganglioside GD2 antibody (NCT00743496). Aerosol IL-2 has 
been observed to stimulate local Natural Killer (NK) cell proliferation and increase NK 
numbers in the lungs of mice, inducing metastatic regression and increased overall 
survival (Guma, Lee, Ling, et al., 2014). Cytotoxic T lymphocytes (CTLs) express PD1, a 
member of the Tumour Necrosis Factor (TNF) receptor family. Inhibition of PD1 by 
tumours leads to decreased CTL proliferation, cytokine production and cytotoxicity, and 
associated tumour progression in mice (Zitvogel & Kroemer, 2012). Both the CTLs which 
infiltrate OS and the OS tumour cells themselves express PD-L1, while inhibition of PD1-
PD-L1 interactions improves outcome, and suppression of PD1 by mono-clonal antibody 
suppresses OS growth in mice models (Kansara, Teng, Smyth, et al., 2014). The anti-
PD-L1 antibody pembrolizumab has already been approved by NICE in patients with 
advanced non-small cell lung cancer. The addition of PEG-interferon 2beta to standard 
MAP chemotherapy has not shown any additional benefit (Bielack, Smeland, Whelan, et 
al., 2015). Many of the signalling pathways with key roles in the immune system such as 
TNF Receptor Superfamily Member 11a (RANK-RANKL) signalling and the cytokines 
Interleukin 1 (IL1), IL6, IL17 and transforming growth factor-β (TGFβ), also have an 
overlapping role in osteoclastogeneis (Kansara, Teng, Smyth, et al., 2014) the equilibrium 
between bone resorption by osteoclasts and bone formation by osteoblasts (Yavropoulou 
& Yovos, 2008). This overlap has been termed osteo-immunology (Kansara, Teng, 




Smyth, et al., 2014). Altered bone phenotypes have been seen in mice which are 
deficient for some of these genes such as interferon (α and β) receptor 1 (Ifnar1), nuclear 
factor-κB (Nfkb) and interferon-γ (Ifng) (Kansara, Teng, Smyth, et al., 2014). Interestingly 
significantly increased survival rates have been observed in those patients with OS who 
develop postoperative infections (84.5% compared to 62.3%) (Jeys, Grimer, Carter, et al., 
2007). At present MTP-PE is the only immunotherapy in OS that is approved by the 
National Institute of Clinical Excellence (NICE) in the treatment of OS, although the true 
value remains unevaluated. Understanding the potential for targeting osteoimmunity is in 
its infancy and the true value remains to be evaluated.  
 
8.3.2 Clinical advances in FGFR inhibition in osteosarcoma 
During this thesis a number of monoclonal antibodies and specific tyrosine kinase 
inhibitors that target the FGFR receptor family have translated into Phase I/II clinical 
trials. Unfortunately, one trial of the inhibitor AZD4547 that aimed to explore efficacy in 
FGFR amplified osteosarcoma (NCT01795768) was suspended due to side effects. The 
FGFR1-4 inhibitor PRN1371 is currently in Phase I trial of patients with advanced solid 
tumours, and an expansion cohort of 20 patients, enriched for solid tumours with 
fibroblast FGFR1-4 genetic alterations (NCT02608125). In addition, other multi-targeted 
kinase inhibitors such as lenvatinib are now in phase II investigation as single agent 
treatment in OS, and in Phase Ib study in combination with ifosfamide and etoposide in 
osteosarcoma (NCT02432274). Although marketed as a VEGF inhibitor, lenvatinib also 
targets FGFR1 with an IC50 of 46nmol/L (Cabanillas & Habra, 2016). The FGFR1-3 
inhibitor INCB054828 is currently in Phase I trial in patients with advanced solid tumours, 
with preliminary data confirming a tolerable safety profile, and signs of efficacy in bladder 
tumours with FGFR genetic alterations (NCT02872714) (personal correspondence with 
Mark Linch). These inhibitors have the potential to be the first targeted kinase inhibitor in 
osteosarcoma, but further research is needed to identify markers of greatest efficacy and 
if there is potential for a durable response. These findings from this thesis provide further 
rationale for investigation of FGFR inhibition as a therapy in OS and the use of both 
FGFR1 amplification and polysomy as molecular biomarkers to target specific patient 
groups. It would be valuable to measure FGFR status in patients on current clinical trials 
to determine whether there is any correlation with response to the therapy. A study of OS 
tumour samples from 288 patients, identified FGFR1 amplification in nearly 10%, and 




polysomy in 50% of tumour samples which suggest that a significant cohort of patients 
might benefit from FGFR1 inhibition (Fernanda Amary, Ye, Berisha, et al., 2014).   
 
 
8.4 LIMITATIONS OF STUDY AND ALTERNATIVE APPROACHES 
8.4.1 Tumour cell line panel 
While use of tumour cell lines grown in two-dimensional culture can provide a pragmatic 
and utilitarian approach, all tumour cell line models have limitations, given that they are 
grown in monolayer cultures on plastic and lack interaction with the surrounding tumour 
microenvironments seen in vivo. Growth of osteosarcoma spheroids in three-dimensional 
culture using murine tumour cell lines (Akeda, Nishimura, Satonaka, et al., 2009) may 
address some of these caveats. However, a recent study investigating genetic 
dependencies and drug sensitivity in breast cancer tumour cell line cultures demonstrated 
a difference between two and three-dimensional culture, although these differences have 
the potential for therapeutical exploitation (Maguire, Peck, Wai, et al., 2016; Imamura, 
Mukohara, Shimono, et al., 2015). An alternative approach could have been to perform 
RNAi and drug screens using both two and three-dimensional culture of osteosarcoma 
tumour cell lines to provide a more complete representation of dependencies. However, 
molecular differences have been observed between tumour cell lines and the tumour 
sample they were derived from (Goodspeed, Heiser, Gray, et al., 2016). Patient derived 
xenograft (PDX) models may help to conserve more of the molecular characteristics of 
the tumour sample, but still lack the interactions with tumour microenvironment 
(Goodspeed, Heiser, Gray, et al., 2016). Mouse models have traditionally not been used 
for unbiased high-throughput screening, but recently 1000 PDX models were used to 
screen 62 drugs (Gao, Korn, Ferretti, et al., 2015). This methodology could improve 
clinical translation, but is costly to run, and as yet is nascent in OS requiring robust 
validation of the relevance of the models. 
 
Additionally, OS tumour samples that are sufficient both in quality and quantity for 
molecular characterisation, are more likely to be from patients with tumours that have 
residual disease post chemotherapy, and thus may skew interpretation of cell line data. In 
particular, interpretation of sensitivity to PARP and platinum chemotherapeutics needs to 
be carefully considered when selecting informative cell lines to evaluate mechanistic 




interactions, and potential clinical applicability to the wider OS population. Generation of 
PDX or tumour cell line models from chemotherapy naïve OS tumour samples at 
diagnosis and subsequent comparison with regular biopsies during treatment would 
provide a more complete understanding of both the molecular evolution of the disease, 
response to selection pressures from chemotherapeutics, and the potential for success of 
drugs such as PARP inhibitors. Tumour evolution has already been reported in other 
malignancies (Gerlinger, Horswell, Larkin, et al., 2014), but the recent evolution of single 
cell based molecular characterisation by DNA and RNA sequencing has enabled even 
greater insights into tumour evolution, and the intra- and inter-heterogeneity of the tumour 
population (Ellsworth, Blackburn, Shriver, et al., 2017; Abbosh, Birkbak, Wilson, et al., 
2017; Jamal-Hanjani, Wilson, McGranahan, et al., 2017). Future fluidic systems to 
simultaneously isolate and analyse the molecular alterations of millions of cells in parallel, 
and comparison of these at different time points, from both the primary site and 
metastatic lesions, could provide further insight into the driver variants of the disease, 
tumour development due to chromosomal instability and response to therapeutics 
(Ellsworth, Blackburn, Shriver, et al., 2017). Single cell profiling in non-small cell lung 
cancer has already provided further understanding of driver events in both clonal and 
subclonal populations (Jamal-Hanjani, Wilson, McGranahan, et al., 2017), but as yet 
detailed DNA and RNA sequencing of single cells in OS remains uncharacterised.  
 
The first genome-wide study of proteomic abundance in osteosarcoma in a tumour cell 
line panel on this scale was also performed, although only a preliminary analysis of this 
data-set has been performed by Colm Ryan, Systems Biology Ireland; as the data was 
only available towards the end of this PhD, only initial descriptive results were reported 
here and form the basis of future work to integrate this with the RNAi and drug 
dependency data set. 
 
8.4.2 High-throughput cell-based screening 
High-throughput screening can provide a rapid way of providing unbiased data, and 
combining parallel drug and siRNA screening has the potential to be complementary and 
provide some cross-validation. However, siRNA and drug screening can present 
technical challenges including off-target effects and identification of false positives and 
negatives (Williamson, Miller, Pemberton, et al., 2016). In-built redundancy in the 
screens, by use of multiple different siRNA species and inhibitors of the same target or 




pathway, and robust quality control measures can help to reduce these challenges (Lord 
& Ashworth, 2012). In addition, since gene silencing with siRNA is only temporary, as 
siRNA are not replicated, the effects become more diluted with each cell division, 
therefore only phenotypes which require short-term silencing can be observed 
(Williamson, Miller, Pemberton, et al., 2016). Also, given that gene silencing by siRNA 
can be transient and incomplete, the negative predictive value of any siRNA screen is 
limited. High-complementarity to the target mRNA is required for silencing of target genes 
by endo-nucleolytic cleavage and degradation, while off-target effects require only partial 
complementarity (Birmingham, Anderson, Reynolds, et al., 2006). A seven to eight 
nucleotide seed region at the 5’ end of the anti-sense strand which binds to the 3’ un-
translated region of a potential off-target gene is most important in generation of off-target 
effects (Birmingham, Anderson, Reynolds, et al., 2006). Hence, validation to confirm an 
observed phenotype is due to an on-target effect is important. Despite these limitations I 
have identified a number of potential candidate genetic dependencies associated with 
RB1 deficiency, and DYRK1A was confirmed in two independent data sets, with 
subsequent revalidation experiments.  
 
Given the recent advances in CRISPR-Cas9 gene editing technology, which have 
enabled genome-wide gene silencing studies to be performed in both in vitro (Wang, Wei, 
Sabatini, et al., 2014) and mouse models (Chen, Sanjana, Zheng, et al., 2015; Burgess, 
2015), such a screen could now be performed in osteosarcoma. CRIPSR-Cas9 
technology is advantageous compared to siRNA technology, providing a stable gene 
silencing instead of a transient reduction in gene expression (Wang, Wei, Sabatini, et al., 
2014) but was not available at the beginning of this thesis. Creation of an isogenic 
DYRK1A deficient model in osteosarcoma with cre:lox controlled expression of 
exogenous DYRK1A may have provided additional benefit during revalidation of the 
synthetic lethality observed with RB1. A CRISPR-Cas9 gene-silencing screen in 
combination with small molecule inhibition of PARP might have been a more powerful 
approach to investigate acquired sensitivity to PARP inhibition in LM7.   
  
 
8.5 FINAL CONCLUSIONS AND FUTURE DIRECTIONS 
This thesis has provided a framework and basis for identification of novel therapeutic 
dependencies in OS, and has provided a number of interesting observations. Future work 




to understand these further will involve a parallel approach: (i) further understanding of 
the mechanism of the RB1 DYRK1A synthetic lethality, and potential therapeutic 
applicability; (ii) validation and investigation into both the additional RB1 synthetic 
lethalities identified in the isogenic RB1 deficient U2OS models, and CDKN2A synthetic 
lethalities identified in the OS tumour cell line panel; (iii) investigation of the association of 
FGFR1 amplification and polysomy with increased sensitivity to FGFR1 small molecule 
inhibition; (iv) further investigation of the synergistic effect of VX970 in combination with 
cisplatin seen in the isogenic RB1 deficient U2OS tumour cell lines models; (v) 
investigation of the association of MTAP / CDKN2A deficiency and sensitivity to 
methotrexate using clinical tumour samples; (vi) further investigation of the mechanism of 
acquired HR deficiency and sensitivity to PARP inhibition in the OS tumour cell line LM7; 
and (vii) investigation if a subset of OS tumour cell lines are sensitive to PARP inhibition 
in combination with other chemotherapeutics and identification of a biomarker of 
sensitivity.  
 
Whilst I’ve established a synthetic lethality between silencing of RB1 and DYRK1A, 
dependent on the kinase activity of DYRK1A, mediated by increased apoptosis, the exact 
mechanism has not been fully determined, in part due to multiple functions of DYRK1A 
and the low potency of the inhibitors available. Although the increase in apoptosis seen 
post exposure to harmine may possibly be explained by off target-effects of activation of 
the Fas/FasL pathway, which have been shown to activate Caspase-8 and Caspase-3 
(Wang, Wang, Jiang, et al., 2015), this would not explain the statistically significant 
difference in levels of apoptosis seen dependent on RB1 context. In addition, tumour cells 
deficient in RB1 haven been shown to harbour a deficiency in caspase-8 expression 
secondary to epigenetic gene silencing by over methylation which prevents apoptosis 
triggered via the Fas/FasL pathway (Poulaki, Mitsiades, McMullan, et al., 2005). It is 
therefore unlikely that potential off-target effects of harmine explain this observation. To 
determine if the Fas/FasL pathway has a role in both G2/M arrest and increased 
apoptosis post exposure to harmine, replication of the apoptosis assay and cell cycle 
profile in the presence on Fas/FasL blockade, or use of a structurally different DYRK1A 
inhibitor such as GNF4877 could be performed with coincident western blotting to 
determine if the Fas/FasL pathway is activated. If the G2/M arrest and resultant 
apoptosis, seen in RB1 deficient tumour cells is due to the deleterious effects of deficient 
RB1 on progression through mitosis (Dyson, 2016), expression of functional RB1 should 
reverse the phenotype. A DNA fibre assay could be performed to identify fork stalling, 




while gamma H2AX assay could investigate for increased DNA damage in RB1 deficient 
cells. In addition to these mechanistic experiments, long-term multiple-dosing 
experiments using the DYRK1A inhibitor GNF4877, alone and in combination with other 
cytotoxic agents, in particular anti-mitotic agents such as cisplatin, paclitaxel or 
vinblastine to look for potential synergy. Future work is under way to establish if these 
findings are replicated in OS primary tumour cell lines, which are thought more likely to 
closely reflect the clinical disease. Further confirmation of any effects would be necessary 
in an orthotopic mouse model or PDX prior to clinical translation. If this effect was also 
replicated with GNF4877 firstly in OS tumour cell lines, and then using either an 
orthotopic mouse model, or PDX, this could provide the rationale for a Phase I clinical 
trial in patients of osteosarcoma tumours that harbour RB1 deficiency. 
 
A number of additional candidate genetic dependencies were identified in the isogenic 
RB1 deficient U2OS models, and CDKN2A synthetic lethalities identified in the OS 
tumour cell line panel could be validated firstly by deconvolution using multiple individual 
siRNA species targeting different regions of the gene, followed by additional orthogonal 
validation such as use of a drug with the same target if available. 
 
Amplification of FGFR1 was found to be significantly associated with increased sensitivity 
to FGFR1 inhibition, concordant with the observation in a mixed panel of tumour cell lines 
which included OS (Guagnano, Kauffmann, Wöhrle, et al., 2012). A novel finding was the 
polysomy was also associated with an increase in sensitivity to both FGFR1 inhibitors. 
Lenvatinib, a multi-targeted kinase inhibitor, marketed as a VEGF inhibitor, but with 
nanomolar inhibition of FGFR1, (IC50 of 46nmol/L (Cabanillas & Habra, 2016)) is already 
in Phase 1b/II investigation both alone and in combination with ifosfamide and etoposide, 
in children and young people with osteosarcoma (NCT02432274). Potential candidates 
are the FGFR1-4 inhibitor PRN1371 currently in Phase I trial of patients with advanced 
solid tumours, and an expansion cohort of 20 patients, enriched for solid tumours with 
fibroblast FGFR1-4 genetic alterations (NCT02608125). Given that the OS tumour cell 
lines demonstrated greater sensitivity to FGFR1 inhibition that the non-osteosarcoma 
tumour cell lines, independent of amplification status, ideally a clinical trial of an FGFR1 
inhibitor in all patients with advanced OS would be performed, parallel to confirmation of 
molecular alterations of FGFR1. However, to increase the power of the study, it is likely 
that enrichment of the patient population by selection of those with alterations of FGFR1 
or FGFR1 amplification and/or polysomy would be necessary. 





The ATR inhibitor VX970 was demonstrated to have a synergistic effect in combination 
with cisplatin in the isogenic RB1 deficient U2OS tumour cell line models. Further 
investigation of this effect in a longer-term multiple dosing experiment, in a panel of OS 
tumour cell lines characterised for RB1 deficiency should be performed. Replication of the 
effect in RB1 deficient and wildtype orthotopic mouse models or PDX models with 
treatment arms comprised of vehicle, VX970, cisplatin, and VX970 in combination with 
cisplatin would be needed prior to clinical translation. To investigate if this relationship is 
due to defective NHEJ, increased reliance on the HR pathway in RB1 deficient tumour 
cells (Huang, Cook & Mittnacht, 2015), and resultant increased importance of the DNA 
damage G2 checkpoint and functional ATR (Nghiem, Park, Kim, et al., 2001; Eguchi, 
Takaki, Itadani, et al., 2007), a number of experiments could be performed to further 
understand the mechanism. FACS could be used to determine if cell cycling is unaffected 
by DNA damage imparted by cisplatin and ATR inhibition. Also the γH2AX assay could 
be used to identify an increase of pan-nuclear γH2AX in response to replication fork 
stress, and DSB by presence of nuclear γH2AX foci (Ward & Chen, 2001) if RB1 deficient 
tumour cells are more sensitive due to an impairment in DNA damage repair. In addition, 
both speed of replication forks, and also replication fork collapse, associated with ATR 
inhibition in combination with cisplatin (Reaper, Griffiths, Long, et al., 2011) could be 
investigated. Further investigation into the mechanism of ATR and cisplatin inhibition in 
RB1 deficient tumour cell lines, using some of the models used in this thesis is planned 
and supports the potential relevance of RB1 as an actionable target in OS (personal 
correspondence Sybille Mittnacht, UCL).  
 
VX970 is already in early phase clinical trials, one in combination with PARP inhibition 
and cisplatin in patients with advanced solid tumours (NCT02723864) and could be easily 
repositioned. Given that cisplatin is one of the established therapeutic agents in OS, 
VX970 has the potential to be used as a biomarker (RB1 deficiency) driven chemo-
sensitiser. However, even though VX970 has reportedly been well tolerated, the most 
frequently reported toxicities are of myelo-suppression. Considering cisplatin and 
doxorubicin in combination are already significantly myelo-suppressive, the practicalities 
of addition to the current schedule could be challenging, and possibly require a longer 
duration between cycles for count recovery or dose reduction of cisplatin; this would need 
to be balanced with possible deleterious effect on outcome due to reduction of dose-
intensity and explored in a trial setting. 





MTAP and CDKN2A were identified as possible biomarkers for sensitivity to 
methotrexate. Further validation could be performed by immunohistochemistry to identify 
MTAP or CDKN2A deficiency on tumour samples from the Royal National Orthopaedic 
Hospital, Stanmore Musculoskeletal Biobank, a satellite of the UCL/UCLH Biobank for 
Studying Health and Disease, and correlated with response to MAP chemotherapy at 
resection. Although confounded by doxorubicin and cisplatin therapy in combination with 
high-dose methotrexate, it could provide the rationale for a clinical biomarker driven trial 
to establish if patients with wildtype MTAP or CDKN2A could achieve the same or better 
outcome with a different agent instead of methotrexate. 
 
The isogenic model such as SAOS2 and LM7 which has acquired HR deficiency and 
sensitivity to PARP inhibition provides an attractive model to identify markers of a 
‘BRCAness’ phenotype and PARP inhibitor sensitivity in OS and a wider context. Mouse 
models of these tumour cell lines are already available (Jia, Worth & Kleinerman, 1999). 
Further work is needed to establish if silencing the genes encoding the proteins 
SMARCA1, HIST2H2AB, or FANCD2, confer an increased sensitivity to PARP inhibition 
on SAOS2, and if over expression of these genes using cDNA in a plasmid, rescues the 
PARP sensitivity seen with LM7. Investigation if any of the other OS tumour cell lines 
harbour an HR defect, by use of the RAD51 assay, could provide further evidence of the 
proportion of BRCAness seen in OS tumour cell lines and inform clinical trials. Finding 
the right subset of patients with OS that could benefit from these agents, by use of a 
biomarker, is critical for the successful translation of these pre-clinical findings into the 
clinic. It is more likely that a PARP inhibitor in combination with other chemotherapeutics 
would be most attractive, although finding a biomarker for sensitivity to PARP 
combinations and choice of additional agents are not without challenges (Dréan, Lord & 
Ashworth, 2016). A high-throughput drug screen with the addition of a PARP inhibitor 
using LM7 and SAOS2 could be performed to isolate the most synergistic combination. 
Confirmation experiments in a mouse model would be needed prior to clinical translation.  
 
In conclusion, the use of integrated screens in this thesis has provided a framework for 
pre-clinical identification and validation of a number of tractable therapeutic targets to 
facilitate translation into development of clinical trials.  
 





Appendix Table 1 Kinome siRNA library 
Gene ID Entrez 
gene ID  
Gene ID Entrez 
gene ID  
Gene ID Entrez 
gene ID  
213H19.1 51765 FYN 2534 PFKM 5213 
AAK1 22848 GAK 2580 PFKP 5214 
AATK 9625 GALK1 2584 PFTK1 5218 
ABL1 25 GALK2 2585 PGK1 5230 
ABL2 27 GCK 2645 PGK2 5232 
ACVR1 90 GK 2710 PHKA1 5255 
ACVR1B 91 GK2 2712 PHKA2 5256 
ACVR1C 130399 GNE 10020 PHKB 5257 
ACVR2 92 GOLGA5 9950 PHKG1 5260 
ACVR2B 93 GRK1 6011 PHKG2 5261 
ACVRL1 94 GRK4 2868 PI4K2B 55300 
ADCK1 57143 GRK5 2869 PI4KII 55361 
ADCK2 90956 GRK6 2870 PIK3C2A 5286 
ADCK4 79934 GRK7 131890 PIK3C2G 5288 
ADCK5 203054 GSG2 83903 PIK3C2G 5288 
ADK 132 GSK3A 2931 PIK3C3 5289 
ADP-GK 83440 GSK3B 2932 PIK3CA 5290 
ADRBK1 156 GTF2H1 2965 PIK3CB 5291 
ADRBK2 157 GUCY2C 2984 PIK3CD 5293 
AIP1 9863 GUCY2D 3000 PIK3CG 5294 
AK1 203 GUCY2F 2986 PIK3R1 5295 
AK2 204 GUK1 2987 PIK3R2 5296 
AK3 205 HAK 115701 PIK3R3 8503 
AK3L1 50808 HCK 3055 PIK3R4 30849 
AK5 26289 HIPK1 204851 PIK4CA 5297 
AK7 122481 HIPK2 28996 PIK4CB 5298 
AKT1 207 HIPK3 10114 PIM1 5292 
AKT2 208 HIPK4 147746 PIM2 11040 
AKT3 10000 HK1 3098 PIM3 415116 




ALK 238 HUNK 30811 PINK1 65018 
ALS2CR2 55437 HUS1 3364 PIP5K1A 8394 
ALS2CR7 65061 ICK 22858 PIP5K1B 8395 
AMHR2 269 IGF1R 3480 PIP5K1C 23396 
ANKK1 255239 IGF2R 3482 PIP5K2A 5305 
ANKRD3 54101 IHPK1 9807 PIP5K2B 8396 
ARAF1 369 IHPK2 51447 PIP5K2C 79837 
ARK5 9891 IHPK3 117283 PIP5K3 200576 
ASK 10926 IKBKAP 8518 PIP5KL1 138429 
ATM 472 IKBKB 3551 PKIA 5569 
ATR 545 IKBKE 9641 PKIB 5570 
AURKA 6790 IKBKG 8517 PKLR 5313 
AURKB 9212 ILK 3611 PKM2 5315 
AURKC 6795 ILK-2 55522 PKMYT1 9088 
AXL 558 INSR 3643 PKN3 29941 
BAIAP1 9223 INSRR 3645 PLK1 5347 
BCKDK 10295 IPMK 253430 PLK2 10769 
BCR 613 IRAK1 3654 PLK3 1263 
BLK 640 IRAK2 3656 PLK4 10733 
BMP2K 55589 IRAK3 11213 PMVK 10654 
BMPR1A 657 IRAK4 51135 PNCK 139728 
BMPR1B 658 ITK 3702 PNKP 11284 
BMPR2 659 ITPK1 3705 PRKAA1 5562 
BMX 660 ITPKA 3706 PRKAA2 5563 
BRAF 673 ITPKB 3707 PRKAB1 5564 
BRD2 6046 ITPKC 80271 PRKAB2 5565 
BRD3 8019 JAK1 3716 PRKACA 5566 
BRD4 23476 JAK2 3717 PRKACB 5567 
BRDT 676 JAK3 3718 PRKAR1B 5575 
BTK 695 JIK 51347 PRKAR2A 5576 
BUB1 699 KALRN 8997 PRKAR2B 5577 
BUB1B 701 KCNH2 3757 PRKCA 5578 
C10ORF89 118672 KCNH8 131096 PRKCB1 5579 
C14ORF20 283629 KDR 3791 PRKCD 5580 




C7ORF2 64327 KHK 3795 PRKCE 5581 
C9ORF12 64768 KIAA0999 23387 PRKCG 5582 
C9ORF96 169436 KIAA1361 57551 PRKCH 5583 
CALM1 801 KIAA1639 57729 PRKCI 5584 
CALM2 805 KIAA1765 85443 PRKCL1 5585 
CALM3 808 KIAA1804 84451 PRKCL2 5586 
CAMK1 8536 KIAA1811 84446 PRKCM 5587 
CAMK1D 57118 KIAA1811 84446 PRKCN 23683 
CAMK1G 57172 KIAA2002 79834 PRKCQ 5588 
CAMK2A 815 KIT 3815 PRKCSH 5589 
CAMK2B 816 KSR 8844 PRKCZ 5590 
CAMK2D 817 KSR2 283455 PRKD2 25865 
CAMK2G 818 KUB3 91419 PRKDC 5591 
CAMK4 814 LAK 80216 PRKG1 5592 
CAMKK1 84254 LATS1 9113 PRKG2 5593 
CAMKK1 84254 LATS2 26524 PRKR 5610 
CAMKK2 10645 LCK 3932 PRKWNK1 65125 
CARKL 23729 LIMK1 3984 PRKWNK2 65268 
CASK 8573 LIMK2 3985 PRKWNK3 65267 
CCRK 23552 LMTK2 22853 PRKX 5613 
CDADC1 81602 LMTK3 114783 PRKY 5616 
CDC2 983 LOC340156 340156 PRPF4B 8899 
CDC2L1 984 LOC390226 390226 PRPS1 5631 
CDC2L2 728642 LOC91461 91461 PRPS1L1 221823 
CDC42BPA 8476 LRRK1 79705 PRPS2 5634 
CDC42BPA 8476 LRRK2 120892 PSKH1 5681 
CDC42BPB 9578 LTK 4058 PSKH2 85481 
CDC7 8317 LYK5 92335 PTK2 5747 
CDK10 8558 LYN 4067 PTK2B 2185 
CDK11 23097 MAGI-3 260425 PTK6 5753 
CDK2 1017 MAK 4117 PTK7 5754 
CDK3 1018 MAP2K1 5604 PTK9 5756 
CDK4 1019 MAP2K2 5605 PTK9L 11344 
CDK5 1020 MAP2K3 5606 PXK 54899 




CDK5R1 8851 MAP2K4 6416 PYCS 5832 
CDK5R2 8941 MAP2K5 5607 RAF1 5894 
CDK6 1021 MAP2K6 5608 RAGE 5891 
CDK7 1022 MAP2K7 5609 RBKS 64080 
CDK8 1024 MAP3K1 4214 RELA 5970 
CDK9 1025 MAP3K10 4294 RET 5979 
CDKL1 8814 MAP3K11 4296 RFK 55312 
CDKL2 8999 MAP3K12 7786 RFP 5987 
CDKL3 51265 MAP3K13 9175 RIOK1 83732 
CDKL4 344387 MAP3K14 9020 RIOK2 55781 
CDKL5 6792 MAP3K15 389840 RIOK3 8780 
CDKN1A 1026 MAP3K2 10746 RIPK1 8737 
CDKN1B 1027 MAP3K3 4215 RIPK2 8767 
CDKN1C 1028 MAP3K4 4216 RIPK3 11035 
CDKN2B 1030 MAP3K5 4217 RNASEL 6041 
CDKN2C 1031 MAP3K6 9064 ROCK1 6093 
CDKN2D 1032 MAP3K7 6885 ROCK2 9475 
CERK 64781 MAP3K7IP1 10454 ROR1 4919 
CHEK1 1111 MAP3K8 1326 ROR2 4920 
CHEK2 11200 MAP4K1 11184 ROS1 6098 
CHKA 1119 MAP4K1 11184 RP6-  
CHKB 1120 MAP4K2 5871 RPS6KA1 6195 
CHUK 1147 MAP4K3 8491 RPS6KA2 6196 
CIB2 10518 MAP4K4 9448 RPS6KA3 6197 
CIT 11113 MAP4K5 11183 RPS6KA4 8986 
CK2A 55450 MAPK1 5594 RPS6KA5 9252 
CKB 1152 MAPK10 5602 RPS6KA6 27330 
CKM 1158 MAPK11 5600 RPS6KB1 6198 
CKMT1B 1159 MAPK12 6300 RPS6KB2 6199 
CKMT2 1160 MAPK13 5603 RPS6KC1 26750 
CKS1B 1163 MAPK14 1432 RPS6KL1 83694 
CKS2 1164 MAPK3 5595 RYK 6259 
CLK1 1195 MAPK4 5596 SAST 22983 
CLK2 1196 MAPK6 5597 SBK1 388228 




CLK3 1198 MAPK7 5598 SCAP1 8631 
CLK4 57396 MAPK8 5599 SCYL1 57410 
COASY 80347 MAPK9 5601 SGK 6446 
CRIM1 51232 MAPKAPK2 9261 SGK2 10110 
CRK7 51755 MAPKAPK3 7867 SGK223 157285 
CRKL 1399 MAPKAPK5 8550 SGKL 23678 
CSF1R 1436 MARK1 4139 SIK2 23235 
CSK 1445 MARK2 2011 SLK 9748 
CSNK1A1 1452 MARK3 4140 SMG1 23049 
CSNK1A1L 122011 MARK4 57787 SNARK 81788 
CSNK1D 1453 MAST2 23139 SNF1LK 150094 
CSNK1E 1454 MAST3 23031 SNRK 54861 
CSNK1G1 53944 MAST4 375449 SPEG 10290 
CSNK1G2 1455 MASTL 84930 SPHK1 8877 
CSNK1G3 1456 MATK 4145 SPHK2 56848 
CSNK2A1 1457 MELK 9833 SRC 6714 
CSNK2A2 1459 MERTK 10461 SRMS 6725 
CSNK2B 1460 MET 4233 SRP72 6731 
DAPK1 1612 MGC16169 93627 SRPK1 6732 
DAPK2 23604 MGC42105 167359 SRPK2 6733 
DAPK3 1613 MGC45428 166614 SSTK 83983 
DCAMKL1 9201 MGC4796 83931 SSTK 83983 
DCK 1633 MGC4796 83931 STK10 6793 
DDR1 780 MGC8407 79012 STK11 6794 
DDR2 4921 MIDORI 57538 STK16 8576 
DGKA 1606 MINK 50488 STK17A 9263 
DGKB 1607 MKNK1 8569 STK17B 9262 
DGKD 8527 MKNK2 2872 STK19 8859 
DGKG 1608 MLCK 91807 STK22B 23617 
DGKH 160851 MULK 55750 STK22C 81629 
DGKI 9162 MUSK 4593 STK22D 83942 
DGKK 139189 MVK 4598 STK22D 83942 
DGKQ 1609 MYLK 4638 STK23 26576 
DGUOK 1716 MYLK2 85366 STK24 8428 




DLG1 1739 MYO3A 53904 STK25 10494 
DLG2 1740 MYO3B 140469 STK29 9024 
DLG3 1741 N4BP2 55728 STK3 6788 
DLG4 1742 NAGK 55577 STK31 56164 
DMPK 1760 NEK1 4750 STK32A 202374 
DTYMK 1841 NEK11 79858 STK32B 55351 
DUSP21 63904 NEK2 4751 STK32C 282974 
DUSTYPK 25778 NEK3 4752 STK33 65975 
DYRK1A 1859 NEK4 6787 STK35 140901 
DYRK1B 9149 NEK5 341676 STK36 27148 
DYRK2 8445 NEK6 10783 STK38 11329 
DYRK3 8444 NEK7 140609 STK38L 23012 
DYRK4 8798 NEK8 284086 STK39 27347 
EEF2K 29904 NEK9 91754 STK4 6789 
EFNA3 1944 NLK 51701 STYK1 55359 
EFNA4 1945 NME1 4830 SYK 6850 
EFNA5 1946 NME2 4831 TAF1 6872 
EFNB3 1949 NME3 4832 TAF1L 138474 
EGFR 1956 NME4 4833 TAO1 9344 
EIF2AK3 9451 NME5 8382 TBK1 29110 
EIF2AK4 440275 NME6 10201 TEC 7006 
EPHA1 2041 NME7 29922 TEK 7010 
EPHA10 284656 NPR2 4882 TESK1 7016 
EPHA2 1969 NRBP 29959 TESK2 10420 
EPHA3 2042 NRBP2 340371 TEX14 56155 
EPHA4 2043 NRK 203447 TGFBR1 7046 
EPHA5 2044 NTRK1 4914 TGFBR2 7048 
EPHA6 285220 NTRK2 4915 TGFBR3 7049 
EPHA7 2045 NTRK3 4916 THNSL1 79896 
EPHA8 2046 NUCKS 64710 TJP2 9414 
EPHB1 2047 NUP62 23636 TK2 7084 
EPHB2 2048 NYD-SP25 89882 TLK1 9874 
EPHB3 2049 OSR1 9943 TLK2 11011 
EPHB4 2050 P101-PI3K 23533 TNIK 23043 




EPHB6 2051 PACE-1 57147 TNK1 8711 
ERBB2 2064 PACSIN1 29993 TNK2 10188 
ERBB3 2065 PAK1 5058 TNNI3K 51086 
ERBB4 2066 PAK2 5062 TOPK 55872 
ERK8 225689 PAK3 5063 TP53RK 112858 
ERN1 2081 PAK4 10298 TPK1 27010 
ERN2 10595 PAK6 56924 TRIB1 10221 
ETNK1 55500 PAK7 57144 TRIB2 28951 
EXOSC10 5394 PANK1 53354 TRIB3 57761 
FASTK 10922 PANK2 80025 TRIO 7204 
FER 2241 PANK3 79646 TRPM6 140803 
FES 2242 PANK4 55229 TRPM7 54822 
FGFR1 2260 PAPSS1 9061 TSKS 60385 
FGFR2 2263 PAPSS2 9060 TTBK1 84630 
FGFR3 2261 PASK 23178 TTBK2 146057 
FGFR4 2264 PCK1 5105 TTK 7272 
FGFRL1 53834 PCK2 5106 TYK2 7297 
FGR 2268 PCTK1 5127 TYRO3 7301 
FLJ10761 55224 PCTK2 5128 UCK1 83549 
FLJ13052 65220 PCTK3 5129 UHMK1 127933 
FLJ23356 84197 PDGFRA 5156 UKL3 25989 
FLJ23356 84197 PDGFRB 5159 ULK1 8408 
FLJ23356 84197 PDGFRL 5157 ULK2 9706 
FLJ25006 124923 PDIK1L 149420 ULK4 54986 
FLJ32685 152110 PDK1 5163 UMP-
CMPK 
51727 
FLJ34389 197259 PDK2 5164 UMPK 7371 
FLT1 2321 PDK3 5165 URKL1 54963 
FLT3 2322 PDK4 5166 VRK1 7443 
FLT4 2324 PDPK1 5170 VRK2 7444 
FN3K 64122 PDXK 8566 VRK3 51231 
FN3KRP 79672 PFKFB1 5207 WEE1 7465 
FRAP1 2475 PFKFB2 5208 WNK4 65266 
FRDA 2395 PFKFB3 5209 XYLB 9942 




FRK 2444 PFKFB4 5210 YES1 7525 









Appendix Table 2 Tumour suppressor gene siRNA library 
Gene ID Entrez 
gene ID  
Gene ID Entrez 
gene ID  
Gene ID Entrez 
gene ID  
APC 324 FANCD2 2177 PRKAR1A 5573 
ATM 472 FANCE 2178 PTCH 5727 
BHD 201163 FANCF 2188 PTEN 5728 
BLM 641 FANCG 2189 RB1 5925 
BMPR1A 657 FAS 355 RECQL4 9401 
BRCA1 672 FBXW7 55294 SBDS 51119 
BRCA2 675 FH 2271 SDHB 6390 
BRIP1 83990 FLJ21816 79728 SDHC 6391 
BUB1B 701 FLJ39827 139285 SDHD 6392 
CDH1 999 GPC3 2719 SMAD4 4089 
CDKN2A 1029 HRPT2 79577 SMARCB1 6598 
CHEK2 11200 MAP2K4 6416 SOCS1 8651 
COPEB 1316 MEN1 4221 STK11 6794 
CYLD 1540 MLH1 4292 SUFU 51684 
DDB2 1643 MSH2 4436 TCF1 6927 
EP300 2033 MSH6 2956 TP53 7157 
ERCC2 2068 MUTYH 4595 TSC1 7248 
ERCC3 2071 NBS1 4683 TSC2 7249 
ERCC4 2072 NF1 4763 VHL 7428 
ERCC5 2073 NF2 4771 WAS 7454 
EXT1 2131 PHOX2B 8929 WRN 7486 
EXT2 2132 PIK3R1 5295 WT1 7490 
FANCA 2175 PMS1 5378 XPA 7507 
FANCC 2176 PMS2 5395 XPC 7508 
    ZNFN1A1 10320 
 
 




Appendix Table 3 Cancer Gene Census siRNA library 
Gene ID Entrez 
gene ID  
Gene ID Entrez 
gene ID  
Gene ID Entrez gene 
ID  
ABI1 10006 GAS7 8522 PMS2 5395 
ACKR3 57007 GATA1 2623 PNKP 11284 
ACSL3 2181 GATA3 2625 POLB 5423 
ACSL6 23305 GEN1 348654 POLD1 5424 
AFF3 3899 GMPS 8833 POLE 5426 
AKAP9 10142 GNA11 2767 POLG 5428 
ALDH2 217 GNAQ 2776 POLH 5429 
ALKBH2 121642 GNAS 2778 POLI 11201 
ALKBH3 221120 GOPC 57120 POLK 51426 
AMER1 139285 GTF2H1 2965 POLL 27343 
APEX1 328 GTF2H2 2966 POLM 27434 
APEX2 27301 GTF2H3 2967 POLN 353497 
APTX 54840 GTF2H4 2968 POLQ 10721 
ARHGAP26 23092 GTF2H5 404672 POT1 25913 
ARHGEF12 23365 H2AFX 3014 POU2AF1 5450 
ARID1A 8289 H3F3A 3020 POU5F1 5460 
ARID2 196528 H3F3A 3020 PPARG 5468 
ARNT 405 HELQ 113510 PPP2R1A 5518 
ASPSCR1 79058 HERPUD1 9709 PRCC 5546 
ASXL1 171023 HEY1 23462 PRDM1 639 
ATF1 466 HIP1 3092 SSX4 6759 
ATM 472 HIST1H4I 8294 STAT3 6774 
ATR 545 HMGA1 3159 STAT5B 6777 
ATRX 546 HMGA2 8091 SUZ12 23512 
AXIN1 8312 HMGN2P46 283651 TAF15 8148 
BAP1 8314 HNRNPA2B1 3181 TAL1 6886 
BCL10 8915 HOOK3 84376 TBL1XR1 79718 
BCL11A 53335 HOXA11 3207 TCEA1 6917 
BCL2 596 HOXA13 3209 TCF12 6938 
BCL3 602 HOXA9 3205 TCF3 6929 
BCL6 604 HOXC11 3227 TCF7L2 6934 




BCL7A 605 HOXC13 3229 TDG 6996 
BCL9 607 HOXD11 3237 TDP1 55775 
BCOR 54880 HOXD13 3239 TDP2 51567 
BIRC3 330 HRAS 3265 TERT 7015 
BLM 641 HSP90AA1 3320 TET2 54790 
BRCA1 672 HSP90AB1 3326 TFE3 7030 
BRCA2 675 HUS1 3364 TFEB 7942 
BRIP1 83990 IDH1 3417 TFG 10342 
C15orf65 145788 IDH2 3418 TFRC 7037 
C19orf40 91442 NFKB2 4791 THRAP3 9967 
C2orf44 80304 NHEJ1 79840 TMPRSS2 7113 
CAMTA1 23261 NIN 51199 TNFAIP3 7128 
CANT1 124583 NKX2-1 7080 TNFRSF14 8764 
CARD11 84433 NONO 4841 TNFRSF17 608 
CBL 867 NOTCH1 4851 TNKS_TNKS2 8658_80351 
CBLB 868 NOTCH2 4853 TOP1 7150 
CBLC 23624 NPM1 4869 TP53 7157 
CCDC6 8030 NR4A3 8013 TP53BP1 7158 
CCNB1IP1 57820 NRAS 4893 TPM3 7170 
CCND1 595 NSD1 64324 TPR 7175 
CCND2 894 NT5C2 22978 TRAF7 84231 
CCND3 896 NTHL1 4913 TREX1 11277 
CCNE1 898 NUDT1 4521 TREX2 11219 
CCNH 902 NUMA1 4926 TRIM24 8805 
CCNL1 57018 NUTM1 256646 TRIM27 5987 
CD74 972 NUTM2A 728118 TRIM33 51592 
CDH11 1009 NUTM2B 729262 TRIP11 9321 
CDK12 51755 OGG1 4968 TSHR 7253 
CDK7 1022 OMD 4958 TTL 150465 
FANCG 2189 P2RY8 286530 U2AF1 7307 
FANCI 55215 PAFAH1B2 5049 UBE2A 7319 
FANCL 55120 PALB2 79728 UBE2B 7320 
FANCM 57697 PARP1 142 UBE2N 7334 
FAS 355 PARP2 10038 UBE2V2 7336 




FASN 2194 PATZ1 23598 UBR5 51366 
FBXO11 80204 PAX3 5077 UNG 7374 
FEN1 2237 PAX7 5081 USP6 9098 
FEV 54738 PAX8 7849 VTI1A 143187 
FGFR1OP 11116 PBRM1 55193 WHSC1 7468 
FHIT 2272 PCM1 5108 WHSC1L1 54904 
FIP1L1 81608 PCNA 5111 WIF1 11197 
FLI1 2313 PCSK7 9159 WRN 7486 
FNBP1 23048 PDCD1LG2 80380 WWTR1 25937 
FOXL2 668 PDGFB 5155 XAB2 56949 
FOXO1 2308 PHF6 84295 XPA 7507 
FOXO3 2309 PICALM 8301 XPC 7508 
FOXP1 27086 PLAG1 5324 XRCC1 7515 
FUBP1 8880 PML 5371 XRCC2 7516 
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